Biomarkers for Monitoring Impdh Pathway Inhibition

ABSTRACT

The present invention is directed to methods for ameliorating reproductive disorders. More specifically, the present invention describes methods and compositions for using IL-17 in the treatment of various infertility-related defects.

The present application claims the benefit of priority of 60/575,076 filed on May 27, 2004. The entire text of this priority application and its appendices is incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to biomarkers useful for monitoring the effects of inhibition of IMPDH in a patient.

BACKGROUND

The synthesis of nucleotides in organisms is required for the cells in those organisms to divide and replicate. Nucleotide synthesis in mammals may be achieved through one of two pathways: the de novo synthesis pathway or the salvage pathway. Different cell types use these pathways to a different extent.

Inosine-5′-monophosphate dehydrogenase (IMPDH; EC 1.1.1.205) is an enzyme involved in the de novo synthesis of guanine nucleotides. IMPDH catalyzes the NAD-dependent oxidation of inosine-5′-monophosphate (IMP) to xanthosine-5′-monophosphate (XMP) [Jackson R. C. et. al., Nature, 256, pp. 331-333, (1975)].

IMPDH is ubiquitous in eukaryotes, bacteria and protozoa [Y. Natsumeda & S. F. Carr, Ann. N.Y. Acad., 696, pp. 88-93 (1993)]. The prokaryotic forms share 30-40% sequence identity with the human enzyme. Two isoforms of human IMPDH, designated type I and type II, have been identified and sequenced [F. R. Collart and E. Huberman, J. Biol. Chem., 263, pp. 15769-15772, (1988); Y. Natsumeda et. al., J. Biol. Chem., 265, pp. 5292-5295, (1990)]. Each is 514 amino acids, and they share 84% sequence identity. Both IMPDH type I and type II form active tetramers in solution, with subunit molecular weights of 56 kDa [Y. Yamada et. al., Biochemistry, 27, pp. 2737-2745 (1988)].

The de novo synthesis of guanosine nucleotides, and thus the activity of IMPDH, is particularly important in B and T-lymphocytes. These cells depend on the de novo, rather than salvage pathway to generate sufficient levels of nucleotides necessary to initiate a proliferative response to mitogen or antigen [A. C. Allison et. al., Lancet II, 1179, (1975) and A. C. Allison et. al., Ciba Found. Symp., 48, 207, (1977)]. Thus, IMPDH is an attractive target for selectively inhibiting the immune system without also inhibiting the proliferation of other cells. Although resting lymphocytes can utilize the alternate salvage nucleotide synthesis pathway (Fairbanks et al, 1995), rapidly proliferating lymphocytes rely predominantly on the de novo pathway for satisfying their requirement for nucleotides. This observation makes enzymes of the de novo pathway attractive targets for pharmacological intervention aimed at inhibiting lymphocyte proliferation (Allison and Eugui, 2000). Blocking IMPDH enzyme activity results in a decrease of cellular guanine nucleotide levels, thereby inhibiting DNA and RNA synthesis, resulting ultimately in antiproliferative, immunosuppressive and antiviral effects (reviewed in Franchetti and Grifantini, 1999).

It is also known that IMPDH plays a role in other metabolic events. Increased IMPDH activity has been observed in rapidly proliferating human leukemia cell lines and other tumor cell lines, indicating IMPDH as a target for anti-cancer as well as immunosuppressive chemotherapy [M. Nagai et. al., Cancer Res., 51, pp. 3886-3890, (1991)].

Inhibitors of IMPDH have been extensively investigated to treat various diseases, e.g., tumors and cancers, immunosuppression, and viral diseases, See, e.g., WO 00/56331. Mycophenolic acid (“MPA”) and VX-944 are two known IMPDH inhibitors. VX-944 is currently being investigated for potential use as an anti-cancer agent. Several IMPDH inhibitors have been used clinically and more are being developed for the treatment of immune cell-mediated, chronic inflammatory, antineoplatic and antiviral indications (Jain et al, 2001, Jain et al, 2002, Dhar et al, 2002). In addition, several new, non-nucleoside IMPDH inhibitors have been designed using a rational drug design approach (Sintchak et al, 1996, reviewed in Saunders and Raybuck, 2000). Of these, VX-497, is currently being investigated in a Phase II trial in combination with pegylated IFN and ribavirin for the treatment of Hepatitis C (Markland et al, 2000, Jain et al, 2001). VX-944 inhibits both IMPDH isozymes with Ki values of 7-10 nM (Jain et al, 2003, ASH poster). VX-944 is also very potent in inhibiting the proliferation of human peripheral lymphocytes stimulated with either T or B-cell mitogens with IC50 values ranging from 20-100 nM, and is more potent than VX-497 or MPA (Eugui et al, 1991a, Jain et al, 2001, Jain et al, 2003 ASH poster, Jain et al, 2004 ASH poster). The inhibition of lymphocyte proliferation by VX-944 is alleviated by the addition of 50 μM guanosine, demonstrating its specificity towards the IMPDH enzyme.

There is a need to develop a reliable biomarker that can be readily used for tracking and monitoring the efficacy of such an IMPDH inhibitor. Such a biomarker should be sensitive to inhibition of IMPDH and be readily detectable by methods that are not unduly burdensome.

SUMMARY OF THE INVENTION

The present invention provides biomarkers that are useful in monitoring the effect of inhibition of IMPDH in a patient. Applicants have identified a group of genes that are up- or downregulated as a result of IMPDH inhibition. Exemplary expression data showing genes that are up- or down-regulated in response to IMPDH inhibition after 24, 48 and 72 hours of exposure to exemplary IMPDH inhibitors are provided in Table IX. Determining the expression of these genes in a biological sample obtained from a subject treated with an IMPDH inhibitor will therefore allow an assessment of whether the individual will be responsive to IMPDH inhibitor therapy.

The invention describes a nucleic acid array consisting essentially of at least 4 polynucleotides selected from the polynucleotides listed in any one or more of Tables I through VIII, wherein said polynucleotides are immobilized on a solid surface, and wherein said array further contains one or more calibration points and one or more housekeeping genes. In some embodiments the nucleic acid array consists of at least 4 polynucleotides selected from the polynucleotides listed in any one or more of Tables I through VIII. The array may have between 1 and 10 calibration spots and also or alternatively may have between 1 to 10 housekeeping genes to serve as controls for the array. The polynucleotides may be cDNAs or oligonucleotides. The arrays may consist of at least 4, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 200, 300 or more polynucleotides. The polynucleotides may be preferred polynucleotides presented herein in Tables I through Table VIII or alternatively may be fragments or variants of those polynucleotides. In one preferred aspect the microarray is one which comprises all of the polynucleotides set forth in Table VI. Another preferred microarray contains all of the polynucleotides set forth in Table V. Another preferred microarray contains all of the polynucleotides set forth in Table IV. In preferred embodiments, the array contains more than one polynucleotide hybridizing to the same gene.

Also encompassed by the invention is a nucleic acid array consisting essentially of at least 4 distinct nucleic acid sequences selected from the group consisting of the polynucleotides listed in Table I, immobilized on the surface at discrete and known positions, wherein said nucleic acids hybridize to nucleic acids in a sample of a subject that are either up-regulated or down-regulated in response to inhibition of IMPDH. In other embodiments, there is provided a nucleic acid array consisting of at least 4 distinct nucleic acid sequences selected from the group consisting of the polynucleotides listed in Table I. Another embodiment is directed to a nucleic acid array consisting essentially of at least 4 distinct nucleic acid sequences selected from the group consisting of the polynucleotides listed in Table IV, immobilized on the surface at discrete and known positions, wherein said nucleic acids hybridize to nucleic acids in a sample of a subject that are either up-regulated or down-regulated in response to inhibition of IMPDH. Another embodiment is directed to a nucleic acid array consisting of at least 4 distinct nucleic acid sequences selected from the group consisting of the polynucleotides listed in Table IV. Still more preferably, the nucleic acids on said microarray are selected from the group consisting, or consisting essentially, of the genes from Table V. Alternatively, the nucleic acids on said microarray are selected from the group consisting, or consisting essentially, of the genes from Table VI.

Other exemplary nucleic acid arrays are those that consist, or consist essentially, of at least 4 distinct nucleic acid sequences selected from the group consisting of the polynucleotides listed in Table VII, immobilized on the surface at discrete and known positions, wherein said nucleic acids hybridize to nucleic acids in a sample of a subject that are either up-regulated or down-regulated in response to inhibition of IMPDH. In the arrays the surface is typically selected from the group consisting of a metal, silicon, a polymer plastic, paper, ceramic, quartz, gallium arsenide, metal, metalloid, cellulose, celluose acetate, nitrocellulose, and a glass. More specifically, the plastic is selected from the group consisting of nylon, polycarbonate, polyethylene, polystyrene, teflon, polypropylene, poly(4-methylbutene), polystyrene/latex, polymethacrylate, poly(ethylene terephthalate), rayon, polyvinylbutyrate, and polyvinylidene difluoride. Preferably, the arrays have at least one control spot consisting of one or more nucleic acids that are known not to be modulated with IMPDH inhibition.

In specific embodiments the array surface comprises a plurality of microarrays separated from each other with a hydrophobic polymer strip. In preferred aspects the hydrophobic polymer strip is selected from the group of polyethylene, silicone, paraffin, and Teflon®.

Also contemplated by the invention is a set of polynucleotides for use in the detection of IMPDH inhibition, wherein said polynucleotides hybridize to 4 to 314 genes selected from the group consisting of the genes set forth in any one or more of Table I, Table II, Table III, Table IV, Table V, Table VI, Table VII and Table VIII wherein the expression of each said nucleic acid is either up- or down-regulated in response to inhibition of IMPDH.

Another aspect of the invention is related to a set of polynucleotides for use in the prediction of efficacy of an IMPDH inhibitor in non-proliferating cells, wherein the set of polynucleotides hybridize to 4 to 38 genes selected from the group consisting of the genes set forth in Table I. Still another aspect is directed to a set of polynucleotides for use in the prediction of efficacy of an IMPDH inhibitor in a proliferating cell, wherein the set of polynucleotides hybridize to 4 to 300 genes selected from the group consisting of the genes set forth in Table II, Table III, and Table IV. Preferably, the proliferating cell is from a hematological cancer and said genes are selected from the group of genes set forth in Table V. Alternatively, the genes are selected from the group of genes set forth in Table VI.

Also part of this invention is a set of nucleic acids for use in the prediction of anti-viral efficacy of an IMPDH inhibitor, wherein the set of polynucleotides hybridize to 4 to 9 genes selected from the group consisting of the genes set forth in Table VII. These are not the only genes identified that may predict antiviral activity of VX-944. The genes listed in Table VII are from the intersection of the genes of Table I and IFN-responsive genes. The skilled person may identify additional anti-viral genes by obtaining the intersection between Table IV and IFN-responsive genes.

Another aspect of the invention is a set of nucleic acids for use in the prediction of efficacy of an IMPDH inhibitor as an anti-cancer agent, wherein the set of polynucleotides hybridize to the 4 genes set forth in Table VIII.

The invention specifically contemplates a method for predicting whether a candidate IMPDH inhibitory agent will produce a therapeutic effect in a subject comprising: contacting a biological sample with said inhibitory agent and determining the expression level of four or more prognostic genes selected from the group consisting of the genes set forth in one or more of Gene Table I, Gene Table II, Gene Table III, Gene Table IV, Gene Table V, Gene Table VI, Gene Table VII and Gene Table VIII in said biological sample, wherein a modulation of the expression level of four or more of genes similar to the modulation resulting from a known IMPDH inhibitor is indicative that said agent is a therapeutically effective IMPDH inhibitory agent.

A candidate IMPDH inhibitor produces an expression pattern that is “similar” to a known IMPDH inhibitor, e.g., VX-944 or MPA, if the qualitative, but not necessarily quantitative, effect on gene expression of the candidate and known inhibitors reliably resemble or mimic each other from the perspective of one of skill in the art. The qualitative effect on expression (i.e., the number of genes exhibiting modulated expression and whether that modulation reflects up- or down-regulation) is distinct from the quantitative effect on expression (i.e., the magnitude of a given change in expression). Preferably, a candidate IMPDH inhibitor is identified as producing an expression pattern similar to a known IMPDH inhibitor if the two modulators exert the same qualitative effect (i.e., up-regulated or down-regulated) on a percentage of the modulated genes that is at least 50%, 60%, 70%, 75%, 80%, 90%, 95% or 99%.

Preferably, the effect is a clinical response. More particularly, the subject is a mammal, more specifically a human patient. The response also may be monitored in vitro in tissues or cells lines from a cancer patient. In the methods described herein the biological sample is preferably a sample from a cancer patient, and wherein said cancer is selected from the group consisting of myeloproliferative diseases, leukemia, breast cancer, ovarian cancer, gastric cancer, colorectal cancer, prostate cancer; pancreatic cancer, lung cancer, etc. The methods are such that the alteration of expression in response to said IMPDH inhibitory agent is preferably similar to the alteration in expression seen in response to administration of VX-944.

Preferably, the subject is a human patient. Or human cell lines or tissues or cells derived from cancers. More preferably, the subject is one who is suffering form a proliferative disorder. Where the proliferative disorder is cancer, the biological sample is a sample from a cancer patient, wherein said cancer is selected from the group consisting of myeloproliferative diseases, leukemia, breast cancer, ovarian cancer, gastric cancer, colorectal cancer, prostate cancer; pancreatic cancer, lung cancer, etc. The method may involve comparing the alteration of expression in response to said IMPDH agent to the level of alteration in expression seen in response to administration of VX-944.

Preferably, the sample is a tissue sample comprising cancer cells. The tissue or cells may be fixed, paraffin-embedded, fresh, or frozen. Preferably, the tissue is obtained through a biopsy, such as for example, a fine needle aspiration, bronchial lavage, or transbronchial biopsy. In specific embodiments, the expression level of said prognostic RNA transcript or transcripts is determined by PCR, immunohistochemistry, in situ hybridization, and the like. The assay for the measurement of said prognostic RNA transcripts or their expression products is provided in the form of a kit or kits.

Also contemplated is a method of preparing a prognostic profile for a subject's response to an IMPDH inhibitor comprising the steps of exposing ex vivo cells of said subject to an IMPDH inhibitor, subjecting RNA extracted from the cells of step (a) to gene expression profiling; determining the expression level of at least four genes selected from the group consisting of the genes set forth in Table I, Table II, Table III, Table IV, Table V, Table VI, Table VII and Table VIII in said cells; and comparing the expression levels obtained in step (c) to expression levels obtained in the absence of said IMPDH inhibitor, wherein a modulation of the expression level of said four or more of genes in response to said IMPDH inhibitor indicates that said subject is likely to be responsive to said inhibitor.

Also contemplated is a method of preparing a prognostic profile for a subject's response to an IMPDH inhibitor comprising the steps of administering to said subject to an IMPDH inhibitor; subjecting RNA extracted from the cells of said subject to gene expression profiling; determining the expression level of at least four genes selected from the group consisting of the genes set forth in Table I, Table II, Table III, Table IV, Table V, Table VI, Table VII and Table VIII in said cells of said subject; and comparing the expression levels obtained in step (c) to expression levels obtained in the absence of said administration of said IMPDH inhibitor, wherein a modulation of the expression level of said four or more of genes in response to said IMPDH inhibitor administration indicates that said IMPDH inhibitor will likely predict the subject's response to said IMPDH inhibitor administration. These methods can be used to monitor a response such as a therapeutic response, toxicity, dose range, and patient stratification.

In these methods, the cells may be cancer cells, e.g., cells selected from the group consisting of breast cancer, ovarian cancer, hematological cancer, gastric cancer, colorectal cancer, pancreatic cancer, and lung cancer. The cells can be fixed or may be from a fresh biopsy or may be from a cancer cell culture. In preferred embodiments, the cancer cells are cultured ex vivo. In the above methods the expression profile may be compiled into a report that includes recommendation for a treatment for said subject with an IMPDH inhibitor. In further embodiments, if altered expression of one or more of the genes selected from the genes set forth in Tables I, II, III, IV, V, VI, VII, and VIII, or the corresponding expression product is determined, said report includes a prediction that said subject is a suitable candidate for IMPDH inhibition-based therapy. In certain embodiments, the method may further comprise treating said patient with an IMPDH inhibitory agent. The biological sample used may be a blood sample, a tissue biopsy, or a tumor cell isolated from a tumor biopsy. The subset of genes could also be useful in conducting animal models or defining biomarkers in animal models used to determine efficacy or PK-PD correlation for IMPDH inhibitors.

The treatment method is one in which subject has been treated with any IMPDH inhibitor. In this regard, several IMPDH inhibitors have been used clinically and more are being developed for the treatment of immune cell-mediated, chronic inflammatory, antineoplatic and antiviral indications (Jain et al, 2001, Jain et al, 2002, Dhar et al, 2002). Mycophenolic acid (MPA), has been demonstrated to inhibit the proliferation of lymphocytes in vitro and in vivo (Eugui et al, 1991a, Allison and Eugui, 2000). An ester pro-drug of MPA, mycophenolate mofetil (CellCept®) is prescribed for the prevention of acute rejection in kidney, heart and liver transplantation (reviewed in Mele and Halloran, 2000), in combination with steroids and cyclosporine A (CsA). Mizoribine (Bredinin®) and ribavirin (Virazole®, Rebetol®) are nucleoside analogs which following intracellular phosphorylation are competitive IMPDH inhibitors (Franchetti and Grifantini, 1999, Saunders and Raybuck, 2000). Mizoribine is approved in Japan for multiple indications including prevention of rejection after renal transplantation, idiopathic glomerulonephritis, lupus nephritis, and rheumatoid arthritis (Ishikawa 1999). Ribavirin is used extensively as an inhaled antiviral agent for treatment of respiratory syncytial virus (RSV) and, orally in combination with interferon-a, for the treatment of chronic hepatitis C viral (HCV) infection (Davis et al 1998, McHutchison et al, 1998, Poynard et al 1998). Antineoplastic and antiviral activities of other nucleoside and NAD analogs, such as tiazofurin for the treatment of CML (reviewed in Jayaram et al, 1999), have been described but these are not yet clinically approved (reviewed in Saunders and Raybuck, 2000). The diverse therapeutic indications for these and other IMPDH inhibitors that are being developed illustrate the unmet clinical need for potent, reversible and lymphocyte-selective inhibitors that are safe, well-tolerated, and suitable for long-term dosing. The methods of the invention will facilitate such evaluations.

Also part of the invention are kits which comprise the nucleic acid arrays described herein in combination with appropriate containers, buffers, reagents and instructions for use in diagnostic and/or therapeutic methods. Such kits may further comprise nucleic acids of a reference subject as calibration standards. Further, the kits also may comprise detectable labels for the compositions of the invention.

Other features and advantages of the invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, because various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE DRAWING(S)

The following drawings form part of the present specification and are included to further illustrate aspects of the present invention. The invention may be better understood by reference to the drawings in combination with the detailed description of the specific embodiments presented herein.

FIG. 1 shows treatment comparisons in which it is observed that there are differences in gene expression (scatter) enhanced at 30 h compared to the 14 h time-point for VX-944 and Mycophenolic acid (MPA).

FIGS. 2A-2C provides % cv's for certain genes for various treatment groups (n=3). There is a heirarchical clustering of certain transcript profiles (data not shown).

FIG. 3 shows exemplary genes co-regulated by VX-944 and MPA.

FIG. 4 shows exemplary genes down-regulated by VX-944 at various time points of exposure.

FIG. 5 shows exemplary genes upregulated by MPA at various time points of exposure.

FIG. 6 shows additional exemplary genes upregulated by VX-944 at various time points of exposure.

FIG. 7 shows exemplary genes upregulated by both VX-944 and MPA at various time points of exposure.

FIG. 8 shows exemplary biomarkers of IMPDH inhibition.

FIG. 9 shows exemplary biomarkers of IMPDH inhibition segregated according to early and late biomarkers.

FIG. 10 shows QRT-PCR data that validates the data obtained using the gene chip data disclosed. These data were generated using expression patterns, impact of the inhibitors on specific pathways, high dynamic range, mechanistic relevance and cancer patient literature to select that candidate biomarker panel that will be useful. From these studies IL1RN (Interleukin 1 receptor antagonist), SPP1 (Secreted phosphoprotein 1), NCF1 (Autosomal chronic granulomatous disease-associated gene) and BCL2 (B-cell CLL/lymphoma 2—Anti-apoptosis marker) were selected as suitable candidate markers for IMPDH inhibition in HL-60 cells.

FIG. 11 shows that candidate marker responses to VX-944 can be monitored in human PBMCs. The same markers discussed above were used in the studies shown in this figure.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION

Traditional therapeutic monitoring of drugs involves the measurement of drug concentrations in patient blood. Several biochemical approaches to measure the biological effect of MPA or MMF (Langman et al 1995, Langman et al 1996, Griesmacher et al, 1997, Gummert et al, 1999, Albrecht et al, 2000, Budde et al, 2000, Qiu et al, 2000, Daxecker et al, 2001), mizoribine (Hirohata and Yamagida, 1995), and ribavirin (Fairbanks et al, 1995, Montero et al, 1995) have been described. In the present invention, the inventors have evaluated gene expression changes in response to VX-944 as an example of a potent and specific IMPDH inhibitor. MPA, a structurally unrelated but mechanistically similar IMPDH inhibitor, was included in some studies to compare its effect with VX-944. Given the similar mechanism of action of the two compounds, genes affected by both VX-944 and MPA are more likely to represent biomarkers for IMPDH inhibition. These results will be valuable in optimizing the dosing regimen and therapeutic benefit of IMPDH-based therapies in a broad range of therapeutic indication. Monitoring these patterns of gene expression changes are also likely to be predictive of a beneficial outcome with other unknown IMPDH pathway inhibitors. The gene expression changes observed with VX-944 and MPA may also allow selection of drugs that may enhance the effect of IMPDH inhibitors in combination treatments. Examples of gene expression changes have been published for Gleevec/STI-571. Based on the two compounds targeting two complementary pathways, we predict that a combination of the two agents is likely to be synergisitic in treating cancer.

The present invention is directed to methods and compositions for using biomarkers that are responsive to changes in IMPDH activity levels. More particularly, in certain preferred embodiments, the invention is directed to biomarkers that are responsive to IMPDH inhibition. In preferred aspects of the present invention there are provided nucleic acid arrays or sets of nucleic acids that are specifically up-regulated or down-regulated in response to IMPDH inhibition. Having identified these specific nucleic acids, it is now possible to prepare microarrays and specific collections of nucleic acids that may be used in order to identify additional IMPDH inhibitors, to verify that a known IMPDH inhibitor is exerting a desired effect in vitro or in vivo, and to provide a genetic profile of a subject under investigation in order to determine whether the individual is responsive to IMPDH inhibition. In one embodiment, the inventors obtained 18 gene chips that contained a total of 8793 genes on the arrays. Out of these 8793 genes there were 3421 genes that were common to all 18 gene chips. Of these, the inventors identified 1355 genes that were responsive to IMPDH inhibition. Gene sets 2 and 3 identified in the examples provided below contain the preferred subset of genes that are responsive to IMPDH inhibition. The following table summarizes the response of those genes to such inhibition and from these analyses the genes that were identified as particularly useful exemplary biomarkers for IMPDH inhibition are listed immediately beneath the table.

No. genes modulated by DMSO 32 No. genes modulated by MPA 75 Increased 39 Decreased 36 No. genes modulated by VX-944 106 Increased 46 Decreased 60 No. genes increased by both 62 No. genes decreased by both 63

Of the above genes, particularly useful exemplary biomarkers include, but are not limited to: ARF4; CCNE2; CGR19; CPR8; EDF1; GTF2F1; LGALS1; PDGFC; PSMC5; PTK9; RABGGTA; SCAP2; SERPINB2; TBPL1.

Monitoring gene expression patterns offers an alternative approach for optimizing the therapeutic window as compared with the traditional method of measuring drug concentrations in blood and correlating either the AUC or Cmax levels with a clinical response. Towards that end, the inventors have comprehensively evaluated several genes affected by treatment with two distinct IMPDH inhibitors in vitro, as potential readouts for assessing their biological activity. The genes that are listed in Tables I through VIII are particularly useful in the present invention. These genes were identified using the specific methods as follows: Most cell culture reagents, unless specified otherwise, were obtained from Gibco-BRL or JRH Biologicals. Complete RPMI was prepared by adding up to a final of 10% heat-inactivated fetal bovine serum (FBS), 55 μM β mercaptoethanol, 50 units/mL penicillin with 50 μg/mL streptomycin, 300 μg/ml L-glutamine and 10 mM HEPES pH 7.5 to RPMI1640. Stock solutions of Phyto-hemagglutinin (PHA-P, Difco) was prepared in FBS-free RPMI and stored at −20° C. VX-944, and MPA (Sigma-Aldrich or Calbiochem), were dissolved in DMSO at a concentration of 20 mM and stored at −20° C.

Peripheral blood mononuclear cells (PBMCs) and T cells were isolated as follows: Human venous blood was drawn from healthy volunteers using heparin as an anti-coagulant. PBMCs were isolated from blood by centrifugation over Ficoll-paque gradient or CPT tubes (Becton-Dickinson, Calif.), using standard conditions. PBMCs were harvested, washed and resuspended in complete RPMI, counted and diluted to 1×10⁶ cells/ml.

In order to monitor PBMC proliferation assay, human PBMC derived T cells (5×10⁴ cells/well), were added to 96-well plates. PHA was added up to a final concentration of 10-20 μg/mL per well for stimulating T cells. The mitogen SPAS was used at a final concentration of 2 mg/mL. DMSO was maintained at a final concentration of 0.1%.

The methods described here are standard techniques that can be implemented at many clinical laboratories. The readouts can be adapted further for pharmacodynamic monitoring of IMPDH inhibitors in a variety of therapeutic indications, ultimately helping to optimize their therapeutic window in patients.

The methods and compositions of the present invention will typically employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, and biochemistry, which are within the skill of the art. Such techniques are explained fully in the literature, such as, “Molecular Cloning: A Laboratory Manual”, 3rd edition (Sambrook et al., 2000); “Oligonucleotide Synthesis” (M. J. Gait, ed., 1984); “Animal Cell Culture” (R. I. Freshney, ed., 1987); “Methods in Enzymology” (Academic Press, Inc.); “Handbook of Experimental Immunology”, 4.sup.th edition (D. M. Weir & C. C. Blackwell, eds., Blackwell Science Inc., 1987); “Gene Transfer Vectors for Mammalian Cells” (J. M. Miller & M. P. Calos, eds., 1987); “Current Protocols in Molecular Biology” (F. M. Ausubel et al., eds., 1987); “PCR: The Polymnerase Chain Reaction”, (Mullis et al., eds., 1994); ); Current Protocols in Immunology.

Exemplary aspects of the present invention will involve partial and/or complete gene expression profiling of a patient in order to assess whether the patient has or will be responsive to IMPDH inhibition. Such gene expression profiling methods include methods based on hybridization analysis of polynucleotides, methods based on sequencing of polynucleotides, and proteomics-based methods. Common methods for the quantification of mRNA expression in a sample include northern blotting and in situ hybridization (Parker & Barnes, Methods in Molecular Biology 106:247-283 (1999)); RNAse protection assays (Hod, Biotechniques 13:852-854 (1992)); and PCR-based methods, such as reverse transcription polymerase chain reaction (RT-PCR) (Weis et al., Trends in Genetics 8:263-264 (1992)). Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. Representative methods for sequencing-based gene expression analysis include Serial Analysis of Gene Expression (SAGE), and gene expression analysis by massively parallel signature sequencing (MPSS).

PCR-based methods of expression profiling include, for example, RT-PCR, differential display (Liang and Pardee, Science 257:967-971 (1992)); amplified fragment length polymorphism (iAFLP) (Kawamoto et al., Genome Res. 12:1305-1312 (1999)); BeadArray™ technology (Illumina, San Diego, Calif.; Oliphant et al., Discovery of Markers for Disease (Supplement to Biotechniques), June 2002; Ferguson et al., Analytical Chemistry 72:5618 (2000)); BeadsArray for Detection of Gene Expression (BADGE), using the commercially available Luminex¹⁰⁰ LabMAP system and multiple color-coded microspheres (Luminex Corp., Austin, Tex.) in a rapid assay for gene expression (Yang et al., Genome Res. 11:1888-1898 (2001)); high coverage expression profiling (HiCEP) analysis (Fukumura et al., Nucl. Acids. Res. 31(16) e94 (2003)), and MassARRAY-based gene expression profiling method, which employs a mass spectrometry detection system.

A TaqMan assay is used to detect and optionally measure specific sequences in Polymerase Chain Reaction (PCR) products by employing the 5′Δ3′ exonuclease activity of Taq DNA polymerase. The TaqMan probe disabled from extension at the 3′ end, consists of a site-specific sequence labeled with a fluorescent reporter dye and a fluorescent quencher dye. During PCR the TaqMan probe set are derived from the genes of Tables I through VIII hybridizes to its complementary single stranded DNA sequence within the PCR target. When amplification occurs the TaqMan probe is degraded due to the 5′→3′ exonuclease activity of Taq DNA polymerase, thereby separating the quencher from the reporter during extension. Due to the release of the quenching effect on the reporter, the fluorescence intensity of the reporter dye increases. During the entire amplification process this light emission increases exponentially, the final level being measured by spectrophotometry after termination of the PCR. Because increase of the fluorescence intensity of the reporter dye is only achieved when probe hybridization and amplification of the target sequence has occurred, the TaqMan assay offers a sensitive method to determine the presence or absence of specific sequences. Therefore, this technique is particularly useful in diagnostic applications, such as the screening of samples for the presence or incorporation of favorable traits and the detection of pathogens and diseases. The TaqMan assay allows high sample throughput because no gel-electrophoresis is required for detection. Each TaqMan® Gene Expression Assay consists minimally of two unlabeled primers and a labeled probe. A more detailed description of this technique is contained in e.g., Bustin, S A. (2000). Journal of Molecular Endocrinology, 25: 169-193.

Sample preparation for use in analysis. In order to conduct sample analysis in the above gene expression profiling methods, a sample containing target polynucleotides is provided. The samples derived from can be any source containing target polynucleotides and obtained from any bodily fluid (blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or other tissue preparations. In preferred embodiments the target nucleic acid is obtained from a biological sample obtained from an individual that has undergone therapy based on IMPDH inhibition. In some embodiments, the expression profile of such a patient is obtained before and after IMPDH inhibition in order to assess the change in gene expression as a result of IMPDH therapy. Such expression profiling may be ongoing throughout the IMPDH therapy in order to assess whether the inhibition is having a sustained effect throughout the therapy.

DNA or RNA can be isolated from the biological sample according to any of a number of methods well known to those of skill in the art. In certain embodiments, the nucleic acid is isolated from a variety of primary tumors, including breast, lung, colorectal, prostate, brain, liver, kidney, pancreas, spleen, thymus, testis, ovary, uterus, etc., tumor, or tumor cell lines, with pooled DNA from healthy donors. More generally, the nucleic acid is isolated from hyperproliferative cells such as those found in immune system disorders such as transplant rejection and autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, juvenile diabetes, asthma, inflammatory bowel disease, as well as in the treatment of cancer and tumors, such as lymphomas and leukemia, vascular diseases, such as restenosis, and viral replication diseases, such as retroviral diseases, hepatitis C, and herpes. If the source of mRNA is a primary tumor or primary tissue from a hyperproliferative disorder, mRNA can be extracted, for example, from frozen or archived paraffin-embedded and fixed (e.g. formalin-fixed) tissue samples. Other methods of purification of nucleic acids are described in Tijssen (1993) Laboratory Techniques in Biochemistry and Molecular Biology: Hybridization With Nucleic Acid Probes, Part I. Theory and Nucleic Acid Preparation, Elsevier, New York N.Y. For example, total RNA is can be isolated using the TRIZOL reagent (Life Technologies, Gaithersburg Md.), and mRNA is isolated using oligo d(T) column chromatography or glass beads. Alternatively, when target polynucleotides are derived from an mRNA, the target polynucleotides can be a cDNA reverse transcribed from an mRNA to generate more stable cDNAs, an RNA transcribed from that cDNA, a DNA amplified from that cDNA, an RNA transcribed from the amplified DNA, and the like. When the target polynucleotide is DNA, it can be derived from a DNA source or from an RNA source by reverse transcription. In yet another embodiment, the targets are target polynucleotides prepared by more than one method.

General methods for mRNA extraction are well known in the art and are disclosed in standard textbooks of molecular biology, including Ausubel et al., Current Protocols of Molecular Biology, John Wiley and Sons (1997). Methods for RNA extraction from paraffin embedded tissues are disclosed, for example, in Rupp and Locker, Lab Invest. 56:A67 (1987), and De Andrs et al., BioTechniques 18:42044 (1995). In particular, RNA isolation can be performed using purification kit, buffer set and protease from commercial manufacturers, such as Qiagen™, according to the manufacturer's instructions. For example, total RNA from cells in culture can be isolated using Qiagen RNeasy mini-columns. Other commercially available RNA isolation kits include MasterPure™ Complete DNA and RNA Purification Kit (EPICENTRE®, Madison, Wis.), and Paraffin Block RNA Isolation Kit, (Ambion, Inc.). Total RNA from tissue samples can be isolated using RNA Stat-60 (Tel-Test). RNA prepared from tumor can be isolated, for example, by cesium chloride density gradient centrifugation. Note that as RNA cannot serve as a template for PCR, the first step in gene expression profiling by RT-PCR is the reverse transcription of the RNA template into cDNA, followed by its exponential amplification in a PCR reaction.

When target polynucleotides are amplified it is desirable to amplify the nucleic acid sample and maintain the relative abundances of the original sample, including low abundance transcripts. Total mRNA can be amplified by reverse transcription using a reverse transcriptase and a primer consisting of oligo d(T) and a sequence encoding the phage T7 promoter to provide a single-stranded DNA template. The second DNA strand is polymerized using a DNA polymerase and a RNAse (e.g., RNAse H) which assists in breaking up the DNA/RNA hybrid. After synthesis of the double-stranded DNA, T7 RNA polymerase can be added, and RNA transcribed from the second DNA strand template (Van Gelder et al. U.S. Pat. No. 5,545,522). RNA can be amplified in vitro, in situ or in vivo (See Eberwine U.S. Pat. No. 5,514,545).

Controls to quantitate the product may be included within the sample to assure that amplification and labeling procedures do not change the relative representation of target polynucleotides in a sample. For this purpose, a sample is spiked with a known amount of a control target polynucleotide and the composition of polynucleotide probes includes reference polynucleotide probes which specifically hybridize with the control target polynucleotides. After hybridization and processing, the hybridization signals obtained should reflect accurately the amounts of control target polynucleotide added to the sample.

Prior to hybridization, it may be desirable to fragment the nucleic acid target polynucleotides. Fragmentation improves hybridization by minimizing secondary structure and cross-hybridization to other nucleic acid target polynucleotides in the sample or noncomplementary polynucleotide probes. Fragmentation can be performed by mechanical or chemical means.

The target polynucleotides may be labeled with one or more labeling moieties to allow for detection of hybridized probe/target polynucleotide complexes. The labeling moieties can include compositions that can be detected by spectroscopic, photochemical, biochemical, bioelectronic, immunochemical, electrical, optical or chemical means. The labeling moieties include radioisotopes, such as ³²P, ³³P or ³⁵S, chemiluminescent compounds, labeled binding proteins, heavy metal atoms, spectroscopic markers, such as fluorescent. markers and dyes, magnetic labels, linked enzymes, mass spectrometry tags, spin labels, electron transfer donors and acceptors, and the like.

Exemplary dyes include quinoline dyes, triarylmethane dyes, phthaleins, azo dyes, cyanine dyes and the like. Preferably, fluorescent markers absorb light above about 300 nm, preferably above 400 nm, and usually emit light at wavelengths at least greater-than 10 nm above the wavelength of the light absorbed. Preferred fluorescent markers include fluorescein, phycoerythrin, rhodamine, lissamine, and C3 and C5 available from Amersham Pharmacia Biotech (Piscataway N.J.).

Labeling can be carried out during an amplification reaction, such as polymerase chain and in vitro transcription reactions, or by nick translation or 5′ or 3′-end-labeling reactions. When the label is incorporated after or without an amplification step, the label is incorporated by using terminal transferase or by kinasing the 5′ end of the target polynucleotide and then incubating overnight with a labeled oligonucleotide in the presence of T4 RNA ligase.

Alternatively, the labeling moiety can be incorporated after hybridization once a probe/target complex has formed.

Nucleic Acid Microarrays: The samples prepared above are hybridized to nucleic acid microarrays of the invention. An array of the invention typically will be a nucleic acid array consisting essentially of at least 4 polynucleotides selected from the polynucleotides listed in any one or more of Gene Tables I through Gene Table VIII, wherein said polynucleotides are immobilized on a solid surface, and wherein the array further contains one or more calibration points and one or more housekeeping genes.

The housekeeping genes are provided as controls for the chip so as to provide signals corresponding to nucleic acids that are constitutively expressed at a known level. These genes are presumed to produce the minimally essential transcripts necessary for normal cellular physiology, and are expressed at a similar level in almost all cells. These controls are useful in normalizing the data, for example to quantify expression levels. As a control gene, any known reference gene can be used, including, for example, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), β-actin, U-snRNP-associated cyclophilin (USA-CYP), ribosomal protein LPO; 18S ribosomal RNA; Glucoronidase beta; and Ribosomal protein L32. Alternatively, normalization can be achieved by correcting for differences between the total of all signals of the tested gene sets (global normalization strategy). The report may include a prognosis for the outcome of the treatment of the patient. The method may additionally comprise the step of treating the subject, e.g. a human patient, if a good prognosis is indicated.

The calibration spot is a signal that is contained on the microarray that will be used to ensure that the microarray is approprotately aligned and being read by a detection device. Typically, such a calibration spot comprises a mixture of the plurality of nucleic acids isolated from the sample that are known not to be modulated with IMPDH inhibition.

In the present invention, 5 or more nucleic acids selected from the distinct sequences of listed in Gene Tables I-VIII may be presented in a DNA microarray for the analysis and expression of these genes in various cell types. Microarray chips are well known to those of skill in the art (e.g., see U.S. Pat. No. 6,308,170; U.S. Pat. No. 6,183,698; U.S. Pat. No. 6,306,643; U.S. Pat. No. 6,297,018; U.S. Pat. No. 6,287,850; U.S. Pat. No. 6,291,183, each incorporated herein by reference. These are merely exemplary patents that disclose nucleic acid microarrays and those of skill in the art will be aware of numerous other methods and compositions for producing microarrays). Given the identification of the above nucleic acids that are specifically responsive to IMPDH inhibition it is possible to use commercially available microarray chips that contain probes that will hybridize to such nucleic acids regardless of any other nucleic acid probes contained on such chips. In this regard a preferred chip is the Affymetrix HG-FOCUS arrays (Affymetrix, CA catalog #900377).

The present invention provides for a composition comprising a plurality of polynucleotide probes for use in detecting changes in expression of a large number of genes from cells in response to IMPDH inhibition. As used in this section, the term “polynucleotide probe” refers to a nucleic acid that hybridize to any one of the nucleic acids listed in Tables I-VIII or hybridizes to any fragment thereof or any nucleic acid that hybridizes specifically to one such nucleic acid. Particularly preferred exemplary markers of IMPDH inhibition are provided in gene sets I through VIII. Other exemplary markers include ARF4; CCNE2; CGR19;CPR8; EDF1; GTF2F1; LGALS1; PDGFC; PSMC5; PTK9; RABGGTA; SCAP2; SERPINB2; TBPL1. Preferably the fragment is longer than 20 base pairs. Such a composition can be employed for the diagnosis and for monitoring the treatment of any disease in which abnormal IMPDH is found, and preferably diseases in which overexpression or increased activity of IMPDH is implicated. IMPDH-mediated disease refers to any disease state in which the IMPDH enzyme plays a regulatory role in the metabolic pathway of that disease. Examples of IMPDH-mediated diseases include transplant rejection and autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, juvenile diabetes, asthma, and inflammatory bowel disease, as well as inflammatory diseases, cancer, viral replication diseases and vascular diseases. In particular embodiments, the compositions of the invention may be used to monitor/track the treatment of transplant rejection (e.g., kidney, liver, heart, lung, pancreas (islet cells), bone marrow, cornea, small bowel and skin allografts and heart valve xenografts), rheumatoid arthritis, multiple sclerosis, juvenile diabetes, asthma, inflammatory bowel disease (Crohn's disease, ulcerative colitis), lupus, diabetes, mellitus myasthenia gravis, psoriasis, dermatitis, eczema, seborrhea, pulmonary inflammation, eye uveitis, hepatitis, Grave's disease, Hashimoto's thyroiditis, Behcet's or Sjorgen's syndrome (dry eyes/mouth), pernicious or immunohaemolytic anaemia, idiopathic adrenal insufficiency, polyglandular autoimmune syndrome, and glomerulonephritis, scleroderma, lichen planus, viteligo (depigmentation of the skin), autoimmune thyroiditis, and alveolitis, inflammatory diseases such as osteoarthritis, acute pancreatitis, chronic pancreatitis, asthma and adult respiratory distress syndrome, as well as in the treatment of cancer and tumors, such as solid tumors, lymphomas and leukemia, vascular diseases, such as restenosis, stenosis and atherosclerosis, and DNA and RNA viral replication diseases, such as retroviral diseases, and herpes.

A particularly useful composition of the present invention is a collection of hybridizable array elements in a microarray for monitoring the expression of a plurality of target polynucleofides. The microarray typically comprises a solid substrate and hybridizable array elements positioned on said substrate. The microarray can be used, for example, in the assessment of the efficacy of IMPDH inhibition on the treatment of a cancer, in immune disorders, in neuropathologies, and the like.

Tables I through VIII herein list the exemplary sequences disclosed herein as being responsive to IMPDH inhibition. In set I there are listed specific genes that are responsive to VX-944 in resting PBMC cells, i.e., genes from normal non-proliferating lymphocytes that were found to be specifically responsive (i.e., their expression levels were either increased or decreased) to VX-944. Gene set I can be described as a set of genes whose expression changes in changes in blood obtained from patients suffering from cancer, autoimmune, inflammatory diseases upon treatment with IMPDH inhibitors. These genes were: thrombospondin 1; interleukin 18 receptor 1; aldehyde dehydrogenase 1 family, member A1; complement component 1, q subcomponent, beta polypeptide; chitinase 3-like 1 (cartilage glycoprotein-39); BCR downstream signaling 1; XIAP associated factor-1; protein kinase N2; interferon-induced protein with tetratricopeptide repeats 5; CD38 antigen (p45); peroxisomal biogenesis factor 19; defensin, alpha 1, myeloid-related sequence; cleavage and polyadenylation specific factor 1, 160 kDa; hemochromatosis; chromosome 1 open reading frame 29; apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B; interferon, alpha-inducible protein 27; ubiquitin specific protease 18; interferon-induced protein with tetratricopeptide repeats 1; tissue inhibitor of metalloproteinase 2; myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse); chemokine (C-C motif) ligand 8; interferon regulatory factor 7; 2′-5′-oligoadenylate synthetase 3, 100 kDa; sialoadhesin; interferon-induced protein 44; myxovirus (influenza virus) resistance 2 (mouse); phospholipid scramblase 1; hect domain and RLD 5; interferon, alpha-inducible protein (clone IFI-6-16); interferon, alpha-inducible protein (clone IFI-15K); suppressor of cytokine signaling 1; chromosome 6 open reading frame 11; chemokine (C-C motif) ligand 13; chemokine (C-C motif) ligand 2; interleukin 1 receptor antagonist; chemokine (C-X-C motif) ligand 10; chemokine (C-X-C motif) ligand 9. The sequences of these genes are provided below in Table 1.

In set II there are listed specific genes that are responsive to VX-944 in resting or non-proliferating and proliferating cells. As such, these genes are those whose gene expression changes in normal human lymphocytes upon treatment with VX-944 or a mitogen or both mitogen and VX-944. This set was determined as follows: the genes altered by VX-944 administration alone in resting lymphocytes were identified by comparing genes altered in VX-944 treated cells as compared to untreated cells. These genes from resting cells were compared with gene expression profile seen in proliferating cells by comparing genes altered in HL60 cells treated with VX-944 compared to untreated HL60 cells. Subsequently, gene expression pattern changes attenuated in proliferating human lymphocytes in the presence of with VX-944 treatment were determined by comparing genes altered in PHA-treated cells compared to untreated cells as compared with genes altered by PHA+VX-944 treated cells. These genes were: chitinase 3-like 1 (cartilage glycoprotein-39) and interleukin 1 receptor antagonist. In gene set III, an assessment was made of the genes that are responsive to VX-944 in resting PBMC cells as well as in HL-60 cells and also genes that were responsive to MPA, another IMPDH inhibitor. These studies again showed that both chitinase 3-like 1 (cartilage glycoprotein-39) and interleukin 1 receptor antagonist are particularly responsive. As such, these two genes will be particularly predictive biomarkers of responsiveness of a given cell to IMPDH inhibition. Gene set II can be monitored in lymphocytes or blood obtained from cancer patients that have been treated with an IMPDH inhibitor such as VX-944.

Set IV shows the genes that could be monitored in proliferating cells from patients treated with VX-944. This set is typical of the gene expression changes that can be monitored in lymphocytes or blood obtained from cancer, autoimmune, transplant-patients, virally infected or otherwise diseased subjects that have been treated with VX-944. These genes represent a subset of genes that are up- or down-regulated in lymphocytes upon stimulation with a mitogen such as PHA (T1), that are modulated in the presence of VX-944.

These genes were identified by first inducing PBMC cells to proliferate, e.g., by stimulating the cells with PHA and determining which genes have an altered expression upon proliferation alone. The PBMC's also were analyzed to obtain the differential expression seen in response to both stimulation with PHA and treatment with VX-944. The overlap between the genes that were expressed in both sets of experiments is listed in Set IV as genes that should preferably be monitored in proliferating lymphocytes or cells of patients treated with VX-944. These genes are: RAD54 homolog B (homolog of S. cerevisiae); chemokine (C-C motif) ligand 2; kinesin family member 4A; spleen focus forming virus (SFFV) proviral integration oncogene spi1; chromosome condensation 1; Fc fragment of IgG, high affinity Ia, receptor for (CD64); asialoglycoprotein receptor 2; aurora kinase B; a disintegrin and metalloproteinase domain 28; growth arrest-specific 7; mucolipin 1; activator of S phase kinase; hexokinase 3 (white cell); nudix (nucleoside diphosphate linked moiety X)-type motif 1; Fc fragment of IgE, low affinity II, receptor for (CD23A); hemopoietic cell kinase; kinesin family member 11; SNARE protein Ykt6; 3-hydroxyisobutyryl-Coenzyme A hydrolase; cytochrome P450, family 1, subfamily B, polypeptide 1; chemokine (C motif) ligand 1; cyclin F; primase, polypeptide 2A, 58 kDa; Charcot-Leyden crystal protein; alpha-2-macroglobulin; exonuclease 1; CDC6 cell division cycle 6 homolog (S. cerevisiae); matrix metalloproteinase 1 (interstitial collagenase); protein regulator of cytokinesis 1; leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1; KIAA0146 protein; CDC28 protein kinase regulatory subunit 1B; baculoviral IAP repeat-containing 5 (survivin); Rac GTPase activating protein 1; zinc finger homeobox 1b; glycoprotein (transmembrane) nmb; IGF-II mRNA-binding protein 2; solute carrier family 27 (fatty acid transporter), member 2; cyclin-dependent kinase inhibitor 3 (CDK2-associated dual specificity phosphatase); chemokine (C-X3-C motif) receptor 1; sperm associated antigen 5; formyl peptide receptor 1; cadherin 3, type 1, P-cadherin (placental); origin recognition complex, subunit 1-like (homolog of yeast); chromosome condensation 1-like; protein tyrosine phosphatase, non-receptor type 12; myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (homolog of mouse); solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1; solute carrier family 7 (cationic amino acid transporter, y+ system), member 7; serine hydroxymethyltransferase 2 (mitochondrial); nuclear receptor subfamily 4, group A, member 2; CDC28 protein kinase regulatory subunit 2; aldehyde dehydrogenase 2 family (mitochondrial); matrix metalloproteinase 19; development and differentiation enhancing factor 2; dipeptidylpeptidase 3; aryl hydrocarbon receptor; chemokine (C-C motif) ligand 8; chromosome 1 open reading frame 29; tensin-like SH2 domain containing 1; killer cell lectin-like receptor subfamily F, member 1; tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor); cat eye syndrome chromosome region, candidate 1; splicing factor 1 [BLAST]; v-fos FBJ murine osteosarcoma viral oncogene homolog; pleckstrin homology-like domain, family A, member 1; geminin, DNA replication inhibitor; hyaluronan-mediated motility receptor (RHAMM); chromosome 1 open reading frame 33; regulator of G-protein signalling 2, 24 kDa; transforming growth factor, beta-induced, 68 kDa; serine/threonine kinase 6; Fc fragment of IgG, low affinity IIa, receptor for (CD32); ribonuclease T2; arachidonate 5-lipoxygenase; cytokine receptor-like factor 2; purinergic receptor P2Y, G-protein coupled, 5; chromobox homolog 5 (HP1 alpha homolog of Drosophila); inositol(myo)-1 (or 4)-monophosphatase 2; 2′-5′-oligoadenylate synthetase 3, 100 kDa; transcription factor EC; chondroitin sulfate proteoglycan 2 (versican); histone 1, H2ac; metallothionein 1X; aquaporin 3; apolipoprotein A-II; chemokine (C motif) ligand 1; RAD51 homolog (RecA homolog of E. coli) (homolog of S. cerevisiae); C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 5; TYRO protein tyrosine kinase binding protein; polymerase (DNA directed), epsilon 2 (p59 subunit); FBJ murine osteosarcoma viral oncogene homolog B; fucosyltransferase 8 (alpha (1,6) fucosyltransferase); CD14 antigen; GLI pathogenesis-related 1 (glioma); CD209 antigen; thymidine kinase 1, soluble; interleukin 9; dihydropyrimidine dehydrogenase; lectin, galactoside-binding, soluble, 2 (galectin 2); Kruppel-like factor 4 (gut); ribonucleotide reductase M2 polypeptide; proliferating cell nuclear antigen; cyclin B2; killer cell lectin-like receptor subfamily B, member 1; chemokine (C-C motif) receptor 1; syntaxin 11; mannose receptor, C type 1; lung type-I cell membrane-associated glycoprotein; guanidinoacetate N-methyltransferase; alanyl (membrane) aminopeptidase (aminopeptidase N, aminopeptidase M, microsomal aminopeptidase, CD13, p150); zinc finger protein 36, C3H type-like 1; 24-dehydrocholesterol reductase; hematological and neurological expressed 1; M-phase phosphoprotein 1; activation-induced cytidine deaminase; interleukin 1 receptor, type II; transforming growth factor, alpha; collagen, type VI, alpha 3; deoxythymidylate kinase (thymidylate kinase); pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 1; TTK protein kinase; ataxia telangiectasia mutated (includes complementation groups A, C and D); histidine decarboxylase; acyloxyacyl hydrolase (neutrophil); G protein-coupled receptor 77; serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2; solute carrier family 7, (cationic amino acid transporter, y+ system) member 11; splicing factor, arginine/serine-rich 1 (splicing factor 2, alternate splicing factor); glutaminyl-peptide cyclotransferase (glutaminyl cyclase); solute carrier family 16 (monocarboxylic acid transporters), member 6; CCAAT/enhancer binding protein (C/EBP), alpha; SKB1 homolog (S. pombe); v-myb myeloblastosis viral oncogene homolog (avian)-like 2; CDC42 effector protein (Rho GTPase binding) 1; integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macrophage antigen alpha polypeptide); centromere protein F, 350/400 ka (mitosin); cystatin C (amyloid angiopathy and cerebral hemorrhage); sialic acid binding Ig-like lectin 7; C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 14 (macrophage-derived); serum/glucocorticoid regulated kinase; uridine monophosphate kinase; Kruppel-like factor 2 (lung); fructose-1,6-bisphosphatase 1; neutrophil cytosolic factor 2 (65 kDa, chronic granulomatous disease, autosomal 2); frizzled homolog 2 (Drosophila); integrin, beta 7; interleukin 12 receptor, beta 2; colony stimulating factor 1 receptor, formerly McDonough feline sarcoma viral (v-fms) oncogene homolog; kinesin family member C3; N-acetylneuraminate pyruvate lyase (dihydrodipicolinate synthase); tensin; complement component 1, q subcomponent, receptor 1; leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4; kinesin-like 7; chemokine (C-C motif) ligand 7; myeloid cell nuclear differentiation antigen; BCL2/adenovirus E1B 19 kDa interacting protein 3; pituitary tumor-transforming 1; interferon-induced protein 44; chemokine (C-X-C motif) ligand 2; SLAM family member 8; transferrin receptor 2; integrin, alpha X (antigen CD11C (p150), alpha polypeptide); serine/threonine kinase 6; ficolin (collagen/fibrinogen domain containing) 1; chromodomain helicase DNA binding protein 1-like; Fc fragment of IgG, low affinity IIb, receptor for (CD32); secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1); CD86 antigen (CD28 antigen ligand 2, B7-2 antigen); achalasia, adrenocortical insufficiency, alacrimia (Allgrove, triple-A); polo-like kinase 1 (hormolog of Drosophila); ectonucleotide pyrophosphatase/phosphodiesterase 2 (autotaxin); nuclear receptor interacting protein 1; thymidylate synthetase; DNA replication complex GINS protein PSF2; CD9 antigen (p24); T-LAK cell-originated protein kinase; RAB31, member RAS oncogene family; centromere protein E, 312 kDa; ZW10 interactor; fibrinogen-like 2; bombesin-like receptor 3; matrix metalloproteinase 12 (macrophage elastase); dual specificity phosphatase 6; chemokine (C-X-C motif) ligand 3; MAD2 mitotic arrest deficient-like 1 (homolog of yeast); leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 2; CD72 antigen; cellular repressor of E1A-stimulated genes; CHK1 checkpoint homolog (homolog of S. pombe); interferon, gamma-inducible protein 30; ubiquitin-conjugating enzyme E2S; ribokinase; serine/threonine kinase 3 (STE20 homolog of yeast); v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (homolog of avian); exonuclease NEF-sp; vascular endothelial growth factor; stathmin 1/oncoprotein 18; MCM2 minichromosome maintenance deficient 2, mitotin (homolog of S. cerevisiae); ribonuclease, RNase A family, k6; G-protein signalling modulator 2 (AGS3-like, homolog of C. elegans); amylase, alpha 2B; pancreatic; tribbles homolog 1 (homolog of Drosophila); C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 6; Ig superfamily protein; baculoviral IAP repeat-containing 1; transgelin; kinesin family member 20A; interleukin 3 (colony-stimulating factor, multiple); oxidised low density lipoprotein (lectin-like) receptor 1; Similar to ribosomal protein L13a; 60S ribosomal protein L13a; 23 kD highly basic protein (LOC399810), mRNA [BLAST]; endoplasmic reticulum chaperone SIL1, homolog of yeast; telomerase-associated protein 1; Fc fragment of IgG, receptor, transporter, alpha; nerve growth factor receptor (TNFRSF 16) associated protein 1; BUB1 budding uninhibited by benzimidazoles 1 homolog (homolog of yeast); cyclin A2; BUB1 budding uninhibited by benzimidazoles 1 homolog beta (homolog of yeast); gamma-glutamyltransferase-like activity 1; immunoglobulin superfamily, member 6; hypothetical protein CG003; fer-1-like 3, myoferlin (homolog of C. elegans); cell division cycle 2, G1 to S and G2 to M; erythrocyte membrane protein band 4.1-like 3; cell division cycle 25C; thyroid hormone receptor interactor 13; thrombospondin 1; TPX2, microtubule-associated protein homolog (homolog of Xenopus laevis); CDC20 cell division cycle 20 homolog (homolog of S. cerevisiae); lymphotoxin beta receptor (TNFR superfamily, member 3); membrane-spanning 4-domains, subfamily A, member 4; polo-like kinase 4 (homolog of Drosophila); cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4); toll-like receptor 8; histamine N-methyltransferase; interleukin 3 receptor, alpha (low affinity); cathepsin L; transforming, acidic coiled-coil containing protein 3; sialyltransferase 4A (beta-galactoside alpha-2,3-sialyltransferase); exosome component 9; BRCA1 associated RING domain 1; reticulon 1; leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member. 1; Transcribed sequences; H2A histone family, member Z; RAD54-like (homolog of S. cerevisiae); chromosome condensation protein G; glutathione transferase zeta 1 (maleylacetoacetate isomerase); kinesin family member 2C; ubiquitin-conjugating enzyme E2C; spinocerebellar ataxia 1 (olivopontocerebellar ataxia 1, autosomal dominant, ataxin 1); v-myb myeloblastosis viral oncogene homolog (homolog of avian); thrombomodulin; centromere protein A, 17 kDa; cytochrome b-245, beta polypeptide (chronic granulomatous disease); endoglin (Osler-Rendu-Weber syndrome 1); formyl peptide receptor-like 2; nucleolar and spindle associated protein 1; tripartite motif-containing 26; BRCA2 and CDKN1A interacting protein; ubiquitin specific protease 18; acid phosphatase 5, tartrate resistant; metallothionein 1H; NIMA (never in mitosis gene a)-related kinase 2; dual specificity phosphatase 1; breast cancer 1, early onset; fatty acid desaturase 2; topoisomerase (DNA) II alpha 170 kDa; neuropilin 1; LIM domain only 2 (rhombotin-like 1); tissue inhibitor of metalloproteinase 2; oncostatin M; S100 calcium binding protein A9 (calgranulin B); chemokine (C-C motif) ligand 24; BTB and CNC homology 1, basic leucine zipper transcription factor 1; leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 3; ribonuclease, RNase A family, 1 (pancreatic); pro-platelet basic protein (chemokine (C-X-C motif) ligand 7); phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma). These genes are listed in Table IV. These genes will be useful in assessing treatment of cancer, autoimmune diseases, inflammatory diseases and the like by VX-944 and are likely to represent attenuation of proliferation by VX-944 in diseases where cell proliferation is implicated. A combination of gene set I and gene set IV reveals markers that can be monitored in hematological malignancies. By hematological malignancies the present application refers to any hematological cancer or hematological disorder that manifests in the proliferation or hyperproliferation of blood cells.

Set V provides a more select marker set of genes from set IV whose expression also is altered in response to VX-944 in AML or PML cancers or other diseases in which the proliferation of lymphocytes is implicated. Thus, gene expression changes that can be monitored in lymphocytes (PBMCs, blood) obtained from hematological cancers, or other diseases in which proliferation of lymphocytes is implicated in the presence of VX-944 to provide an assessment of the efficacy of VX-944 or IMPDH inhibition in general. This subset of genes includes: kinesin family member 4A; Fc fragment of IgG, high affinity Ia, receptor for (CD64); aurora kinase B; growth arrest-specific 7; solute carrier family 27 (fatty acid transporter), member 2; cyclin-dependent kinase inhibitor 3 (CDK2-associated dual specificity phosphatase); sperm associated antigen 5; formyl peptide receptor 1; chromosome condensation 1-like; tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor); pleckstrin homology-like domain, family A, member 1; hyaluronan-mediated motility receptor (RHAMM); regulator of G-protein signalling 2, 24 kDa; serine/threonine kinase 6; arachidonate 5-lipoxygenase; inositol(myo)-1(or 4)-monophosphatase 2; metallothionein IX; C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 5; ribonucleotide reductase M2 polypeptide; cyclin B2; chemokine (C-C motif) receptor 1; mannose receptor, C type 1; collagen, type VI, alpha 3; histidine decarboxylase; G protein-coupled receptor 77; serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2; CCAAT/enhancer binding protein (C/EBP), alpha; integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macrophage antigen alpha polypeptide); serum/glucocorticoid regulated kinase; neutrophil cytosolic factor 2 (65 kDa, chronic granulomatous disease, autosomal 2); N-acetylneuraminate pyruvate lyase (dihydrodipicolinate synthase); pituitary tumor-transforming 1; integrin, alpha X (antigen CD11C (p150), alpha polypeptide); serine/threonine kinase 6; polo-like kinase 1 (homolog of Drosophila); RAB31, member RAS oncogene family; CD72 antigen; interferon, gamma-inducible protein 30; v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (homolog of avian); tribbles homolog 1 (homolog of Drosophila); oxidised low density lipoprotein (lectin-like) receptor 1; BUB1 budding uninhibited by benzimidazoles 1 homolog beta (homolog of yeast); hypothetical protein CG003; CDC20 cell division cycle 20 homolog (homolog of S. cerevisiae); toll-like receptor 8; kinesin family member 2C; ubiquitin-conjugating enzyme E2C; v-myb myeloblastosis viral oncogene homolog (homolog of avian); centromere protein A, 17 kDa; cytochrome b-245, beta polypeptide (chronic granulomatous disease); nucleolar and spindle associated protein 1; metallothionein 1H; S100 calcium binding protein A9 (calgranulin B); and are listed herein below in Table V.

The genes in Table IV were further analysed and narrowed to those genes that are responsive to VX-944 and to the unrelated IMPDH inhibitor MPA to provide a subset of IV, that is further narrower than subset V by using genes commonly affected by both VX-944 and MPA in HL60 cells. This subset of genes included the following genes: kinesin family member 4A; Fc fragment of IgG, high affinity Ia, receptor for (CD64); growth arrest-specific 7; solute carrier family 27 (fatty acid transporter), member 2; cyclin-dependent kinase inhibitor 3 (CDK2-associated dual specificity phosphatase); sperm associated antigen 5; formyl peptide receptor 1; chromosome condensation 1-like; tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor); pleckstrin homology-like domain, family A, member 1; regulator of G-protein signalling 2, 24 kDa; arachidonate 5-lipoxygenase; inositol(myo)-1(or 4)-monophosphatase 2; metallothionein 1X; C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 5; ribonucleotide reductase M2 polypeptide; chemokine (C-C motif) receptor 1; collagen, type VI, alpha 3; histidine decarboxylase; serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2; integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macrophage antigen alpha polypeptide); serum/glucocorticoid regulated kinase; neutrophil cytosolic factor 2 (65 kDa, chronic granulomatous disease, autosomal 2); N-acetylneuraminate pyruvate lyase (dihydrodipicolinate synthase); integrin, alpha X (antigen CD11C (p150), alpha polypeptide); RAB31, member RAS oncogene family; CD72 antigen; interferon, gamma-inducible protein 30; v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (homolog of avian); tribbles homolog 1 (homolog of Drosophila); v-myb myeloblastosis viral oncogene homolog (homolog of avian); cytochrome b-245, beta polypeptide (chronic granulomatous disease); nucleolar and spindle associated protein 1; metallothionein 1H; S100 calcium binding protein A9 (calgranulin B); and the sequences of these genes are listed in Table VI.

VX-944 also has been used as an antiviral agent. Genes that are predictive of the antiviral efficacy of VX-944 are found in Set VII (see Table VII), which were identified as the subset of genes from set I which are also modified in response to interferon. These genes will be useful for monitoring gene expression changes that in lymphocytes (PBMCs, blood) obtained from patients suffering from viral diseases such as HCV, or other diseases in which interferon treatment is useful. These genes were: interferon, alpha-inducible protein (clone IFI-6-16); interferon, alpha-inducible protein (clone IFI-15K); interferon-induced protein with tetratricopeptide repeats 5; interferon-induced protein with tetratricopeptide repeats 1; interferon-induced protein 44; myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse); chemokine (C-C motif) ligand 2; chemokine (C-X-C motif) ligand 10; chemokine (C-X-C motif) ligand 9 and the sequences of these genes is provided in Table VII.

In set VIII there are listed the apoptosis genes that are responsive to VX-944. This is a narrower subset of genes from subset IV whose gene expression changes can predict beneficial response to VX-944 and be monitored in lymphocytes (PBMCs, blood) obtained from cancer patients. Out of the 67 genes implicated in cancers, 4 are down-regulated by VX-944 in proliferating lymphocytes. These genes will be predictive of the anti-cancer cancer efficacy of VX-944 in leukemias and/or solid tumors. The sequences of these genes are listed below in Table VIII.

Alternatively, the above subsets of genes may be segregated according to function and it may be desirable to prepare microarrays that will be useful in providing an indication of the effects of VX-944 or any other IMPDH inhibitor on a specific functional pathway. In this regard, genes involved in apoptosis and whose expression is altered in response to IMPDH inhibition are: nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105); TNF receptor-associated factor 2; TRK-fused gene; lymphotoxin alpha (TNF superfamily, member 1); inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon; nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; tumor necrosis factor receptor superfamily, member 5; tumor necrosis factor (ligand) superfamily, member 6; ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase); Fas (TNFRSF6)-associated via death domain; nerve growth factor, beta polypeptide; TNFRSF1A-associated via death domain; BH3 interacting domain death agonist; receptor (TNFRSF)-interacting serine-threonine kinase 1; tumor protein p53 (Li-Fraumeni syndrome); Mdm2, transformed 3T3 cell double minute 2, p53 binding protein (homolog of mouse); caspase 7, apoptosis-related cysteine protease; tumor necrosis factor (TNF superfamily, member 2); myeloid cell leukemia sequence 1 (BCL2-related); caspase 10, apoptosis-related cysteine protease; BCL2-related ovarian killer; tumor necrosis factor receptor superfamily, member 1A; baculoviral IAP repeat-containing 3; B-cell CLL/lymphoma 2; BCL2-associated X protein; TRK-fused gene; tumor necrosis factor receptor superfamily, member 1B; caspase 6, apoptosis-related cysteine protease; tumor necrosis factor (ligand) superfamily, member 10; caspase 9, apoptosis-related cysteine protease; protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase); TNF receptor-associated factor 6; cytochrome c, somatic; mitogen-activated protein kinase kinase 4; v-myc myelocytomatosis viral oncogene homolog (homolog of avian); BCL2-like 2; v-jun sarcoma virus 17 oncogene homolog (homolog of avian); BCL2-antagonist/killer 1; mitogen-activated protein kinase kinase kinase 14;splicing factor, arginine/serine-rich 2, interacting protein; caspase 2, apoptosis-related cysteine protease (neural precursor cell expressed, developmentally down-regulated 2); apoptotic protease activating factor; perforin 1 (pore forming protein); BCL2-antagonist of cell death; BCL2-related protein A1; harakiri, BCL2 interacting protein (contains only BH3 domain); tumor necrosis factor receptor superfamily, member 6; tumor necrosis factor (ligand) superfamily, member 5 (hyper-IgM syndrome); mitogen-activated protein kinase 10; TNF receptor-associated factor 3; TNF receptor-associated factor 1; caspase 8, apoptosis-related cysteine protease; granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1); baculoviral IAP repeat-containing 2; caspase 4, apoptosis-related cysteine protease; CASP2 and RIPK1 domain containing adaptor with death domain; caspase 1, apoptosis-related cysteine protease (interleukin 1, beta, convertase); DNA fragmentation factor, 45 kDa, alpha polypeptide; DNA fragmentation factor, 40 kDa, beta polypeptide (caspase-activated DNase); baculoviral IAP repeat-containing 4; inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma; caspase 3, apoptosis-related cysteine protease; nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor); v-rel reticuloendotheliosis viral oncogene homolog A, nuclear factor of kappa light polypeptide gene enhancer in B-cells 3, p65 (homolog of avian); nerve growth factor receptor (TNFR superfamily, member 16). Thus a microarray may be prepared to determine the efficacy of IMPDH inhibition by monitoring genes involved in apoptosis wherein the microarray comprises at least two or more of the above VX-944-responsive apoptosis-associated genes.

Genes involved in cellular metabolism that are responsive to VX-944 and IMPDH inhibition include: dehydrogenase/reductase (SDR family) member 4; dehydrogenase/reductase (SDR family) member 10; prion protein (p27-30) (Creutzfeld-Jakob disease, Gerstmann-Strausler-Scheinker syndrome, fatal familial insomnia); phosphomannomutase 1; arylsulfatase B; UDP glycosyltransferase 1 family, polypeptide A10; branched chain keto acid dehydrogenase E1, alpha polypeptide (maple syrup urine disease); 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1; chitinase 1 (chitotriosidase); ATPase, Ca++ transporting, plasma membrane 3; tyrosinase-related protein 1; 1-acylglycerol-3-phosphate O-acyltransferase 1 (lysophosphatidic acid acyltransferase, alpha); aldehyde dehydrogenase 1 family, member B1; dehydrogenase/reductase (SDR family) member 6; 3-hydroxyisobutyryl-Coenzyme A hydrolase; isocitrate dehydrogenase 3 (NAD+) alpha; pyruvate dehydrogenase complex, component X; 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2; galactokinase 2; pyruvate dehydrogenase (lipoamide) alpha 1; hydroxyprostaglandin dehydrogenase 15-(NAD); flightless I homolog (homolog of Drosophila); glutathione S-transferase M3 (brain); ATPase, H+/K+ exchanging, alpha polypeptide; ATPase, Ca++ transporting, type 2C, member 1; N-sulfoglucosamine sulfohydrolase(sulfamidase); aldehyde dehydrogenase 1 family, member A3; 5,10-methenyltetrahydrofolate synthetase(5-formyltetrahydrofolate cyclo-ligase); succinate-CoA ligase, ADP-forming, beta subunit; carboxypeptidase E; alkaline phosphatase, intestinal; chromodomain protein, Y-like; aldehyde dehydrogenase 5 family, member A1 (succinate-semialdehyde dehydrogenase); aldehyde dehydrogenase 4 family, member A1; branched chain aminotransferase 2, mitochondrial; isocitrate dehydrogenase 3 (NAD+) beta; acyl-CoA synthetase long-chain family member 3; hydroxysteroid (17-beta) dehydrogenase 4; ankyrin 2, neuronal; tryptophan hydroxylase 1 (tryptophan 5-monooxygenase); fibroblast growth factor 16; N-acetyltransferase 2 (arylamine N-acetyltransferase); solute carrier family 27 (fatty acid transporter), member 2; peroxisomal trans-2-enoyl-CoA reductase; phosphoserine aminotransferase 1; alanine-glyoxylate aminotransferase (oxalosis I; hyperoxaluria I; glycolicaciduria; serine-pyruvate aminotransferase); tafazzin (cardiomyopathy, dilated 3A (X-linked); endocardial fibroelastosis 2; Barth syndrome); liver-specific bHLH-Zip transcription factor; UDP glycosyltransferase 8 (UDP-galactose ceramide galactosyltransferase); pyruvate dehydrogenase (lipoamide) alpha 2; arylsulfatase A; alanine-glyoxylate aminotransferase (oxalosis I; hyperoxaluria I; glycolicaciduria; serine-pyruvate aminotransferase); ATPase, Na+/K+ transporting, alpha 1 polypeptide; arylsulfatase F; hydroxysteroid (17-beta) dehydrogenase 12; G protein-coupled receptor 56; phosphoribosyl pyrophosphate amidotransferase; eyes absent homolog 4 (homolog of Drosophila); hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), alpha subunit; lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase); family with sequence similarity 16, member A, X-linked; alkaline phosphatase, placental (Regan isozyme); acyl-CoA synthetase long-chain family member 1; alkaline phosphatase, liver/bone/kidney; eosinophil chemotactic cytokine; hydroxysteroid (11-beta) dehydrogenase 1; isocitrate dehydrogenase 2 (NADP+), mitochondrial; pyruvate carboxylase; galactosamine (N-acetyl)-6-sulfate sulfatase (Morquio syndrome, mucopolysaccharidosis type IVA); phenylalanine hydroxylase; matrix metalloproteinase 24 (membrane-inserted); nucleolar protein 5A (56 kDa with KKE/D repeat); phosphoglycerate mutase 2 (muscle); AU RNA binding protein/enoyl-Coenzyme A hydratase; retinol dehydrogenase 8 (all-trans); glutathione S-transferase A1; glutamine-fructose-6-phosphate transaminase 1; phosphatidylglycerophosphate synthase; WW domain containing oxidoreductase; serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 4; glutamine-fructose-6-phosphate transaminase 2; phosphoserine phosphatase; aspartoacylase (aminoacylase 2, Canavan disease); oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide); eyes absent homolog 3 (homolog of Drosophila); glyoxylate reductase/hydroxypyruvate reductase; aldehyde dehydrogenase 3 family, member B1; glutathione S-transferase M4; hydroxysteroid (17-beta) dehydrogenase 1; ATP citrate lyase; iduronate 2-sulfatase (Hunter syndrome); WW domain containing oxidoreductase; chitinase 3-like 1 (cartilage glycoprotein-39); propionyl Coenzyme A carboxylase, alpha polypeptide; dopachrome tautomerase (dopachrome delta-isomerase, tyrosine-related protein 2); inorganic pyrophosphatase 2; methylmalonyl Coenzyme A mutase; aldehyde dehydrogenase 1 family, member A2; hydroxysteroid (17-beta) dehydrogenase 3; chitobiase, di-N-acetyl-; ATPase, Ca++ transporting, cardiac muscle, slow twitch 2; UDP glycosyltransferase 2 family, polypeptide B17; selenocysteine lyase; ATPase, Ca++ transporting, ubiquitous; quinoid dihydropteridine reductase; peroxisomal D3,D2-enoyl-CoA isomerase; SA hypertension-associated homolog (homolog of rat); chromosome 1 open reading frame 10; insulin induced gene 1; NEL-like 1 (homolog of chicken); rTS beta protein; sepiapterin reductase (7,8-dihydrobiopterin:NADP+ oxidoreductase); phosphoserine phosphatase; pyrophosphatase (inorganic); branched chain aminotransferase 1, cytosolic; UDP glycosyltransferase 1 family, polypeptide A10; oviductal glycoprotein 1, 120 kDa (mucin 9, oviductin); chromosome 5 open reading frame 4; retinol dehydrogenase 5 (11-cis and 9-cis); chromosome 5 open reading frame 4; ATPase, Na+/K+ transporting, alpha 3 polypeptide; arylsulfatase D; dehydrogenase/reductase (SDR family) member 2; UDP glycosyltransferase 2 family, polypeptide A1; solute carrier family 27 (fatty acid transporter), member 5; glyceronephosphate O-acyltransferase; steroid sulfatase (microsomal), arylsulfatase C, isozyme S; acyl-CoA synthetase long-chain family member 1; glutathione S-transferase pi; aldehyde dehydrogenase 8 family, member A1; 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4; ATPase, Ca++ transporting, cardiac muscle, fast twitch 1; aconitase 1, soluble; hydroxysteroid (17-beta) dehydrogenase 7; 1-acylglycerol-3-phosphate O-acyltransferase 3; UDP-glucose pyrophosphorylase 2; chromosome 12 open reading frame 5; glutathione S-transferase M5; phospholipase D1, phophatidylcholine-specific; dehydrogenase/reductase (SDR family) member 8; phospholipase D2; fumarylacetoacetate hydrolase (fumarylacetoacetase); glutathione S-transferase omega 1; 3-hydroxysteroid epimerase; ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide; 2,4-dienoyl CoA reductase 1, mitochondrial; arylsulfatase E (chondrodysplasia punctata 1); 2,4-dienoyl CoA reductase 2, peroxisomal; E-1 enzyme; chitinase 3-like 2; solute carrier family 27 (fatty acid transporter), member 6; phosphoglycerate mutase 1 (brain); hydroxysteroid (17-beta) dehydrogenase 2; 1-acylglycerol-3-phosphate O-acyltransferase 4 (lysophosphatidic acid acyltransferase, delta); aldehyde dehydrogenase 3 family, member A1; iduronate 2-sulfatase (Hunter syndrome); UDP glycosyltransferase 1 family, polypeptide A10; dehydrogenase/reductase (SDR family) member 3; ATPase, Cu++ transporting, alpha polypeptide (Menkes syndrome); matrix metalloproteinase 24 (membrane-inserted); galactokinase 1; ATPase, Ca++ transporting, plasma membrane 1; isocitrate dehydrogenase 1 (NADP+), soluble; 1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid acyltransferase, beta); succinate-CoA ligase, GDP-forming, alpha subunit; glutathione S-transferase M1; glutathione S-transferase A4; UDP-N-acteylglucosamine pyrophosphorylase 1; glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease IIID); ATPase, Ca++ transporting, plasma membrane 4; glutathione S-transferase A3; fatty acid 2-hydroxylase; 1-acylglycerol-3-phosphate O-acyltransferase 1 (lysophosphatidic acid acyltransferase, alpha); dehydrogenase/reductase (SDR family) member 9; glutathione S-transferase M4; 3-oxoacid CoA transferase 1; sterol-C4-methyl oxidase-like; carboxylesterase 1 (monocyte/macrophage serine esterase 1); acetyl-Coenzyme A carboxylase alpha; acyl-CoA synthetase long-chain family member 5; methylcrotonoyl-Coenzyme A carboxylase 1 (alpha); UDP glycosyltransferase 1 family, polypeptide A10; hydroxysteroid (11-beta) dehydrogenase 2; COP9 constitutive photomorphogenic homolog subunit 8 (Arabidopsis); ATPase, H+/K+ transporting, nongastric, alpha polypeptide; integrin beta 4 binding protein; ATPase, Cu++ transporting, beta polypeptide (Wilson disease); eyes absent homolog 1 (homolog of Drosophila); 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3; asparagine synthetase; formiminotransferase cyclodeaminase; eyes absent homolog 2 (homolog of Drosophila); 2,3-bisphosphoglycerate mutase; amiloride binding protein 1 (amine oxidase (copper-containing)); alpha-methylacyl-CoA racemase; ubiquitin associated and SH3 domain containing, A; acetyl-Coenzyme A carboxylase beta; proprotein convertase subtilisin/kexin type 1; tyrosinase (oculocutaneous albinism IA); ATPase, Ca++ transporting, plasma membrane 2; dicarbonyl/L-xylulose reductase; phosphomannomutase 2; carbonyl reductase 3; arylacetamide deacetylase (esterase); carbonyl reductase 1; NFS1 nitrogen fixation 1 (homolog of S. cerevisiae). As such another contemplated microarray would be one which comprises two or more of the above genes to specifically monitor the efficacy of IMPDH inhibition on metabolic pathways in general.

Genes involved in the citric acid cycle that are responsive to VX-944 and IMPDH inhibition include: malate dehydrogenase 2, NAD (mitochondrial); isocitrate dehydrogenase 3 (NAD+) alpha; succinate dehydrogenase complex, subunit A, flavoprotein (Fp); isocitrate dehydrogenase 3 (NAD+) beta; dihydrolipoamide dehydrogenase (E3 component of pyruvate dehydrogenase complex, 2-oxo-glutarate complex, branched chain keto acid dehydrogenase complex); aconitase 2, mitochondrial; isocitrate dehydrogenase 3 (NAD+) gamma; succinate dehydrogenase complex, subunit B, iron sulfur (Ip); isocitrate dehydrogenase 2 (NADP+), mitochondrial; pyruvate carboxylase; fumarate hydratase; phosphoenolpyruvate carboxykinase 1 (soluble); oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide); aconitase 1, soluble; isocitrate dehydrogenase 1 (NADP+), soluble; malate dehydrogenase 1, NAD (soluble); succinate-CoA ligase, GDP-forming, alpha subunit. As such another contemplated microarray would be one which comprises two or more of the above genes to specifically monitor the efficacy of IMPDH inhibition on glycolysis and the citric acid cycle in general.

An array designed to monitor the IMPDH inhibition on genes involved in purine metabolism will advantageously determine the expression levels of two or more genes selected from the group consisting of adenosine monophosphate deaminase 2 (isoform L); hypoxanthine phosphoribosyltransferase 1 (Lesch-Nyhan syndrome); methylenetetrahydrofolate dehydrogenase (NADP+ dependent), methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate synthetase; adenosine kinase; adenylosuccinate synthase; IMP (inosine monophosphate) dehydrogenase 1; ATP-binding cassette, sub-family G (WHITE), member 1; phosphoribosyl pyrophosphate amidotransferase; cat eye syndrome chromosome region, candidate 1; thiopurine S-methyltransferase; solute carrier family 28 (sodium-coupled nucleoside transporter), member 2; phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase; adenosine monophosphate deaminase (isoform E); IMP (inosine monophosphate) dehydrogenase 2; adenosine monophosphate deaminase 1 (isoform M); phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase; adenylosuccinate lyase; nucleoside phosphorylase; 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase; 8-oxoguanine DNA glycosylase; guanine monphosphate synthetase; adenosine deaminase; adenine phosphoribosyltransferase. Specific microarrays comprising these genes are contemplated as part of the invention.

Another advantage array may be one which can be used to determine the expression levels of lysosomal enzymes that are altered in response to IMPDH inhibition. Such specific arrays may comprise two or more of the following genes: arylsulfatase B; prolylcarboxypeptidase (angiotensinase C); scavenger receptor class B, member 2; acid phosphatase 2, lysosomal; cystinosis, nephropathic; coronin, actin binding protein, 1A; lysosomal-associated membrane protein 2; CD63 antigen (melanoma 1 antigen); lysosomal-associated membrane protein 3.

An array for monitoring chemokines that are responsive to IMPDH inhibition will advantageously comprise a plurality of genes selected from the group consisting of: chemokine (C-X-C motif) ligand 14;chemokine (C-X-C motif) ligand 11; chemokine (C motif) ligand 1; chemokine-like factor; chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2); platelet factor 4 (chemokine (C-X-C motif) ligand 4); chemokine (C-C motif) receptor-like 1; chemokine (C-X3-C motif) ligand 1; Burkitt lymphoma receptor 1, GTP binding protein (chemokine (C-X-C motif) receptor 5); chemokine (C-X3-C motif) receptor 1; chemokine-like receptor 1; chemokine (C-X-C motif) receptor 6; chemokine (C-C motif) ligand 8; chemokine (C-C motif) ligand 25; chemokine (C motif) ligand 1; tumor necrosis factor receptor superfamily, member 1B; chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated); chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant); G protein-coupled receptor 17; chemokine binding protein 2; chemokine (C-C motif) ligand 3; chemokine (C-X-C motif) ligand 5; chemokine (C-C motif) ligand 1; chemokine (C-C motif) ligand 17; chemokine (C-C motif) receptor-like 2; chemokine(C-X-C motif) ligand 2; chemokine (C-C motif) ligand 20; cardiotrophin-like cytokine; chemokine (C-C motif) ligand 16; G protein-coupled receptor 2; chemokine (C-X-C motif) ligand 3; colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage); chemokine (C-C motif) ligand 27; chemokine (C-C motif) ligand 22; chemokine (C-C motif) ligand 15 [BLAST]; chemokine (C-C motif) ligand 21; chemokine (C-X-C motif) ligand 9; chemokine (C-C motif) ligand 19; chemokine (C-C motif) ligand 13; platelet factor 4 variant 1; chemokine (C-C motif) ligand 24; and interleukin 18 (interferon-gamma-inducing factor).

A cell-adhesion microarray that contains genes responsive to IMPDH inhibition also is part of the invention and will comprise a plurality of genes selected from the group consisting of: chemokine (C-C motif) ligand 2; protocadherin gamma subfamily C, 3; brain-specific angiogenesis inhibitor 1; cell adhesion molecule with homology to L1CAM (close homolog of L1); catenin (cadherin-associated protein), alpha 1, 102 kDa; sushi-repeat-containing protein, X-linked; EGF-like repeats and discoidin I-like domains 3; cadherin 1, type 1, E-cadherin (epithelial); Clone IMAGE:5301388, mRNA; Rho GTPase activating protein 5; retinal outer segment membrane protein 1; bystin-like; myelin associated glycoprotein; protein disulfide isomerase, pancreatic; limbic system-associated membrane protein; cadherin 17, LI cadherin (liver-intestine); poliovirus receptor-related 1 (herpesvirus entry mediator C; nectin); cadherin 9, type 2 (T1-cadherin); CD226 antigen; parvin, alpha; trophinin associated protein (tastin); protocadherin gamma subfamily C, 3; selectin P (granule membrane protein 140 kDa, antigen CD62); ephrin-B1; plakophilin 2; sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D; desmocollin 2; selectin E (endothelial adhesion molecule 1); cadherin, EGF LAG seven-pass G-type receptor 2 (flamingo homolog of Drosophila); calsyntenin 2; myosin binding protein C, cardiac; ARS component B; sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5A; neural precursor cell expressed, developmentally down-regulated 9; intercellular adhesion molecule 2; alpha-1-microglobulinlbikunin precursor; sialic acid binding Ig-like lectin 5; plakophilin 3; laminin, gamma 1 (formerly LAMB2); flotillin 2; integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide); myosin binding protein C, slow type; retinoschisis (X-linked, juvenile) 1; desmocollin 1; CD44 antigen (homing function and Indian blood group system); thrombospondin 2; fasciculation and elongation protein zeta 1 (zygin I); BH-protocadherin (brain-heart); protocadherin beta 12; leupaxin; insulin-like growth factor binding protein, acid labile subunit; pinin, desmosome associated protein; parvin, beta; chemokine (C-X3-C motif) ligand 1; scavenger receptor class B, member 2; amyloid beta (A4) precursor-like protein 1; Rho GDP dissociation inhibitor (GDI) alpha; parvin, beta; collagen, type V, alpha 3; sialophorin (gpL115, leukosialin, CD43); laminin, gamma 3; hyaluronan and proteoglycan link protein 2; collagen, type XIX, alpha 1; cadherin 15, M-cadherin (myotubule); chemokine (C-X3-C motif) receptor 1; laminin, alpha 2 (merosin, congenital muscular dystrophy); cadherin 3, type 1, P-cadherin (placental); bone gamma-carboxyglutamate (gla) protein (osteocalcin); lectin, galactoside-binding, soluble, 7 (galectin 7); protocadherin 11 X-linked; protocadherin alpha 2; chondroitin sulfate proteoglycan 4 (melanoma-associated); tumor necrosis factor (TNF superfamily, member 2); myosin binding protein H; TYRO3 protein tyrosine kinase; plakophilin 1 (ectodermal dysplasia/skin fragility syndrome); neuropilin 2; vascular cell adhesion molecule 1; acetylcholinesterase (YT blood group); erbb2 interacting protein; a disintegrin and metalloproteinase domain 2 (fertilin beta); polycystic kidney disease 1 (autosomal dominant); thrombospondin 4; multimerin 1; laminin, beta 3; cadherin 11, type 2, OB-cadherin (osteoblast); contactin 1; Lutheran blood group (Auberger b antigen included); protein tyrosine phosphatase, receptor type, U; catenin (cadherin-associated protein), alpha 2; desmoglein 3 (pemphigus vulgaris antigen); collagen, type XVI, alpha 1; chemokine (C-X-C motif) receptor 3; desmoglein 2; tenascin R (restrictin, janusin); growth arrest-specific 6; comeodesmosin; transforming growth factor, beta-induced, 68 kDa; collagen, type VIII, alpha 1; FXYD domain containing ion transport regulator 5; transforming growth factor beta 1 induced transcript 1; spondin 2, extracellular matrix protein; dystonin; intercellular adhesion molecule 3; DiGeorge syndrome critical region gene 2; collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive); CD99 antigen; L1 cell adhesion molecule (hydrocephalus, stenosis of aqueduct of Sylvius 1, MASA (mental retardation, aphasia, shuffling gait and adducted thumbs) syndrome, spastic paraplegia 1); laminin, beta 1; calcium and integrin binding 1 (calmyrin); collagen, type V, alpha 1; WNT1 inducible signaling pathway protein 1; cadherin 7, type 2; tissue specific transplantation antigen P35B; collagen, type XVIII, alpha 1; vinexin beta (SH3-containing adaptor molecule-1); desmocollin 3; brevican; protocadherin beta 6; collagen, type XV, alpha 1; cadherin, EGF LAG seven-pass G-type receptor 1 (flamingo homolog of Drosophila); amine oxidase, copper containing 3 (vascular adhesion protein 1); glycoprotein Ib (platelet), alpha polypeptide; CD209 antigen; integrin, alpha 7; trophoblast glycoprotein; pancreatitis-associated protein; crumbs homolog 1 (homolog of Drosophila); oligodendrocyte myelin glycoprotein; sialic acid binding Ig-like lectin 7; integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41B); discs, large homolog 5 (homolog of Drosophila); slit homolog 2 (homolog of Drosophila); NEL-like 2 (homolog of chicken); protocadherin beta 11; protocadherin alpha 2; nephronophthisis 1 (juvenile); neuroligin 3; intercellular adhesion molecule 5, telencephalin; protocadherin beta 5; collagen, type VI, alpha 3; phosphoglucomutase 5; contactin 2 (axonal); deleted in liver cancer 1; cadherin 5, type 2, VE-cadherin (vascular epithelium); slit homolog 3 (homolog of Drosophila); AE binding protein 1; ATPase, Ca++ transporting, cardiac muscle, slow twitch 2; chemokine (C-C motif) receptor 3; spastic paraplegia 7, paraplegin (pure and complicated autosomal recessive); myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog of Drosophila); translocated to, 4; CD209 antigen-like; heparan sulfate proteoglycan 2 (perlecan); activated leukocyte cell adhesion molecule; cadherin 12, type 2 (N-cadherin 2); PTK2B protein tyrosine kinase 2 beta; nidogen (enactin); chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1); glycoprotein V (platelet); discoidin domain receptor family, member 1; epithelial V-like antigen 1; chromosome 1 open reading frame 10; lectin, galactoside-binding, soluble, 3 binding protein; NEL-like 1 (homolog of chicken); neuronal cell adhesion molecule; amyloid beta (A4) precursor protein-binding, family A, member 1 (X11); melanoma cell adhesion molecule; sialic acid binding Ig-like lectin 7; protocadherin alpha 2; CD84 antigen (leukocyte antigen); colony stimulating factor 3 receptor (granulocyte); protocadherin 8; sialoadhesin; protein tyrosine phosphatase, receptor type, S; neural cell adhesion molecule 2; ectonucleoside triphosphate diphosphohydrolase 1; vitronectin (serum spreading factor, somatomedin B, complement S-protein); mesothelin; adhesion regulating molecule 1; coagulation factor V (proaccelerin, labile factor); intercellular adhesion molecule 1 (CD54), human rhinovirus receptor; protocadherin alpha 2; junction plakoglobin; chemokine (C-C motif) receptor 8; CD22 antigen; complement component 1, q subcomponent, receptor 1; neural cell adhesion molecule 1; protocadherin beta 1; aggrecan 1 (chondroitin sulfate proteoglycan 1, large aggregating proteoglycan, antigen identified by monoclonal antibody A0122); protocadherin alpha 2; integrin-binding sialoprotein (bone sialoprotein, bone sialoprotein II); CD33 antigen (gp67); stromal interaction molecule 1; armadillo repeat gene deletes in velocardiofacial syndrome; laminin, beta 2 (laminin S); signal-induced proliferation-associated gene 1; tetraspan 2; von Willebrand factor; elastin microfibril interfacer 1; reelin; endothelial differentiation, sphingolipid G-protein-coupled receptor, 1; protein tyrosine phosphatase, receptor type, F; protocadherin 9; cadherin 16, KSP-cadherin; alpha-2-glycoprotein 1, zinc; CD36 antigen (collagen type I receptor, thrombospondin receptor); symplekin; contactin 6; sialic acid binding Ig-like lectin 8; chondroitin sulfate proteoglycan 3 (neurocan); cadherin, EGF LAG seven-pass G-type receptor 2 (flamingo homolog of Drosophila); CD9 antigen (p24); nephrosis 1, congenital, Finnish type (nephrin); selectin L (lymphocyte adhesion molecule 1); natural killer cell transcript 4; FAT tumor suppressor homolog 1 (homolog of Drosophila); cadherin 8, type 2; coagulation factor VIII, procoagulant component (hemophilia A); integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 (mac-1) beta subunit); Kallmann syndrome 1 sequence; proline-serine-threonine phosphatase interacting protein 1; mucosal vascular addressin cell adhesion molecule 1; periostin, osteoblast specific factor; sarcospan (Kras oncogene-associated gene); hyaluronan binding protein 2; Rho family GTPase 1; catenin (cadherin-associated protein), delta 1; glycoprotein Ib (platelet), beta polypeptide; amyloid beta (A4) precursor protein (protease nexin-II, Alzheimer disease); protocadherin beta 8; junctional adhesion molecule 2; a disintegrin and metalloproteinase domain 22; CD72 antigen; tenascin C (hexabrachion); collectin sub-family member 10 (C-type lectin); vinculin; catenin (cadherin-associated protein), beta 1, 88 kDa; trophinin; catenin (cadherin-associated protein), delta 2 (neural plakophilin-related arm-repeat protein); vascular endothelial growth factor; protein tyrosine phosphatase, non-receptor type substrate 1; CD44 antigen (homing function and Indian blood group system); CD2 antigen (p50), sheep red blood cell receptor; cysteine-rich secretory protein 3; C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 6; cadherin 6, type 2, K-cadherin (fetal kidney); Usher syndrome 2A (autosomal recessive, mild); myosin binding protein C, fast type; cell adhesion molecule-related/down-regulated by oncogenes; fibronectin leucine rich transmembrane protein 3; scavenger receptor class B, member 1; carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 4; hyaluronan synthase 1; retinal degeneration, slow; roundabout, axon guidance receptor, homolog 1 (homolog of Drosophila); WNT1 inducible signaling pathway protein 2; chromosome 1 open reading frame 38; egf-like module containing, mucin-like, hormone receptor-like 1; immunoglobulin superfamily, member 1; tumor necrosis factor (ligand) superfamily, member 5 (hyper-IgM syndrome); desmoglein 1; intercellular adhesion molecule 4, Landsteiner-Wiener blood group; selectin P ligand; spastic paraplegia 7, paraplegin (pure and complicated autosomal recessive); claudin 1; leucine rich repeat neuronal 5; likely ortholog of mouse gene rich cluster, C10 gene; protocadherin beta 3; contactin associated protein 1; glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase; CD6 antigen; milk fat globule-EGF factor 8 protein; KIT ligand; calcium/calmodulin-dependent serine protein kinase (MAGUK family); zyxin; discoidin domain receptor family, member 2; adenomatosis polyposis coli; tetraspan 1; glycoprotein IX (platelet); thrombospondin 1; sialic acid binding Ig-like lectin 6; embryonal Fyn-associated substrate; protocadherin gamma subfamily C, 3; claudin 10; tumor necrosis factor, alpha-induced protein 6; lectin, galactoside-binding, soluble, 4 (galectin 4); FAT tumor suppressor homolog 2 (homolog of Drosophila); formyl peptide receptor-like 1; osteomodulin; carbohydrate sulfotransferase 10; Rho GDP dissociation inhibitor (GDI) beta; collagen, type VIII, alpha 1; neogenin homolog 1 (homolog of chicken); a disintegrin and metalloproteinase domain 10; protocadherin gamma subfamily C, 3; CD97 antigen; kininogen 1; protocadherin gamma subfamily C, 3; lymphocyte antigen 6 complex, locus D; cadherin 4, type 1, R-cadherin (retinal); lysyl oxidase-like 2; GDP-mannose 4,6-dehydratase; collagen, type XI, alpha 1; chemokine (C-C motif) ligand 11; RAB13, member RAS oncogene family; integrin beta 3 binding-protein (beta3-endonexin); protocadherin gamma subfamily C, 3; cartilage oligomeric matrix protein; DiGeorge syndrome critical region gene 6; spleen tyrosine kinase; connective tissue growth factor; cadherin, EGF LAG seven-pass G-type receptor 3 (flamingo homolog of Drosophila); scavenger receptor class F, member 1; hyaluronan and proteoglycan link protein 1; CD151 antigen; cadherin 2, type 1, N-cadherin (neuronal); neurotrimin; a disintegrin and metalloproteinase domain 12 (meltrin alpha); plexin C1; endoglin (Osler-Rendu-Weber syndrome 1); ret proto-oncogene (multiple endocrine neoplasia and medullary thyroid carcinoma 1, Hirschsprung disease); cadherin 19, type 2; immunoglobulin superfamily containing leucine-rich repeat; protocadherin gamma subfamily C, 3; protocadherin 12; dermatopontin; CD58 antigen, (lymphocyte function-associated antigen 3); ADAM-like, decysin 1; CD164 antigen, sialomucin; neurexin 3; tumor necrosis factor receptor superfamily, member 12A; PTK7 protein tyrosine kinase 7; cysteine-rich, angiogenic inducer, 61; CD34 antigen; protocadherin alpha 2; neuropilin 1; laminin, alpha 4; serum amyloid A2; nidogen 2 (osteonidogen); plakophilin 4; tuberous sclerosis 1; cadherin 18, type 2; transmembrane protein 8 (five membrane-spanning domains); macrophage erythroblast attacher; opioid binding protein/cell adhesion molecule-like; interleukin 18 (interferon-gamma-inducing factor); and ninjurin 2.

Glycosylation-associated genes that were found to be responsive to IMPDH inhibition and that could be used to prepare a microarray include: core 2 beta-1,6-N-acetylglucosaminyltransferase 3; sialyltransferase 8E (alpha-2,8-polysialyltransferase); mannosyl(alpha-1,6-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase; low density lipoprotein-related protein 2; glucosaminyl (N-acetyl) transferase 3, mucin type; mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase; UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-T1); stress-associated endoplasmic reticulum protein 1; transmembrane 4 superfamily member 5; lipase, hepatic; asparagine-linked glycosylation 3 homolog (yeast, alpha-1,3-mannosyltransferase); mannosyl(alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase; UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3; mannosidase, alpha, class 1A, member 1; UDP-glucose ceramide glucosyltransferase-like 2; mannosyl (beta-1,4-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase; sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase; GM3 synthase); fucosyltransferase 1 (galactoside 2-alpha-L-fucosyltransferase); fucosyltransferase 9 (alpha (1,3) fucosyltransferase); sialyltransferase 8D (alpha-2,8-polysialyltransferase); fucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-specific); asparagine-linked glycosylation 6 homolog (homolog of yeast, alpha-1,3-glucosyltransferase); ribophorin I; Kell blood group; low density lipoprotein receptor (familial hypercholesterolemia); UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 3; beta-1,3-glucuronyltransferase 1 (glucuronosyltransferase P); transmembrane 4 superfamily member 4; UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 4; tissue specific transplantation antigen P35B; UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 2 (GaINAc-T2); phosphatidylinositol glycan, class B; protein-O-mannosyltransferase 1; sialyltransferase 8C (alpha2,3Galbeta1,4GlcNAcalpha 2,8-sialyltransferase); sialyltransferase 1 (beta-galactoside alpha-2,6-sialyltransferase); ribophorin II; interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8); fucosyltransferase 7 (alpha (1,3) fucosyltransferase); UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 2; dolichyl-phosphate mannosyltransferase polypeptide 1, catalytic subunit; component of oligomeric golgi complex 2; fucosyltransferase 5 (alpha (1,3) fucosyltransferase); stromal cell-derived factor 2; integral membrane protein 1; sialyltransferase 8A (alpha-N-acetylneuraminate: alpha-2,8-sialyltransferase, GD3 synthase); galactose-3-O-sulfotransferase 1; glucosaminyl (N-acetyl) transferase 2, I-branching enzyme; protein-O-mannosyltransferase 2; O-linked N-acetylglucosamine (GIcNAc) transferase (UDP-N-acetylglucosamine:polypeptide-N-acetylglucosaminyl transferase); mannosidase, alpha, class 1C, member 1; UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 4; transmembrane 4 superfamily member 3; asparagine-linked glycosylation 5 homolog (homolog of yeast, dolichyl-phosphate beta-glucosyltransferase); UDP-glucose ceramide glucosyltransferase-like 1; transmembrane 4 superfamily member 2; mannosidase, alpha, class 1B, member 1; sialyltransferase 4C (beta-galactoside alpha-2,3-sialyltransferase); alpha-1,4-N-acetylglucosaminyltransferase; sialyltransferase 7 ((alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1,3)-N-acetyl galactosaminide alpha-2,6-sialyltransferase) B; CD37 antigen; fucosyltransferase 6 (alpha (1,3) fucosyltransferase); sialyltransferase 10 (alpha-2,3-sialyltransferase VI); UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1; CDNA clone IMAGE:5093665, partial cds; sialyltransferase 4A (beta-galactoside alpha-2,3-sialyltransferase); sialyltransferase 7 ((alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1,3)-N-acetyl galactosaminide alpha-2,6-sialyltransferase) E; glycophorin C (Gerbich blood group); glucosaminyl (N-acetyl) transferase 1, core 2 (beta-1,6-N-acetylglucosaminyltransferase); UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 1; mannosidase, alpha, class 2B, member 1; fucosyltransferase 3 (galactoside 3(4)-L-fucosyltransferase, Lewis blood group included); sialyltransferase 7D ((alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1,3)-N-acetyl galactosaminide alpha-2,6-sialyltransferase); lipase A, lysosomal acid, cholesterol esterase (Wolman disease); UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 5; sialyltransferase 8B (alpha-2,8-sialyltransferase); dolichyl-diphosphooligosaccharide-protein glycosyltransferase; dolichyl-phosphate mannosyltransferase polypeptide 2, regulatory subunit; phosphomannomutase 2; and glucosidase I.

Microarrays that comprise chemotaxis-associated genes that are responsive to IMPDH inhibition would advantageously include a plurality of genes selected from the group consisting of: chemokine (C-C motif) receptor 7; chemokine (C-C motif) ligand 2; chemokine (C-X-C motif) ligand 14;chemokine (C-X-C motif) ligand 11; interleukin 8; chemokine (C-C motif) receptor 9; chemokine (C motif) ligand 1; chemokine-like factor; interleukin 4; chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2); platelet factor 4 (chemokine (C-X-C motif) ligand 4); leukocyte cell-derived chemotaxin 2; chemokine (C-C motif) receptor-like 1; fibroblast growth factor 2 (basic); chemokine (C-X3-C motif) ligand 1; sialophorin (gpL115, leukosialin, CD43); plasminogen activator, urokinase receptor; chemokine (C-X3-C motif) receptor 1; chemokine-like receptor 1; chemokine (C-C motif) ligand 8; complement component 5; interleukin 8 receptor, beta; chemokine (C-C motif) ligand 25; azurocidin 1 (cationic antimicrobial protein 37); complement component 3a receptor 1; chemokine (C motif) receptor 1; chemokine (C-X-C motif) receptor 3; G protein-coupled receptor 77; phosphoinositide-3-kinase, catalytic, beta polypeptide; ribonuclease, RNase A family, 2 (liver, eosinophil-derived neurotoxin); chemokine (C motif) ligand 1; chemokine (C-C motif) receptor 5; chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated); slit homolog 2 (homolog of Drosophila); chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant); v-ral simian leukemia viral oncogene homolog A (ras related); chemokine (C-C motif) receptor 3; G protein-coupled receptor 77; chemokine binding protein 2; chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1); mitogen-activated protein kinase 14;chemokine (C-X-C motif) ligand 2; chemokine (C-X-C motif) ligand 5; chemokine (C-C motif) ligand 1; chemokine (C-C motif) ligand 17; chemokine (C-X-C motif) ligand 10; serine (or cysteine) proteinase inhibitor, clade D (heparin cofactor), member 1; chemokine (C-C motif) receptor 8; endothelial cell growth factor 1 (platelet-derived); chemokine (C-X-C motif) ligand 2; FOS-like antigen 1; secretogranin III; chemokine (C-C motif) ligand 23; interleukin 10; secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1); ectonucleotide pyrophosphatase/phosphodiesterase 2 (autotaxin); platelet-activating factor receptor; chemokine (C-C motif) ligand 20; chemokine (C-C motif) receptor 6; phospholipase D1, phophatidylcholine-specific; chemokine (C-C motif) ligand 16; Kallmann syndrome 1 sequence; chemokine (C-C motif) ligand 15; chemokine (C-X-C motif) ligand 3; roundabout, axon guidance receptor, homolog 3 (homolog of Drosophila); mitogen-activated protein kinase 1; ralA binding protein 1; plasminogen activator, urokinase; defensin, beta 4; roundabout, axon guidance receptor, homolog 1 (homolog of Drosophila); interleukin 16 (lymphocyte chemoattractant factor); chemokine (C-C motif) ligand 27; chemokine (C-C motif) ligand 22; formyl peptide receptor-like 1; small inducible cytokine subfamily E, member 1 (endothelial monocyte-activating); v-Ha-ras Harvey rat sarcoma viral oncogene homolog; Transcribed sequences; chemokine (C-C motif) ligand 11; spleen tyrosine kinase; chemokine (C-C motif) receptor 4; chemokine (C-C motif) ligand 21; chemokine (C-X-C motif) ligand 9; formyl peptide receptor-like 2; chemokine (C-C motif) ligand 19; mitogen-activated protein kinase kinase 1; chemokine (C-C motif) ligand 13; cysteine-rich, angiogenic inducer, 61; serum amyloid A2; chemokine (C-C motif) ligand 24; and pro-platelet basic protein (chemokine (C-X-C motif) ligand 7).

Microarrays that are specific for cell-cell signaling pathway response to IMPDH would include a plurality of genes selected from the group consisting of G protein-coupled receptor 50; glutamyl aminopeptidase (aminopeptidase A); chemokine (C-X-C motif) ligand 14;chemokine (C-X-C motif) ligand 11; vasoactive intestinal peptide; interferon, alpha 8; ephrin-A5; gap junction protein, beta 1, 32 kDa (connexin 32, Charcot-Marie-Tooth neuropathy, X-linked); interferon, alpha 10; a disintegrin and metalloproteinase domain 17 (tumor necrosis factor, alpha, converting enzyme); S100 calcium binding protein A6 (calcyclin); poliovirus receptor-related 1 (herpesvirus entry mediator C; nectin); netrin 1; interleukin 8; carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen); neuregulin 2; ephrin-B1; pan-hematopoietic expression; plakophilin 2; adrenergic, alpha-1A-, receptor; lymphotoxin alpha (TNF superfamily, member 1); interferon, gamma; fatty acid binding protein 1, liver; somatostatin receptor 3; wingless-type MMTV integration site family, member 4; chemokine (C motif) ligand 1; granulin; sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5A; leptin (obesity homolog of mouse); TGFB inducible early growth response; intercellular adhesion molecule 2; thioredoxin; tachykinin, precursor 1 (substance K, substance P, neurokinin 1, neurokinin 2, neuromedin L, neurokinin alpha, neuropeptide K, neuropeptide gamma); sonic hedgehog homolog (homolog of, Drosophila); chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2); tumor necrosis factor (ligand) superfamily, member 6; ephrin-A4; fibroblast growth factor 17; CD44 antigen (homing function and Indian blood group system); nerve growth factor, beta polypeptide; fibroblast growth factor 4 (heparin secretory transforming protein 1, Kaposi sarcoma oncogene); adrenergic, alpha-2C-, receptor; fibroblast growth factor 2 (basic); CD80 antigen (CD28 antigen ligand 1, B7-1 antigen); fibroblast growth factor 8 (androgen-induced); fibroblast growth factor 3 (murine mammary tumor virus integration site (v-int-2) oncogene homolog); myelin protein zero-like 1; fibroblast growth factor 16; gap junction protein, alpha 3, 46 kDa (connexin 46); adenosine A1 receptor; bone morphogenetic protein 10; tumor suppressor candidate 2; fibroblast growth factor 1 (acidic); thyrotropin-releasing hormone degrading ectoenzyme; tumor necrosis factor (TNF superfamily, member 2); bone morphogenetic protein 3 (osteogenic); gap junction protein, alpha 1, 43 kDa (connexin 43); colony stimulating factor 3 (granulocyte); vasoactive intestinal peptide receptor 2; proprotein convertase subtilisin/kexin type 5; vascular cell adhesion molecule 1; transforming growth factor, beta 3; tumor necrosis factor (ligand) superfamily, member 8; chemokine (C-C motif) ligand 8; ephrin-A1; somatostatin receptor 2; chorionic somatomammotropin hormone 1 (placental lactogen); IK cytokine, down-regulator of HLA II; tumor necrosis factor (ligand) superfamily, member 9; sprouty homolog 2 (homolog of Drosophila); fibroblast growth factor 6; motilin; TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and mucosal); cardiotrophin 1; FXYD domain containing ion transport regulator 5; WNT inhibitory factor 1; intercellular adhesion molecule 3; GRB2-related adaptor protein 2; gonadotropin-releasing hormone 1 (leutinizing-releasing hormone); estrogen receptor 2 (ER beta); bone morphogenetic protein 2; WNT1 inducible signaling pathway protein 1; steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2); calcitonin/calcitonin-related polypeptide, alpha; desmoplakin, tumor necrosis factor (ligand) superfamily, member 7; fibroblast growth factor 14;nitric oxide synthase 1 (neuronal); microsomal glutathione S-transferase 2; chemokine (C motif) ligand 1; thyrotropin-releasing hormone; protocadherin beta 6; interferon, alpha 4; epiregulin; proprotein convertase subtilisin/kexin type 2; CD209 antigen; chemokine (C-C motif) receptor 5; interleukin 9; nuclear receptor subfamily 5, group A, member 1; growth factor receptor-bound protein 10; crumbs homolog 1 (homolog of Drosophila); GRB2-related adaptor protein; pre-B-cell colony enhancing factor 1; chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated); discs, large homolog 5 (homolog of Drosophila); angiotensinogen (serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 8); fibroblast growth factor 20; protocadherin beta 11; interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8); nephronophthisis 1 (juvenile); ephrin-A2; somatostatin receptor 1; proprotein convertase subtilisin/kexin type 6; intercellular adhesion molecule 5, telencephalin; protocadherin beta 5; transforming growth factor, alpha; tumor necrosis factor (ligand) superfamily, member 10; chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant); phosphoglucomutase 5; adrenergic, alpha-1D-, receptor; proopiomelanocortin (adrenocorticotropin/beta-lipotropin/alpha-melanocyte stimulating hormone/beta-melanocyte stimulating hormone/beta-endorphin); thyroid stimulating hormone, beta; agouti signaling protein, nonagouti homolog (homolog of mouse); interferon, alpha 10; phosphate regulating endopeptidase homolog, X-linked (hypophosphatemia, vitamin D resistant rickets); placental growth factor, vascular endothelial growth factor-related protein; prostaglandin I2 (prostacyclin) receptor (IP); inhibin, alpha; c-mer proto-oncogene tyrosine kinase; lymphotoxin beta (TNF superfamily, member 3); myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog of Drosophila); translocated to, 4; CD209 antigen-like; endothelin 3; tumor necrosis factor receptor superfamily, member 11a, activator of NFKB; adrenergic, alpha-2B-, receptor; chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1); wingless-type MMTV integration site family, member 8B; tumor necrosis factor (ligand) superfamily, member 18; chromosome 1 open reading frame 10; SH2 domain containing phosphatase anchor protein 1; tumor necrosis factor (ligand) superfamily, member 4 (tax-transcriptionally activated glycoprotein 1, 34 kDa); interleukin 11; interleukin 6 (interferon, beta 2); neuronal cell adhesion molecule; endometrial bleeding associated factor (left-right determination, factor A; transforming growth factor beta superfamily); chemokine (C-X-C motif) ligand 5; protocadherin 8; sialoadhesin; adrenomedullin; chemokine (C-C motif) ligand 1; ectonucleoside triphosphate diphosphohydrolase 1; wingless-type MMTV integration site family, member 5A; chemokine (C-C motif) ligand 17; chemokine (C-X-C motif) ligand 10; amphiregulin (schwannoma-derived growth factor); intercellular adhesion molecule 1 (CD54), human rhinovirus receptor; complement component 1, q subcomponent, receptor 1; furin (paired basic amino acid cleaving enzyme); erythropoietin; endothelial cell growth factor 1 (platelet-derived); neuromedin B; interleukin 22; neural cell adhesion molecule 1; thyroid stimulating hormone receptor; CD33 antigen (gp67); stromal interaction molecule 1; sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4F; ephrin-B2; growth differentiation factor 5 (cartilage-derived morphogenetic protein-1); insulin; chemokine (C-C motif) ligand 23; fibroblast growth factor binding protein 1; interleukin 10; secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1); proenkephalin; CD86 antigen (CD28 antigen ligand 2, B7-2 antigen); fibroblast growth factor 13; lactalbumin, alpha-; stanniocalcin 2; steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1); wingless-type MMTV integration site family, member 3; stanniocalcin 1; chemokine (C-C motif) ligand 20; adenylate cyclase activating polypeptide 1 (pituitary); ephrin-B3; insulin-like 4 (placenta); FAT tumor suppressor homolog 1 (homolog of Drosophila); chemokine (C-C motif) ligand 16; nudix (nucleoside diphosphate linked moiety X)-type motif 3; interferon, alpha 21; integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 (mac-1) beta subunit); arginine vasopressin (neurophysin II, antidiuretic hormone, diabetes insipidus, neurohypophyseal); interferon, alpha 2; transcription factor AP-2 gamma (activating enhancer binding protein 2 gamma); interleukin 1 receptor-like 1 ligand; peptide YY; chemokine (C-C motif) ligand 15; WNT1 inducible signaling pathway protein 3; catenin (cadherin-associated protein), delta 1; junctional adhesion molecule 2; prostaglandin D2 synthase, hematopoietic; fibroblast growth factor 21; endothelin 1; CD44 antigen (homing function and Indian blood group system); CD2 antigen (p50), sheep red blood cell receptor; cysteine-rich secretory protein 3; discs, large (Drosophila) homolog-associated protein 1; endothelin 2; wingless-type MMTV integration site family, member 7A; carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 4; platelet-derived growth factor alpha polypeptide; membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase, CALLA, CD10); interleukin 3 (colony-stimulating factor, multiple); islet amyloid polypeptide; WNT1 inducible signaling pathway protein 2; interleukin 17B; major intrinsic protein of lens fiber; growth hormone releasing hormone; parathyroid hormone-like hormone; intercellular adhesion molecule 4, Landsteiner-Wiener blood group; ephrin-A3; protocadherin beta 3; sema domain, immunoglobulin domain,(Ig), short basic domain, secreted, (semaphorin) 3B; pro-melanin-concentrating hormone; neurotrophin 3; zyxin; interleukin 13; sialic acid binding Ig-like lectin 6; chemokine (C-C motif) ligand 27; interleukin 15; chorionic gonadotropin, beta polypeptide; Norrie disease (pseudoglioma); glycoprotein hormones, alpha polypeptide; tumor necrosis factor, alpha-induced protein 6; androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease); chemokine (C-C motif) ligand 22; bone marrow stromal cell antigen 2; midkine (neurite growth-promoting factor 2); fibroblast growth factor 9 (glia-activating factor); wingless-type MMTV integration site family, member 11; SH2 domain protein 1A, Duncan's disease (lymphoproliferative syndrome); discs, large (homolog of Drosophila) homolog-associated protein 2; neogenin homolog 1 (homolog of chicken); a disintegrin and metalloproteinase domain 10; fibroblast growth factor 1 (acidic); CD97 antigen; small inducible cytokine subfamily E, member 1 (endothelial monocyte-activating); SH2 domain protein 1A, Duncan's disease (lymphoproliferative syndrome); inhibin, beta A (activin A, activin AB alpha polypeptide); parathyroid hormone; jagged 2; collagen, type XI, alpha 1; chemokine (C-C motif) ligand 11; interleukin 1 family, member 9; complement component 1, q subcomponent, alpha polypeptide; leukemia inhibitory factor (cholinergic differentiation factor); chemokine (C-C motif) ligand 21; hydroxysteroid (11-beta) dehydrogenase 2; chemokine (C-X-C motif) ligand 9; adrenergic, alpha-1B-, receptor; cocaine- and amphetamine-regulated transcript; interferon, alpha-inducible protein (clone IFI-15K); fibroblast growth factor 5; CD58 antigen, (lymphocyte function-associated antigen 3); interleukin 7; anti-Mullerian hormone; chemokine (C-C motif) ligand 13; proprotein convertase subtilisin/kexin type 1; interleukin 1, beta; interleukin 26; neuropilin 1; oncostatin M; sorbin and SH3 domain containing 1; S100 calcium binding protein A9 (calgranulin B); chemokine (C-C motif) ligand 24; interleukin 18 (interferon-gamma-inducing factor); and insulin-degrading enzyme.

Microarrays affecting translation in response to IMPDH inhibitors would include a plurality of genes selected from the group consisting of methionine-tRNA synthetase; alanyl-tRNA synthetase; solute carrier family 22 (organic cation transporter), member 17; tyrosyl-tRNA synthetase; histidyl-tRNA synthetase; seryl-tRNA synthetase; phenylalanine-tRNA synthetase 1 (mitochondrial); N-acylaminoacyl-peptide hydrolase; valyl-tRNA synthetase 2; aminoacylase 1; aspartoacylase (aminoacylase 2, Canavan disease); isoleucine-tRNA synthetase; arginyl-tRNA synthetase; transcription factor binding to IGHM enhancer 3; lysyl-tRNA synthetase; phenylalanine-tRNA synthetase-like, alpha subunit; threonyl-tRNA synthetase; cysteinyl-tRNA synthetase; tryptophanyl tRNA synthetase 2 (mitochondrial); glycyl-tRNA synthetase; asparaginyl-tRNA synthetase; glutaminyl-tRNA synthetase; solute carrier family 22 (organic cation transporter), member 17; aspartyl-tRNA synthetase; small inducible cytokine subfamily E, member 1 (endothelial monocyte-activating); glutamyl-prolyl-tRNA synthetase; lysyl-tRNA synthetase; and tryptophanyl-tRNA synthetase.

Microarrays that are specific for genes required for mitochondrial function that are responsive to IMPDH would include a plurality of geres selected from the group consisting of succinate dehydrogenase complex, subunit C, integral membrane protein, 15 kDa; mitochondrial ribosomal protein L3; malate dehydrogenase 2, NAD (mitochondrial); hexokinase 2; uncoupling protein 3 (mitochondrial, proton carrier); death associated protein 3; 4-aminobutyrate aminotransferase; ubiquinol-cytochrome c reductase binding protein; mitochondrial ribosomal protein L12; mitochondrial intermediate peptidase; ubiquinol-cytochrome c reductase complex (7.2 kD); translocase of inner mitochondrial membrane 17 homolog A (yeast); ATP-binding cassette, sub-family F (GCN20), member 2; ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F6; solute carrier family 25 (mitochondrial carrier, brain), member 14; thiosulfate sulfurtransferase (rhodanese); cytochrome c oxidase subunit VIa polypeptide 2; BH3 interacting domain death agonist; aldehyde dehydrogenase 4 family, member A1; translocase of outer mitochondrial membrane 40 homolog (yeast); heat shock 60 kDa protein 1 (chaperonin); mercaptopyruvate sulfurtransferase; NADH dehydrogenase (ubiquinone) Fe—S protein 6, 13 kDa (NADH-coenzyme Q reductase); NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 8 kDa; mitochondrial ribosomal protein S12; glycerol kinase; NADH dehydrogenase (ubiquinone) Fe—S protein 4, 18 kDa (NADH-coenzyme Q reductase); myeloid cell leukemia sequence 1 (BCL2-related); NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 2, 14.5 kDa; translocase of inner mitochondrial membrane 22 homolog (homolog of yeast); acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain; solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 3; cytochrome c oxidase subunit Vb; popeye domain containing 2; peptidase (mitochondrial processing) beta; mitochondrial ribosomal protein L23; NADH dehydrogenase (ubiquinone) Fe—S protein 1, 75 kDa (NADH-coenzyme Q reductase); dynamin 1-like; translocase of inner mitochondrial membrane 13 homolog (yeast); NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6, 14 kDa; cytochrome c oxidase subunit VIa polypeptide 1; sarcosine dehydrogenase; B-cell CLL/lymphoma 2; voltage-dependent anion channel 1; 3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase (hydroxymethylglutaricaciduria); BCL2-associated X protein; NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1, 6 kDa; omithine aminotransferase (gyrate atrophy); camitine palmitoyltransferase II; solute carrier family 25 (mitochondrial oxodicarboxylate carrier), member 21; monoamine oxidase B; NADH dehydrogenase (ubiquinone) Fe—S protein 2, 49 kDa (NADH-coenzyme Q reductase); ornithine carbamoyltransferase; NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5, 16 kDa; ubiquinol-cytochrome c reductase core protein I; solute carrier family 25 (mitochondrial carrier; omithine transporter) member 15; surfeit 1; voltage-dependent anion channel 3; hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), beta subunit; translocase of inner mitochondrial membrane 8 homolog B (homolog of yeast); ubiquinol-cytochrome c reductase (6.4 kD) subunit; electron-transferring-flavoprotein dehydrogenase; NADH dehydrogenase (ubiquinone) Fe—S protein 8, 23 kDa (NADH-coenzyme Q reductase); NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3, 12 kDa; phosphoprotein enriched in astrocytes 15 [BLAST]; carbonic anhydrase VA, mitochondrial; NADH dehydrogenase (ubiquinone) Fe—S protein 5, 15 kDa (NADH-coenzyme Q reductase); inner membrane protein, mitochondrial (mitofilin); translocase of inner mitochondrial membrane 9 homolog (yeast); oxidase (cytochrome c) assembly 1-like; transcription factor A, mitochondrial; translocase of outer mitochondrial membrane 20 homolog (homolog of yeast); DnaJ (Hsp40) homolog, subfamily A, member 3; NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17 kDa; endothelial cell growth factor 1 (platelet-derived); hypothetical protein LOC114971; NADH dehydrogenase (ubiquinone) flavoprotein 1, 51 kDa; electron-transfer-flavoprotein, beta polypeptide; transcription factor A, mitochondrial; mitochondrial folate transporter/carrier; NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39 kDa; v-raf-1 murine leukemia viral oncogene homolog 1; ubiquinol-cytochrome c reductase core protein II; solute carrier family 25 (mitochondrial carrier; peroxisomal membrane protein, 34 kDa), member 17; NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8, 19 kDa; uncoupling protein 1 (mitochondrial, proton carrier); START domain containing 3; BCL2-antagonist/killer 1; nicotinamide nucleotide transhydrogenase; translocase of outer mitochondrial membrane 34; holocytochrome c synthase (cytochrome c heme-lyase); mitochondrial carrier family protein; ATP-binding cassette, sub-family B (MDR/TAP), member 8; BCL2-antagonist of cell death; cytochrome c oxidase subunit IV isoform 2; succinate dehydrogenase complex, subunit D, integral membrane protein; solute carrier family 25 (camitine/acylcamitine translocase), member 20; solute carrier family 25 (mitochondrial carrier; oxoglutarate carrier), member 11; translocase of inner mitochondrial membrane 17 homolog B (yeast); solute carrier family 25 (mitochondrial carrier, Aralar), member 12; uncoupling protein 2 (mitochondrial, proton carrier); NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 5, 13 kDa; cytochrome c-1; methylcrotonoyl-Coenzyme A carboxylase 1 (alpha); NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 4, 15 kDa; isovaleryl Coenzyme A dehydrogenase; mitochondrial ribosomal protein S15; benzodiazapine receptor (peripheral); fracture callus 1 homolog (homolog of rat); protein (peptidyl-prolyl cis/trans isomerase) NIMA-interacting, 4 (parvulin); cytochrome c oxidase subunit VIIb; metaxin 2; mitochondrial ribosomal protein L40; NADH dehydrogenase (ubiquinone) flavoprotein 2, 24 kDa; translocase of inner mitochondrial membrane 44 homolog (yeast); translocase of inner mitochondrial membrane 23 homolog (homolog of yeast); electron-transfer-flavoprotein, alpha polypeptide (glutaric aciduria II); solute carrier family 25, and member 13 (citrin).

Microarrays that are specific for genes from cGMP biosynthesis pathway that are responsive to IMPDH inhibitors would include a plurality of genes selected from the group consisting of guanylate cyclase 1, soluble, beta 3; natriuretic peptide receptor B/guanylate cyclase B (atrionatriuretic peptide receptor B); protein kinase, cGMP-dependent, type II; phosphodiesterase 6B, cGMP-specific, rod, beta (congenital stationary night blindness 3, autosomal dominant); phosphodiesterase 6C, cGMP-specific, cone, alpha prime; phosphodiesterase 6A, cGMP-specific, rod, alpha; guanylate cyclase 2F, retinal; natriuretic peptide receptor A/guanylate cyclase A (atrionatriuretic peptide receptor A); guanylate cyclase 1, soluble, alpha 2; phosphodiesterase 3B, cGMP-inhibited; phosphodiesterase 9A; phosphodiesterase 3B, cGMP-inhibited; guanylate cyclase 2D, membrane (retina-specific); phosphodiesterase 2A, cGMP-stimulated; cyclic nucleotide gated channel alpha 3; phosphodiesterase 6G, cGMP-specific, rod, gamma; phosphodiesterase 6H, cGMP-specific, cone, gamma; cyclic nucleotide gated channel alpha 1; and phosphodiesterase 3A, cGMP-inhibited.

Microarrays that are specific for genes from cAMP biosynthesis pathway that are responsive to IMPDH inhibitors would include a plurality of genes selected from the group consisting of phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog of Drosophila); cholinergic receptor, muscarinic 2; adenylate cyclase 7; protein kinase, cGMP-dependent, type I; adenylate cyclase 6; Rap guanine nucleotide exchange factor (GEF) 3; glucagon-like peptide 2 receptor; protein kinase, X-linked; melanocortin 4 receptor; adrenergic, beta-3-, receptor; calcitonin/calcitonin-related polypeptide, alpha; phosphodiesterase 4B, cAMP-specific (phosphodiesterase E4 dunce homolog, Drosophila); cAMP responsive element modulator; adenylate cyclase 3; calcium-binding tyrosine-(Y)-phosphorylation regulated (fibrousheathin 2); adrenergic, alpha-1D-, receptor; protein kinase, AMP-activated, gamma 1 non-catalytic subunit; cyclic nucleotide gated channel beta 1; chemokine (C-C motif) receptor 3; testicular soluble adenylyl cyclase; adenylate cyclase 8 (brain); phosphodiesterase 7B; protein kinase, cAMP-dependent, catalytic, alpha; adrenomedullin; Rap guanine nucleotide exchange factor (GEF) 2; A kinase (PRKA) anchor protein 4; adenylate cyclase 9; Rap guanine nucleotide exchange factor (GEF) 4; phosphodiesterase 4C, cAMP-specific (phosphodiesterase E1 dunce homolog of Drosophila); prostaglandin E receptor 4 (subtype EP4); G protein-coupled receptor kinase 5; protein kinase (cAMP-dependent, catalytic) inhibitor alpha; galanin receptor 2; protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1); arginine vasopressin receptor 2 (nephrogenic diabetes insipidus); protein kinase, cAMP-dependent, catalytic, beta; corticotropin releasing hormone receptor 2; growth hormone releasing hormone; parathyroid hormone-like hormone; adenosine A2a receptor; protein kinase, cAMP-dependent, regulatory, type II, alpha; corticotropin releasing hormone receptor 1; parathyroid hormone; hyperpolarization activated cyclic nucleotide-gated potassium channel 2; adrenergic, alpha-1B-, receptor; ret proto-oncogene (multiple endocrine neoplasia and medullary thyroid carcinoma 1, Hirschsprung disease); phosphodiesterase 4A, cAMP-specific (phosphodiesterase E2 dunce homolog of Drosophila); protein kinase, cAMP-dependent, regulatory, type II, beta; and protein kinase (cAMP-dependent, catalytic) inhibitor gamma.

The term “microarray” refers to an ordered arrangement of hybridizable array elements (i.e., the above-described polynucleotide probes). The array elements are arranged so that there are preferably at least one or more different array elements, more preferably at least 100 array elements, and most preferably at least 1,000 array elements, on a 1 cm² substrate surface. The hybridization signal from each of the array elements is individually distinguishable. In a preferred embodiment, the array elements comprise polynucleotide probes.

A “polynucleotide” refers to a chain of nucleotides, preferably a single-stranded chain. Preferably, the chain has from about 75 to 10,000 nucleotides, more preferably from about 100 to 3,500 nucleotides. The term “probe” refers to a polynucleotide sequence capable of hybridizing with a target sequence to form a polynucleotide probe/target complex. A “target polynucleotide” refers to a chain of nucleotides to which a polynucleotide probe can hybridize by base pairing. In some instances, the sequences will be complementary (no mismatches) when aligned. In other instances, there may be up to a 10%. mismatch.

A “plurality” is given its ordinary meaning of 2 or more. In the present context, a plurality of polynucleotide probes (elements) refers preferably to a group of at least least 4, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 200, 300 or more polynucleotides or more elements, more preferably to a group of at least about 100, and even more preferably to a group of at least about 1,000, elements. The maximum number of members is unlimited, but is at least about 100,000 members.

The term “gene” or “genes” refers to polynucleotide sequence of a gene which may be the partial or complete gene and may comprise regulatory, untranslated, or coding regions.

The microarray can be used for large-scale genetic or gene expression analysis of a number of target polynucleotides. The microarray can also be used in the diagnosis of diseases and in the monitoring of treatments. Further, the microarray can be employed to investigate an individual's predisposition to a disease. Furthermore, the microarray can be employed to investigate cellular responses to carcinogens, mitogens, drug treatment, and the like.

The hybridizable array elements in a microarray of the invention may be organized in an ordered fashion so that each element is present at a specified location on the substrate. As such, each of the nucleic acids on the array will have its own “address” such that hybridization to that nucleic acid will allow specific identification of the complementary nucleic acid in a biological sample. Because the array elements are at specified locations on the substrate, the hybridization patterns and intensities can be interpreted in terms of expression levels of particular genes. Collectively, the expression profile obtained with the microarrays of the invention are tightly correlated to a particular disease or condition or treatment. Hence, the invention provides dramatically enhanced reliability in profiling and obtaining prognostic indicators of response to IMPDH inhibition.

The composition comprising a plurality of polynucleotide probes can also be used to purify a subpopulation of mRNAs, cDNAs, genomic fragments and the like, in a sample. This may be particularly useful in identifying subsets of the above-identified nucleic acids that are more highly indicative of modulated/abnormal IMPDH activity.

The nucleic acids identified herein as being responsive to IMPDH inhibition will be used in microarray production and can be genomic DNA or cDNA or mRNA, or any RNA-like or DNA-like material, such as peptide nucleic acids, branched DNAs and the like. The polynucleotide probes can be sense or antisense polynucleotide probes. Where target polynucleotides are double-stranded, the probes may be either sense or antisense strands. Where the target polynucleotides are single-stranded, the nucleotide probes are complementary single strands.

In one embodiment, the polynucleotide probes are cDNAs. The size of the DNA sequence of interest may vary and is preferably from 20 to 10,000 nucleotides, more preferably from 20 to 200 nucleotides. The polynucleotide probes can be prepared by a variety of synthetic or enzymatic schemes which are well known in the art. The probes can be synthesized, in whole or in part, using chemical methods well known in the art Caruthers et al. (1980) Nucleic Acids Res. Symp. Ser. 215-233). Alternatively, the probes can be generated, in whole or in part, enzymatically.

Nucleotide analogues can be incorporated into the polynucleotide probes by methods well known in the art. The only requirement is that the incorporated nucleotide analogues must serve to base pair with target polynucleotide sequences. For example, certain guanine nucleotides can be substituted with hypoxanthine which base pairs with cytosine residues. However, these base pairs are less stable than those between guanine and cytosine. Alternatively, adenine nucleotides can be substituted with 2,6-diaminopurine which can form stronger base pairs than those between adenine and thymidine.

Additionally, the polynucleotide probes can include nucleotides that have been derivatized chemically or enzymatically. Typical chemical modifications include derivatization with acyl, alkyl, aryl or amino groups.

The polynucleotide probes can be immobilized on a substrate. Preferred substrates are any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which the polynucleotide probes are bound. Preferably, the substrates are optically transparent.

Complementary DNA (cDNA) can be arranged and then immobilized on a substrate. The probes can be immobilized by covalent means such as by chemical bonding procedures or UV. In one such method, a cDNA is bound to a glass surface which has been modified to contain epoxide or aldehyde groups. In another case, a cDNA probe is placed on a polylysine coated surface and then UV cross-linked (Shalon et al. PCT publication WO95/35505, herein incorporated by reference). In yet another method, a DNA is actively transported from a solution to a given position on a substrate by electrical means (Heller et al. U.S. Pat. No. 5,605,662). Alternatively, individual DNA clones can be gridded on a filter.

Furthermore, the probes do not have to be directly bound to the substrate, but rather can be bound to the substrate through a linker group. The linker groups are typically about 6 to 50 atoms long to provide exposure to the attached polynucleotide probe. Preferred linker groups include ethylene glycol oligomers, diamines, diacids and the like. Reactive groups on the substrate surface react with one of the terminal portions of the linker to bind the linker to the substrate. The other terminal portion of the linker is then functionalized for binding the polynucleotide probe.

The polynucleotide probes can be attached to a substrate by dispensing reagents for probe synthesis on the substrate surface or by dispensing preformed DNA fragments or clones on the substrate surface. Typical dispensers include a micropipette delivering solution to the substrate with a robotic system to control the position of the micropipette with respect to the substrate. There can be a multiplicity of dispensers so that reagents can be delivered to the reaction regions simultaneously.

Hybridization of Nitcleic Acids from Biological Sample to Microarray. In order to detect the presence of a given nucleic acid in a biological sample it will be desirable to hybridize the nucleic acid isolated from that sample to the microarray. Hybridization causes a denatured polynucleotide probe and a denatured complementary target to form a stable duplex through base pairing. Hybridization methods are well known to those skilled in the art (See, e.g., Ausubel (1997; Short Protocols in Molecular Biology, John Wiley & Sons, New York N.Y., units 2.8-2.11, 3.18-3.19 and 4-6-4.9). Conditions can be selected for hybridization where exactly complementary target and polynucleotide probe can hybridize, i.e., each base pair must interact with its complementary base pair. Alternatively, conditions can be selected where target and polynucleotide probes have mismatches but are still able to hybridize. Suitable conditions can be selected, for example, by varying the concentrations of salt in the prehybridization, hybridization and wash solutions, or by varying the hybridization and wash temperatures. With some membranes, the temperature can be decreased by adding formamide to the prehybridization and hybridization solutions.

Hybridization can be performed at low stringency with buffers, such as 6 x SSPE with 0.005% Triton X-100 at 37° C., which permits hybridization between target and polynucleotide probes that contain some mismatches to form target polynucleotide/probe complexes. Subsequent washes are performed at higher stringency with buffers, such as 0.5×SSPE with 0.005% Triton X-100 at 50° C., to retain hybridization of only those target/probe complexes that contain exactly complementary sequences. Alternatively, hybridization can be performed with buffers, such as 5×SSC/0.2% SDS at 60° C. and washes are performed in 2×SSC/0.2% SDS and then in 0.1×SSC. Background signals can be reduced by the use of detergent, such as sodium dodecyl sulfate, Sarcosyl or Triton X-100, or a blocking agent, such as salmon sperm DNA.

After hybridization, the microarray is washed to remove nonhybridized nucleic acids, and complex formation between the hybridizable array elements and the target polynucleotides is detected. Methods for detecting complex formation are well known to those skilled in the art. In a preferred embodiment, the target polynucleotides are labeled with a fluorescent label, and measurement of levels and patterns of fluorescence indicative of complex formation is accomplished by fluorescence microscopy, preferably confocal fluorescence microscopy. An argon ion laser excites the fluorescent label, emissions are directed to a photomultiplier, and the amount of emitted light is detected and quantitated. The detected signal should be proportional to the amount of probe/target polynucleotide complex at each position of the microarray. The fluorescence microscope can be associated with a computer-driven scanner device to generate a quantitative two-dimensional image of hybridization intensity. The scanned image is examined to determine the abundance/expression level of each hybridized target polynucleotide.

Typically, microarray fluorescence intensities can be normalized to take into account variations in hybridization intensities when more than one microarray is used under similar test conditions. In a preferred embodiment, individual polynucleotide probe/target complex hybridization intensities are normalized using the intensities derived from internal normalization controls contained on each microarray.

Microarray Expression Profiles. As discussed above an important aspect of the present invention is a method of obtaining an expression profile, using the microarray compositions of the invention, of a subject that has or is about to undergo therapy based on IMPDH inhibition. The expression profile can be used to detect changes in the expression of genes in response to such inhibition and to provide a prognosis of a patient's response to an IMPDH inhibitor comprising the steps of: (a) subjecting RNA extracted from the cells obtained from the patient to gene expression analysis on one of the microarrays of the invention in the presence and absence of said IMPDH inhibitor. In doing so, the expression level of at least one gene selected from the genes in Tables I through VIII is determined and compared to the amount of expression found in a corresponding reference tissue set that has not been treated with an IMPDH inhibitor. Subsequently, a report summarizing the data obtained by such gene expression analysis can be prepared and used to determine whether the patient will likely be responsive to IMPDH inhibition.

The expression profile comprises determining the level of expression the nucleic acids that have been identified herein as being responsive to IMPDH inhibition and may further involve categorizing said nucleic acids into functional categories (e.g., the gene has a cell-cycle function, a cell proliferation function, is involved in lipid metabolism some other metabolic pathway, and the like). It is contemplated that at least one of the nucleic acids identified herein, and preferably a plurality thereof, is hybridized to a complementary target polynucleotide forming at least one, and preferably a plurality, of complexes. A complex is preferably detected by incorporating at least one labeling moiety in the complex as described above. The expression profiles provide “snapshots” that can show unique expression patterns that are characteristic of that individual's response to IMPDH inhibition.

After performing hybridization experiments and interpreting detected signals from a microarray, particular polynucleotide probes can be identified and selected based on their expression patterns (e.g., those that are consistently and dramatically up- or down-regulated upon IMPDH inhibition). Such polynucleotide probe sequences can be used to clone a full length sequence of the gene for further analysis, provide an alternative diagnostic tool, or to produce the encoded polypeptide.

In one situation, the microarray is used to monitor the progression of disease and the response of that disease to IMPDH inhibition. Researchers can assess and catalog the differences in gene expression between healthy and diseased tissues or cells. By analyzing changes in patterns of gene expression, disease can be diagnosed at earlier stages before the patient is symptomatic. The invention can also be used to monitor the efficacy of treatment. For some treatments with known side effects, the microarray is employed to “fine tune” the treatment regimen. A dosage of IMPDH inhibitor is established that causes a change in genetic expression patterns indicative of successful treatment. Expression patterns associated with undesirable side effects are avoided. This approach may be more sensitive and rapid than waiting for the patient to show inadequate improvement, or to manifest side effects, before altering the course of treatment.

Alternatively, animal models which mimic a disease, rather than patients having the disease, can be used to characterize expression profiles associated with a particular inhibitor. This gene expression data may be useful in diagnosing and monitoring the course of disease in a patient, in determining gene targets for intervention, and in testing treatment regimens.

Also, researchers can use the microarray to rapidly screen large numbers of candidate IMPDH inhibitory drug molecules, looking for ones that produce an expression profile similar to those of known therapeutic drugs e.g., VX-944, MPA, Nucleoside analogs such as tiazofurin, ribavirin and mizoribine, and other agents listed in e.g., U.S. Pat. Nos. 5,807,876, 5,932,600, 6,054,472, 6,344,465, 6,395,763, 6,399,773, 6,420,403, 6,867,299, 6,826,488, 6,825,224, 6,653,309, 6,624,184, 6,617,323, 6,541,496, 6,518,291, and 6,498,178 (each specifically incorporated herein by reference in its entirety for its teaches of IMPDH inhibitor compositions and methods of administering the same for the treatment of IMPDH related disorders), with the expectation that molecules with the same expression profile will have similar therapeutic effects. Thus, the invention provides the means to determine the molecular mode of action of an IPDH inhibitor or IMPDH pathway inhibitor, as well as to facilitate identification of new such drugs.

EXAMPLES

The following examples are included to demonstrate certain embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus are considered to constitute certain aspects for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

Example 1 VX-944-Biomarker Identification by Transcript Profiling

Inosine monophosphate dehydrogenase (IMPDH) catalyzes a rate-limiting step in guanine nucleotide biosynthesis, the NAD-dependent reduction of IMP to XMP. Inhibition of IMPDH activity results in the cessation of DNA synthesis and is an important target for immunosuppressive, anticancer and antiviral therapy.

Mycophenolate mofetil, an approved immunosuppressive agent (CellCept® from Roche) used for the prevention of kidney, heart or liver transplant rejections is the 2-morpholinoethyl ester of mycophenolic acid (MPA). VX-944 is currently being developed for the treatment of hematological malignancies. Both MPA and VX-944 are selective inhibitors of IMPDH with VX-944 being 3-4 fold more potent in cell assays (see FIG. 1).

IC50 values in uM VX-944 MPA VX-497 PBMCs PHA-T cell IC50 0.021 0.089 0.105 PHA-T cell IC50 in the presence of 7.8 >20 6.5 guanosine Ratio of PHA-T cell IC50 in the 373 >224 62 presence and absence of guanosine

In order to arrive at the conclusion that the expression of certain nucleic acids is modulated in response to IMPDH inhibition, the following inhibitors were employed:

The above agents were tested in HL-60 cells at a concentration of 500 nM for VX-944 and 1000 nM for MPA or with 0.1% DMSO as the vehicle control. The cells were harvested at 14 or 30 hours post addition of compound or vehicle. Briefly, the culture medium was removed at the appropriate time-points and the cells washed with PBS. The cells were then harvested, and pelleted by-gentle centrifugation. The supernatant was discarded and the pellets snap-frozen on an ethanol/dry-ice slurry. RNA was isolated from cells by using a RNEasy kit from Qiagen. RNAs were quality controlled using the Agilent 2100 Bioanalyzer to determine the presence of RNAs.

The results from the Affymetrix array analyses are summarized in the Table below. Data from the arrays corresponding to VX-944 and MPA at the two time-points—14 hours (Early) and 30 hours (Late) were analyzed using Spotfire™, microarray data analysis software. Some of the data analysis parameters used are outlined below:

a) All the arrays were normalized by using trimmed means, with a 5% exclusion limit

b) Only genes present in at least 5 of the 6 chips used for the analyses were included in the genesets

c) Only statistically significant genes (ANOVA, p<0.05) were included in the final analyses to generate gene lists.

Number of Genes Upregulated Downregulated Total VX-944: treated vs. DMSO (early) 172 119 291 VX-944: treated vs. DMSO (late) 434 0 434 MPA: treated vs. DMSO (early) 105 0 105 MPA: treated vs. DMSO (late) 602 560 1162 VX-944 (early) vs. MPA (early) 77 0 77 VX-944 (late) vs. MPA (late) 335 0 335 VX-944 (early) vs. VX-944 (late) 102 0 102 MPA (early) vs. MPA (late) 66 0 66 VX-944 (Early and Late) vs MPA 43 0 43 (early and late)

A global view of datasets identified by comparing VX-944 and MPA at the early (14 h) time-point showed that there were 77 genes in common between VX-944 and MPA. At the late (30 h) time-point, 335 genes were identified as overlapping between the VX-944 and MPA datasets. A global view of datasets identified by comparing VX-944 and MPA at the two time-points, 14 h (EARLY) and 30 h (LATE) showed that with VX-944 102 genes modulated at the early time-point were also modulated at the late time-point. With MPA 66 genes are in common between the two time-points. As to a comparison between the two data sets, of the 102 genes modulated by VX-944 and the 66 genes modulated by MPA, 43 genes modulated at 14 hours were also modulated at 30 hours. To add additional value to the gene lists and provide additional information to the investigator, the genes underlying each of these expression patterns was queried against publicly available databases. These databases included Locus Link, Gene Cards, KEGG, GO annotations, OMIM, PubMed. The information gathered from such an analysis is organized below in data tables.

VX-944 (Early) vs. MPA (Early): 77 genes were found to be common between these two comparisons. These genes were further assigned to the following functional categories:

CATEGORY NUMBER of Genes nucleobase, nucleoside, nucleotide 13 and nucleic acid metabolism protein metabolism 10 response to biotic stimulus 10 biosynthesis 9 signal transduction 9 cell proliferation 8 lipid metabolism 8 response to pest/pathogen/parasite 7 response to wounding 7 organic acid metabolism 6 cell adhesion 5 organogenesis 5 catabolism 4 cell-cell signaling 4 electron transport 4 carbohydrate metabolism 3 cell death 3 cell organization and biogenesis 3 energy pathways 3 phosphorus metabolism 3 programmed cell death 3 transport 3 unclassified 30

Interestingly, for this dataset a large number of genes were classified into the Nucleotide metabolism functional category. Some of the other major categories include protein metabolism, response to biotic stimulus, biosynthesis, signal transduction, cell proliferation, lipid metabolism and response to pest/pathogen/parasite. However, 30/77 genes could not be readily classified using the GO functional categorization. Even with these genes, every effort has been made to provide as much information as possible.

The genes in some of these categories are shown below:

Nucleotide Metabolism

LOCUS AFFX_ID LINK GENE NAME CLASSIFICATION 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- alcohol metabolism acetylmannosamine kinase 201612_at 223 aldehyde dehydrogenase 9 family, member A1 aldehyde metabolism 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- amine metabolism acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase amine metabolism 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- biosynthesis acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase biosynthesis 219649_at 29929 dolichyl-P-Glc:Man9GlcNAc2-PP- biosynthesis dolichylglucosyltransferase 200962_at 6160 ribosomal protein L31 biosynthesis 204446_s_at 240 arachidonate 5-lipoxygenase biosynthesis 204174_at 241 arachidonate 5-lipoxygenase-activating protein biosynthesis 202912_at 133 adrenomedullin biosynthesis 204044_at 23475 quinolinate phosphoribosyltransferase (nicotinate- biosynthesis nucleotide pyrophosphorylase (carboxylating)) 208771_s_at 4048 leukotriene A4 hydrolase biosynthesis 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- carbohydrate metabolism acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase carbohydrate metabolism 202499_s_at 6515 solute carrier family 2 (facilitated glucose carbohydrate metabolism transporter), member 3 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- catabolism acetylmannosamine kinase 208771_s_at 4048 leukotriene A4 hydrolase catabolism 212190_at 5270 serine (or cysteine) proteinase inhibitor, clade E catabolism (nexin, plasminogen activator inhibitor type 1), member 2 218875_s_at 26271 F-box only protein 5 catabolism 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- cell adhesion acetylmannosamine kinase 211506_s_at 3576 interleukin 8 cell adhesion 203336_s_at 9270 integrin cytoplasmic domain-associated protein 1 cell adhesion 216250_s_at 9404 leupaxin cell adhesion 219890_at 23601 C-type (calcium dependent, carbohydrate- cell adhesion recognition domain) lectin, superfamily member 5 214727_at 675 breast cancer 2, early onset cell death 201710_at 4605 v-myb myeloblastosis viral oncogene homolog cell death (avian)-like 2 204614_at 5055 serine (or cysteine) proteinase inhibitor, clade B cell death (ovalbumin), member 2 212190_at 5270 serine (or cysteine) proteinase inhibitor, clade E cell migration (nexin, plasminogen activator inhibitor type 1), member 2 214727_at 675 breast cancer 2, early onset cell organization and biogenesis 201714_at 7283 tubulin, gamma 1 cell organization and biogenesis 201999_s_at 6993 t-complex-associated-testis-expressed 1-like 1 cell organization and biogenesis 1053_at 5982 replication factor C (activator 1) 2, 40 kDa cell proliferation 205053_at 5557 primase, polypeptide 1, 49 kDa cell proliferation 214727_at 675 breast cancer 2, early onset cell proliferation 209773_s_at 6241 ribonucleotide reductase M2 polypeptide cell proliferation 211506_s_at 3576 interleukin 8 cell proliferation 201710_at 4605 v-myb myeloblastosis viral oncogene homolog cell proliferation (avian)-like 2 200660_at 6282 S100 calcium binding protein A11 (calgizzarin) cell proliferation 201641_at 684 bone marrow stromal cell antigen 2 cell proliferation 211506_s_at 3576 interleukin 8 cell-cell signaling 202912_at 133 adrenomedullin cell-cell signaling 201641_at 684 bone marrow stromal cell antigen 2 cell-cell signaling 204044_at 23475 quinolinate phosphoribosyltransferase (nicotinate- cell-cell signaling nucleotide pyrophosphorylase (carboxylating)) 204044_at 23475 quinolinate phosphoribosyltransferase (nicotinate- coenzymes and prosthetic group nucleotide pyrophosphorylase (carboxylating)) metabolism 203923_s_at 1536 cytochrome b-245, beta polypeptide (chronic electron transport granulomatous disease) 204446_s_at 240 arachidonate 5-lipoxygenase electron transport 202437_s_at 1545 cytochrome P450, family 1, subfamily B, electron transport polypeptide 1 206662_at 2745 glutaredoxin (thioltransferase) electron transport 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- energy pathways acetylmannosamine kinase 203923_s_at 1536 cytochrome b-245, beta polypeptide (chronic energy pathways granulomatous disease) 204044_at 23475 quinolinate phosphoribosyltransferase (nicotinate- energy pathways nucleotide pyrophosphorylase (carboxylating)) 202912_at 133 adrenomedullin hormone metabolism 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- lipid metabolism acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase lipid metabolism 204446_s_at 240 arachidonate 5-lipoxygenase lipid metabolism 204174_at 241 arachidonate 5-lipoxygenase-activating protein lipid metabolism 202912_at 133 adrenomedullin lipid metabolism 201963_at 2180 fatty-acid-Coenzyme A ligase, long-chain 2 lipid metabolism 208771_s_at 4048 leukotriene A4 hydrolase lipid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long-chain 1 lipid metabolism 1053_at 5982 replication factor C (activator 1) 2, 40 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- nucleobase, nucleoside, nucleotide acetylmannosamine kinase and nucleic acid metabolism 218258_at 51082 polymerase (RNA) I polypeptide D, 16 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 205053_at 5557 primase, polypeptide 1, 49 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 203409_at 1643 damage-specific DNA binding protein 2, 48 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 214727_at 675 breast cancer 2, early onset nucleobase, nucleoside, nucleotide and nucleic acid metabolism 209773_s_at 6241 ribonucleotide reductase M2 polypeptide nucleobase, nucleoside, nucleotide and nucleic acid metabolism 202678_at 2958 general transcription factor IIA, 2, 12 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 201710_at 4605 v-myb myeloblastosis viral oncogene homolog nucleobase, nucleoside, nucleotide (avian)-like 2 and nucleic acid metabolism 202912_at 133 adrenomedullin nucleobase, nucleoside, nucleotide and nucleic acid metabolism 200660_at 6282 S100 calcium binding protein A11 (calgizzarin) nucleobase, nucleoside, nucleotide and nucleic acid metabolism 209930_s_at 4778 nuclear factor (erythroid-derived 2), 45 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 201989_s_at 1389 cAMP responsive element binding protein-like 2 nucleobase, nucleoside, nucleotide and nucleic acid metabolism

Protein Metabolism

LOCUS AFFX_ID LINK GENE NAME CLASSIFICATION 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- alcohol metabolism acetylmannosamine kinase 201612_at 223 aldehyde dehydrogenase 9 family, member aldehyde metabolism A1 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- amine metabolism acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase amine metabolism 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- biosynthesis acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase biosynthesis 219649_at 29929 dolichyl-P-Glc:Man9GlcNAc2-PP- biosynthesis dolichylglucosyltransferase 200962_at 6160 ribosomal protein L31 biosynthesis 204446_s_at 240 arachidonate 5-lipoxygenase biosynthesis 204174_at 241 arachidonate 5-lipoxygenase-activating biosynthesis protein 202912_at 133 adrenomedullin biosynthesis 204044_at 23475 quinolinate phosphoribosyltransferase biosynthesis (nicotinate-nucleotide pyrophosphorylase (carboxylating)) 208771_s_at 4048 leukotriene A4 hydrolase biosynthesis 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- carbohydrate metabolism acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase carbohydrate metabolism 202499_s_at 6515 solute carrier family 2 (facilitated glucose carbohydrate metabolism transporter), member 3 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- catabolism acetylmannosamine kinase 208771_s_at 4048 leukotriene A4 hydrolase catabolism 212190_at 5270 serine (or cysteine) proteinase inhibitor, catabolism clade E (nexin, plasminogen activator inhibitor type 1), member 2 218875_s_at 26271 F-box only protein 5 catabolism 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- cell adhesion acetylmannosamine kinase 211506_s_at 3576 interleukin 8 cell adhesion 203336_s_at 9270 integrin cytoplasmic domain-associated cell adhesion protein 1 216250_s_at 9404 leupaxin cell adhesion 219890_at 23601 C-type (calcium dependent, carbohydrate- cell adhesion recognition domain) lectin, superfamily member 5 214727_at 675 breast cancer 2, early onset cell death 201710_at 4605 v-myb myeloblastosis viral oncogene cell death homolog (avian)-like 2 204614_at 5055 serine (or cysteine) proteinase inhibitor, cell death clade B (ovalbumin), member 2 212190_at 5270 serine (or cysteine) proteinase inhibitor, cell migration clade E (nexin, plasminogen activator inhibitor type 1), member 2 214727_at 675 breast cancer 2, early onset cell organization and biogenesis 201714_at 7283 tubulin, gamma 1 cell organization and biogenesis 201999_s_at 6993 t-complex-associated-testis-expressed 1- cell organization and biogenesis like 1 1053_at 5982 replication factor C (activator 1) 2, 40 kDa cell proliferation 205053_at 5557 primase, polypeptide 1, 49 kDa cell proliferation 214727_at 675 breast cancer 2, early onset cell proliferation 209773_s_at 6241 ribonucleotide reductase M2 polypeptide cell proliferation 211506_s_at 3576 interleukin 8 cell proliferation 201710_at 4605 v-myb myeloblastosis viral oncogene cell proliferation homolog (avian)-like 2 200660_at 6282 S100 calcium binding protein A11 cell proliferation (calgizzarin) 201641_at 684 bone marrow stromal cell antigen 2 cell proliferation 211506_s_at 3576 interleukin 8 cell-cell signaling 202912_at 133 adrenomedullin cell-cell signaling 201641_at 684 bone marrow stromal cell antigen 2 cell-cell signaling 204044_at 23475 quinolinate phosphoribosyltransferase cell-cell signaling (nicotinate-nucleotide pyrophosphorylase (carboxylating)) 204044_at 23475 quinolinate phosphoribosyltransferase coenzymes and prosthetic (nicotinate-nucleotide pyrophosphorylase group metabolism (carboxylating)) 203923_s_at 1536 cytochrome b-245, beta polypeptide electron transport (chronic granulomatous disease) 204446_s_at 240 arachidonate 5-lipoxygenase electron transport 202437_s_at 1545 cytochrome P450, family 1, subfamily B, electron transport polypeptide 1 206662_at 2745 glutaredoxin (thioltransferase) electron transport 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- energy pathways acetylmannosamine kinase 203923_s_at 1536 cytochrome b-245, beta polypeptide energy pathways (chronic granulomatous disease) 204044_at 23475 quinolinate phosphoribosyltransferase energy pathways (nicotinate-nucleotide pyrophosphorylase (carboxylating)) 202912_at 133 adrenomedullin hormone metabolism 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- lipid metabolism acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase lipid metabolism 204446_s_at 240 arachidonate 5-lipoxygenase lipid metabolism 204174_at 241 arachidonate 5-lipoxygenase-activating lipid metabolism protein 202912_at 133 adrenomedullin lipid metabolism 201963_at 2180 fatty-acid-Coenzyme A ligase, long-chain 2 lipid metabolism 208771_s_at 4048 leukotriene A4 hydrolase lipid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long-chain 1 lipid metabolism 1053_at 5982 replication factor C (activator 1) 2, 40 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- nucleobase, nucleoside, acetylmannosamine kinase nucleotide and nucleic acid metabolism 218258_at 51082 polymerase (RNA) I polypeptide D, 16 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 205053_at 5557 primase, polypeptide 1, 49 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 203409_at 1643 damage-specific DNA binding protein 2, nucleobase, nucleoside, 48 kDa nucleotide and nucleic acid metabolism 214727_at 675 breast cancer 2, early onset nucleobase, nucleoside, nucleotide and nucleic acid metabolism 209773_s_at 6241 ribonucleotide reductase M2 polypeptide nucleobase, nucleoside, nucleotide and nucleic acid metabolism 202678_at 2958 general transcription factor IIA, 2, 12 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 201710_at 4605 v-myb myeloblastosis viral oncogene nucleobase, nucleoside, homolog (avian)-like 2 nucleotide and nucleic acid metabolism 202912_at 133 adrenomedullin nucleobase, nucleoside, nucleotide and nucleic acid metabolism 200660_at 6282 S100 calcium binding protein A11 nucleobase, nucleoside, (calgizzarin) nucleotide and nucleic acid metabolism 209930_s_at 4778 nuclear factor (erythroid-derived 2), 45 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 201989_s_at 1389 cAMP responsive element binding protein- nucleobase, nucleoside, like 2 nucleotide and nucleic acid metabolism 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- organic acid metabolism acetylmannosamine kinase 204446_s_at 240 arachidonate 5-lipoxygenase organic acid metabolism 204174_at 241 arachidonate 5-lipoxygenase-activating organic acid metabolism protein 201963_at 2180 fatty-acid-Coenzyme A ligase, long-chain 2 organic acid metabolism 208771_s_at 4048 leukotriene A4 hydrolase organic acid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long-chain 1 organic acid metabolism 206734_at 8690 jerky homolog-like (mouse) organogenesis 211506_s_at 3576 interleukin 8 organogenesis 205807_s_at 7286 tuftelin 1 organogenesis 218224_at 9240 paraneoplastic antigen MA1 organogenesis 202437_s_at 1545 cytochrome P450, family 1, subfamily B, organogenesis polypeptide 1 205807_s_at 7286 tuftelin 1 ossification 202437_s_at 1545 cytochrome P450, family 1, subfamily B, perception of external stimulus polypeptide 1 202933_s_at 7525 v-yes-1 Yamaguchi sarcoma viral phosphorus metabolism oncogene homolog 1 209457_at 1847 dual specificity phosphatase 5 phosphorus metabolism 209585_s_at 9562 multiple inositol polyphosphate histidine phosphorus metabolism phosphatase, 1 214727_at 675 breast cancer 2, early onset programmed cell death 201710_at 4605 v-myb myeloblastosis viral oncogene programmed cell death homolog (avian)-like 2 204614_at 5055 serine (or cysteine) proteinase inhibitor, programmed cell death clade B (ovalbumin), member 2 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- protein metabolism acetylmannosamine kinase 202933_s_at 7525 v-yes-1 Yamaguchi sarcoma viral oncogene protein metabolism homolog 1 209457_at 1847 dual specificity phosphatase 5 protein metabolism 210942_s_at 10402 alpha2,3-sialyltransferase protein metabolism 219649_at 29929 dolichyl-P-Glc:Man9GlcNAc2-PP- protein metabolism dolichylglucosyltransferase 200962_at 6160 ribosomal protein L31 protein metabolism 216250_s_at 9404 leupaxin protein metabolism 208771_s_at 4048 leukotriene A4 hydrolase protein metabolism 212190_at 5270 serine (or cysteine) proteinase inhibitor, clade E protein metabolism (nexin, plasminogen activator inhibitor type 1), member 2 218875_s_at 26271 F-box only protein 5 protein metabolism

Response to Biotic Stimulus

LOCUS AFFX_ID LINK GENE NAME CLASSIFICATION 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- alcohol metabolism acetylmannosamine kinase 201612_at 223 aldehyde dehydrogenase 9 family, member aldehyde metabolism A1 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- amine metabolism acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase amine metabolism 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- biosynthesis acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase biosynthesis 219649_at 29929 dolichyl-P-Glc:Man9GlcNAc2-PP- biosynthesis dolichylglucosyltransferase 200962_at 6160 ribosomal protein L31 biosynthesis 204446_s_at 240 arachidonate 5-lipoxygenase biosynthesis 204174_at 241 arachidonate 5-lipoxygenase-activating biosynthesis protein 202912_at 133 adrenomedullin biosynthesis 204044_at 23475 quinolinate phosphoribosyltransferase biosynthesis (nicotinate-nucleotide pyrophosphorylase (carboxylating)) 208771_s_at 4048 leukotriene A4 hydrolase biosynthesis 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- carbohydrate metabolism acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase carbohydrate metabolism 202499_s_at 6515 solute carrier family 2 (facilitated glucose carbohydrate metabolism transporter), member 3 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- catabolism acetylmannosamine kinase 208771_s_at 4048 leukotriene A4 hydrolase catabolism 212190_at 5270 serine (or cysteine) proteinase inhibitor, catabolism clade E (nexin, plasminogen activator inhibitor type 1), member 2 218875_s_at 26271 F-box only protein 5 catabolism 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- cell adhesion acetylmannosamine kinase 211506_s_at 3576 interleukin 8 cell adhesion 203336_s_at 9270 integrin cytoplasmic domain-associated cell adhesion protein 1 216250_s_at 9404 leupaxin cell adhesion 219890_at 23601 C-type (calcium dependent, carbohydrate- cell adhesion recognition domain) lectin, superfamily member 5 214727_at 675 breast cancer 2, early onset cell death 201710_at 4605 v-myb myeloblastosis viral oncogene cell death homolog (avian)-like 2 204614_at 5055 serine (or cysteine) proteinase inhibitor, cell death clade B (ovalbumin), member 2 212190_at 5270 serine (or cysteine) proteinase inhibitor, cell migration clade E (nexin, plasminogen activator inhibitor type 1), member 2 214727_at 675 breast cancer 2, early onset cell organization and biogenesis 201714_at 7283 tubulin, gamma 1 cell organization and biogenesis 201999_s_at 6993 t-complex-associated-testis-expressed 1- cell organization and biogenesis like 1 1053_at 5982 replication factor C (activator 1) 2, 40 kDa cell proliferation 205053_at 5557 primase, polypeptide 1, 49 kDa cell proliferation 214727_at 675 breast cancer 2, early onset cell proliferation 209773_s_at 6241 ribonucleotide reductase M2 polypeptide cell proliferation 211506_s_at 3576 interleukin 8 cell proliferation 201710_at 4605 v-myb myeloblastosis viral oncogene cell proliferation homolog (avian)-like 2 200660_at 6282 S100 calcium binding protein A11 cell proliferation (calgizzarin) 201641_at 684 bone marrow stromal cell antigen 2 cell proliferation 211506_s_at 3576 interleukin 8 cell-cell signaling 202912_at 133 adrenomedullin cell-cell signaling 201641_at 684 bone marrow stromal cell antigen 2 cell-cell signaling 204044_at 23475 quinolinate phosphoribosyltransferase cell-cell signaling (nicotinate-nucleotide pyrophosphorylase (carboxylating)) 204044_at 23475 quinolinate phosphoribosyltransferase coenzymes and prosthetic (nicotinate-nucleotide pyrophosphorylase group metabolism (carboxylating)) 203923_s_at 1536 cytochrome b-245, beta polypeptide electron transport (chronic granulomatous disease) 204446_s_at 240 arachidonate 5-lipoxygenase electron transport 202437_s_at 1545 cytochrome P450, family 1, subfamily B, electron transport polypeptide 1 206662_at 2745 glutaredoxin (thioltransferase) electron transport 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- energy pathways acetylmannosamine kinase 203923_s_at 1536 cytochrome b-245, beta polypeptide energy pathways (chronic granulomatous disease) 204044_at 23475 quinolinate phosphoribosyltransferase energy pathways (nicotinate-nucleotide pyrophosphorylase (carboxylating)) 202912_at 133 adrenomedullin hormone metabolism 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- lipid metabolism acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase lipid metabolism 204446_s_at 240 arachidonate 5-lipoxygenase lipid metabolism 204174_at 241 arachidonate 5-lipoxygenase-activating lipid metabolism protein 202912_at 133 adrenomedullin lipid metabolism 201963_at 2180 fatty-acid-Coenzyme A ligase, long-chain 2 lipid metabolism 208771_s_at 4048 leukotriene A4 hydrolase lipid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long-chain 1 lipid metabolism 1053_at 5982 replication factor C (activator 1) 2, 40 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- nucleobase, nucleoside, acetylmannosamine kinase nucleotide and nucleic acid metabolism 218258_at 51082 polymerase (RNA) I polypeptide D, 16 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 205053_at 5557 primase, polypeptide 1, 49 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 203409_at 1643 damage-specific DNA binding protein 2, nucleobase, nucleoside, 48 kDa nucleotide and nucleic acid metabolism 214727_at 675 breast cancer 2, early onset nucleobase, nucleoside, nucleotide and nucleic acid metabolism 209773_s_at 6241 ribonucleotide reductase M2 polypeptide nucleobase, nucleoside, nucleotide and nucleic acid metabolism 202678_at 2958 general transcription factor IIA, 2, 12 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 201710_at 4605 v-myb myeloblastosis viral oncogene nucleobase, nucleoside, homolog (avian)-like 2 nucleotide and nucleic acid metabolism 202912_at 133 adrenomedullin nucleobase, nucleoside, nucleotide and nucleic acid metabolism 200660_at 6282 S100 calcium binding protein A11 nucleobase, nucleoside, (calgizzarin) nucleotide and nucleic acid metabolism 209930_s_at 4778 nuclear factor (erythroid-derived 2), 45 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 201989_s_at 1389 cAMP responsive element binding protein- nucleobase, nucleoside, like 2 nucleotide and nucleic acid metabolism 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- organic acid metabolism acetylmannosamine kinase 204446_s_at 240 arachidonate 5-lipoxygenase organic acid metabolism 204174_at 241 arachidonate 5-lipoxygenase-activating organic acid metabolism protein 201963_at 2180 fatty-acid-Coenzyme A ligase, long-chain 2 organic acid metabolism 208771_s_at 4048 leukotriene A4 hydrolase organic acid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long-chain 1 organic acid metabolism 206734_at 8690 jerky homolog-like (mouse) organogenesis 211506_s_at 3576 interleukin 8 organogenesis 205807_s_at 7286 tuftelin 1 organogenesis 218224_at 9240 paraneoplastic antigen MA1 organogenesis 202437_s_at 1545 cytochrome P450, family 1, subfamily B, organogenesis polypeptide 1 205807_s_at 7286 tuftelin 1 ossification 202437_s_at 1545 cytochrome P450, family 1, subfamily B, perception of external stimulus polypeptide 1 202933_s_at 7525 v-yes-1 Yamaguchi sarcoma viral phosphorus metabolism oncogene homolog 1 209457_at 1847 dual specificity phosphatase 5 phosphorus metabolism 209585_s_at 9562 multiple inositol polyphosphate histidine phosphorus metabolism phosphatase, 1 214727_at 675 breast cancer 2, early onset programmed cell death 201710_at 4605 v-myb myeloblastosis viral oncogene programmed cell death homolog (avian)-like 2 204614_at 5055 serine (or cysteine) proteinase inhibitor, programmed cell death clade B (ovalbumin), member 2 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- protein metabolism acetylmannosamine kinase 202933_s_at 7525 v-yes-1 Yamaguchi sarcoma viral protein metabolism oncogene homolog 1 209457_at 1847 dual specificity phosphatase 5 protein metabolism 210942_s_at 10402 alpha2,3-sialyltransferase protein metabolism 219649_at 29929 dolichyl-P-Glc:Man9GlcNAc2-PP- protein metabolism dolichylglucosyltransferase 200962_at 6160 ribosomal protein L31 protein metabolism 216250_s_at 9404 leupaxin protein metabolism 208771_s_at 4048 leukotriene A4 hydrolase protein metabolism 212190_at 5270 serine (or cysteine) proteinase inhibitor, protein metabolism clade E (nexin, plasminogen activator inhibitor type 1), member 2 218875_s_at 26271 F-box only protein 5 protein metabolism 212190_at 5270 serine (or cysteine) proteinase inhibitor, regulation of metabolism clade E (nexin, plasminogen activator inhibitor type 1), member 2 205557_at 671 bactericidal/permeability-increasing protein response to abiotic stimulus 202437_s_at 1545 cytochrome P450, family 1, subfamily B, response to abiotic stimulus polypeptide 1 211506_s_at 3576 interleukin 8 response to biotic stimulus 205557_at 671 bactericidal/permeability-increasing protein response to biotic stimulus 203923_s_at 1536 cytochrome b-245, beta polypeptide (chronic response to biotic stimulus granulomatous disease) 204446_s_at 240 arachidonate 5-lipoxygenase response to biotic stimulus 204174_at 241 arachidonate 5-lipoxygenase-activating protein response to biotic stimulus 202912_at 133 adrenomedullin response to biotic stimulus 201641_at 684 bone marrow stromal cell antigen 2 response to biotic stimulus 208771_s_at 4048 leukotriene A4 hydrolase response to biotic stimulus 209575_at 3588 interleukin 10 receptor, beta response to biotic stimulus 216950_s_at 2209 Fc fragment of IgG, high affinity Ia, receptor for response to biotic stimulus (CD64)

Biosynthesis

LOCUS AFFX_ID LINK GENE NAME CLASSIFICATION 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- alcohol metabolism acetylmannosamine kinase 201612_at 223 aldehyde dehydrogenase 9 family, member aldehyde metabolism A1 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- amine metabolism acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase amine metabolism 205042_at 10020 UDP-N-acetylglucosamine-2-epimerase/N- biosynthesis acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase biosynthesis 219649_at 29929 dolichyl-P-Glc:Man9GlcNAc2-PP- biosynthesis dolichylglucosyltransferase 200962_at 6160 ribosomal protein L31 biosynthesis 204446_s_at 240 arachidonate 5-lipoxygenase biosynthesis 204174_at 241 arachidonate 5-lipoxygenase-activating protein biosynthesis 202912_at 133 adrenomedullin biosynthesis 204044_at 23475 quinolinate phosphoribosyltransferase biosynthesis (nicotinate-nucleotide pyrophosphorylase (carboxylating)) 208771_s_at 4048 leukotriene A4 hydrolase biosynthesis

Signal Transduction

LOCUS AFFX_ID LINK GENE NAME CLASSIFICATION 205042_at 10020 UDP-N-acetylglucosamine-2- alcohol metabolism epimerase/N-acetylmannosamine kinase 201612_at 223 aldehyde dehydrogenase 9 family, aldehyde metabolism member A1 205042_at 10020 UDP-N-acetylglucosamine-2- amine metabolism epimerase/N-acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase amine metabolism 205042_at 10020 UDP-N-acetylglucosamine-2- biosynthesis epimerase/N-acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase biosynthesis 219649_at 29929 dolichyl-P-Glc:Man9GlcNAc2-PP- biosynthesis dolichylglucosyltransferase 200962_at 6160 ribosomal protein L31 biosynthesis 204446_s_at 240 arachidonate 5-lipoxygenase biosynthesis 204174_at 241 arachidonate 5-lipoxygenase-activating biosynthesis protein 202912_at 133 adrenomedullin biosynthesis 204044_at 23475 quinolinate phosphoribosyltransferase biosynthesis (nicotinate-nucleotide pyrophosphorylase (carboxylating)) 208771_s_at 4048 leukotriene A4 hydrolase biosynthesis 205042_at 10020 UDP-N-acetylglucosamine-2- carbohydrate metabolism epimerase/N-acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase carbohydrate metabolism 202499_s_at 6515 solute carrier family 2 (facilitated glucose carbohydrate metabolism transporter), member 3 205042_at 10020 UDP-N-acetylglucosamine-2- catabolism epimerase/N-acetylmannosamine kinase 208771_s_at 4048 leukotriene A4 hydrolase catabolism 212190_at 5270 serine (or cysteine) proteinase inhibitor, catabolism clade E (nexin, plasminogen activator inhibitor type 1), member 2 218875_s_at 26271 F-box only protein 5 catabolism 205042_at 10020 UDP-N-acetylglucosamine-2- cell adhesion epimerase/N-acetylmannosamine kinase 211506_s_at 3576 interleukin 8 cell adhesion 203336_s_at 9270 integrin cytoplasmic domain-associated cell adhesion protein 1 216250_s_at 9404 leupaxin cell adhesion 219890_at 23601 C-type (calcium dependent, cell adhesion carbohydrate-recognition domain) lectin, superfamily member 5 214727_at 675 breast cancer 2, early onset cell death 201710_at 4605 v-myb myeloblastosis viral oncogene cell death homolog (avian)-like 2 204614_at 5055 serine (or cysteine) proteinase inhibitor, cell death clade B (ovalbumin), member 2 212190_at 5270 serine (or cysteine) proteinase inhibitor, cell migration clade E (nexin, plasminogen activator inhibitor type 1), member 2 214727_at 675 breast cancer 2, early onset cell organization and biogenesis 201714_at 7283 tubulin, gamma 1 cell organization and biogenesis 201999_s_at 6993 t-complex-associated-testis-expressed 1- cell organization and biogenesis like 1 1053_at 5982 replication factor C (activator 1) 2, 40 kDa cell proliferation 205053_at 5557 primase, polypeptide 1, 49 kDa cell proliferation 214727_at 675 breast cancer 2, early onset cell proliferation 209773_s_at 6241 ribonucleotide reductase M2 polypeptide cell proliferation 211506_s_at 3576 interleukin 8 cell proliferation 201710_at 4605 v-myb myeloblastosis viral oncogene cell proliferation homolog (avian)-like 2 200660_at 6282 S100 calcium binding protein A11 cell proliferation (calgizzarin) 201641_at 684 bone marrow stromal cell antigen 2 cell proliferation 211506_s_at 3576 interleukin 8 cell-cell signaling 202912_at 133 adrenomedullin cell-cell signaling 201641_at 684 bone marrow stromal cell antigen 2 cell-cell signaling 204044_at 23475 quinolinate phosphoribosyltransferase cell-cell signaling (nicotinate-nucleotide pyrophosphorylase (carboxylating)) 204044_at 23475 quinolinate phosphoribosyltransferase coenzymes and prosthetic (nicotinate-nucleotide pyrophosphorylase group metabolism (carboxylating)) 203923_s_at 1536 cytochrome b-245, beta polypeptide electron transport (chronic granulomatous disease) 204446_s_at 240 arachidonate 5-lipoxygenase electron transport 202437_s_at 1545 cytochrome P450, family 1, subfamily B, electron transport polypeptide 1 206662_at 2745 glutaredoxin (thioltransferase) electron transport 205042_at 10020 UDP-N-acetylglucosamine-2- energy pathways epimerase/N-acetylmannosamine kinase 203923_s_at 1536 cytochrome b-245, beta polypeptide energy pathways (chronic granulomatous disease) 204044_at 23475 quinolinate phosphoribosyltransferase energy pathways (nicotinate-nucleotide pyrophosphorylase (carboxylating)) 202912_at 133 adrenomedullin hormone metabolism 205042_at 10020 UDP-N-acetylglucosamine-2- lipid metabolism epimerase/N-acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase lipid metabolism 204446_s_at 240 arachidonate 5-lipoxygenase lipid metabolism 204174_at 241 arachidonate 5-lipoxygenase-activating lipid metabolism protein 202912_at 133 adrenomedullin lipid metabolism 201963_at 2180 fatty-acid-Coenzyme A ligase, long-chain 2 lipid metabolism 208771_s_at 4048 leukotriene A4 hydrolase lipid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long-chain 1 lipid metabolism 1053_at 5982 replication factor C (activator 1) 2, 40 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 205042_at 10020 UDP-N-acetylglucosamine-2- nucleobase, nucleoside, epimerase/N-acetylmannosamine kinase nucleotide and nucleic acid metabolism 218258_at 51082 polymerase (RNA) I polypeptide D, nucleobase, nucleoside, 16 kDa nucleotide and nucleic acid metabolism 205053_at 5557 primase, polypeptide 1, 49 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 203409_at 1643 damage-specific DNA binding protein 2, nucleobase, nucleoside, 48 kDa nucleotide and nucleic acid metabolism 214727_at 675 breast cancer 2, early onset nucleobase, nucleoside, nucleotide and nucleic acid metabolism 209773_s_at 6241 ribonucleotide reductase M2 polypeptide nucleobase, nucleoside, nucleotide and nucleic acid metabolism 202678_at 2958 general transcription factor IIA, 2, 12 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 201710_at 4605 v-myb myeloblastosis viral oncogene nucleobase, nucleoside, homolog (avian)-like 2 nucleotide and nucleic acid metabolism 202912_at 133 adrenomedullin nucleobase, nucleoside, nucleotide and nucleic acid metabolism 200660_at 6282 S100 calcium binding protein A11 nucleobase, nucleoside, (calgizzarin) nucleotide and nucleic acid metabolism 209930_s_at 4778 nuclear factor (erythroid-derived 2), nucleobase, nucleoside, 45 kDa nucleotide and nucleic acid metabolism 201989_s_at 1389 cAMP responsive element binding nucleobase, nucleoside, protein-like 2 nucleotide and nucleic acid metabolism 205042_at 10020 UDP-N-acetylglucosamine-2- organic acid metabolism epimerase/N-acetylmannosamine kinase 204446_s_at 240 arachidonate 5-lipoxygenase organic acid metabolism 204174_at 241 arachidonate 5-lipoxygenase-activating organic acid metabolism protein 201963_at 2180 fatty-acid-Coenzyme A ligase, long-chain 2 organic acid metabolism 208771_s_at 4048 leukotriene A4 hydrolase organic acid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long-chain 1 organic acid metabolism 206734_at 8690 jerky homolog-like (mouse) organogenesis 211506_s_at 3576 interleukin 8 organogenesis 205807_s_at 7286 tuftelin 1 organogenesis 218224_at 9240 paraneoplastic antigen MA1 organogenesis 202437_s_at 1545 cytochrome P450, family 1, subfamily B, organogenesis polypeptide 1 205807_s_at 7286 tuftelin 1 ossification 202437_s_at 1545 cytochrome P450, family 1, subfamily B, perception of external stimulus polypeptide 1 202933_s_at 7525 v-yes-1 Yamaguchi sarcoma viral phosphorus metabolism oncogene homolog 1 209457_at 1847 dual specificity phosphatase 5 phosphorus metabolism 209585_s_at 9562 multiple inositol polyphosphate histidine phosphorus metabolism phosphatase, 1 214727_at 675 breast cancer 2, early onset programmed cell death 201710_at 4605 v-myb myeloblastosis viral oncogene programmed cell death homolog (avian)-like 2 204614_at 5055 serine (or cysteine) proteinase inhibitor, programmed cell death clade B (ovalbumin), member 2 205042_at 10020 UDP-N-acetylglucosamine-2- protein metabolism epimerase/N-acetylmannosamine kinase 202933_s_at 7525 v-yes-1 Yamaguchi sarcoma viral protein metabolism oncogene homolog 1 209457_at 1847 dual specificity phosphatase 5 protein metabolism 210942_s_at 10402 alpha2,3-sialyltransferase protein metabolism 219649_at 29929 dolichyl-P-Glc:Man9GlcNAc2-PP- protein metabolism dolichylglucosyltransferase 200962_at 6160 ribosomal protein L31 protein metabolism 216250_s_at 9404 leupaxin protein metabolism 208771_s_at 4048 leukotriene A4 hydrolase protein metabolism 212190_at 5270 serine (or cysteine) proteinase inhibitor, protein metabolism clade E (nexin, plasminogen activator inhibitor type 1), member 2 218875_s_at 26271 F-box only protein 5 protein metabolism 212190_at 5270 serine (or cysteine) proteinase inhibitor, regulation of metabolism clade E (nexin, plasminogen activator inhibitor type 1), member 2 205557_at 671 bactericidal/permeability-increasing response to abiotic stimulus protein 202437_s_at 1545 cytochrome P450, family 1, subfamily B, response to abiotic stimulus polypeptide 1 211506_s_at 3576 interleukin 8 response to biotic stimulus 205557_at 671 bactericidal/permeability-increasing response to biotic stimulus protein 203923_s_at 1536 cytochrome b-245, beta polypeptide response to biotic stimulus (chronic granulomatous disease) 204446_s_at 240 arachidonate 5-lipoxygenase response to biotic stimulus 204174_at 241 arachidonate 5-lipoxygenase-activating response to biotic stimulus protein 202912_at 133 adrenomedullin response to biotic stimulus 201641_at 684 bone marrow stromal cell antigen 2 response to biotic stimulus 208771_s_at 4048 leukotriene A4 hydrolase response to biotic stimulus 209575_at 3588 interleukin 10 receptor, beta response to biotic stimulus 216950_s_at 2209 Fc fragment of IgG, high affinity Ia, response to biotic stimulus receptor for (CD64) 211506_s_at 3576 interleukin 8 response to pest/pathogen/parasite 203923_s_at 1536 cytochrome b-245, beta polypeptide response to (chronic granulomatous disease) pest/pathogen/parasite 204446_s_at 240 arachidonate 5-lipoxygenase response to pest/pathogen/parasite 204174_at 241 arachidonate 5-lipoxygenase-activating response to protein pest/pathogen/parasite 201641_at 684 bone marrow stromal cell antigen 2 response to pest/pathogen/parasite 208771_s_at 4048 leukotriene A4 hydrolase response to pest/pathogen/parasite 209575_at 3588 interleukin 10 receptor, beta response to pest/pathogen/parasite 211506_s_at 3576 interleukin 8 response to wounding 203923_s_at 1536 cytochrome b-245, beta polypeptide response to wounding (chronic granulomatous disease) 204446_s_at 240 arachidonate 5-lipoxygenase response to wounding 204174_at 241 arachidonate 5-lipoxygenase-activating response to wounding protein 202912_at 133 adrenomedullin response to wounding 208771_s_at 4048 leukotriene A4 hydrolase response to wounding 209575_at 3588 interleukin 10 receptor, beta response to wounding 218224_at 9240 paraneoplastic antigen MA1 sexual reproduction 202933_s_at 7525 v-yes-1 Yamaguchi sarcoma viral oncogene signal transduction homolog 1 211506_s_at 3576 interleukin 8 signal transduction 202912_at 133 adrenomedullin signal transduction 203336_s_at 9270 integrin cytoplasmic domain-associated signal transduction protein 1 216250_s_at 9404 leupaxin signal transduction 209154_at 30851 Tax interaction protein 1 signal transduction 209575_at 3588 interleukin 10 receptor, beta signal transduction 216950_s_at 2209 Fc fragment of IgG, high affinity Ia, receptor signal transduction for (CD64) 201989_s_at 1389 cAMP responsive element binding protein-like 2 signal transduction

Programmed Cell Death

LOCUS AFFX_ID LINK GENE NAME CLASSIFICATION 205042_at 10020 UDP-N-acetylglucosamine-2- alcohol metabolism epimerase/N-acetylmannosamine kinase 201612_at 223 aldehyde dehydrogenase 9 family, aldehyde metabolism member A1 205042_at 10020 UDP-N-acetylglucosamine-2- amine metabolism epimerase/N-acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase amine metabolism 205042_at 10020 UDP-N-acetylglucosamine-2- biosynthesis epimerase/N-acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase biosynthesis 219649_at 29929 dolichyl-P-Glc:Man9GlcNAc2-PP- biosynthesis dolichylglucosyltransferase 200962_at 6160 ribosomal protein L31 biosynthesis 204446_s_at 240 arachidonate 5-lipoxygenase biosynthesis 204174_at 241 arachidonate 5-lipoxygenase-activating biosynthesis protein 202912_at 133 adrenomedullin biosynthesis 204044_at 23475 quinolinate phosphoribosyltransferase biosynthesis (nicotinate-nucleotide pyrophosphorylase (carboxylating)) 208771_s_at 4048 leukotriene A4 hydrolase biosynthesis 205042_at 10020 UDP-N-acetylglucosamine-2- carbohydrate metabolism epimerase/N-acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase carbohydrate metabolism 202499_s_at 6515 solute carrier family 2 (facilitated glucose carbohydrate metabolism transporter), member 3 205042_at 10020 UDP-N-acetylglucosamine-2- catabolism epimerase/N-acetylmannosamine kinase 208771_s_at 4048 leukotriene A4 hydrolase catabolism 212190_at 5270 serine (or cysteine) proteinase inhibitor, catabolism clade E (nexin, plasminogen activator inhibitor type 1), member 2 218875_s_at 26271 F-box only protein 5 catabolism 205042_at 10020 UDP-N-acetylglucosamine-2- cell adhesion epimerase/N-acetylmannosamine kinase 211506_s_at 3576 interleukin 8 cell adhesion 203336_s_at 9270 integrin cytoplasmic domain-associated cell adhesion protein 1 216250_s_at 9404 leupaxin cell adhesion 219890_at 23601 C-type (calcium dependent, carbohydrate- cell adhesion recognition domain) lectin, superfamily member 5 214727_at 675 breast cancer 2, early onset cell death 201710_at 4605 v-myb myeloblastosis viral oncogene cell death homolog (avian)-like 2 204614_at 5055 serine (or cysteine) proteinase inhibitor, cell death clade B (ovalbumin), member 2 212190_at 5270 serine (or cysteine) proteinase inhibitor, cell migration clade E (nexin, plasminogen activator inhibitor type 1), member 2 214727_at 675 breast cancer 2, early onset cell organization and biogenesis 201714_at 7283 tubulin, gamma 1 cell organization and biogenesis 201999_s_at 6993 t-complex-associated-testis-expressed 1- cell organization and biogenesis like 1 1053_at 5982 replication factor C (activator 1) 2, 40 kDa cell proliferation 205053_at 5557 primase, polypeptide 1, 49 kDa cell proliferation 214727_at 675 breast cancer 2, early onset cell proliferation 209773_s_at 6241 ribonucleotide reductase M2 polypeptide cell proliferation 211506_s_at 3576 interleukin 8 cell proliferation 201710_at 4605 v-myb myeloblastosis viral oncogene cell proliferation homolog (avian)-like 2 200660_at 6282 S100 calcium binding protein A11 cell proliferation (calgizzarin) 201641_at 684 bone marrow stromal cell antigen 2 cell proliferation 211506_s_at 3576 interleukin 8 cell-cell signaling 202912_at 133 adrenomedullin cell-cell signaling 201641_at 684 bone marrow stromal cell antigen 2 cell-cell signaling 204044_at 23475 quinolinate phosphoribosyltransferase cell-cell signaling (nicotinate-nucleotide pyrophosphorylase (carboxylating)) 204044_at 23475 quinolinate phosphoribosyltransferase coenzymes and prosthetic (nicotinate-nucleotide pyrophosphorylase group metabolism (carboxylating)) 203923_s_at 1536 cytochrome b-245, beta polypeptide electron transport (chronic granulomatous disease) 204446_s_at 240 arachidonate 5-lipoxygenase electron transport 202437_s_at 1545 cytochrome P450, family 1, subfamily B, electron transport polypeptide 1 206662_at 2745 glutaredoxin (thioltransferase) electron transport 205042_at 10020 UDP-N-acetylglucosamine-2- energy pathways epimerase/N-acetylmannosamine kinase 203923_s_at 1536 cytochrome b-245, beta polypeptide energy pathways (chronic granulomatous disease) 204044_at 23475 quinolinate phosphoribosyltransferase energy pathways (nicotinate-nucleotide pyrophosphorylase (carboxylating)) 202912_at 133 adrenomedullin hormone metabolism 205042_at 10020 UDP-N-acetylglucosamine-2- lipid metabolism epimerase/N-acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase lipid metabolism 204446_s_at 240 arachidonate 5-lipoxygenase lipid metabolism 204174_at 241 arachidonate 5-lipoxygenase-activating lipid metabolism protein 202912_at 133 adrenomedullin lipid metabolism 201963_at 2180 fatty-acid-Coenzyme A ligase, long-chain 2 lipid metabolism 208771_s_at 4048 leukotriene A4 hydrolase lipid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long-chain 1 lipid metabolism 1053_at 5982 replication factor C (activator 1) 2, 40 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 205042_at 10020 UDP-N-acetylglucosamine-2- nucleobase, nucleoside, epimerase/N-acetylmannosamine kinase nucleotide and nucleic acid metabolism 218258_at 51082 polymerase (RNA) I polypeptide D, 16 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 205053_at 5557 primase, polypeptide 1, 49 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 203409_at 1643 damage-specific DNA binding protein 2, nucleobase, nucleoside, 48 kDa nucleotide and nucleic acid metabolism 214727_at 675 breast cancer 2, early onset nucleobase, nucleoside, nucleotide and nucleic acid metabolism 209773_s_at 6241 ribonucleotide reductase M2 polypeptide nucleobase, nucleoside, nucleotide and nucleic acid metabolism 202678_at 2958 general transcription factor IIA, 2, 12 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 201710_at 4605 v-myb myeloblastosis viral oncogene nucleobase, nucleoside, homolog (avian)-like 2 nucleotide and nucleic acid metabolism 202912_at 133 adrenomedullin nucleobase, nucleoside, nucleotide and nucleic acid metabolism 200660_at 6282 S100 calcium binding protein A11 nucleobase, nucleoside, (calgizzarin) nucleotide and nucleic acid metabolism 209930_s_at 4778 nuclear factor (erythroid-derived 2), nucleobase, nucleoside, 45 kDa nucleotide and nucleic acid metabolism 201989_s_at 1389 cAMP responsive element binding nucleobase, nucleoside, protein-like 2 nucleotide and nucleic acid metabolism 205042_at 10020 UDP-N-acetylglucosamine-2- organic acid metabolism epimerase/N-acetylmannosamine kinase 204446_s_at 240 arachidonate 5-lipoxygenase organic acid metabolism 204174_at 241 arachidonate 5-lipoxygenase-activating organic acid metabolism protein 201963_at 2180 fatty-acid-Coenzyme A ligase, long-chain 2 organic acid metabolism 208771_s_at 4048 leukotriene A4 hydrolase organic acid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long-chain 1 organic acid metabolism 206734_at 8690 jerky homolog-like (mouse) organogenesis 211506_s_at 3576 interleukin 8 organogenesis 205807_s_at 7286 tuftelin 1 organogenesis 218224_at 9240 paraneoplastic antigen MA1 organogenesis 202437_s_at 1545 cytochrome P450, family 1, subfamily B, organogenesis polypeptide 1 205807_s_at 7286 tuftelin 1 ossification 202437_s_at 1545 cytochrome P450, family 1, subfamily B, perception of external stimulus polypeptide 1 202933_s_at 7525 v-yes-1 Yamaguchi sarcoma viral phosphorus metabolism oncogene homolog 1 209457_at 1847 dual specificity phosphatase 5 phosphorus metabolism 209585_s_at 9562 multiple inositol polyphosphate histidine phosphorus metabolism phosphatase, 1 214727_at 675 breast cancer 2, early onset programmed cell death 201710_at 4605 v-myb myeloblastosis viral oncogene homolog programmed cell death (avian)-like 2 204614_at 5055 serine (or cysteine) proteinase inhibitor, clade programmed cell death B (ovalbumin), member 2

Pathogen Response

LOCUS AFFX_ID LINK GENE NAME CLASSIFICATION 205042_at 10020 UDP-N-acetylglucosamine-2- alcohol metabolism epimerase/N-acetylmannosamine kinase 201612_at 223 aldehyde dehydrogenase 9 family, aldehyde metabolism member A1 205042_at 10020 UDP-N-acetylglucosamine-2- amine metabolism epimerase/N-acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase amine metabolism 205042_at 10020 UDP-N-acetylglucosamine-2- biosynthesis epimerase/N-acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase biosynthesis 219649_at 29929 dolichyl-P-Glc:Man9GlcNAc2-PP- biosynthesis dolichylglucosyltransferase 200962_at 6160 ribosomal protein L31 biosynthesis 204446_s_at 240 arachidonate 5-lipoxygenase biosynthesis 204174_at 241 arachidonate 5-lipoxygenase-activating biosynthesis protein 202912_at 133 adrenomedullin biosynthesis 204044_at 23475 quinolinate phosphoribosyltransferase biosynthesis (nicotinate-nucleotide pyrophosphorylase (carboxylating)) 208771_s_at 4048 leukotriene A4 hydrolase biosynthesis 205042_at 10020 UDP-N-acetylglucosamine-2- carbohydrate metabolism epimerase/N-acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase carbohydrate metabolism 202499_s_at 6515 solute carrier family 2 (facilitated glucose carbohydrate metabolism transporter), member 3 205042_at 10020 UDP-N-acetylglucosamine-2- catabolism epimerase/N-acetylmannosamine kinase 208771_s_at 4048 leukotriene A4 hydrolase catabolism 212190_at 5270 serine (or cysteine) proteinase inhibitor, catabolism clade E (nexin, plasminogen activator inhibitor type 1), member 2 218875_s_at 26271 F-box only protein 5 catabolism 205042_at 10020 UDP-N-acetylglucosamine-2- cell adhesion epimerase/N-acetylmannosamine kinase 211506_s_at 3576 interleukin 8 cell adhesion 203336_s_at 9270 integrin cytoplasmic domain-associated cell adhesion protein 1 216250_s_at 9404 leupaxin cell adhesion 219890_at 23601 C-type (calcium dependent, cell adhesion carbohydrate-recognition domain) lectin, superfamily member 5 214727_at 675 breast cancer 2, early onset cell death 201710_at 4605 v-myb myeloblastosis viral oncogene cell death homolog (avian)-like 2 204614_at 5055 serine (or cysteine) proteinase inhibitor, cell death clade B (ovalbumin), member 2 212190_at 5270 serine (or cysteine) proteinase inhibitor, cell migration clade E (nexin, plasminogen activator inhibitor type 1), member 2 214727_at 675 breast cancer 2, early onset cell organization and biogenesis 201714_at 7283 tubulin, gamma 1 cell organization and biogenesis 201999_s_at 6993 t-complex-associated-testis-expressed 1- cell organization and biogenesis like 1 1053_at 5982 replication factor C (activator 1) 2, 40 kDa cell proliferation 205053_at 5557 primase, polypeptide 1, 49 kDa cell proliferation 214727_at 675 breast cancer 2, early onset cell proliferation 209773_s_at 6241 ribonucleotide reductase M2 polypeptide cell proliferation 211506_s_at 3576 interleukin 8 cell proliferation 201710_at 4605 v-myb myeloblastosis viral oncogene cell proliferation homolog (avian)-like 2 200660_at 6282 S100 calcium binding protein A11 cell proliferation (calgizzarin) 201641_at 684 bone marrow stromal cell antigen 2 cell proliferation 211506_s_at 3576 interleukin 8 cell-cell signaling 202912_at 133 adrenomedullin cell-cell signaling 201641_at 684 bone marrow stromal cell antigen 2 cell-cell signaling 204044_at 23475 quinolinate phosphoribosyltransferase cell-cell signaling (nicotinate-nucleotide pyrophosphorylase (carboxylating)) 204044_at 23475 quinolinate phosphoribosyltransferase coenzymes and prosthetic (nicotinate-nucleotide pyrophosphorylase group metabolism (carboxylating)) 203923_s_at 1536 cytochrome b-245, beta polypeptide electron transport (chronic granulomatous disease) 204446_s_a 240 arachidonate 5-lipoxygenase electron transport 202437_s_at 1545 cytochrome P450, family 1, subfamily B, electron transport polypeptide 1 206662_at 2745 glutaredoxin (thioltransferase) electron transport 205042_at 10020 UDP-N-acetylglucosamine-2- energy pathways epimerase/N-acetylmannosamine kinase 203923_s_at 1536 cytochrome b-245, beta polypeptide energy pathways (chronic granulomatous disease) 204044_at 23475 quinolinate phosphoribosyltransferase energy pathways (nicotinate-nucleotide pyrophosphorylase (carboxylating)) 202912_at 133 adrenomedullin hormone metabolism 205042_at 10020 UDP-N-acetylglucosamine-2- lipid metabolism epimerase/N-acetylmannosamine kinase 210942_s_at 10402 alpha2,3-sialyltransferase lipid metabolism 204446_s_at 240 arachidonate 5-lipoxygenase lipid metabolism 204174_at 241 arachidonate 5-lipoxygenase-activating lipid metabolism protein 202912_at 133 adrenomedullin lipid metabolism 201963_at 2180 fatty-acid-Coenzyme A ligase, long-chain 2 lipid metabolism 208771_s_at 4048 leukotriene A4 hydrolase lipid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long-chain 1 lipid metabolism 1053_at 5982 replication factor C (activator 1) 2, 40 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 205042_at 10020 UDP-N-acetylglucosamine-2- nucleobase, nucleoside, epimerase/N-acetylmannosamine kinase nucleotide and nucleic acid metabolism 218258_at 51082 polymerase (RNA) I polypeptide D, nucleobase, nucleoside, 16 kDa nucleotide and nucleic acid metabolism 205053_at 5557 primase, polypeptide 1, 49 kDa nucleobase, nucleoside,. nucleotide and nucleic acid metabolism 203409_at 1643 damage-specific DNA binding protein 2, nucleobase, nucleoside, 48 kDa nucleotide and nucleic acid metabolism 214727_at 675 breast cancer 2, early onset nucleobase, nucleoside, nucleotide and nucleic acid metabolism 209773_s_at 6241 ribonucleotide reductase M2 polypeptide nucleobase, nucleoside,. nucleotide and nucleic acid metabolism 202678_at 2958 general transcription factor IIA, 2, 12 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 201710_at 4605 v-myb myeloblastosis viral oncogene nucleobase, nucleoside, homolog (avian)-like 2 nucleotide and nucleic acid metabolism 202912_at 133 adrenomedullin nucleobase, nucleoside, nucleotide and nucleic acid metabolism 200660_at 6282 S100 calcium binding protein A11 nucleobase, nucleoside, (calgizzarin) nucleotide and nucleic acid metabolism 209930_s_at 4778 nuclear factor (erythroid-derived 2), nucleobase, nucleoside,. 45 kDa nucleotide and nucleic acid metabolism 201989_s_at 1389 cAMP responsive element binding nucleobase, nucleoside, protein-like 2 nucleotide and nucleic acid metabolism 205042_at 10020 UDP-N-acetylglucosamine-2- organic acid metabolism epimerase/N-acetylmannosamine kinase 204446_s_at 240 arachidonate 5-lipoxygenase organic acid metabolism 204174_at 241 arachidonate 5-lipoxygenase-activating organic acid metabolism protein 201963_at 2180 fatty-acid-Coenzyme A ligase, long-chain 2 organic acid metabolism 208771_s_at 4048 leukotriene A4 hydrolase organic acid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long-chain 1 organic acid metabolism 206734_at 8690 jerky homolog-like (mouse) organogenesis 211506_s_at 3576 interleukin 8 organogenesis 205807_s_at 7286 tuftelin 1 organogenesis 218224_at 9240 paraneoplastic antigen MA1 organogenesis 202437_s_at 1545 cytochrome P450, family 1, subfamily B, organogenesis polypeptide 1 205807_s_at 7286 tuftelin 1 ossification 202437_s_at 1545 cytochrome P450, family 1, subfamily B, perception of external stimulus polypeptide 1 202933_s_at 7525 v-yes-1 Yamaguchi sarcoma viral phosphorus metabolism oncogene homolog 1 209457_at 1847 dual specificity phosphatase 5 phosphorus metabolism 209585_s_at 9562 multiple inositol polyphosphate histidine phosphorus metabolism phosphatase, 1 214727_at 675 breast cancer 2, early onset programmed cell death 201710_at 4605 v-myb myeloblastosis viral oncogene programmed cell death homolog (avian)-like 2 204614_at 5055 serine (or cysteine) proteinase inhibitor, programmed cell death clade B (ovalbumin), member 2 205042_at 10020 UDP-N-acetylglucosamine-2- protein metabolism epimerase/N-acetylmannosamine kinase 202933_s_at 7525 v-yes-1 Yamaguchi sarcoma viral protein metabolism oncogene homolog 1 209457_at 1847 dual specificity phosphatase 5 protein metabolism 210942_s_at 10402 alpha2,3-sialyltransferase protein metabolism 219649_at 29929 dolichyl-P-Glc:Man9GlcNAc2-PP- protein metabolism dolichylglucosyltransferase 200962_at 6160 ribosomal protein L31 protein metabolism 216250_s_at 9404 leupaxin protein metabolism 208771_s_at 4048 leukotriene A4 hydrolase protein metabolism 212190_at 5270 serine (or cysteine) proteinase inhibitor, protein metabolism clade E (nexin, plasminogen activator inhibitor type 1), member 2 218875_s_at 26271 F-box only protein 5 protein metabolism 212190_at 5270 serine (or cysteine) proteinase inhibitor, regulation of metabolism clade E (nexin, plasminogen activator inhibitor type 1), member 2 205557_at 671 bactericidal/permeability-increasing response to abiotic stimulus protein 202437_s_at 1545 cytochrome P450, family 1, subfamily B, response to abiotic stimulus polypeptide 1 211506_s_at 3576 interleukin 8 response to biotic stimulus 205557_at 671 bactericidal/permeability-increasing response to biotic stimulus protein 203923_s_at 1536 cytochrome b-245, beta polypeptide response to biotic stimulus (chronic granulomatous disease) 204446_s_at 240 arachidonate 5-lipoxygenase response to biotic stimulus 204174_at 241 arachidonate 5-lipoxygenase-activating response to biotic stimulus protein 202912_at 133 adrenomedullin response to biotic stimulus 201641_at 684 bone marrow stromal cell antigen 2 response to biotic stimulus 208771_s_at 4048 leukotriene A4 hydrolase response to biotic stimulus 209575_at 3588 interleukin 10 receptor, beta response to biotic stimulus 216950_s_at 2209 Fc fragment of IgG, high affinity Ia, response to biotic stimulus receptor for (CD64) 211506_s_at 3576 interleukin 8 response to pest/pathogen/parasite 203923_s_at 1536 cytochrome b-245, beta polypeptide (chronic response to pest/pathogen/parasite granulomatous disease) 204446_s_at 240 arachidonate 5-lipoxygenase response to pest/pathogen/parasite 204174_at 241 arachidonate 5-lipoxygenase-activating response to pest/pathogen/parasite protein 201641_at 684 bone marrow stromal cell antigen 2 response to pest/pathogen/parasite 208771_s_at 4048 leukotriene A4 hydrolase response to pest/pathogen/parasite 209575_at 3588 interleukin 10 receptor, beta response to pest/pathogen/parasite VX-944 (Late) vs. MPA (Late): 335 genes were found to be common between these two comparisons. These genes were further assigned to the following functional categories:

NUMBER of Genes Phosphatidylinositol signaling system 15 Cell cycle 7 Apoptosis 6 Inositol phosphatemetabolism 4 Integrin-mediated celladhesion 4 Arginine and proline metabolism 3 Fatty acid metabolism 3 Purine metabolism 3 Oxidative phosphorylation 2 Parkinson's disease 2 Prostaglandin andleukotriene metabolism 2 Pyrimidine metabolism 2 Pyruvate metabolism 2 Ribosome 2 Starch and sucrosemetabolism 2 Urea cycle and metabolism ofamino groups 2 Glycosylphosphatidylinositol(GPI)-anchor 2 biosynthesis ATP synthesis 1 Androgen and estrogen metabolism 1 Benzoate degradation viaCoA ligation 1 Carbon fixation 1 DNApolymerase 1 Glutathione metabolism 1 Glycerolipid metabolism 1 Glycolysis/Gluconeogenesis 1 Histidine metabolism 1 N-Glycandegradation 1 Nitrogen metabolism 1 Proteasome 1 Selenoamino acid metabolism 1 Sphingoglycolipidmetabolism 1 Sulfur metabolism 1 Transcription factors 1 Tryptophan metabolism 1 Ubiquinonebiosynthesis 1 gamma-Hexachlorocyclohexane degradation 1 unclassified 277

Phosphatidyl Inositol Signaling System:

LOCUS AFFYID LINK GENE NAME PATHWAY 208745_at 10632 ATP synthase, H+ transporting, ATP synthesis mitochondrial F0 complex, subunit g 201413_at 3295 hydroxysteroid (17-beta) Androgen and estrogen dehydrogenase 4 metabolism 200797_s_at 4170 myeloid cell leukemia sequence 1 Apoptosis (BCL2-related) 201502_s_at 4792 nuclear factor of kappa light Apoptosis polypeptide gene enhancer in B-cells inhibitor, alpha 205681_at 597 BCL2-related protein A1 Apoptosis 207113_s_at 7124 tumor necrosis factor (TNF Apoptosis superfamily, member 2) 203508_at 7133 tumor necrosis factor receptor Apoptosis superfamily, member 1B 203984_s_at 842 caspase 9, apoptosis-related Apoptosis cysteine protease 200884_at 1152 creatine kinase, brain Arginine and proline metabolism 206177_s_at 383 arginase, liver Arginine and proline metabolism 203455_s_at 6303 spermidine/spermine N1- Arginine and proline metabolism acetyltransferase 205260_s_at 97 acylphosphatase 1, erythrocyte Benzoate degradation viaCoA (common) type ligation 204059_s_at 4199 malic enzyme 1, NADP(+)- Carbon fixation dependent, cytosolic 205899_at 8900 cyclin A1 Cell cycle 201700_at 896 cyclin D3 Cell cycle 205034_at 9134 cyclin E2 Cell cycle 38158_at 9700 extra spindle poles like 1 (S. cerevisiae) Cell cycle 204695_at 993 cell division cycle 25A Cell cycle 201853_s_at 994 cell division cycle 25B Cell cycle 205167_s_at 995 cell division cycle 25C Cell cycle 205053_at 5557 primase, polypeptide 1, 49 kDa DNApolymerase 202437_s_at 1545 cytochrome P450, family 1, Fatty acid metabolism subfamily B, polypeptide 1 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long- Fatty acid metabolism chain 1 201963_at 2180 fatty-acid-Coenzyme A ligase, long- Fatty acid metabolism chain 2 202554_s_at 2947 glutathione S-transferase M3 (brain) Glutathione metabolism 203385_at 1606 diacylglycerol kinase, alpha 80 kDa Glycerolipid metabolism 205260_s_at 97 acylphosphatase 1, erythrocyte Glycolysis/Gluconeogenesis (common) type 206643_at 3034 histidine ammonia-lyase Histidine metabolism 202794_at 3628 inositol polyphosphate-1- Inositol phosphatemetabolism phosphatase 204552_at 3631 inositol polyphosphate-4- Inositol phosphatemetabolism phosphatase, type I, 107 kDa 201598_s_at 3636 inositol polyphosphate phosphatase- Inositol phosphatemetabolism like 1 212990_at 8867 synaptojanin 1 Inositol phosphatemetabolism 218807_at 10451 vav 3 oncogene Integrin-mediated celladhesion 207121_s_at 5597 mitogen-activated protein kinase 6 Integrin-mediated celladhesion 200931_s_at 7414 vinculin Integrin-mediated celladhesion 208683_at 824 calpain 2, (m/II) large subunit Integrin-mediated celladhesion 208926_at 4758 sialidase 1 (lysosomal sialidase) N-Glycandegradation 206643_at 3034 histidine ammonia-lyase Nitrogen metabolism 208745_at 10632 ATP synthase, H+ transporting, Oxidative phosphorylation mitochondrial F0 complex, subunit g 206790_s_at 4707 NADH dehydrogenase (ubiquinone) Oxidative phosphorylation 1 beta subcomplex, 1, 7 kDa 202530_at 1432 mitogen-activated protein kinase 14 Parkinson's disease 203984_s_at 842 caspase 9, apoptosis-related Parkinson's disease cysteine protease 204446_s_at 240 arachidonate 5-lipoxygenase Prostaglandin andleukotriene metabolism 208771_s_at 4048 leukotriene A4 hydrolase Prostaglandin andleukotriene metabolism 200882_s_at 5710 proteasome (prosome, macropain) Proteasome 26S subunit, non-ATPase, 4 209773_s_at 6241 ribonucleotide reductase M2 Purine metabolism polypeptide 209043_at 9061 3′-phosphoadenosine 5′- Purine metabolism phosphosulfate synthase 1 209473_at 953 ectonucleoside triphosphate Purine metabolism diphosphohydrolase 1 209773_s_at 6241 ribonucleotide reductase M2 Pyrimidine metabolism polypeptide 209473_at 953 ectonucleoside triphosphate Pyrimidine metabolism diphosphohydrolase 1 204059_s_at 4199 malic enzyme 1, NADP(+)- Pyruvate metabolism dependent, cytosolic 205260_s_at 97 acylphosphatase 1, erythrocyte Pyruvate metabolism (common) type 221989_at 6134 ribosomal protein L10 Ribosome 200962_at 6160 ribosomal protein L31 Ribosome 209043_at 9061 3′-phosphoadenosine 5′- Selenoamino acidmetabolism phosphosulfate synthase 1 208926_at 4758 sialidase 1 (lysosomal sialidase) Sphingoglycolipidmetabolism 208498_s_at 276 amylase, alpha 1A; salivary Starch and sucrosemetabolism 202990_at 5836 phosphorylase, glycogen; liver (Hers Starch and sucrosemetabolism disease, glycogen storage disease type VI) 209043_at 9061 3′-phosphoadenosine 5′- Sulfur metabolism phosphosulfate synthase 1 210053_at 6877 TAF5 RNA polymerase II, TATA box Transcription factors binding protein (TBP)-associated factor, 100 kDa 202437_s_at 1545 cytochrome P450, family 1, Tryptophan metabolism subfamily B, polypeptide 1 206790_s_at 4707 NADH dehydrogenase (ubiquinone) Ubiquinonebiosynthesis 1 beta subcomplex, 1, 7 kDa 200884_at 1152 creatine kinase, brain Urea cycle and metabolism ofamino groups 206177_s_at 383 arginase, liver Urea cycle and metabolism ofamino groups 205281_s_at 5277 phosphatidylinositol glycan, class A Glycosylphosphatidylinositol(GPI)- (paroxysmal nocturnal anchor biosynthesis hemoglobinuria) 205452_at 9488 phosphatidylinositol glycan, class B Glycosylphosphatidylinositol(GPI)- anchor biosynthesis 209714_s_at 1033 cyclin-dependent kinase inhibitor 3 Phosphatidylinositol signaling (CDK2-associated dual specificity system phosphatase) 221563_at 11221 dual specificity phosphatase 10 Phosphatidylinositol signaling system 203385_at 1606 diacylglycerol kinase, alpha 80 kDa Phosphatidylinositol signaling system 209457_at 1847 dual specificity phosphatase 5 Phosphatidylinositol signaling system 208892_s_at 1848 dual specificity phosphatase 6 Phosphatidylinositol signaling system 202794_at 3628 inositol polyphosphate-1- Phosphatidylinositol signaling phosphatase system 204552_at 3631 inositol polyphosphate-4- Phosphatidylinositol signaling phosphatase, type I, 107 kDa system 201598_s_at 3636 inositol polyphosphate phosphatase- Phosphatidylinositol signaling like 1 system 204852_s_at 5778 protein tyrosine phosphatase, non- Phosphatidylinositol signaling receptor type 7 system 202006_at 5782 protein tyrosine phosphatase, non- Phosphatidylinositol signaling receptor type 12 system 221840_at 5791 protein tyrosine phosphatase, Phosphatidylinositol signaling receptor type, E system 212990_at 8867 synaptojanin 1 Phosphatidylinositol signaling system 204695_at 993 cell division cycle 25A Phosphatidylinositol signaling system 201853_s_at 994 cell division cycle 25B Phosphatidylinositol signaling system 205167_s_at 995 cell division cycle 25C Phosphatidylinositol signaling system

Cell Cycle

LOCUS AFFYID LINK GENE NAME PATHWAY 208745_at 10632 ATP synthase, H+ transporting, ATP synthesis mitochondrial F0 complex, subunit g 201413_at 3295 hydroxysteroid (17-beta) Androgen and estrogen dehydrogenase 4 metabolism 200797_s_at 4170 myeloid cell leukemia sequence 1 Apoptosis (BCL2-related) 201502_s_at 4792 nuclear factor of kappa light Apoptosis polypeptide gene enhancer in B-cells inhibitor, alpha 205681_at 597 BCL2-related protein A1 Apoptosis 207113_s_at 7124 tumor necrosis factor (TNF Apoptosis superfamily, member 2) 203508_at 7133 tumor necrosis factor receptor Apoptosis superfamily, member 1B 203984_s_at 842 caspase 9, apoptosis-related Apoptosis cysteine protease 200884_at 1152 creatine kinase, brain Arginine and proline metabolism 206177_s_at 383 arginase, liver Arginine and proline metabolism 203455_s_at 6303 spermidine/spermine N1- Arginine and proline metabolism acetyltransferase 205260_s_at 97 acylphosphatase 1, erythrocyte Benzoate degradation viaCoA (common) type ligation 204059_s_at 4199 malic enzyme 1, NADP(+)- Carbon fixation dependent, cytosolic 205899_at 8900 cyclin A1 Cell cycle 201700_at 896 cyclin D3 Cell cycle 205034_at 9134 cyclin E2 Cell cycle 38158_at 9700 extra spindle poles like 1 (S. cerevisiae) Cell cycle 204695_at 993 cell division cycle 25A Cell cycle 201853_s_at 994 cell division cycle 25B Cell cycle 205167_s_at 995 cell division cycle 25C Cell cycle

Apoptosis

LOCUS AFFYID LINK GENE NAME PATHWAY 208745_at 10632 ATP synthase, H+ transporting, ATP synthesis mitochondrial F0 complex, subunit g 201413_at 3295 hydroxysteroid (17-beta) Androgen and estrogen dehydrogenase 4 metabolism 200797_s_at 4170 myeloid cell leukemia sequence 1 Apoptosis (BCL2-related) 201502_s_at 4792 nuclear factor of kappa light polypeptide Apoptosis gene enhancer in B-cells inhibitor, alpha 205681_at 597 BCL2-related protein A1 Apoptosis 207113_s_at 7124 tumor necrosis factor (TNF superfamily, Apoptosis member 2) 203508_at 7133 tumor necrosis factor receptor Apoptosis superfamily, member 1B 203984_s_at 842 caspase 9, apoptosis-related cysteine Apoptosis protease

Inositol Phosphate Metabolism

LOCUS AFFYID LINK GENE NAME PATHWAY 208745_at 10632 ATP synthase, H+ transporting, ATP synthesis mitochondrial F0 complex, subunit g 201413_at 3295 hydroxysteroid (17-beta) Androgen and estrogen dehydrogenase 4 metabolism 200797_s_at 4170 myeloid cell leukemia sequence 1 Apoptosis (BCL2-related) 201502_s_at 4792 nuclear factor of kappa light Apoptosis polypeptide gene enhancer in B-cells inhibitor, alpha 205681_at 597 BCL2-related protein A1 Apoptosis 207113_s_at 7124 tumor necrosis factor (TNF Apoptosis superfamily, member 2) 203508_at 7133 tumor necrosis factor receptor Apoptosis superfamily, member 1B 203984_s_at 842 caspase 9, apoptosis-related Apoptosis cysteine protease 200884_at 1152 creatine kinase, brain Arginine and proline metabolism 206177_s_at 383 arginase, liver Arginine and proline metabolism 203455_s_at 6303 spermidine/spermine N1- Arginine and proline metabolism acetyltransferase 205260_s_at 97 acylphosphatase 1, erythrocyte Benzoate degradation viaCoA (common) type ligation 204059_s_at 4199 malic enzyme 1, NADP(+)- Carbon fixation dependent, cytosolic 205899_at 8900 cyclin A1 Cell cycle 201700_at 896 cyclin D3 Cell cycle 205034_at 9134 cyclin E2 Cell cycle 38158_at 9700 extra spindle poles like 1 (S. cerevisiae) Cell cycle 204695_at 993 cell division cycle 25A Cell cycle 201853_s_at 994 cell division cycle 25B Cell cycle 205167_s_at 995 cell division cycle 25C Cell cycle 205053_at 5557 primase, polypeptide 1, 49 kDa DNApolymerase 202437_s_at 1545 cytochrome P450, family 1, Fatty acid metabolism subfamily B, polypeptide 1 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long- Fatty acid metabolism chain 1 201963_at 2180 fatty-acid-Coenzyme A ligase, long- Fatty acid metabolism chain 2 202554_s_at 2947 glutathione S-transferase M3 (brain) Glutathione metabolism 203385_at 1606 diacylglycerol kinase, alpha 80 kDa Glycerolipid metabolism 205260_s_at 97 acylphosphatase 1, erythrocyte Glycolysis/Gluconeogenesis (common) type 206643_at 3034 histidine ammonia-lyase Histidine metabolism 202794_at 3628 inositol polyphosphate-1-phosphatase Inositol phosphatemetabolism 204552_at 3631 inositol polyphosphate-4-phosphatase, Inositol phosphatemetabolism type I, 107 kDa 201598_s_at 3636 inositol polyphosphate phosphatase-like 1 Inositol phosphatemetabolism 212990_at 8867 synaptojanin 1 Inositol phosphatemetabolism

Fatty Acid Metabolism

LOCUS AFFYID LINK GENE NAME PATHWAY 208745_at 10632 ATP synthase, H+ transporting, ATP synthesis mitochondrial F0 complex, subunit g 201413_at 3295 hydroxysteroid (17-beta) Androgen and estrogen dehydrogenase 4 metabolism 200797_s_at 4170 myeloid cell leukemia sequence 1 Apoptosis (BCL2-related) 201502_s_at 4792 nuclear factor of kappa light Apoptosis polypeptide gene enhancer in B-cells inhibitor, alpha 205681_at 597 BCL2-related protein A1 Apoptosis 207113_s_at 7124 tumor necrosis factor (TNF Apoptosis superfamily, member 2) 203508_at 7133 tumor necrosis factor receptor Apoptosis superfamily, member 1B 203984_s_at 842 caspase 9, apoptosis-related Apoptosis cysteine protease 200884_at 1152 creatine kinase, brain Arginine and proline metabolism 206177_s_at 383 arginase, liver Arginine and proline metabolism 203455_s_at 6303 spermidine/spermine N1- Arginine and proline metabolism acetyltransferase 205260_s_at 97 acylphosphatase 1, erythrocyte Benzoate degradation viaCoA (common) type ligation 204059_s_at 4199 malic enzyme 1, NADP(+)- Carbon fixation dependent, cytosolic 205899_at 8900 cyclin A1 Cell cycle 201700_at 896 cyclin D3 Cell cycle 205034_at 9134 cyclin E2 Cell cycle 38158_at 9700 extra spindle poles like 1 (S. cerevisiae) Cell cycle 204695_at 993 cell division cycle 25A Cell cycle 201853_s_at 994 cell division cycle 25B Cell cycle 205167_s_at 995 cell division cycle 25C Cell cycle 205053_at 5557 primase, polypeptide 1, 49 kDa DNApolymerase 202437_s_at 1545 cytochrome P450, family 1, subfamily B, Fatty acid metabolism polypeptide 1 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long-chain 1 Fatty acid metabolism 201963_at 2180 fatty-acid-Coenzyme A ligase, long-chain 2 Fatty acid metabolism VX-944 (Early) vs. VX-944 (Late): 102 genes found common between these two comparisons were binned into the following functional categories.

Signal Transduction:

LOCUS AFFX_ID LINK GENE NAME CLASSIFICATION 210942_s_at 10402 alpha2,3-sialyltransferase amine metabolism 202532_s_at 1719 dihydrofolate reductase amine metabolism 202532_s_at 1719 dihydrofolate reductase amino acid and derivative metabolism 218212_s_at 4338 molybdenum cofactor synthesis 2 aromatic compound metabolism 210942_s_at 10402 alpha2,3-sialyltransferase biosynthesis 218212_s_at 4338 molybdenum cofactor synthesis 2 biosynthesis 207563_s_at 8473 O-linked N-acetylglucosamine (GlcNAc) biosynthesis transferase (UDP-N- acetylglucosamine:polypeptide-N- acetylglucosaminyl transferase) 200962_at 6160 ribosomal protein L31 biosynthesis 204446_s_at 240 arachidonate 5-lipoxygenase biosynthesis 204174_at 241 arachidonate 5-lipoxygenase-activating biosynthesis protein 202532_s_at 1719 dihydrofolate reductase biosynthesis 208771_s_at 4048 leukotriene A4 hydrolase biosynthesis 210845_s_at 5329 plasminogen activator, urokinase receptor blood coagulation 209473_at 953 ectonucleoside triphosphate blood coagulation diphosphohydrolase 1 210942_s_at 10402 alpha2,3-sialyltransferase carbohydrate metabolism 202499_s_at 6515 solute carrier family 2 (facilitated glucose carbohydrate metabolism transporter), member 3 219373_at 54344 dolichyl-phosphate mannosyltransferase carbohydrate metabolism polypeptide 3 206111_at 6036 ribonuclease, RNase A family, 2 (liver, catabolism eosinophil-derived neurotoxin) 201069_at 4313 matrix metalloproteinase 2 (gelatinase A, catabolism 72 kDa gelatinase, 72 kDa type IV collagenase) 208771_s_at 4048 leukotriene A4 hydrolase catabolism 212190_at 5270 serine (or cysteine) proteinase inhibitor, catabolism clade E (nexin, plasminogen activator inhibitor type 1), member 2 211506_s_at 3576 interleukin 8 cell adhesion 209473_at 953 ectonucleoside triphosphate cell adhesion diphosphohydrolase 1 204655_at 6352 chemokine (C-C motif) ligand 5 cell adhesion 205176_s_at 23421 integrin beta 3 binding protein (beta3- cell adhesion endonexin) 216250_s_at 9404 leupaxin cell adhesion 219890_at 23601 C-type (calcium dependent, carbohydrate- cell adhesion recognition domain) lectin, superfamily member 5 208892_s_at 1848 dual specificity phosphatase 6 cell death 202644_s_at 7128 tumor necrosis factor, alpha-induced cell death protein 3 214727_at 675 breast cancer 2, early onset cell death 214467_at 8477 G protein-coupled receptor 65 cell death 205681_at 597 BCL2-related protein A1 cell death 201710_at 4605 v-myb myeloblastosis viral oncogene cell death homolog (avian)-like 2 204614_at 5055 serine (or cysteine) proteinase inhibitor, cell death clade B (ovalbumin), member 2 204655_at 6352 chemokine (C-C motif) ligand 5 cell homeostasis 210946_at 8611 phosphatidic acid phosphatase type 2A cell migration 212190_at 5270 serine (or cysteine) proteinase inhibitor, cell migration clade E (nexin, plasminogen activator inhibitor type 1), member 2 203358_s_at 2146 enhancer of zeste homolog 2 (Drosophila) cell organization and biogenesis 214727_at 675 breast cancer 2, early onset cell organization and biogenesis 201999_s_at 6993 t-complex-associated-testis-expressed 1- cell organization and biogenesis like 1 205046_at 1062 centromere protein E, 312 kDa cell proliferation 208892_s_at 1848 dual specificity phosphatase 6 cell proliferation 205053_at 5557 primase, polypeptide 1, 49 kDa cell proliferation 203564_at 2189 Fanconi anemia, complementation group G cell proliferation 214727_at 675 breast cancer 2, early onset cell proliferation 209773_s_at 6241 ribonucleotide reductase M2 polypeptide cell proliferation 211506_s_at 3576 interleukin 8 cell proliferation 202811_at 10617 associated molecule with the SH3 domain cell proliferation of STAM 201710_at 4605 v-myb myeloblastosis viral oncogene cell proliferation homolog (avian)-like 2 200660_at 6282 S100 calcium binding protein A11 cell proliferation (calgizzarin) 202191_s_at 8522 growth arrest-specific 7 cell proliferation 211506_s_at 3576 interleukin 8 cell-cell signaling 209473_at 953 ectonucleoside triphosphate cell-cell signaling diphosphohydrolase 1 204655_at 6352 chemokine (C-C motif) ligand 5 cell-cell signaling 207339_s_at 4050 lymphotoxin beta (TNF superfamily, cell-cell signaling member 3) 205204_at 4828 neuromedin B cell-cell signaling 218212_s_at 4338 molybdenum cofactor synthesis 2 coenzymes and prosthetic group metabolism 203923_s_at 1536 cytochrome b-245, beta polypeptide electron transport (chronic granulomatous disease) 204446_s_at 240 arachidonate 5-lipoxygenase electron transport 202437_s_at 1545 cytochrome P450, family 1, subfamily B, electron transport polypeptide 1 202942_at 2109 electron-transfer-flavoprotein, beta electron transport polypeptide 203923_s_at 1536 cytochrome b-245, beta polypeptide energy pathways (chronic granulomatous disease) 210942_s_at 10402 alpha2,3-sialyltransferase lipid metabolism 204446_s_at 240 arachidonate 5-lipoxygenase lipid metabolism 204174_at 241 arachidonate 5-lipoxygenase-activating lipid metabolism protein 201012_at 301 annexin A1 lipid metabolism 210946_at 8611 phosphatidic acid phosphatase type 2A lipid metabolism 201963_at 2180 fatty-acid-Coenzyme A ligase, long-chain 2 lipid metabolism 208771_s_at 4048 leukotriene A4 hydrolase lipid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long-chain 1 lipid metabolism 206066_s_at 5889 RAD51 homolog C (S. cerevisiae) nucleobase, nucleoside, nucleotide and nucleic acid metabolism 203358_s_at 2146 enhancer of zeste homolog 2 (Drosophila) nucleobase, nucleoside, nucleotide and nucleic acid metabolism. 205053_at 5557 primase, polypeptide 1, 49 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 203564_at 2189 Fanconi anemia, complementation group G nucleobase, nucleoside, nucleotide and nucleic acid metabolism 203409_at 1643 damage-specific DNA binding protein 2, nucleobase, nucleoside, 48 kDa nucleotide and nucleic acid metabolism 214727_at 675 breast cancer 2, early onset nucleobase, nucleoside, nucleotide and nucleic acid metabolism 209773_s_at 6241 ribonucleotide reductase M2 polypeptide nucleobase, nucleoside, nucleotide and nucleic acid metabolism 206111_at 6036 ribonuclease, RNase A family, 2 (liver, nucleobase, nucleoside, eosinophil-derived neurotoxin) nucleotide and nucleic acid metabolism 201710_at 4605 v-myb myeloblastosis viral oncogene nucleobase, nucleoside, homolog (avian)-like 2 nucleotide and nucleic acid metabolism 200660_at 6282 S100 calcium binding protein A11 nucleobase, nucleoside, (calgizzarin) nucleotide and nucleic acid metabolism 202532_s_at 1719 dihydrofolate reductase nucleobase, nucleoside, nucleotide and nucleic acid metabolism 202532_s_at 1719 dihydrofolate reductase one-carbon compound metabolism 204446_s_at 240 arachidonate 5-lipoxygenase organic acid metabolism 204174_at 241 arachidonate 5-lipoxygenase-activating organic acid metabolism protein 202532_s_at 1719 dihydrofolate reductase organic acid metabolism 201963_at 2180 fatty-acid-Coenzyme A ligase, long-chain 2 organic acid metabolism 208771_s_at 4048 leukotriene A4 hydrolase organic acid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long-chain 1 organic acid metabolism 206734_at 8690 jerky homolog-like (mouse) organogenesis 211506_s_at 3576 interleukin 8 organogenesis 205807_s_at 7286 tuftelin 1 organogenesis 202191_s_at 8522 growth arrest-specific 7 organogenesis 218224_at 9240 paraneoplastic antigen MA1 organogenesis 202437_s_at 1545 cytochrome P450, family 1, subfamily B, organogenesis polypeptide 1 201908_at 1857 dishevelled, dsh homolog 3 (Drosophila) organogenesis 202554_s_at 2947 glutathione S-transferase M3 (brain) organogenesis 205807_s_at 7286 tuftelin 1 ossification 204655_at 6352 chemokine (C-C motif) ligand 5 oxygen and reactive oxygen species metabolism 202554_s_at 2947 glutathione S-transferase M3 (brain) oxygen and reactive oxygen species metabolism 202437_s_at 1545 cytochrome P450, family 1, subfamily B, perception of external stimulus polypeptide 1 208892_s_at 1848 dual specificity phosphatase 6 phosphorus metabolism 209457_at 1847 dual specificity phosphatase 5 phosphorus metabolism 221563_at 11221 dual specificity phosphatase 10 phosphorus metabolism 205260_s_at 97 acylphosphatase 1, erythrocyte (common) phosphorus metabolism type 221840_at 5791 protein tyrosine phosphatase, receptor phosphorus metabolism type, E 208892_s_at 1848 dual specificity phosphatase 6 programmed cell death 202644_s_at 7128 tumor necrosis factor, alpha-induced programmed cell death protein 3 214727_at 675 breast cancer 2, early onset programmed cell death 214467_at 8477 G protein-coupled receptor 65 programmed cell death 205681_at 597 BCL2-related protein A1 programmed cell death 201710_at 4605 v-myb myeloblastosis viral oncogene programmed cell death homolog (avian)-like 2 204614_at 5055 serine (or cysteine) proteinase inhibitor, programmed cell death clade B (ovalbumin), member 2 208892_s_at 1848 dual specificity phosphatase 6 protein metabolism 209457_at 1847 dual specificity phosphatase 5 protein metabolism 210942_s_at 10402 alpha2,3-sialyltransferase protein metabolism 221563_at 11221 dual specificity phosphatase 10 protein metabolism 207563_s_at 8473 O-linked N-acetylglucosamine (GlcNAc) protein metabolism transferase (UDP-N- acetylglucosamine:polypeptide-N- acetylglucosaminyl transferase) 200962_at 6160 ribosomal protein L31 protein metabolism 216250_s_at 9404 leupaxin protein metabolism 201069_at 4313 matrix metalloproteinase 2 (gelatinase A, protein metabolism 72 kDa gelatinase, 72 kDa type IV collagenase) 221840_at 5791 protein tyrosine phosphatase, receptor protein metabolism type, E 208771_s_at 4048 leukotriene A4 hydrolase protein metabolism 212190_at 5270 serine (or cysteine) proteinase inhibitor, protein metabolism clade E (nexin, plasminogen activator inhibitor type 1), member 2 212190_at 5270 serine (or cysteine) proteinase inhibitor, regulation of metabolism clade E (nexin, plasminogen activator inhibitor type 1), member 2 205557_at 671 bactericidal/permeability-increasing protein response to abiotic stimulus 207563_s_at 8473 O-linked N-acetylglucosamine (GlcNAc) response to abiotic stimulus transferase (UDP-N- acetylglucosamine:polypeptide-N- acetylglucosaminyl transferase) 202437_s_at 1545 cytochrome P450, family 1, subfamily B, response to abiotic stimulus polypeptide 1 211506_s_at 3576 interleukin 8 response to biotic stimulus 214467_at 8477 G protein-coupled receptor 65 response to biotic stimulus 205419_at 1880 Epstein-Barr virus induced gene 2 response to biotic stimulus (lymphocyte-specific G protein-coupled receptor) 205557_at 671 bactericidal/permeability-increasing protein response to biotic stimulus 209473_at 953 ectonucleoside triphosphate response to biotic stimulus diphosphohydrolase 1 203923_s_at 1536 cytochrome b-245, beta polypeptide response to biotic stimulus (chronic granulomatous disease) 204655_at 6352 chemokine (C-C motif) ligand 5 response to biotic stimulus 204446_s_at 240 arachidonate 5-lipoxygenase response to biotic stimulus 204174_at 241 arachidonate 5-lipoxygenase-activating response to biotic stimulus protein 207339_s_at 4050 lymphotoxin beta (TNF superfamily, response to biotic stimulus member 3) 201012_at 301 annexin A1 response to biotic stimulus 208771_s_at 4048 leukotriene A4 hydrolase response to biotic stimulus 209575_at 3588 interleukin 10 receptor, beta response to biotic stimulus 216950_s_at 2209 Fc fragment of IgG, high affinity Ia, receptor response to biotic stimulus for (CD64) 205269_at 3937 lymphocyte cytosolic protein 2 (SH2 response to biotic stimulus domain containing leukocyte protein of 76 kDa) 207563_s_at 8473 O-linked N-acetylglucosamine (GlcNAc) response to extracellular transferase (UDP-N- stimulus acetylglucosamine:polypeptide-N- acetylglucosaminyl transferase) 204655_at 6352 chemokine (C-C motif) ligand 5 response to oxidative stress 211506_s_at 3576 interleukin 8 response to pest/pathogen/parasite 209473_at 953 ectonucleoside triphosphate response to diphosphohydrolase 1 pest/pathogen/parasite 203923_s_at 1536 cytochrome b-245, beta polypeptide response to (chronic granulomatous disease) pest/pathogen/parasite 204655_at 6352 chemokine (C-C motif) ligand 5 response to pest/pathogen/parasite 204446_s_at 240 arachidonate 5-lipoxygenase response to pest/pathogen/parasite 204174_at 241 arachidonate 5-lipoxygenase-activating response to protein pest/pathogen/parasite 201012_at 301 annexin A1 response to pest/pathogen/parasite 208771_s_at 4048 leukotriene A4 hydrolase response to pest/pathogen/parasite 209575_at 3588 interleukin 10 receptor, beta response to pest/pathogen/parasite 211506_s_at 3576 interleukin 8 response to wounding 203923_s_at 1536 cytochrome b-245, beta polypeptide response to wounding (chronic granulomatous disease) 204655_at 6352 chemokine (C-C motif) ligand 5 response to wounding 204446_s_at 240 arachidonate 5-lipoxygenase response to wounding 204174_at 241 arachidonate 5-lipoxygenase-activating response to wounding protein 201012_at 301 annexin A1 response to wounding 208771_s_at 4048 leukotriene A4 hydrolase response to wounding 209575_at 3588 interleukin 10 receptor, beta response to wounding 210946_at 8611 phosphatidic acid phosphatase type 2A sexual reproduction 218224_at 9240 paraneoplastic antigen MA1 sexual reproduction 208892_s_at 1848 dual specificity phosphatase 6 signal transduction 211506_s_at 3576 interleukin 8 signal transduction 214467_at 8477 G protein-coupled receptor 65 signal transduction 205419_at 1880 Epstein-Barr virus induced gene 2 (lymphocyte- signal transduction specific G protein-coupled receptor) 210845_s_at 5329 plasminogen activator, urokinase receptor signal transduction 202207_at 10123 ADP-ribosylation factor-like 7 signal transduction 210840_s_at 8826 IQ motif containing GTPase activating protein 1 signal transduction 202811_at 10617 associated molecule with the SH3 domain of signal transduction STAM 221563_at 11221 dual specificity phosphatase 10 signal transduction 207563_s_at 8473 O-linked N-acetylglucosamine (GlcNAc) signal transduction transferase (UDP-N- acetylglucosamine:polypeptide-N- acetylglucosaminyl transferase) 221830_at 5911 RAP2A, member of RAS oncogene family signal transduction 204655_at 6352 chemokine (C-C motif) ligand 5 signal transduction 217941_s_at 55914 erbb2 interacting protein signal transduction 207339_s_at 4050 lymphotoxin beta (TNF superfamily, member 3) signal transduction 201012_at 301 annexin A1 signal transduction 205176_s_at 23421 integrin beta 3 binding protein (beta3-endonexin) signal transduction 216250_s_at 9404 leupaxin signal transduction 209288_s_at 10602 CDC42 effector protein (Rho GTPase binding) 3 signal transduction 205204_at 4828 neuromedin B signal transduction 201908_at 1857 dishevelled, dsh homolog 3 (Drosophila) signal transduction 209575_at 3588 interleukin 10 receptor, beta signal transduction 216950_s_at 2209 Fc fragment of IgG, high affinity Ia, receptor for signal transduction (CD64) 205269_at 3937 lymphocyte cytosolic protein 2 (SH2 domain signal transduction containing leukocyte protein of 76 kDa)

Response to Biotic Stimulus

LOCUS AFFX_ID LINK GENE NAME CLASSIFICATION 210942_s_at 10402 alpha2,3-sialyltransferase amine metabolism 202532_s_at 1719 dihydrofolate reductase amine metabolism 202532_s_at 1719 dihydrofolate reductase amino acid and derivative metabolism 218212_s_at 4338 molybdenum cofactor synthesis 2 aromatic compound metabolism 210942_s_at 10402 alpha2,3-sialyltransferase biosynthesis 218212_s_at 4338 molybdenum cofactor synthesis 2 biosynthesis 207563_s_at 8473 O-linked N-acetylglucosamine (GlcNAc) biosynthesis transferase (UDP-N- acetylglucosamine:polypeptide-N- acetylglucosaminyl transferase) 200962_at 6160 ribosomal protein L31 biosynthesis 204446_s_at 240 arachidonate 5-lipoxygenase biosynthesis 204174_at 241 arachidonate 5-lipoxygenase-activating biosynthesis protein 202532_s_at 1719 dihydrofolate reductase biosynthesis 208771_s_at 4048 leukotriene A4 hydrolase biosynthesis 210845_s_at 5329 plasminogen activator, urokinase receptor blood coagulation 209473_at 953 ectonucleoside triphosphate blood coagulation diphosphohydrolase 1 210942_s_at 10402 alpha2,3-sialyltransferase carbohydrate metabolism 202499_s_at 6515 solute carrier family 2 (facilitated glucose carbohydrate metabolism transporter), member 3 219373_at 54344 dolichyl-phosphate mannosyltransferase carbohydrate metabolism polypeptide 3 206111_at 6036 ribonuclease, RNase A family, 2 (liver, catabolism eosinophil-derived neurotoxin) 201069_at 4313 matrix metalloproteinase 2 (gelatinase A, catabolism 72 kDa gelatinase, 72 kDa type IV collagenase) 208771_s_at 4048 leukotriene A4 hydrolase catabolism 212190_at 5270 serine (or cysteine) proteinase inhibitor, catabolism clade E (nexin, plasminogen activator inhibitor type 1), member 2 211506_s_at 3576 interleukin 8 cell adhesion 209473_at 953 ectonucleoside triphosphate cell adhesion diphosphohydrolase 1 204655_at 6352 chemokine (C-C motif) ligand 5 cell adhesion 205176_s_at 23421 integrin beta 3 binding protein (beta3- cell adhesion endonexin) 216250_s_at 9404 leupaxin cell adhesion 219890_at 23601 C-type (calcium dependent, carbohydrate- cell adhesion recognition domain) lectin, superfamily member 5 208892_s_at 1848 dual specificity phosphatase 6 cell death 202644_s_at 7128 tumor necrosis factor, alpha-induced cell death protein 3 214727_at 675 breast cancer 2, early onset cell death 214467_at 8477 G protein-coupled receptor 65 cell death 205681_at 597 BCL2-related protein A1 cell death 201710_at 4605 v-myb myeloblastosis viral oncogene cell death homolog (avian)-like 2 204614_at 5055 serine (or cysteine) proteinase inhibitor, cell death clade B (ovalbumin), member 2 204655_at 6352 chemokine (C-C motif) ligand 5 cell homeostasis 210946_at 8611 phosphatidic acid phosphatase type 2A cell migration 212190_at 5270 serine (or cysteine) proteinase inhibitor, cell migration clade E (nexin, plasminogen activator inhibitor type 1), member 2 203358_s_at 2146 enhancer of zeste homolog 2 (Drosophila) cell organization and biogenesis 214727_at 675 breast cancer 2, early onset cell organization and biogenesis 201999_s_at 6993 t-complex-associated-testis-expressed 1- cell organization and biogenesis like 1 205046_at 1062 centromere protein E, 312 kDa cell proliferation 208892_s_at 1848 dual specificity phosphatase 6 cell proliferation 205053_at 5557 primase, polypeptide 1, 49 kDa cell proliferation 203564_at 2189 Fanconi anemia, complementation group G cell proliferation 214727_at 675 breast cancer 2, early onset cell proliferation 209773_s_at 6241 ribonucleotide reductase M2 polypeptide cell proliferation 211506_s_at 3576 interleukin 8 cell proliferation 202811_at 10617 associated molecule with the SH3 domain cell proliferation of STAM 201710_at 4605 v-myb myeloblastosis viral oncogene cell proliferation homolog (avian)-like 2 200660_at 6282 S100 calcium binding protein A11 cell proliferation (calgizzarin) 202191_s_at 8522 growth arrest-specific 7 cell proliferation 211506_s_at 3576 interleukin 8 cell-cell signaling 209473_at 953 ectonucleoside triphosphate cell-cell signaling diphosphohydrolase 1 204655_at 6352 chemokine (C-C motif) ligand 5 cell-cell signaling 207339_s_at 4050 lymphotoxin beta (TNF superfamily, cell-cell signaling member 3) 205204_at 4828 neuromedin B cell-cell signaling 218212_s_at 4338 molybdenum cofactor synthesis 2 coenzymes and prosthetic group metabolism 203923_s_at 1536 cytochrome b-245, beta polypeptide electron transport (chronic granulomatous disease) 204446_s_at 240 arachidonate 5-lipoxygenase electron transport 202437_s_at 1545 cytochrome P450, family 1, subfamily B, electron transport polypeptide 1 202942_at 2109 electron-transfer-flavoprotein, beta electron transport polypeptide 203923_s_at 1536 cytochrome b-245, beta polypeptide energy pathways (chronic granulomatous disease) 210942_s_at 10402 alpha2,3-sialyltransferase lipid metabolism 204446_s_at 240 arachidonate 5-lipoxygenase lipid metabolism 204174_at 241 arachidonate 5-lipoxygenase-activating lipid metabolism protein 201012_at 301 annexin A1 lipid metabolism 210946_at 8611 phosphatidic acid phosphatase type 2A lipid metabolism 201963_at 2180 fatty-acid-Coenzyme A ligase, long-chain 2 lipid metabolism 208771_s_at 4048 leukotriene A4 hydrolase lipid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long-chain 1 lipid metabolism 206066_s_at 5889 RAD51 homolog C (S. cerevisiae) nucleobase, nucleoside, nucleotide and nucleic acid metabolism 203358_s_at 2146 enhancer of zeste homolog 2 (Drosophila) nucleobase, nucleoside, nucleotide and nucleic acid metabolism 205053_at 5557 primase, polypeptide 1, 49 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 203564_at 2189 Fanconi anemia, complementation group G nucleobase, nucleoside, nucleotide and nucleic acid metabolism 203409_at 1643 damage-specific DNA binding protein 2, nucleobase, nucleoside, 48 kDa nucleotide and nucleic acid metabolism 214727_at 675 breast cancer 2, early onset nucleobase, nucleoside, nucleotide and nucleic acid metabolism 209773_s_at 6241 ribonucleotide reductase M2 polypeptide nucleobase, nucleoside, nucleotide and nucleic acid metabolism 206111_at 6036 ribonuclease, RNase A family, 2 (liver, nucleobase, nucleoside, eosinophil-derived neurotoxin) nucleotide and nucleic acid metabolism 201710_at 4605 v-myb myeloblastosis viral oncogene nucleobase, nucleoside, homolog (avian)-like 2 nucleotide and nucleic acid metabolism 200660_at 6282 S100 calcium binding protein A11 nucleobase, nucleoside, (calgizzarin) nucleotide and nucleic acid metabolism 202532_s_at 1719 dihydrofolate reductase nucleobase, nucleoside, nucleotide and nucleic acid metabolism 202532_s_at 1719 dihydrofolate reductase one-carbon compound metabolism 204446_s_at 240 arachidonate 5-lipoxygenase organic acid metabolism 204174_at 241 arachidonate 5-lipoxygenase-activating organic acid metabolism protein 202532_s_at 1719 dihydrofolate reductase organic acid metabolism 201963_at 2180 fatty-acid-Coenzyme A ligase, long-chain 2 organic acid metabolism 208771_s_at 4048 leukotriene A4 hydrolase organic acid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long-chain 1 organic acid metabolism 206734_at 8690 jerky homolog-like (mouse) organogenesis 211506_s_at 3576 interleukin 8 organogenesis 205807_s_at 7286 tuftelin 1 organogenesis 202191_s_at 8522 growth arrest-specific 7 organogenesis 218224_at 9240 paraneoplastic antigen MA1 organogenesis 202437_s_at 1545 cytochrome P450, family 1, subfamily B, organogenesis polypeptide 1 201908_at 1857 dishevelled, dsh homolog 3 (Drosophila) organogenesis 202554_s_at 2947 glutathione S-transferase M3 (brain) organogenesis 205807_s_at 7286 tuftelin 1 ossification 204655_at 6352 chemokine (C-C motif) ligand 5 oxygen and reactive oxygen species metabolism 202554_s_at 2947 glutathione S-transferase M3 (brain) oxygen and reactive oxygen species metabolism 202437_s_at 1545 cytochrome P450, family 1, subfamily B, perception of external stimulus polypeptide 1 208892_s_at 1848 dual specificity phosphatase 6 phosphorus metabolism 209457_at 1847 dual specificity phosphatase 5 phosphorus metabolism 221563_at 11221 dual specificity phosphatase 10 phosphorus metabolism 205260_s_at 97 acylphosphatase 1, erythrocyte (common) phosphorus metabolism type 221840_at 5791 protein tyrosine phosphatase, receptor phosphorus metabolism type, E 208892_s_at 1848 dual specificity phosphatase 6 programmed cell death 202644_s_at 7128 tumor necrosis factor, alpha-induced programmed cell death protein 3 214727_at 675 breast cancer 2, early onset programmed cell death 214467_at 8477 G protein-coupled receptor 65 programmed cell death 205681_at 597 BCL2-related protein A1 programmed cell death 201710_at 4605 v-myb myeloblastosis viral oncogene programmed cell death homolog (avian)-like 2 204614_at 5055 serine (or cysteine) proteinase inhibitor, programmed cell death clade B (ovalbumin), member 2 208892_s_at 1848 dual specificity phosphatase 6 protein metabolism 209457_at 1847 dual specificity phosphatase 5 protein metabolism 210942_s_at 10402 alpha2,3-sialyltransferase protein metabolism 221563_at 11221 dual specificity phosphatase 10 protein metabolism 207563_s_at 8473 O-linked N-acetylglucosamine (GlcNAc) protein metabolism transferase (UDP-N- acetylglucosamine:polypeptide-N- acetylglucosaminyl transferase) 200962_at 6160 ribosomal protein L31 protein metabolism 216250_s_at 9404 leupaxin protein metabolism 201069_at 4313 matrix metalloproteinase 2 (gelatinase A, protein metabolism 72 kDa gelatinase, 72 kDa type IV collagenase) 221840_at 5791 protein tyrosine phosphatase, receptor protein metabolism type, E 208771_s_at 4048 leukotriene A4 hydrolase protein metabolism 212190_at 5270 serine (or cysteine) proteinase inhibitor, protein metabolism clade E (nexin, plasminogen activator inhibitor type 1), member 2 212190_at 5270 serine (or cysteine) proteinase inhibitor, regulation of metabolism clade E (nexin, plasminogen activator inhibitor type 1), member 2 205557_at 671 bactericidal/permeability-increasing protein response to abiotic stimulus 207563_s_at 8473 O-linked N-acetylglucosamine (GlcNAc) response to abiotic stimulus transferase (UDP-N- acetylglucosamine:polypeptide-N- acetylglucosaminyl transferase) 202437_s_at 1545 cytochrome P450, family 1, subfamily B, response to abiotic stimulus polypeptide 1 211506_s_at 3576 interleukin 8 response to biotic stimulus 214467_at 8477 G protein-coupled receptor 65 response to biotic stimulus 205419_at 1880 Epstein-Barr virus induced gene 2 response to biotic stimulus (lymphocyte-specific G protein-coupled receptor) 205557_at 671 bactericidal/permeability-increasing protein response to biotic stimulus 209473_at 953 ectonucleoside triphosphate response to biotic stimulus diphosphohydrolase 1 203923_s_at 1536 cytochrome b-245, beta polypeptide (chronic response to biotic stimulus granulomatous disease) 204655_at 6352 chemokine (C-C motif) ligand 5 response to biotic stimulus 204446_s_at 240 arachidonate 5-lipoxygenase response to biotic stimulus 204174_at 241 arachidonate 5-lipoxygenase-activating response to biotic stimulus protein 207339_s_at 4050 lymphotoxin beta (TNF superfamily, member response to biotic stimulus 3) 201012_at 301 annexin A1 response to biotic stimulus 208771_s_at 4048 leukotriene A4 hydrolase response to biotic stimulus 209575_at 3588 interleukin 10 receptor, beta response to biotic stimulus 216950_s_at 2209 Fc fragment of IgG, high affinity Ia, receptor response to biotic stimulus for (CD64) 205269_at 3937 lymphocyte cytosolic protein 2 (SH2 domain response to biotic stimulus containing leukocyte protein of 76 kDa)

Cell Proliferation

LOCUS AFFX_ID LINK GENE NAME CLASSIFICATION 210942_s_at 10402 alpha2,3-sialyltransferase amine metabolism 202532_s_at 1719 dihydrofolate reductase amine metabolism 202532_s_at 1719 dihydrofolate reductase amino acid and derivative metabolism 218212_s_at 4338 molybdenum cofactor synthesis 2 aromatic compound metabolism 210942_s_at 10402 alpha2,3-sialyltransferase biosynthesis 218212_s_at 4338 molybdenum cofactor synthesis 2 biosynthesis 207563_s_at 8473 O-linked N-acetylglucosamine (GlcNAc) biosynthesis transferase (UDP-N- acetylglucosamine:polypeptide-N- acetylglucosaminyl transferase) 200962_at 6160 ribosomal protein L31 biosynthesis 204446_s_at 240 arachidonate 5-lipoxygenase biosynthesis 204174_at 241 arachidonate 5-lipoxygenase-activating biosynthesis protein 202532_s_at 1719 dihydrofolate reductase biosynthesis 208771_s_at 4048 leukotriene A4 hydrolase biosynthesis 210845_s_at 5329 plasminogen activator, urokinase blood coagulation receptor 209473_at 953 ectonucleoside triphosphate blood coagulation diphosphohydrolase 1 210942_s_at 10402 alpha2,3-sialyltransferase carbohydrate metabolism 202499_s_at 6515 solute carrier family 2 (facilitated glucose carbohydrate metabolism transporter), member 3 219373_at 54344 dolichyl-phosphate mannosyltransferase carbohydrate metabolism polypeptide 3 206111_at 6036 ribonuclease, RNase A family, 2 (liver, catabolism eosinophil-derived neurotoxin) 201069_at 4313 matrix metalloproteinase 2 (gelatinase A, catabolism 72 kDa gelatinase, 72 kDa type IV collagenase) 208771_s_at 4048 leukotriene A4 hydrolase catabolism 212190_at 5270 serine (or cysteine) proteinase inhibitor, catabolism clade E (nexin, plasminogen activator inhibitor type 1), member 2 211506_s_at 3576 interleukin 8 cell adhesion 209473_at 953 ectonucleoside triphosphate cell adhesion diphosphohydrolase 1 204655_at 6352 chemokine (C-C motif) ligand 5 cell adhesion 205176_s_at 23421 integrin beta 3 binding protein (beta3- cell adhesion endonexin) 216250_s_at 9404 leupaxin cell adhesion 219890_at 23601 C-type (calcium dependent, cell adhesion carbohydrate-recognition domain) lectin, superfamily member 5 208892_s_at 1848 dual specificity phosphatase 6 cell death 202644_s_at 7128 tumor necrosis factor, alpha-induced cell death protein 3 214727_at 675 breast cancer 2, early onset cell death 214467_at 8477 G protein-coupled receptor 65 cell death 205681_at 597 BCL2-related protein A1 cell death 201710_at 4605 v-myb myeloblastosis viral oncogene cell death homolog (avian)-like 2 204614_at 5055 serine (or cysteine) proteinase inhibitor, cell death clade B (ovalbumin), member 2 204655_at 6352 chemokine (C-C motif) ligand 5 cell homeostasis 210946_at 8611 phosphatidic acid phosphatase type 2A cell migration 212190_at 5270 serine (or cysteine) proteinase inhibitor, cell migration clade E (nexin, plasminogen activator inhibitor type 1), member 2 203358_s_at 2146 enhancer of zeste homolog 2 cell organization and biogenesis (Drosophila) 214727_at 675 breast cancer 2, early onset cell organization and biogenesis 201999_s_at 6993 t-complex-associated-testis-expressed 1- cell organization and biogenesis like 1 205046_at 1062 centromere protein E, 312 kDa cell proliferation 208892_s_at 1848 dual specificity phosphatase 6 cell proliferation 205053_at 5557 primase, polypeptide 1, 49 kDa cell proliferation 203564_at 2189 Fanconi anemia, complementation group G cell proliferation 214727_at 675 breast cancer 2, early onset cell proliferation 209773_s_at 6241 ribonucleotide reductase M2 polypeptide cell proliferation 211506_s_at 3576 interleukin 8 cell proliferation 202811_at 10617 associated molecule with the SH3 domain of cell proliferation STAM 201710_at 4605 v-myb myeloblastosis viral oncogene cell proliferation homolog (avian)-like 2 200660_at 6282 S100 calcium binding protein A11 cell proliferation (calgizzarin) 202191_s_at 8522 growth arrest-specific 7 cell proliferation

Nucleotide Metabolism

LOCUS AFFX_ID LINK GENE NAME CLASSIFICATION 210942_s_at 10402 alpha2,3-sialyltransferase amine metabolism 202532_s_at 1719 dihydrofolate reductase amine metabolism 202532_s_at 1719 dihydrofolate reductase amino acid and derivative metabolism 218212_s_at 4338 molybdenum cofactor synthesis 2 aromatic compound metabolism 210942_s_at 10402 alpha2,3-sialyltransferase biosynthesis 218212_s_at 4338 molybdenum cofactor synthesis 2 biosynthesis 207563_s_at 8473 O-linked N-acetylglucosamine (GlcNAc) biosynthesis transferase (UDP-N- acetylglucosamine:polypeptide-N- acetylglucosaminyl transferase) 200962_at 6160 ribosomal protein L31 biosynthesis 204446_s_at 240 arachidonate 5-lipoxygenase biosynthesis 204174_at 241 arachidonate 5-lipoxygenase-activating biosynthesis protein 202532_s_at 1719 dihydrofolate reductase biosynthesis 208771_s_at 4048 leukotriene A4 hydrolase biosynthesis 210845_s_at 5329 plasminogen activator, urokinase blood coagulation receptor 209473_at 953 ectonucleoside triphosphate blood coagulation diphosphohydrolase 1 210942_s_at 10402 alpha2,3-sialyltransferase carbohydrate metabolism 202499_s_at 6515 solute carrier family 2 (facilitated glucose carbohydrate metabolism transporter), member 3 219373_at 54344 dolichyl-phosphate mannosyltransferase carbohydrate metabolism polypeptide 3 206111_at 6036 ribonuclease, RNase A family, 2 (liver, catabolism eosinophil-derived neurotoxin) 201069_at 4313 matrix metalloproteinase 2 (gelatinase A, catabolism 72 kDa gelatinase, 72 kDa type IV collagenase) 208771_s_at 4048 leukotriene A4 hydrolase catabolism 212190_at 5270 serine (or cysteine) proteinase inhibitor, catabolism clade E (nexin, plasminogen activator inhibitor type 1), member 2 211506_s_at 3576 interleukin 8 cell adhesion 209473_at 953 ectonucleoside triphosphate cell adhesion diphosphohydrolase 1 204655_at 6352 chemokine (C-C motif) ligand 5 cell adhesion 205176_s_at 23421 integrin beta 3 binding protein (beta3- cell adhesion endonexin) 216250_s_at 9404 leupaxin cell adhesion 219890_at 23601 C-type (calcium dependent, cell adhesion carbohydrate-recognition domain) lectin, superfamily member 5 208892_s_at 1848 dual specificity phosphatase 6 cell death 202644_s_at 7128 tumor necrosis factor, alpha-induced cell death protein 3 214727_at 675 breast cancer 2, early onset cell death 214467_at 8477 G protein-coupled receptor 65 cell death 205681_at 597 BCL2-related protein A1 cell death 201710_at 4605 v-myb myeloblastosis viral oncogene cell death homolog (avian)-like 2 204614_at 5055 serine (or cysteine) proteinase inhibitor, cell death clade B (ovalbumin), member 2 204655_at 6352 chemokine (C-C motif) ligand 5 cell homeostasis 210946_at 8611 phosphatidic acid phosphatase type 2A cell migration 212190_at 5270 serine (or cysteine) proteinase inhibitor, cell migration clade E (nexin, plasminogen activator inhibitor type 1), member 2 203358_s_at 2146 enhancer of zeste homolog 2 cell organization and biogenesis (Drosophila) 214727_at 675 breast cancer 2, early onset cell organization and biogenesis 201999_s_at 6993 t-complex-associated-testis-expressed 1- cell organization and biogenesis like 1 205046_at 1062 centromere protein E, 312 kDa cell proliferation 208892_s_at 1848 dual specificity phosphatase 6 cell proliferation 205053_at 5557 primase, polypeptide 1, 49 kDa cell proliferation 203564_at 2189 Fanconi anemia, complementation group G cell proliferation 214727_at 675 breast cancer 2, early onset cell proliferation 209773_s_at 6241 ribonucleotide reductase M2 polypeptide cell proliferation 211506_s_at 3576 interleukin 8 cell proliferation 202811_at 10617 associated molecule with the SH3 cell proliferation domain of STAM 201710_at 4605 v-myb myeloblastosis viral oncogene cell proliferation homolog (avian)-like 2 200660_at 6282 S100 calcium binding protein A11 cell proliferation (calgizzarin) 202191_s_at 8522 growth arrest-specific 7 cell proliferation 211506_s_at 3576 interleukin 8 cell-cell signaling 209473_at 953 ectonucleoside triphosphate cell-cell signaling diphosphohydrolase 1 204655_at 6352 chemokine (C-C motif) ligand 5 cell-cell signaling 207339_s_at 4050 lymphotoxin beta (TNF superfamily, cell-cell signaling member 3) 205204_at 4828 neuromedin B cell-cell signaling 218212_s_at 4338 molybdenum cofactor synthesis 2 coenzymes and prosthetic group metabolism 203923_s_at 1536 cytochrome b-245, beta polypeptide electron transport (chronic granulomatous disease) 204446_s_at 240 arachidonate 5-lipoxygenase electron transport 202437_s_at 1545 cytochrome P450, family 1, subfamily B, electron transport polypeptide 1 202942_at 2109 electron-transfer-flavoprotein, beta electron transport polypeptide 203923_s_at 1536 cytochrome b-245, beta polypeptide energy pathways (chronic granulomatous disease) 210942_s_at 10402 alpha2,3-sialyltransferase lipid metabolism 204446_s_at 240 arachidonate 5-lipoxygenase lipid metabolism 204174_at 241 arachidonate 5-lipoxygenase-activating lipid metabolism protein 201012_at 301 annexin A1 lipid metabolism 210946_at 8611 phosphatidic acid phosphatase type 2A lipid metabolism 201963_at 2180 fatty-acid-Coenzyme A ligase, long-chain 2 lipid metabolism 208771_s_at 4048 leukotriene A4 hydrolase lipid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long-chain 1 lipid metabolism 206066_s_at 5889 RAD51 homolog C (S. cerevisiae) nucleobase, nucleoside, nucleotide and nucleic acid metabolism 203358_s_at 2146 enhancer of zeste homolog 2 (Drosophila) nucleobase, nucleoside, nucleotide and nucleic acid metabolism 205053_at 5557 primase, polypeptide 1, 49 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 203564_at 2189 Fanconi anemia, complementation group G nucleobase, nucleoside, nucleotide and nucleic acid metabolism 203409_at 1643 damage-specific DNA binding protein 2, nucleobase, nucleoside, nucleotide 48 kDa and nucleic acid metabolism 214727_at 675 breast cancer 2, early onset nucleobase, nucleoside, nucleotide and nucleic acid metabolism 209773_s_at 6241 ribonucleotide reductase M2 polypeptide nucleobase, nucleoside, nucleotide and nucleic acid metabolism 206111_at 6036 ribonuclease, RNase A family, 2 (liver, nucleobase, nucleoside, nucleotide eosinophil-derived neurotoxin) and nucleic acid metabolism 201710_at 4605 v-myb myeloblastosis viral oncogene nucleobase, nucleoside, nucleotide homolog (avian)-like 2 and nucleic acid metabolism 200660_at 6282 S100 calcium binding protein A11 nucleobase, nucleoside, nucleotide (calgizzarin) and nucleic acid metabolism 202532_s_at 1719 dihydrofolate reductase nucleobase, nucleoside, nucleotide and nucleic acid metabolism

Programmed Cell Death

LOCUS AFFX_ID LINK GENE NAME CLASSIFICATION 210942_s_at 10402 alpha2,3-sialyltransferase amine metabolism 202532_s_at 1719 dihydrofolate reductase amine metabolism 202532_s_at 1719 dihydrofolate reductase amino acid and derivative metabolism 218212_s_at 4338 molybdenum cofactor synthesis 2 aromatic compound metabolism 210942_s_at 10402 alpha2,3-sialyltransferase biosynthesis 218212_s_at 4338 molybdenum cofactor synthesis 2 biosynthesis 207563_s_at 8473 O-linked N-acetylglucosamine (GlcNAc) biosynthesis transferase (UDP-N- acetylglucosamine:polypeptide-N- acetylglucosaminyl transferase) 200962_at 6160 ribosomal protein L31 biosynthesis 204446_s_at 240 arachidonate 5-lipoxygenase biosynthesis 204174_at 241 arachidonate 5-lipoxygenase-activating biosynthesis protein 202532_s_at 1719 dihydrofolate reductase biosynthesis 208771_s_at 4048 leukotriene A4 hydrolase biosynthesis 210845_s_at 5329 plasminogen activator, urokinase blood coagulation receptor 209473_at 953 ectonucleoside triphosphate blood coagulation diphosphohydrolase 1 210942_s_at 10402 alpha2,3-sialyltransferase carbohydrate metabolism 202499_s_at 6515 solute carrier family 2 (facilitated glucose carbohydrate metabolism transporter), member 3 219373_at 54344 dolichyl-phosphate mannosyltransferase carbohydrate metabolism polypeptide 3 206111_at 6036 ribonuclease, RNase A family, 2 (liver, catabolism eosinophil-derived neurotoxin) 201069_at 4313 matrix metalloproteinase 2 (gelatinase A, catabolism 72 kDa gelatinase, 72 kDa type IV collagenase) 208771_s_at 4048 leukotriene A4 hydrolase catabolism 212190_at 5270 serine (or cysteine) proteinase inhibitor, catabolism clade E (nexin, plasminogen activator inhibitor type 1), member 2 211506_s_at 3576 interleukin 8 cell adhesion 209473_at 953 ectonucleoside triphosphate cell adhesion diphosphohydrolase 1 204655_at 6352 chemokine (C-C motif) ligand 5 cell adhesion 205176_s_at 23421 integrin beta 3 binding protein (beta3- cell adhesion endonexin) 216250_s_at 9404 leupaxin cell adhesion 219890_at 23601 C-type (calcium dependent, cell adhesion carbohydrate-recognition domain) lectin, superfamily member 5 208892_s_at 1848 dual specificity phosphatase 6 cell death 202644_s_at 7128 tumor necrosis factor, alpha-induced cell death protein 3 214727_at 675 breast cancer 2, early onset cell death 214467_at 8477 G protein-coupled receptor 65 cell death 205681_at 597 BCL2-related protein A1 cell death 201710_at 4605 v-myb myeloblastosis viral oncogene cell death homolog (avian)-like 2 204614_at 5055 serine (or cysteine) proteinase inhibitor, cell death clade B (ovalbumin), member 2 204655_at 6352 chemokine (C-C motif) ligand 5 cell homeostasis 210946_at 8611 phosphatidic acid phosphatase type 2A cell migration 212190_at 5270 serine (or cysteine) proteinase inhibitor, cell migration clade E (nexin, plasminogen activator inhibitor type 1), member 2 203358_s_at 2146 enhancer of zeste homolog 2 cell organization and biogenesis (Drosophila) 214727_at 675 breast cancer 2, early onset cell organization and biogenesis 201999_s_at 6993 t-complex-associated-testis-expressed 1- cell organization and biogenesis like 1 205046_at 1062 centromere protein E, 312 kDa cell proliferation 208892_s_at 1848 dual specificity phosphatase 6 cell proliferation 205053_at 5557 primase, polypeptide 1, 49 kDa cell proliferation 203564_at 2189 Fanconi anemia, complementation group G cell proliferation 214727_at 675 breast cancer 2, early onset cell proliferation 209773_s_at 6241 ribonucleotide reductase M2 polypeptide cell proliferation 211506_s_at 3576 interleukin 8 cell proliferation 202811_at 10617 associated molecule with the SH3 cell proliferation domain of STAM 201710_at 4605 v-myb myeloblastosis viral oncogene cell proliferation homolog (avian)-like 2 200660_at 6282 S100 calcium binding protein A11 cell proliferation (calgizzarin) 202191_s_at 8522 growth arrest-specific 7 cell proliferation 211506_s_at 3576 interleukin 8 cell-cell signaling 209473_at 953 ectonucleoside triphosphate cell-cell signaling diphosphohydrolase 1 204655_at 6352 chemokine (C-C motif) ligand 5 cell-cell signaling 207339_s_at 4050 lymphotoxin beta (TNF superfamily, cell-cell signaling member 3) 205204_at 4828 neuromedin B cell-cell signaling 218212_s_at 4338 molybdenum cofactor synthesis 2 coenzymes and prosthetic group metabolism 203923_s_at 1536 cytochrome b-245, beta polypeptide electron transport (chronic granulomatous disease) 204446_s_at 240 arachidonate 5-lipoxygenase electron transport 202437_s_at 1545 cytochrome P450, family 1, subfamily B, electron transport polypeptide 1 202942_at 2109 electron-transfer-flavoprotein, beta electron transport polypeptide 203923_s_at 1536 cytochrome b-245, beta polypeptide energy pathways (chronic granulomatous disease) 210942_s_at 10402 alpha2,3-sialyltransferase lipid metabolism 204446_s_at 240 arachidonate 5-lipoxygenase lipid metabolism 204174_at 241 arachidonate 5-lipoxygenase-activating lipid metabolism protein 201012_at 301 annexin A1 lipid metabolism 210946_at 8611 phosphatidic acid phosphatase type 2A lipid metabolism 201963_at 2180 fatty-acid-Coenzyme A ligase, long-chain 2 lipid metabolism 208771_s_at 4048 leukotriene A4 hydrolase lipid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long-chain 1 lipid metabolism 206066_s_at 5889 RAD51 homolog C (S. cerevisiae) nucleobase, nucleoside, nucleotide and nucleic acid metabolism 203358_s_at 2146 enhancer of zeste homolog 2 nucleobase, nucleoside, (Drosophila) nucleotide and nucleic acid metabolism 205053_at 5557 primase, polypeptide 1, 49 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 203564_at 2189 Fanconi anemia, complementation group G nucleobase, nucleoside, nucleotide and nucleic acid metabolism 203409_at 1643 damage-specific DNA binding protein 2, nucleobase, nucleoside, 48 kDa nucleotide and nucleic acid metabolism 214727_at 675 breast cancer 2, early onset nucleobase, nucleoside, nucleotide and nucleic acid metabolism 209773_s_at 6241 ribonucleotide reductase M2 polypeptide nucleobase, nucleoside, nucleotide and nucleic acid metabolism 206111_at 6036 ribonuclease, RNase A family, 2 (liver, nucleobase, nucleoside, eosinophil-derived neurotoxin) nucleotide and nucleic acid metabolism 201710_at 4605 v-myb myeloblastosis viral oncogene nucleobase, nucleoside, homolog (avian)-like 2 nucleotide and nucleic acid metabolism 200660_at 6282 S100 calcium binding protein A11 nucleobase, nucleoside, (calgizzarin) nucleotide and nucleic acid metabolism 202532_s_at 1719 dihydrofolate reductase nucleobase, nucleoside, nucleotide and nucleic acid metabolism 202532_s_at 1719 dihydrofolate reductase one-carbon compound metabolism 204446_s_at 240 arachidonate 5-lipoxygenase organic acid metabolism 204174_at 241 arachidonate 5-lipoxygenase-activating organic acid metabolism protein 202532_s_at 1719 dihydrofolate reductase organic acid metabolism 201963_at 2180 fatty-acid-Coenzyme A ligase, long-chain 2 organic acid metabolism 208771_s_at 4048 leukotriene A4 hydrolase organic acid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long-chain 1 organic acid metabolism 206734_at 8690 jerky homolog-like (mouse) organogenesis 211506_s_at 3576 interleukin 8 organogenesis 205807_s_at 7286 tuftelin 1 organogenesis 202191_s_at 8522 growth arrest-specific 7 organogenesis 218224_at 9240 paraneoplastic antigen MA1 organogenesis 202437_s_at 1545 cytochrome P450, family 1, subfamily B, organogenesis polypeptide 1 201908_at 1857 dishevelled, dsh homolog 3 (Drosophila) organogenesis 202554_s_at 2947 glutathione S-transferase M3 (brain) organogenesis 205807_s_at 7286 tuftelin 1 ossification 204655_at 6352 chemokine (C-C motif) ligand 5 oxygen and reactive oxygen species metabolism 202554_s_at 2947 glutathione S-transferase M3 (brain) oxygen and reactive oxygen species metabolism 202437_s_at 1545 cytochrome P450, family 1, subfamily B, perception of external stimulus polypeptide 1 208892_s_at 1848 dual specificity phosphatase 6 phosphorus metabolism 209457_at 1847 dual specificity phosphatase 5 phosphorus metabolism 221563_at 11221 dual specificity phosphatase 10 phosphorus metabolism 205260_s_at 97 acylphosphatase 1, erythrocyte phosphorus metabolism (common) type 221840_at 5791 protein tyrosine phosphatase, receptor phosphorus metabolism type, E 208892_s_at 1848 dual specificity phosphatase 6 programmed cell death 202644_s_at 7128 tumor necrosis factor, alpha-induced protein 3 programmed cell death 214727_at 675 breast cancer 2, early onset programmed cell death 214467_at 8477 G protein-coupled receptor 65 programmed cell death 205681_at 597 BCL2-related protein A1 programmed cell death 201710_at 4605 v-myb myeloblastosis viral oncogene programmed cell death homolog (avian)-like 2 204614_at 5055 serine (or cysteine) proteinase inhibitor, clade programmed cell death B (ovalbumin), member 2

Lipid Metabolism

LOCUS AFFX_ID LINK GENE NAME CLASSIFICATION 210942_s_at 10402 alpha2,3-sialyltransferase amine metabolism 202532_s_at 1719 dihydrofolate reductase amine metabolism 202532_s_at 1719 dihydrofolate reductase amino acid and derivative metabolism 218212_s_at 4338 molybdenum cofactor synthesis 2 aromatic compound metabolism 210942_s_at 10402 alpha2,3-sialyltransferase biosynthesis 218212_s_at 4338 molybdenum cofactor synthesis 2 biosynthesis 207563_s_at 8473 O-linked N-acetylglucosamine (GlcNAc) biosynthesis transferase (UDP-N- acetylglucosamine:polypeptide-N- acetylglucosaminyl transferase) 200962_at 6160 ribosomal protein L31 biosynthesis 204446_s_at 240 arachidonate 5-lipoxygenase biosynthesis 204174_at 241 arachidonate 5-lipoxygenase-activating biosynthesis protein 202532_s_at 1719 dihydrofolate reductase biosynthesis 208771_s_at 4048 leukotriene A4 hydrolase biosynthesis 210845_s_at 5329 plasminogen activator, urokinase blood coagulation receptor 209473_at 953 ectonucleoside triphosphate blood coagulation diphosphohydrolase 1 210942_s_at 10402 alpha2,3-sialyltransferase carbohydrate metabolism 202499_s_at 6515 solute carrier family 2 (facilitated glucose carbohydrate metabolism transporter), member 3 219373_at 54344 dolichyl-phosphate mannosyltransferase carbohydrate metabolism polypeptide 3 206111_at 6036 ribonuclease, RNase A family, 2 (liver, catabolism eosinophil-derived neurotoxin) 201069_at 4313 matrix metalloproteinase 2 (gelatinase A, catabolism 72 kDa gelatinase, 72 kDa type IV collagenase) 208771_s_at 4048 leukotriene A4 hydrolase catabolism 212190_at 5270 serine (or cysteine) proteinase inhibitor, catabolism clade E (nexin, plasminogen activator inhibitor type 1), member 2 211506_s_at 3576 interleukin 8 cell adhesion 209473_at 953 ectonucleoside triphosphate cell adhesion diphosphohydrolase 1 204655_at 6352 chemokine (C-C motif) ligand 5 cell adhesion 205176_s_at 23421 integrin beta 3 binding protein (beta3- cell adhesion endonexin) 216250_s_at 9404 leupaxin cell adhesion 219890_at 23601 C-type (calcium dependent, cell adhesion carbohydrate-recognition domain) lectin, superfamily member 5 208892_s_at 1848 dual specificity phosphatase 6 cell death 202644_s_at 7128 tumor necrosis factor, alpha-induced cell death protein 3 214727_at 675 breast cancer 2, early onset cell death 214467_at 8477 G protein-coupled receptor 65 cell death 205681_at 597 BCL2-related protein A1 cell death 201710_at 4605 v-myb myeloblastosis viral oncogene cell death homolog (avian)-like 2 204614_at 5055 serine (or cysteine) proteinase inhibitor, cell death clade B (ovalbumin), member 2 204655_at 6352 chemokine (C-C motif) ligand 5 cell homeostasis 210946_at 8611 phosphatidic acid phosphatase type 2A cell migration 212190_at 5270 serine (or cysteine) proteinase inhibitor, cell migration clade E (nexin, plasminogen activator inhibitor type 1), member 2 203358_s_at 2146 enhancer of zeste homolog 2 cell organization and biogenesis (Drosophila) 214727_at 675 breast cancer 2, early onset cell organization and biogenesis 201999_s_at 6993 t-complex-associated-testis-expressed 1- cell organization and biogenesis like 1 205046_at 1062 centromere protein E, 312 kDa cell proliferation 208892_s_at 1848 dual specificity phosphatase 6 cell proliferation 205053_at 5557 primase, polypeptide 1, 49 kDa cell proliferation 203564_at 2189 Fanconi anemia, complementation group G cell proliferation 214727_at 675 breast cancer 2, early onset cell proliferation 209773_s_at 6241 ribonucleotide reductase M2 polypeptide cell proliferation 211506_s_at 3576 interleukin 8 cell proliferation 202811_at 10617 associated molecule with the SH3 cell proliferation domain of STAM 201710_at 4605 v-myb myeloblastosis viral oncogene cell proliferation homolog (avian)-like 2 200660_at 6282 S100 calcium binding protein A11 cell proliferation (calgizzarin) 202191_s_at 8522 growth arrest-specific 7 cell proliferation 211506_s_at 3576 interleukin 8 cell-cell signaling 209473_at 953 ectonucleoside triphosphate cell-cell signaling diphosphohydrolase 1 204655_at 6352 chemokine (C-C motif) ligand 5 cell-cell signaling 207339_s_at 4050 lymphotoxin beta (TNF superfamily, cell-cell signaling member 3) 205204_at 4828 neuromedin B cell-cell signaling 218212_s_at 4338 molybdenum cofactor synthesis 2 coenzymes and prosthetic group metabolism 203923_s_at 1536 cytochrome b-245, beta polypeptide electron transport (chronic granulomatous disease) 204446_s_at 240 arachidonate 5-lipoxygenase electron transport 202437_s_at 1545 cytochrome P450, family 1, subfamily B, electron transport polypeptide 1 202942_at 2109 electron-transfer-flavoprotein, beta electron transport polypeptide 203923_s_at 1536 cytochrome b-245, beta polypeptide energy pathways (chronic granulomatous disease) 210942_s_at 10402 alpha2,3-sialyltransferase lipid metabolism 204446_s_at 240 arachidonate 5-lipoxygenase lipid metabolism 204174_at 241 arachidonate 5-lipoxygenase-activating lipid metabolism protein 201012_at 301 annexin A1 lipid metabolism 210946_at 8611 phosphatidic acid phosphatase type 2A lipid metabolism 201963_at 2180 fatty-acid-Coenzyme A ligase, long-chain 2 lipid metabolism 208771_s_at 4048 leukotriene A4 hydrolase lipid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long-chain 1 lipid metabolism MPA (Early) vs. MPA (Late): 66 genes were binned into this category. These genes were further binned into the following functional categories.

Nucleotide Metabolism

LOCUS AFFX_ID LINK GENE NAME CLASSIFICATION 201612_at 223 aldehyde dehydrogenase 9 family, aldehyde metabolism member A1 210942_s_at 10402 alpha2,3-sialyltransferase amine metabolism 206643_at 3034 histidine ammonia-lyase amine metabolism 206643_at 3034 histidine ammonia-lyase amino acid and derivative metabolism 210942_s_at 10402 alpha2,3-sialyltransferase biosynthesis 219649_at 29929 dolichyl-P-Glc:Man9GlcNAc2-PP- biosynthesis dolichylglucosyltransferase 200962_at 6160 ribosomal protein L31 biosynthesis 206643_at 3034 histidine ammonia-lyase biosynthesis 204446_s_at 240 arachidonate 5-lipoxygenase biosynthesis 204174_at 241 arachidonate 5-lipoxygenase- biosynthesis activating protein 208771_s_at 4048 leukotriene A4 hydrolase biosynthesis 210942_s_at 10402 alpha2,3-sialyltransferase carbohydrate metabolism 202499_s_at 6515 solute carrier family 2 (facilitated carbohydrate metabolism glucose transporter), member 3 206643_at 3034 histidine ammonia-lyase catabolism 202551_s_at 51232 cysteine-rich motor neuron 1 catabolism 208771_s_at 4048 leukotriene A4 hydrolase catabolism 212190_at 5270 serine (or cysteine) proteinase catabolism inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 211506_s_at 3576 interleukin 8 cell adhesion 207113_s_at 7124 tumor necrosis factor (TNF cell adhesion superfamily, member 2) 201105_at 3956 lectin, galactoside-binding, soluble, 1 cell adhesion (galectin 1) 216250_s_at 9404 leupaxin cell adhesion 219890_at 23601 C-type (calcium dependent, cell adhesion carbohydrate-recognition domain) lectin, superfamily member 5 214727_at 675 breast cancer 2, early onset cell death 207113_s_at 7124 tumor necrosis factor (TNF cell death superfamily, member 2) 204614_at 5055 serine (or cysteine) proteinase cell death inhibitor, clade B (ovalbumin), member 2 201105_at 3956 lectin, galactoside-binding, soluble, 1 cell death (galectin 1) 202551_s_at 51232 cysteine-rich motor neuron 1 cell growth 212190_at 5270 serine (or cysteine) proteinase cell migration inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 214727_at 675 breast cancer 2, early onset cell organization and biogenesis 201999_s_at 6993 t-complex-associated-testis- cell organization and biogenesis expressed 1-like 1 204603_at 9156 exonuclease 1 cell proliferation 205053_at 5557 primase, polypeptide 1, 49 kDa cell proliferation 214727_at 675 breast cancer 2, early onset cell proliferation 209773_s_at 6241 ribonucleotide reductase M2 cell proliferation polypeptide 211506_s_at 3576 interleukin 8 cell proliferation 200660_at 6282 S100 calcium binding protein A11 cell proliferation (calgizzarin) 202769_at 901 cyclin G2 cell proliferation 201700_at 896 cyclin D3 cell proliferation 211506_s_at 3576 interleukin 8 cell-cell signaling 207113_s_at 7124 tumor necrosis factor (TNF cell-cell signaling superfamily, member 2) 203923_s_at 1536 cytochrome b-245, beta polypeptide electron transport (chronic granulomatous disease) 204446_s_at 240 arachidonate 5-lipoxygenase electron transport 202437_s_at 1545 cytochrome P450, family 1, electron transport subfamily B, polypeptide 1 203923_s_at 1536 cytochrome b-245, beta polypeptide energy pathways (chronic granulomatous disease) 210942_s_at 10402 alpha2,3-sialyltransferase lipid metabolism 204446_s_at 240 arachidonate 5-lipoxygenase lipid metabolism 204174_at 241 arachidonate 5-lipoxygenase- lipid metabolism activating protein 201963_at 2180 fatty-acid-Coenzyme A ligase, long- lipid metabolism chain 2 208771_s_at 4048 leukotriene A4 hydrolase lipid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long- lipid metabolism chain 1 209906_at 719 complement component 3a receptor 1 muscle contraction 204603_at 9156 exonuclease 1 nucleobase, nucleoside, nucleotide and nucleic acid metabolism 202338_at 7083 thymidine kinase 1, soluble nucleobase, nucleoside, nucleotide and nucleic acid metabolism 218384_at 23589 calcium regulated heat stable protein 1, nucleobase, nucleoside, nucleotide 24 kDa and nucleic acid metabolism 205053_at 5557 primase, polypeptide 1, 49 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 203409_at 1643 damage-specific DNA binding protein 2, nucleobase, nucleoside, nucleotide 48 kDa and nucleic acid metabolism 214727_at 675 breast cancer 2, early onset nucleobase, nucleoside, nucleotide and nucleic acid metabolism 209773_s_at 6241 ribonucleotide reductase M2 polypeptide nucleobase, nucleoside, nucleotide and nucleic acid metabolism 207113_s_at 7124 tumor necrosis factor (TNF superfamily, nucleobase, nucleoside, nucleotide member 2) and nucleic acid metabolism 200660_at 6282 S100 calcium binding protein A11 nucleobase, nucleoside, nucleotide (calgizzarin) and nucleic acid metabolism 209930_s_at 4778 nuclear factor (erythroid-derived 2), nucleobase, nucleoside, nucleotide 45 kDa and nucleic acid metabolism 201989_s_at 1389 cAMP responsive element binding nucleobase, nucleoside, nucleotide protein-like 2 and nucleic acid metabolism

Response to Biotic Stimuli

LOCUS AFFX_ID LINK GENE NAME CLASSIFICATION 201612_at 223 aldehyde dehydrogenase 9 family, aldehyde metabolism member A1 210942_s_at 10402 alpha2,3-sialyltransferase amine metabolism 206643_at 3034 histidine ammonia-lyase amine metabolism 206643_at 3034 histidine ammonia-lyase amino acid and derivative metabolism 210942_s_at 10402 alpha2,3-sialyltransferase biosynthesis 219649_at 29929 dolichyl-P-Glc:Man9GlcNAc2-PP- biosynthesis dolichylglucosyltransferase 200962_at 6160 ribosomal protein L31 biosynthesis 206643_at 3034 histidine ammonia-lyase biosynthesis 204446_s_at 240 arachidonate 5-lipoxygenase biosynthesis 204174_at 241 arachidonate 5-lipoxygenase-activating biosynthesis protein 208771_s_at 4048 leukotriene A4 hydrolase biosynthesis 210942_s_at 10402 alpha2,3-sialyltransferase carbohydrate metabolism 202499_s_at 6515 solute carrier family 2 (facilitated carbohydrate metabolism glucose transporter), member 3 206643_at 3034 histidine ammonia-lyase catabolism 202551_s_at 51232 cysteine-rich motor neuron 1 catabolism 208771_s_at 4048 leukotriene A4 hydrolase catabolism 212190_at 5270 serine (or cysteine) proteinase inhibitor, catabolism clade E (nexin, plasminogen activator inhibitor type 1), member 2 211506_s_at 3576 interleukin 8 cell adhesion 207113_s_at 7124 tumor necrosis factor (TNF superfamily, cell adhesion member 2) 201105_at 3956 lectin, galactoside-binding, soluble, 1 cell adhesion (galectin 1) 216250_s_at 9404 leupaxin cell adhesion 219890_at 23601 C-type (calcium dependent, cell adhesion carbohydrate-recognition domain) lectin, superfamily member 5 214727_at 675 breast cancer 2, early onset cell death 207113_s_at 7124 tumor necrosis factor (TNF superfamily, cell death member 2) 204614_at 5055 serine (or cysteine) proteinase inhibitor, cell death clade B (ovalbumin), member 2 201105_at 3956 lectin, galactoside-binding, soluble, 1 cell death (galectin 1) 202551_s_at 51232 cysteine-rich motor neuron 1 cell growth 212190_at 5270 serine (or cysteine) proteinase inhibitor, cell migration clade E (nexin, plasminogen activator inhibitor type 1), member 2 214727_at 675 breast cancer 2, early onset cell organization and biogenesis 201999_s_at 6993 t-complex-associated-testis-expressed cell organization and biogenesis 1-like 1 204603_at 9156 exonuclease 1 cell proliferation 205053_at 5557 primase, polypeptide 1, 49 kDa cell proliferation 214727_at 675 breast cancer 2, early onset cell proliferation 209773_s_at 6241 ribonucleotide reductase M2 cell proliferation polypeptide 211506_s_at 3576 interleukin 8 cell proliferation 200660_at 6282 S100 calcium binding protein A11 cell proliferation (calgizzarin) 202769_at 901 cyclin G2 cell proliferation 201700_at 896 cyclin D3 cell proliferation 211506_s_at 3576 interleukin 8 cell-cell signaling 207113_s_at 7124 tumor necrosis factor (TNF superfamily, cell-cell signaling member 2) 203923_s_at 1536 cytochrome b-245, beta polypeptide electron transport (chronic granulomatous disease) 204446_s_at 240 arachidonate 5-lipoxygenase electron transport 202437_s_at 1545 cytochrome P450, family 1, subfamily electron transport B, polypeptide 1 203923_s_at 1536 cytochrome b-245, beta polypeptide energy pathways (chronic granulomatous disease) 210942_s_at 10402 alpha2,3-sialyltransferase lipid metabolism 204446_s_at 240 arachidonate 5-lipoxygenase lipid metabolism 204174_at 241 arachidonate 5-lipoxygenase-activating lipid metabolism protein 201963_at 2180 fatty-acid-Coenzyme A ligase, long- lipid metabolism chain 2 208771_s_at 4048 leukotriene A4 hydrolase lipid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long- lipid metabolism chain 1 209906_at 719 complement component 3a receptor 1 muscle contraction 204603_at 9156 exonuclease 1 nucleobase, nucleoside, nucleotide and nucleic acid metabolism 202338_at 7083 thymidine kinase 1, soluble nucleobase, nucleoside, nucleotide and nucleic acid metabolism 218384_at 23589 calcium regulated heat stable protein 1, nucleobase, nucleoside, 24 kDa nucleotide and nucleic acid metabolism 205053_at 5557 primase, polypeptide 1, 49 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 203409_at 1643 damage-specific DNA binding protein nucleobase, nucleoside, 2, 48 kDa nucleotide and nucleic acid metabolism 214727_at 675 breast cancer 2, early onset nucleobase, nucleoside, nucleotide and nucleic acid metabolism 209773_s_at 6241 ribonucleotide reductase M2 nucleobase, nucleoside, polypeptide nucleotide and nucleic acid metabolism 207113_s_at 7124 tumor necrosis factor (TNF superfamily, nucleobase, nucleoside, member 2) nucleotide and nucleic acid metabolism 200660_at 6282 S100 calcium binding protein A11 nucleobase, nucleoside, (calgizzarin) nucleotide and nucleic acid metabolism 209930_s_at 4778 nuclear factor (erythroid-derived 2), nucleobase, nucleoside, 45 kDa nucleotide and nucleic acid metabolism 201989_s_at 1389 cAMP responsive element binding nucleobase, nucleoside, protein-like 2 nucleotide and nucleic acid metabolism 209301_at 760 carbonic anhydrase II one-carbon compound metabolism 206643_at 3034 histidine ammonia-lyase organic acid metabolism 204446_s_at 240 arachidonate 5-lipoxygenase organic acid metabolism 204174_at 241 arachidonate 5-lipoxygenase-activating organic acid metabolism protein 201963_at 2180 fatty-acid-Coenzyme A ligase, long- organic acid metabolism chain 2 208771_s_at 4048 leukotriene A4 hydrolase organic acid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long- organic acid metabolism chain 1 211506_s_at 3576 interleukin 8 organogenesis 205807_s_at 7286 tuftelin 1 organogenesis 218224_at 9240 paraneoplastic antigen MA1 organogenesis 202551_s_at 51232 cysteine-rich motor neuron 1 organogenesis 202437_s_at 1545 cytochrome P450, family 1, subfamily organogenesis B, polypeptide 1 205807_s_at 7286 tuftelin 1 ossification 202437_s_at 1545 cytochrome P450, family 1, subfamily perception of external stimulus B, polypeptide 1 209457_at 1847 dual specificity phosphatase 5 phosphorus metabolism 214727_at 675 breast cancer 2, early onset programmed cell death 207113_s_at 7124 tumor necrosis factor (TNF superfamily, programmed cell death member 2) 204614_at 5055 serine (or cysteine) proteinase inhibitor, programmed cell death clade B (ovalbumin), member 2 201105_at 3956 lectin, galactoside-binding, soluble, 1 programmed cell death (galectin 1) 209457_at 1847 dual specificity phosphatase 5 protein metabolism 210942_s_at 10402 alpha2,3-sialyltransferase protein metabolism 219649_at 29929 dolichyl-P-Glc:Man9GlcNAc2-PP- protein metabolism dolichylglucosyltransferase 200962_at 6160 ribosomal protein L31 protein metabolism 216250_s_at 9404 leupaxin protein metabolism 202551_s_at 51232 cysteine-rich motor neuron 1 protein metabolism 208771_s_at 4048 leukotriene A4 hydrolase protein metabolism 212190_at 5270 serine (or cysteine) proteinase inhibitor, protein metabolism clade E (nexin, plasminogen activator inhibitor type 1), member 2 212190_at 5270 serine (or cysteine) proteinase inhibitor, regulation of metabolism clade E (nexin, plasminogen activator inhibitor type 1), member 2 205557_at 671 bactericidal/permeability-increasing response to abiotic stimulus protein 202437_s_at 1545 cytochrome P450, family 1, subfamily response to abiotic stimulus B, polypeptide 1 209906_at 719 complement component 3a receptor 1 response to biotic stimulus 211506_s_at 3576 interleukin 8 response to biotic stimulus 205557_at 671 bactericidal/permeability-increasing protein response to biotic stimulus 207113_s_at 7124 tumor necrosis factor (TNF superfamily, response to biotic stimulus member 2) 203923_s_at 1536 cytochrome b-245, beta polypeptide response to biotic stimulus (chronic granulomatous disease) 204446_s_at 240 arachidonate 5-lipoxygenase response to biotic stimulus 204174_at 241 arachidonate 5-lipoxygenase-activating response to biotic stimulus protein 204118_at 962 CD48 antigen (B-cell membrane protein) response to biotic stimulus 208771_s_at 4048 leukotriene A4 hydrolase response to biotic stimulus 216950_s_at 2209 Fc fragment of IgG, high affinity Ia, receptor response to biotic stimulus for (CD64)

Cell Proliferation

LOCUS AFFX_ID LINK GENE NAME CLASSIFICATION 201612_at 223 aldehyde dehydrogenase 9 family, aldehyde metabolism member A1 210942_s_at 10402 alpha2,3-sialyltransferase amine metabolism 206643_at 3034 histidine ammonia-lyase amine metabolism 206643_at 3034 histidine ammonia-lyase amino acid and derivative metabolism 210942_s_at 10402 alpha2,3-sialyltransferase biosynthesis 219649_at 29929 dolichyl-P-Glc:Man9GlcNAc2-PP- biosynthesis dolichylglucosyltransferase 200962_at 6160 ribosomal protein L31 biosynthesis 206643_at 3034 histidine ammonia-lyase biosynthesis 204446_s_at 240 arachidonate 5-lipoxygenase biosynthesis 204174_at 241 arachidonate 5-lipoxygenase- biosynthesis activating protein biosynthesis 208771_s_at 4048 leukotriene A4 hydrolase biosynthesis 210942_s_at 10402 alpha2,3-sialyltransferase carbohydrate metabolism 202499_s_at 6515 solute carrier family 2 (facilitated carbohydrate metabolism glucose transporter), member 3 206643_at 3034 histidine ammonia-lyase catabolism 202551_s_at 51232 cysteine-rich motor neuron 1 catabolism 208771_s_at 4048 leukotriene A4 hydrolase catabolism 212190_at 5270 serine (or cysteine) proteinase catabolism inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 211506_s_at 3576 interleukin 8 cell adhesion 207113_s_at 7124 tumor necrosis factor (TNF cell adhesion superfamily, member 2) 201105_at 3956 lectin, galactoside-binding, soluble, 1 cell adhesion (galectin 1) 216250_s_at 9404 leupaxin cell adhesion 219890_at 23601 C-type (calcium dependent, cell adhesion carbohydrate-recognition domain) lectin, superfamily member 5 214727_at 675 breast cancer 2, early onset cell death 207113_s_at 7124 tumor necrosis factor (TNF cell death superfamily, member 2) 204614_at 5055 serine (or cysteine) proteinase cell death inhibitor, clade B (ovalbumin), member 2 201105_at 3956 lectin, galactoside-binding, soluble, 1 cell death (galectin 1) 202551_s_at 51232 cysteine-rich motor neuron 1 cell growth 212190_at 5270 serine (or cysteine) proteinase cell migration inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 214727_at 675 breast cancer 2, early onset cell organization and biogenesis 201999_s_at 6993 t-complex-associated-testis- cell organization and biogenesis expressed 1-like 1 204603_at 9156 exonuclease 1 cell proliferation 205053_at 5557 primase, polypeptide 1, 49 kDa cell proliferation 214727_at 675 breast cancer 2, early onset cell proliferation 209773_s_at 6241 ribonucleotide reductase M2 polypeptide cell proliferation 211506_s_at 3576 interleukin 8 cell proliferation 200660_at 6282 S100 calcium binding protein A11 cell proliferation (calgizzarin) 202769_at 901 cyclin G2 cell proliferation 201700_at 896 cyclin D3 cell proliferation

Lipid Metabolism

LOCUS AFFX_ID LINK GENE NAME CLASSIFICATION 201612_at 223 aldehyde dehydrogenase 9 family, aldehyde metabolism member A1 210942_s_at 10402 alpha2,3-sialyltransferase amine metabolism 206643_at 3034 histidine ammonia-lyase amine metabolism 206643_at 3034 histidine ammonia-lyase amino acid and derivative metabolism 210942_s_at 10402 alpha2,3-sialyltransferase biosynthesis 219649_at 29929 dolichyl-P-Glc:Man9GlcNAc2-PP- biosynthesis dolichylglucosyltransferase 200962_at 6160 ribosomal protein L31 biosynthesis 206643_at 3034 histidine ammonia-lyase biosynthesis 204446_s_at 240 arachidonate 5-lipoxygenase biosynthesis 204174_at 241 arachidonate 5-lipoxygenase- biosynthesis activating protein 208771_s_at 4048 leukotriene A4 hydrolase biosynthesis 210942_s_at 10402 alpha2,3-sialyltransferase carbohydrate metabolism 202499_s_at 6515 solute carrier family 2 (facilitated carbohydrate metabolism glucose transporter), member 3 206643_at 3034 histidine ammonia-lyase catabolism 202551_s_at 51232 cysteine-rich motor neuron 1 catabolism 208771_s_at 4048 leukotriene A4 hydrolase catabolism 212190_at 5270 serine (or cysteine) proteinase catabolism inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 211506_s_at 3576 interleukin 8 cell adhesion 207113_s_at 7124 tumor necrosis factor (TNF cell adhesion superfamily, member 2) 201105_at 3956 lectin, galactoside-binding, soluble, 1 cell adhesion (galectin 1) 216250_s_at 9404 leupaxin cell adhesion 219890_at 23601 C-type (calcium dependent, cell adhesion carbohydrate-recognition domain) lectin, superfamily member 5 214727_at 675 breast cancer 2, early onset cell death 207113_s_at 7124 tumor necrosis factor (TNF cell death superfamily, member 2) 204614_at 5055 serine (or cysteine) proteinase cell death inhibitor, clade B (ovalbumin), member 2 201105_at 3956 lectin, galactoside-binding, soluble, 1 cell death (galectin 1) 202551_s_at 51232 cysteine-rich motor neuron 1 cell growth 212190_at 5270 serine (or cysteine) proteinase cell migration inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 214727_at 675 breast cancer 2, early onset cell organization and biogenesis 201999_s_at 6993 t-complex-associated-testis- cell organization and biogenesis expressed 1-like 1 204603_at 9156 exonuclease 1 cell proliferation 205053_at 5557 primase, polypeptide 1, 49 kDa cell proliferation 214727_at 675 breast cancer 2, early onset cell proliferation 209773_s_at 6241 ribonucleotide reductase M2 cell proliferation polypeptide 211506_s_at 3576 interleukin 8 cell proliferation 200660_at 6282 S100 calcium binding protein A11 cell proliferation (calgizzarin) 202769_at 901 cyclin G2 cell proliferation 201700_at 896 cyclin D3 cell proliferation 211506_s_at 3576 interleukin 8 cell-cell signaling 207113_s_at 7124 tumor necrosis factor (TNF cell-cell signaling superfamily, member 2) 203923_s_at 1536 cytochrome b-245, beta polypeptide electron transport (chronic granulomatous disease) 204446_s_at 240 arachidonate 5-lipoxygenase electron transport 202437_s_at 1545 cytochrome P450, family 1, electron transport subfamily B, polypeptide 1 203923_s_at 1536 cytochrome b-245, beta polypeptide energy pathways (chronic granulomatous disease) 210942_s_at 10402 alpha2,3-sialyltransferase lipid metabolism 204446_s_at 240 arachidonate 5-lipoxygenase lipid metabolism 204174_at 241 arachidonate 5-lipoxygenase-activating lipid metabolism protein 201963_at 2180 fatty-acid-Coenzyme A ligase, long-chain 2 lipid metabolism 208771_s_at 4048 leukotriene A4 hydrolase lipid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long-chain 1 lipid metabolism

Programmed Cell Death

LOCUS AFFX_ID LINK GENE NAME CLASSIFICATION 201612_at 223 aldehyde dehydrogenase 9 family, aldehyde metabolism member A1 210942_s_at 10402 alpha2,3-sialyltransferase amine metabolism 206643_at 3034 histidine ammonia-lyase amine metabolism 206643_at 3034 histidine ammonia-lyase amino acid and derivative metabolism 210942_s_at 10402 alpha2,3-sialyltransferase biosynthesis 219649_at 29929 dolichyl-P-Glc:Man9GlcNAc2-PP- biosynthesis dolichylglucosyltransferase 200962_at 6160 ribosomal protein L31 biosynthesis 206643_at 3034 histidine ammonia-lyase biosynthesis 204446_s_at 240 arachidonate 5-lipoxygenase biosynthesis 204174_at 241 arachidonate 5-lipoxygenase- biosynthesis activating protein 208771_s_at 4048 leukotriene A4 hydrolase biosynthesis 210942_s_at 10402 alpha2,3-sialyltransferase carbohydrate metabolism 202499_s_at 6515 solute carrier family 2 (facilitated carbohydrate metabolism glucose transporter), member 3 206643_at 3034 histidine ammonia-lyase catabolism 202551_s_at 51232 cysteine-rich motor neuron 1 catabolism 208771_s_at 4048 leukotriene A4 hydrolase catabolism 212190_at 5270 serine (or cysteine) proteinase catabolism inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 211506_s_at 3576 interleukin 8 cell adhesion 207113_s_at 7124 tumor necrosis factor (TNF cell adhesion superfamily, member 2) 201105_at 3956 lectin, galactoside-binding, soluble, 1 cell adhesion (galectin 1) 216250_s_at 9404 leupaxin cell adhesion 219890_at 23601 C-type (calcium dependent, cell adhesion carbohydrate-recognition domain) lectin, superfamily member 5 214727_at 675 breast cancer 2, early onset cell death 207113_s_at 7124 tumor necrosis factor (TNF cell death superfamily, member 2) 204614_at 5055 serine (or cysteine) proteinase cell death inhibitor, clade B (ovalbumin), member 2 201105_at 3956 lectin, galactoside-binding, soluble, 1 cell death (galectin 1) 202551_s_at 51232 cysteine-rich motor neuron 1 cell growth 212190_at 5270 serine (or cysteine) proteinase cell migration inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 214727_at 675 breast cancer 2, early onset cell organization and biogenesis 201999_s_at 6993 t-complex-associated-testis- cell organization and biogenesis expressed 1-like 1 204603_at 9156 exonuclease 1 cell proliferation 205053_at 5557 primase, polypeptide 1, 49 kDa cell proliferation 214727_at 675 breast cancer 2, early onset cell proliferation 209773_s_at 6241 ribonucleotide reductase M2 cell proliferation polypeptide 211506_s_at 3576 interleukin 8 cell proliferation 200660_at 6282 S100 calcium binding protein A11 cell proliferation (calgizzarin) 202769_at 901 cyclin G2 cell proliferation 201700_at 896 cyclin D3 cell proliferation 211506_s_at 3576 interleukin 8 cell-cell signaling 207113_s_at 7124 tumor necrosis factor (TNF cell-cell signaling superfamily, member 2) 203923_s_at 1536 cytochrome b-245, beta polypeptide electron transport (chronic granulomatous disease) 204446_s_at 240 arachidonate 5-lipoxygenase electron transport 202437_s_at 1545 cytochrome P450, family 1, electron transport subfamily B, polypeptide 1 203923_s_at 1536 cytochrome b-245, beta polypeptide energy pathways (chronic granulomatous disease) 210942_s_at 10402 alpha2,3-sialyltransferase lipid metabolism 204446_s_at 240 arachidonate 5-lipoxygenase lipid metabolism 204174_at 241 arachidonate 5-lipoxygenase- lipid metabolism activating protein 201963_at 2180 fatty-acid-Coenzyme A ligase, long- lipid metabolism chain 2 208771_s_at 4048 leukotriene A4 hydrolase lipid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long- lipid metabolism chain 1 209906_at 719 complement component 3a receptor 1 muscle contraction 204603_at 9156 exonuclease 1 nucleobase, nucleoside, nucleotide and nucleic acid metabolism 202338_at 7083 thymidine kinase 1, soluble nucleobase, nucleoside, nucleotide and nucleic acid metabolism 218384_at 23589 calcium regulated heat stable protein nucleobase, nucleoside, 1, 24 kDa nucleotide and nucleic acid metabolism 205053_at 5557 primase, polypeptide 1, 49 kDa nucleobase, nucleoside, nucleotide and nucleic acid metabolism 203409_at 1643 damage-specific DNA binding nucleobase, nucleoside, protein 2, 48 kDa nucleotide and nucleic acid metabolism 214727_at 675 breast cancer 2, early onset nucleobase, nucleoside, nucleotide and nucleic acid metabolism 209773_s_at 6241 ribonucleotide reductase M2 nucleobase, nucleoside, polypeptide nucleotide and nucleic acid metabolism 207113_s_at 7124 tumor necrosis factor (TNF nucleobase, nucleoside, superfamily, member 2) nucleotide and nucleic acid metabolism 200660_at 6282 S100 calcium binding protein A11 nucleobase, nucleoside, (calgizzarin) nucleotide and nucleic acid metabolism 209930_s_at 4778 nuclear factor (erythroid-derived 2), nucleobase, nucleoside, 45 kDa nucleotide and nucleic acid metabolism 201989_s_at 1389 cAMP responsive element binding nucleobase, nucleoside, protein-like 2 nucleotide and nucleic acid metabolism 209301_at 760 carbonic anhydrase II one-carbon compound metabolism 206643_at 3034 histidine ammonia-lyase organic acid metabolism 204446_s_at 240 arachidonate 5-lipoxygenase organic acid metabolism 204174_at 241 arachidonate 5-lipoxygenase- organic acid metabolism activating protein 201963_at 2180 fatty-acid-Coenzyme A ligase, long- organic acid metabolism chain 2 208771_s_at 4048 leukotriene A4 hydrolase organic acid metabolism 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long- organic acid metabolism chain 1 211506_s_at 3576 interleukin 8 organogenesis 205807_s_at 7286 tuftelin 1 organogenesis 218224_at 9240 paraneoplastic antigen MA1 organogenesis 202551_s_at 51232 cysteine-rich motor neuron 1 organogenesis 202437_s_at 1545 cytochrome P450, family 1, organogenesis subfamily B, polypeptide 1 205807_s_at 7286 tuftelin 1 ossification 202437_s_at 1545 cytochrome P450, family 1, perception of external stimulus subfamily B, polypeptide 1 209457_at 1847 dual specificity phosphatase 5 phosphorus metabolism 214727_at 675 breast cancer 2, early onset programmed cell death 207113_s_at 7124 tumor necrosis factor (TNF superfamily, programmed cell death member 2) 204614_at 5055 serine (or cysteine) proteinase inhibitor, programmed cell death clade B (ovalbumin), member 2 201105_at 3956 lectin, galactoside-binding, soluble, 1 programmed cell death (galectin 1) VX-944 (Early n Late) vs. MPA (Early ∩ Late): 43 genes were found to be in common for this stringent comparison. These genes were binned into the following functional

Fatty Acid Metabolism

LOCUS AFFYID LINK GENE NAME CLASSIFICATION 203455_s_at 6303 spermidine/spermine N1- Arginine and proline acetyltransferase metabolism 205053_at 5557 primase, polypeptide 1, DNApolymerase 49 kDa 202437_s_at 1545 cytochrome P450, Fatty acid family 1, subfamily B, metabolism polypeptide 1 207275_s_at 2179 fatty-acid-Coenzyme A Fatty acid ligase, long-chain 1 metabolism 201963_at 2180 fatty-acid-Coenzyme A Fatty acid ligase, long-chain 2 metabolism

Prostaglandin and Leukotriene Metabolism

LOCUS AFFYID LINK GENE NAME CLASSIFICATION 203455_s_at 6303 spermidine/spermine N1- Arginine and proline metabolism acetyltransferase 205053_at 5557 primase, polypeptide 1, 49 kDa DNApolymerase 202437_s_at 1545 cytochrome P450, family 1, Fatty acid metabolism subfamily B, polypeptide 1 207275_s_at 2179 fatty-acid-Coenzyme A ligase, long- Fatty acid metabolism chain 1 201963_at 2180 fatty-acid-Coenzyme A ligase, long- Fatty acid metabolism chain 2 204446_s_at 240 arachidonate 5-lipoxygenase Prostaglandin and leukotriene metabolism 208771_s_at 4048 leukotriene A4 hydrolase Prostaglandin and leukotriene metabolism

Others

LOCUS AFFYID LINK GENE NAME CLASSIFICATION 203455_s_at 6303 spermidine/spermine N1-acetyltransferase Arginine and proline metabolism 205053_at 5557 primase, polypeptide 1, 49 kDa DNApolymerase 204446_s_at 240 arachidonate 5-lipoxygenase Prostaglandin andleukotriene metabolism 208771_s_at 4048 leukotriene A4 hydrolase Prostaglandin andleukotriene metabolism 209773_s_at 6241 ribonucleotide reductase M2 polypeptide Purine metabolism 209773_s_at 6241 ribonucleotide reductase M2 polypeptide Pyrimidine metabolism 200962_at 6160 ribosomal protein L31 Ribosome 202437_s_at 1545 cytochrome P450, family 1, subfamily B, Tryptophan metabolism polypeptide 1 209457_at 1847 dual specificity phosphatase 5 Phosphatidylinositol signaling system 202437_s_at 1545 cytochrome P450, family 1, subfamily B, gamma-Hexachlorocyclohexane polypeptide 1 degradation 214086_s_at 10038 ADP-ribosyltransferase (NAD+; poly(ADP- ribose) polymerase)-like 2 210942_s_at 10402 alpha2,3-sialyltransferase 202814_s_at 10614 HMBA-inducible 203923_s_at 1536 cytochrome b-245, beta polypeptide (chronic granulomatous disease) 203409_at 1643 damage-specific DNA binding protein 2, 48 kDa 205229_s_at 1690 coagulation factor C homolog, cochlin (Limulus polyphemus) 213572_s_at 1992 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 1 216950_s_at 2209 Fc fragment of IgG, high affinity Ia, receptor for (CD64) 219890_at 23601 C-type (calcium dependent, carbohydrate- recognition domain) lectin, superfamily member 5 204174_at 241 arachidonate 5-lipoxygenase-activating protein 211506_s_at 3576 interleukin 8 200618_at 3927 LIM and SH3 protein 1 204614_at 5055 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2 203960_s_at 51668 HSPCO34 protein 212190_at 5270 serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 219296_at 54503 HIP14-related protein 219148_at 55872 T-LAK cell-originated protein kinase 221882_s_at 58986 transmembrane protein 8 (five membrane- spanning domains) 203344_s_at 5932 retinoblastoma binding protein 8 200660_at 6282 S100 calcium binding protein A11 (calgizzarin) 204351_at 6286 S100 calcium binding protein P 202499_s_at 6515 solute carrier family 2 (facilitated glucose transporter), member 3 205557_at 671 bactericidal/permeability-increasing protein 214727_at 675 breast cancer 2, early onset 203303_at 6990 t-complex-associated-testis-expressed 1-like 201999_s_at 6993 t-complex-associated-testis-expressed 1-like 1 205807_s_at 7286 tuftelin 1 201426_s_at 7431 vimentin 203046_s_at 8914 timeless homolog (Drosophila) 218224_at 9240 paraneoplastic antigen MA1 216250_s_at 9404 leupaxin 200704_at 9516 lipopolysaccharide-induced TNF factor 211429_s_at

Processed Data—Gene Lists

For each of the comparative analyses set up for this project, the processed data in the form of gene lists with hyperlinks to various databases has been prepared and is represented in Appendix III.

A snapshot of one of these gene lists is shown below. Each of the columns referring to an external database (GENE CARDS at the Weizmann Institute, Locus Link and OMIM at the NIH) has a hyperlink, which when accessed will pull in data corresponding to that gene.

FOLD FOLD CHANGE CHANGE Path- Gene (944, (MPA, Functional GENE LOCUS Pathways ways Symbol TITLE EARLY) EARLY) Annotation CARDS LINK OMIM GenMAPP KEGG C6orf18 chromosome 6 open reading 2.0 1.5 C6orf18 54535 605310 — — frame 18 TMEM8 transmembrane protein 8 (five 1.5 1.7 biological_proce

TMEM8 58986 — — membrane-spanning domains) MGC13024 hypothetical protein 1.6 1.5 MGC13024 93129 — — MGC13024 C8orf2 chromosome 8 open reading 1.7 1.5 biological_proce

C8orf2 11160 — — frame 2 RAGD Rag D protein 1.7 1.5 RAGD 58528 — — MLC-B myosin regulatory light chain 1.9 1.8 calcium ion bind

MRLC2 103910 — — MRLC2 CLECSF5 C-type (calcium dependent, 2.1 1.5 heterophilic cell CLECSF5 23601 604987 — — carbohydrate-recognition domain) lectin, superfamily member 5 ALG6 dolichyl-P- 1.6 1.5 N-linked glycos

ALG6 29929 604566 GPCRs_Other — Glc:Man9GlcNAc2-PP- dolichylglucosyltransferase C21orf4 chromosome 21 open reading 1.5 1.5 biological_proce

C21orf4 757 — — frame 4 FLJ10852 HIP14-related protein 1.7 1.5 HIP14L 54503 — — KLHL2 kelch-like 2, Mayven 2.0 1.6 actin binding ac

KLHL2 11275 605774 — — (Drosophila) TOPK T-LAK cell-originated protein 1.7 1.5 TOPK 55872 — — kinase FBXO5 F-box only protein 5 1.7 1.6 proteolysis and FBXO5 26271 606013 — — SNX10 sorting nexin 10 1.8 1.5 SNX10 29887 — — RPAC2 polymerase (RNA) I 1.5 1.5 DNA binding act

POLR1D 51082 — — polypeptide D, 16 kDa

indicates data missing or illegible when filed

In addition, a subset of the data was mapped onto relevant pathways, using the KEGG database. The following gene sets 2 and 3 also may be used in the arrays of the invention and are useful predictors of IMPDH inhibition. Particularly preferred exemplary markers of IMPDH inhibition are ARF4 (SEQ ID NO:______); CCNE2 (SEQ ID NO:______); CGR19 (SEQ ID NO:______); CPR8 (SEQ ID NO:______); EDF1 (SEQ ID NO:______); GTF2F1 (______); LGALS1 (SEQ ID NO:______); PDGFC (SEQ ID NO:______); PSMC5 (SEQ ID NO:______); PTK9 (SEQ ID NO:______); RABGGTA (SEQ ID NO:______); SCAP2 (SEQ ID NO:______); SERPINB2 (SEQ ID NO:______); TBPL1 (SEQ ID NO:______).

Gene Set 2

Affymetrix_ID Title Gene Symbol 200618_at LIM and SH3 protein 1 LASP1 200644_at MARCKS-like protein MLP 200660_at S100 calcium binding protein A11 (calgizzarin) S100A11 200704_at LPS-induced TNF-alpha factor PIG7 200788_s_at phosphoprotein enriched in astrocytes 15 PEA15 200904_at major histocompatibility complex, class I, E HLA-E 200911_s_at transforming, acidic coiled-coil containing protein 1 TACC1 200931_s_at vinculin VCL 200962_at Homo sapiens cDNA FLJ36224 fis, clone — THYMU2000990, mRNA sequence 201012_at annexin A1 ANXA1 201034_at adducin 3 (gamma) ADD3 201069_at matrix metalloproteinase 2 (gelatinase A, 72 kDa MMP2 gelatinase, 72 kDa type IV collagenase) 201097_s_at ADP-ribosylation factor 4 ARF4 201136_at proteolipid protein 2 (colonic epithelium-enriched) PLP2 201170_s_at basic helix-loop-helix domain containing, class B, 2 BHLHB2 201300_s_at prion protein (p27-30) (Creutzfeld-Jakob disease, PRNP Gerstmann-Strausler-Scheinker syndrome, fatal familial insomnia) 201329_s_at v-ets erythroblastosis virus E26 oncogene homolog 2 ETS2 (avian) 201362_at NS1-binding protein NS1-BP 201422_at interferon, gamma-inducible protein 30 IFI30 201426_s_at vimentin VIM 201468_s_at NAD(P)H dehydrogenase, quinone 1 NQO1 201471_s_at sequestosome 1 SQSTM1 201502_s_at nuclear factor of kappa light polypeptide gene NFKBIA enhancer in B-cells inhibitor, alpha 201590_x_at annexin A2 ANXA2 201612_at aldehyde dehydrogenase 9 family, member A1 ALDH9A1 201628_s_at Ras-related GTP-binding protein RAGA 201641_at bone marrow stromal cell antigen 2 BST2 201656_at integrin, alpha 6 ITGA6 201666_at tissue inhibitor of metalloproteinase 1 (erythroid TIMP1 potentiating activity, collagenase inhibitor) 201710_at v-myb myeloblastosis viral oncogene homolog MYBL2 (avian)-like 2 201714_at tubulin, gamma 1 TUBG1 201745_at PTK9 protein tyrosine kinase 9 /// PTK9 protein PTK9 tyrosine kinase 9 201772_at ornithine decarboxylase antizyme inhibitor OAZIN 201850_at capping protein (actin filament), gelsolin-like CAPG 201908_at dishevelled, dsh homolog 3 (Drosophila) DVL3 201920_at solute carrier family 20 (phosphate transporter), SLC20A1 member 1 201921_at guanine nucleotide binding protein (G protein), GNG10 gamma 10 201925_s_at decay accelerating factor for complement (CD55, DAF Cromer blood group system) 201963_at fatty-acid-Coenzyme A ligase, long-chain 2 FACL2 201969_at nuclear autoantigenic sperm protein (histone-binding) NASP 201999_s_at t-complex-associated-testis-expressed 1-like 1 TCTEL1 202145_at lymphocyte antigen 6 complex, locus E LY6E 202191_s_at growth arrest-specific 7 GAS7 202197_at myotubularin related protein 3 MTMR3 202207_at ADP-ribosylation factor-like 7 ARL7 202241_at phosphoprotein regulated by mitogenic pathways C8FW 202256_at CD2 antigen (cytoplasmic tail) binding protein 2 CD2BP2 202276_at Deleted in split-hand/split-foot 1 region DSS1 202355_s_at general transcription factor IIF, polypeptide 1, 74 kDa GTF2F1 202384_s_at Treacher Collins-Franceschetti syndrome 1 TCOF1 202393_s_at TGFB inducible early growth response TIEG 202405_at Homo sapiens cDNA FLJ43274 fis, clone — KIDNE2008914 202437_s_at cytochrome P450, subfamily I (dioxin-inducible), CYP1B1 polypeptide 1 (glaucoma 3, primary infantile) 202447_at 2,4-dienoyl CoA reductase 1, mitochondrial DECR1 202506_at sperm specific antigen 2 SSFA2 202528_at galactose-4-epimerase, UDP- GALE 202530_at mitogen-activated protein kinase 14 MAPK14 202532_s_at dihydrofolate reductase DHFR 202551_s_at cysteine-rich motor neuron 1 CRIM1 202554_s_at glutathione S-transferase M3 (brain) GSTM3 202569_s_at MAP/microtubule affinity-regulating kinase 3 MARK3 202589_at thymidylate synthetase TYMS 202611_s_at cofactor required for Sp1 transcriptional activation, CRSP2 subunit 2, 150 kDa 202611_s_at cofactor required for Sp1 transcriptional activation, CRSP2 subunit 2, 150 kDa 202644_s_at tumor necrosis factor, alpha-induced protein 3 TNFAIP3 202679_at Niemann-Pick disease, type C1 NPC1 202745_at ubiquitin specific protease 8 USP8 202769_at Homo sapiens mRNA; cDNA DKFZp434B142 (from — clone DKFZp434B142), mRNA sequence 202794_at inositol polyphosphate-1-phosphatase INPP1 202811_at associated molecule with the SH3 domain of STAM AMSH 202814_s_at HMBA-inducible HIS1 202842_s_at DnaJ (Hsp40) homolog, subfamily B, member 9 DNAJB9 202917_s_at S100 calcium binding protein A8 (calgranulin A) S100A8 202933_s_at v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1 YES1 202942_at electron-transfer-flavoprotein, beta polypeptide ETFB 202951_at serine/threonine kinase 38 STK38 202957_at hematopoietic cell-specific Lyn substrate 1 HCLS1 202990_at phosphorylase, glycogen; liver (Hers disease, PYGL glycogen storage disease type VI) 203006_at inositol polyphosphate-5-phosphatase, 40 kDa INPP5A 203046_s_at timeless homolog (Drosophila) TIMELESS 203185_at Ras association (RalGDS/AF-6) domain family 2 RASSF2 203201_at phosphomannomutase 2 PMM2 203274_at coagulation factor VIII-associated (intronic transcript) F8A 203275_at interferon regulatory factor 2 IRF2 203301_s_at cyclin D binding myb-like transcription factor 1 DMTF1 203303_at H1 histone family, member X H1FX 203314_at pseudoautosomal GTP-binding protein-like PGPL 203320_at lymphocyte adaptor protein LNK 203335_at phytanoyl-CoA hydroxylase (Refsum disease) PHYH 203344_s_at retinoblastoma binding protein 8 RBBP8 203349_s_at ets variant gene 5 (ets-related molecule) ETV5 203358_s_at enhancer of zeste homolog 2 (Drosophila) EZH2 203370_s_at enigma (LIM domain protein) ENIGMA 203388_at arrestin, beta 2 ARRB2 203401_at phosphoribosyl pyrophosphate synthetase 2 PRPS2 203409_at damage-specific DNA binding protein 2, 48 kDa DDB2 203414_at monocyte to macrophage differentiation-associated MMD 203455_s_at spermidine/spermine N1-acetyltransferase SAT 203471_s_at pleckstrin PLEK 203521_s_at endocrine regulator ZFP318 203535_at S100 calcium binding protein A9 (calgranulin B) S100A9 203559_s_at amiloride binding protein 1 (amine oxidase (copper- ABP1 containing)) 203560_at gamma-glutamyl hydrolase (conjugase, GGH folylpolygammaglutamyl hydrolase) 203564_at Fanconi anemia, complementation group G FANCG 203573_s_at Rab geranylgeranyltransferase, alpha subunit RABGGTA 203574_at nuclear factor, interleukin 3 regulated NFIL3 203611_at telomeric repeat binding factor 2 TERF2 203659_s_at ret finger protein 2 RFP2 203706_s_at frizzled homolog 7 (Drosophila) FZD7 203752_s_at jun D proto-oncogene JUND 203757_s_at carcinoembryonic antigen-related cell adhesion CEACAM6 molecule 6 (non-specific cross reacting antigen) 203761_at Src-like-adaptor SLA 203880_at popeye domain containing 2 POPDC2 203923_s_at cytochrome b-245, beta polypeptide (chronic CYBB granulomatous disease) 203943_at kinesin family member 3B KIF3B 203960_s_at HSPCO34 protein LOC51668 204023_at replication factor C (activator 1) 4, 37 kDa RFC4 204026_s_at ZW10 interactor ZWINT 204116_at interleukin 2 receptor, gamma (severe combined IL2RG immunodeficiency) 204143_s_at rTS beta protein HSRTSBETA 204146_at RAD51-interacting protein PIR51 204162_at highly expressed in cancer, rich in leucine heptad HEC repeats 204174_at arachidonate 5-lipoxygenase-activating protein ALOX5AP 204203_at CCAAT/enhancer binding protein (C/EBP), gamma CEBPG 204220_at glia maturation factor, gamma GMFG 204232_at Fc fragment of IgE, high affinity I, receptor for; FCER1G gamma polypeptide 204275_at small optic lobes homolog (Drosophila) SOLH 204286_s_at phorbol-12-myristate-13-acetate-induced protein 1 PMAIP1 204351_at S100 calcium binding protein P S100P 204362_at src family associated phosphoprotein 2 SCAP2 204417_at galactosylceramidase (Krabbe disease) GALC 204440_at CD83 antigen (activated B lymphocytes, CD83 immunoglobulin superfamily) 204444_at kinesin-like 1 KNSL1 204446_s_at arachidonate 5-lipoxygenase ALOX5 204490_s_at CD44 antigen (homing function and Indian blood CD44 group system) 204493_at BH3 interacting domain death agonist BID 204531_s_at breast cancer 1, early onset BRCA1 204603_at exonuclease 1 EXO1 204605_at cell growth regulator with ring finger domain 1 CGRRF1 204614_at serine (or cysteine) proteinase inhibitor, clade B SERPINB2 (ovalbumin), member 2 204635_at ribosomal protein S6 kinase, 90 kDa, polypeptide 5 RPS6KA5 204655_at chemokine (C-C motif) ligand 5 CCL5 204690_at syntaxin 8 STX8 204695_at cell division cycle 25A CDC25A 204742_s_at androgen-induced proliferation inhibitor APRIN 204759_at chromosome condensation 1-like CHC1L 204774_at ecotropic viral integration site 2A EVI2A 204786_s_at interferon (alpha, beta and omega) receptor 2 IFNAR2 204857_at MAD1 mitotic arrest deficient-like 1 (yeast) MAD1L1 204887_s_at serine/threonine kinase 18 STK18 204961_s_at neutrophil cytosolic factor 1 (47 kDa, chronic NCF1 granulomatous disease, autosomal 1) 204971_at cystatin A (stefin A) CSTA 205034_at cyclin E2 CCNE2 205041_s_at orosomucoid 1 ORM1 205053_at primase, polypeptide 1, 49 kDa PRIM1 205063_at survival of motor neuron protein interacting protein 1 SIP1 205070_at inhibitor of growth family, member 3 ING3 205098_at chemokine (C-C motif) receptor 1 CCR1 205142_x_at ATP-binding cassette, sub-family D (ALD), member 1 ABCD1 205176_s_at integrin beta 3 binding protein (beta3-endonexin) ITGB3BP 205204_at neuromedin B NMB 205214_at serine/threonine kinase 17b (apoptosis-inducing) STK17B 205229_s_at coagulation factor C homolog, cochlin (Limulus COCH polyphemus) 205260_s_at acylphosphatase 1, erythrocyte (common) type ACYP1 205269_at lymphocyte cytosolic protein 2 (SH2 domain LCP2 containing leukocyte protein of 76 kDa) 205282_at low density lipoprotein receptor-related protein 8, LRP8 apolipoprotein e receptor 205345_at BRCA1 associated RING domain 1 BARD1 205361_s_at prefoldin 4 PFDN4 205419_at Epstein-Barr virus induced gene 2 (lymphocyte- EBI2 specific G protein-coupled receptor) 205546_s_at tyrosine kinase 2 TYK2 205548_s_at BTG family, member 3 BTG3 205557_at bactericidal/permeability-increasing protein BPI 205658_s_at small nuclear RNA activating complex, polypeptide 4, SNAPC4 190 kDa 205681_at BCL2-related protein A1 BCL2A1 205726_at diaphanous homolog 2 (Drosophila) DIAPH2 205756_s_at coagulation factor VIII, procoagulant component F8 (hemophilia A) 205756_s_at coagulation factor VIII, procoagulant component F8 (hemophilia A) 205769_at solute carrier family 27 (fatty acid transporter), SLC27A2 member 2 205807_s_at tuftelin 1 TUFT1 206060_s_at protein tyrosine phosphatase, non-receptor type 22 PTPN22 (lymphoid) 206066_s_at RAD51 homolog C (S. cerevisiae) RAD51C 206111_at ribonuclease, RNase A family, 2 (liver, eosinophil- RNASE2 derived neurotoxin) 206157_at pentaxin-related gene, rapidly induced by IL-1 beta PTX3 206332_s_at interferon, gamma-inducible protein 16 IFI16 206332_s_at interferon, gamma-inducible protein 16 IFI16 206550_s_at nucleoporin 155 kDa NUP155 206571_s_at mitogen-activated protein kinase kinase kinase kinase 4 MAP4K4 206572_x_at zinc finger protein 85 (HPF4, HTF1) ZNF85 206589_at growth factor independent 1 GFI1 206643_at histidine ammonia-lyase HAL 206676_at carcinoembryonic antigen-related cell adhesion CEACAM8 molecule 8 206695_x_at zinc finger protein 43 (HTF6) ZNF43 206734_at jerky homolog-like (mouse) JRKL 206790_s_at NADH dehydrogenase (ubiquinone) 1 beta NDUFB1 subcomplex, 1, 7 kDa 207121_s_at mitogen-activated protein kinase 6 MAPK6 207153_s_at FKBP-associated protein FAP48 207198_s_at LIM and senescent cell antigen-like domains 1 LIMS1 207275_s_at fatty-acid-Coenzyme A ligase, long-chain 1 FACL1 207338_s_at zinc finger protein 200 ZNF200 207339_s_at lymphotoxin beta (TNF superfamily, member 3) LTB 207522_s_at ATPase, Ca++ transporting, ubiquitous ATP2A3 207563_s_at O-linked N-acetylglucosamine (GlcNAc) transferase OGT (UDP-N-acetylglucosamine:polypeptide-N- acetylglucosaminyl transferase) 208082_x_at makorin, ring finger protein, 4 MKRN4 208107_s_at exonuclease NEF-sp LOC81691 208151_x_at DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 17, DDX17 72 kDa 208369_s_at glutaryl-Coenzyme A dehydrogenase GCDH 208398_s_at TBP-like 1 TBPL1 208540_x_at S100 calcium binding protein A11 pseudogene S100A11P 208611_s_at spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) SPTAN1 208624_s_at eukaryotic translation initiation factor 4 gamma, 1 EIF4G1 208683_at calpain 2, (m/II) large subunit CAPN2 208703_s_at amyloid beta (A4) precursor-like protein 2 APLP2 208771_s_at leukotriene A4 hydrolase LTA4H 208892_s_at dual specificity phosphatase 6 DUSP6 208925_at chromosome 3 open reading frame 4 C3orf4 208949_s_at lectin, galactoside-binding, soluble, 3 (galectin 3) LGALS3 209043_at 3′-phosphoadenosine 5′-phosphosulfate synthase 1 PAPSS1 209058_at endothelial differentiation-related factor 1 EDF1 209094_at dimethylarginine dimethylaminohydrolase 1 DDAH1 209154_at Tax interaction protein 1 TIP-1 209179_s_at leukocyte receptor cluster (LRC) member 4 LENG4 209185_s_at insulin receptor substrate 2 IRS2 209250_at degenerative spermatocyte homolog, lipid desaturase DEGS (Drosophila) 209272_at NGFI-A binding protein 1 (EGR1 binding protein 1) NAB1 209288_s_at CDC42 effector protein (Rho GTPase binding) 3 CDC42EP3 209337_at PC4 and SFRS1 interacting protein 2 PSIP2 209396_s_at chitinase 3-like 1 (cartilage glycoprotein-39) CHI3L1 209407_s_at deformed epidermal autoregulatory factor 1 DEAF1 (Drosophila) 209413_at UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, B4GALT2 polypeptide 2 209457_at dual specificity phosphatase 5 DUSP5 209473_at ectonucleoside triphosphate diphosphohydrolase 1 ENTPD1 209503_s_at proteasome (prosome, macropain) 26S subunit, PSMC5 ATPase, 5 /// proteasome (prosome, macropain) 26S subunit, ATPase, 5 209575_at interleukin 10 receptor, beta IL10RB 209585_s_at multiple inositol polyphosphate histidine phosphatase, 1 MINPP1 209585_s_at multiple inositol polyphosphate histidine phosphatase, 1 MINPP1 209666_s_at conserved helix-loop-helix ubiquitous kinase CHUK 209714_s_at cyclin-dependent kinase inhibitor 3 (CDK2-associated CDKN3 dual specificity phosphatase) 209773_s_at ribonucleotide reductase M2 polypeptide RRM2 209798_at nuclear protein, ataxia-telangiectasia locus NPAT 209906_at complement component 3a receptor 1 C3AR1 209930_s_at nuclear factor (erythroid-derived 2), 45 kDa NFE2 210555_s_at nuclear factor of activated T-cells, cytoplasmic, NFATC3 calcineurin-dependent 3 210840_s_at IQ motif containing GTPase activating protein 1 IQGAP1 210845_s_at plasminogen activator, urokinase receptor PLAUR 210942_s_at alpha2,3-sialyltransferase ST3GALVI 210946_at phosphatidic acid phosphatase type 2A PPAP2A 211004_s_at aldehyde dehydrogenase 3 family, member B1 ALDH3B1 211317_s_at CASP8 and FADD-like apoptosis regulator CFLAR 211429_s_at serine (or cysteine) proteinase inhibitor, clade A SERPINA1 (alpha-1 antiproteinase, antitrypsin), member 1 211506_s_at interleukin 8 IL8 212063_at CD44 antigen (homing function and Indian blood CD44 group system) 212223_at iduronate 2-sulfatase (Hunter syndrome) IDS 212410_at hypothetical protein FLJ34588 FLJ34588 212481_s_at tropomyosin 4 TPM4 212588_at protein tyrosine phosphatase, receptor type, C PTPRC 212657_s_at interleukin 1 receptor antagonist IL1RN 212681_at erythrocyte membrane protein band 4.1-like 3 EPB41L3 212753_at hypothetical protein MGC40413 MGC40413 212990_at synaptojanin 1 SYNJ1 213164_at mitochondrial ribosomal protein S6 MRPS6 213253_at SMC2 structural maintenance of chromosomes 2-like SMC2L1 1 (yeast) 213326_at vesicle-associated membrane protein 1 VAMP1 (synaptobrevin 1) 213373_s_at caspase 8, apoptosis-related cysteine protease CASP8 213457_at malignant fibrous histiocytoma amplified sequence 1 MFHAS1 213572_s_at serine (or cysteine) proteinase inhibitor, clade B SERPINB1 (ovalbumin), member 1 213587_s_at vacuolar proton-ATPase subunit LOC155066 213650_at golgin-67 GOLGIN-67 213698_at hypothetical protein MGC14276 MGC14276 213791_at proenkephalin PENK 213915_at natural killer cell group 7 sequence NKG7 213951_s_at GT198, complete ORF HUMGT198A 214075_at secreted protein of unknown function SPUF 214086_s_at ADP-ribosyltransferase (NAD+; poly(ADP-ribose) ADPRTL2 polymerase)-like 2 214086_s_at ADP-ribosyltransferase (NAD+; poly(ADP-ribose) ADPRTL2 polymerase)-like 2 214157_at GNAS complex locus GNAS 214182_at ADP-ribosylation factor 6 ARF6 214467_at G protein-coupled receptor 65 GPR65 214684_at MADS box transcription enhancer factor 2, MEF2A polypeptide A (myocyte enhancer factor 2A) 214727_at breast cancer 2, early onset BRCA2 216250_s_at leupaxin LPXN 216268_s_at jagged 1 (Alagille syndrome) JAG1 216521_s_at — — 216598_s_at chemokine (C-C motif) ligand 2 CCL2 216950_s_at FcRI b form (AA 1-344) [Homo sapiens], mRNA — sequence 217028_at chemokine (C—X—C motif) receptor 4 CXCR4 217478_s_at major histocompatibility complex, class II, DM alpha HLA-DMA 217738_at pre-B-cell colony-enhancing factor PBEF 217762_s_at RAB31, member RAS oncogene family RAB31 217782_s_at G protein pathway suppressor 1 GPS1 217931_at trinucleotide repeat containing 5 TNRC5 217941_s_at erbb2 interacting protein ERBB2IP 217967_s_at chromosome 1 open reading frame 24 C1orf24 218039_at nucleolar protein ANKT ANKT 218061_at male-enhanced antigen MEA 218084_x_at FXYD domain containing ion transport regulator 5 FXYD5 218111_s_at cytidine monophosphate N-acetylneuraminic acid CMAS synthetase 218111_s_at cytidine monophosphate N-acetylneuraminic acid CMAS synthetase 218212_s_at molybdenum cofactor synthesis 2 MOCS2 218224_at paraneoplastic antigen MA1 PNMA1 218224_at paraneoplastic antigen MA1 PNMA1 218263_s_at transposon-derived Buster1 transposase-like protein LOC58486 218276_s_at WW45 protein WW45 218276_s_at salvador homolog 1 (Drosophila) SAV1 218285_s_at oxidoreductase UCPA LOC56898 218327_s_at synaptosomal-associated protein, 29 kDa SNAP29 218384_at calcium regulated heat stable protein 1, 24 kDa CARHSP1 218662_s_at chromosome condensation protein G HCAP-G 218718_at platelet derived growth factor C PDGFC 218718_at platelet derived growth factor C PDGFC 218767_at XPMC2 prevents mitotic catastrophe 2 homolog XPMC2H (Xenopus laevis) 218966_at myosin 5C MYO5C 218983_at complement C1r-like proteinase precursor, LOC51279 219020_at hypothetical protein FLJ14249 similar to HS1 binding FLJ14249 protein 3 219098_at MYB binding protein (P160) 1a MYBBP1A 219148_at T-LAK cell-originated protein kinase TOPK 219157_at kelch-like 2, Mayven (Drosophila) KLHL2 219161_s_at chemokine-like factor 1 CKLF1 219228_at zinc finger protein 331; zinc finger protein 463 ZNF361 219296_at hypothetical protein similar to ankyrin repeat- FLJ10852 containing priotein AKR1 219373_at dolichyl-phosphate mannosyltransferase polypeptide 3 DPM3 219649_at dolichyl-P-Glc:Man9GlcNAc2-PP- ALG6 dolichylglucosyltransferase 219767_s_at crystallin, zeta (quinone reductase)-like 1 CRYZL1 219863_at cyclin-E binding protein 1 CEB1 219890_at C-type (calcium dependent, carbohydrate-recognition CLECSF5 domain) lectin, superfamily member 5 220046_s_at cyclin L ania-6a LOC57018 220059_at BCR downstream signaling 1 BRDG1 220162_s_at caspase recruitment domain family, member 9 CARD9 220330_s_at SAM domain, SH3 domain and nuclear localisation SAMSN1 signals, 1 220397_at nuclear protein double minute 1 MDM1 220740_s_at solute carrier family 12 (potassium/chloride SLC12A6 transporters), member 6 221060_s_at toll-like receptor 4 TLR4 221156_x_at cell cycle progression 8 protein CPR8 221156_x_at cell cycle progression 8 protein CPR8 221158_at chromosome 21 open reading frame 66 C21orf66 221190_s_at colon cancer-associated protein Mic1 MIC1 221191_at DKFZp434A0131 protein DKFZP434A0131 221381_s_at mortality factor 4 MORF4 221563_at dual specificity phosphatase 10 DUSP10 221571_at TNF receptor-associated factor 3 TRAF3 221645_s_at zinc finger protein 83 (HPF1) ZNF83 221649_s_at peter pan homolog (Drosophila) PPAN 221676_s_at coronin, actin binding protein, 1C CORO1C 221830_at RAP2A, member of RAS oncogene family RAP2A 221840_at protein tyrosine phosphatase, receptor type, E PTPRE 221882_s_at transmembrane protein 8 (five membrane-spanning TMEM8 domains) 221989_at ribosomal protein L10 RPL10 222201_s_at CASP8 associated protein 2 CASP8AP2 37424_at chromosome 6 open reading frame 18 C6orf18 204655_at chemokine (C-C motif) ligand 5 CCL5 216598_s_at chemokine (C-C motif) ligand 2 CCL2 210946_at phosphatidic acid phosphatase type 2A PPAP2A 211429_s_at serine (or cysteine) proteinase inhibitor, clade A SERPINA1 (alpha-1 antiproteinase, antitrypsin), member 1 203140_at B-cell CLL/lymphoma 6 (zinc finger protein 51) BCL6 206157_at pentaxin-related gene, rapidly induced by IL-1 beta PTX3 204351_at S100 calcium binding protein P S100P 205034_at cyclin E2 CCNE2 205681_at BCL2-related protein A1 BCL2A1 203455_s_at spermidine/spermine N1-acetyltransferase SAT 211506_s_at interleukin 8 IL8 204961_s_at neutrophil cytosolic factor 1 (47 kDa, chronic NCF1 granulomatous disease, autosomal 1) 201426_s_at vimentin VIM 209457_at dual specificity phosphatase 5 DUSP5 209906_at complement component 3a receptor 1 C3AR1 203388_at arrestin, beta 2 ARRB2 213915_at natural killer cell group 7 sequence NKG7 200660_at S100 calcium binding protein A11 (calgizzarin) S100A11 219890_at C-type (calcium dependent, carbohydrate-recognition CLECSF5 domain) lectin, superfamily member 5 203303_at H1 histone family, member X H1FX 202551_s_at cysteine-rich motor neuron 1 CRIM1 210942_s_at alpha2,3-sialyltransferase ST3GALVI 202814_s_at HMBA-inducible HIS1 200904_at major histocompatibility complex, class I, E HLA-E 205807_s_at tuftelin 1 TUFT1 207275_s_at fatty-acid-Coenzyme A ligase, long-chain 1 FACL1 204286_s_at phorbol-12-myristate-13-acetate-induced protein 1 PMAIP1 206643_at histidine ammonia-lyase HAL 208107_s_at exonuclease NEF-sp LOC81691 217762_s_at RAB31, member RAS oncogene family RAB31 204174_at arachidonate 5-lipoxygenase-activating protein ALOX5AP 214086_s_at ADP-ribosyltransferase (NAD+; poly(ADP-ribose) ADPRTL2 polymerase)-like 2 201925_s_at decay accelerating factor for complement (CD55, DAF Cromer blood group system) 212223_at Homo sapiens mRNA; cDNA DKFZp434G012 (from — clone DKFZp434G012), mRNA sequence 203923_s_at cytochrome b-245, beta polypeptide (chronic CYBB granulomatous disease) 203409_at damage-specific DNA binding protein 2, 48 kDa DDB2 221830_at RAP2A, member of RAS oncogene family RAP2A 205557_at bactericidal/permeability-increasing protein BPI 209773_s_at ribonucleotide reductase M2 polypeptide RRM2 205098_at chemokine (C-C motif) receptor 1 CCR1 218224_at paraneoplastic antigen MA1 PNMA1 201710_at v-myb myeloblastosis viral oncogene homolog MYBL2 (avian)-like 2 204614_at serine (or cysteine) proteinase inhibitor, clade B SERPINB2 (ovalbumin), member 2 200618_at LIM and SH3 protein 1 LASP1 204116_at interleukin 2 receptor, gamma (severe combined IL2RG immunodeficiency) 204446_s_at arachidonate 5-lipoxygenase ALOX5 207610_s_at egf-like module containing, mucin-like, hormone EMR2 receptor-like sequence 2 216950_s_at FcRI b form (AA 1-344) [Homo sapiens], mRNA — sequence 209473_at ectonucleoside triphosphate diphosphohydrolase 1 ENTPD1 207339_s_at lymphotoxin beta (TNF superfamily, member 3) LTB 213622_at collagen, type IX, alpha 2 COL9A2 202393_s_at TGFB inducible early growth response TIEG 209094_at dimethylarginine dimethylaminohydrolase 1 DDAH1 201963_at fatty-acid-Coenzyme A ligase, long-chain 2 FACL2 201850_at capping protein (actin filament), gelsolin-like CAPG 206111_at ribonuclease, RNase A family, 2 (liver, eosinophil- RNASE2 derived neurotoxin) 204786_s_at interferon (alpha, beta and omega) receptor 2 IFNAR2 218384_at calcium regulated heat stable protein 1, 24 kDa CARHSP1 201012_at annexin A1 ANXA1 203535_at S100 calcium binding protein A9 (calgranulin B) S100A9 214727_at breast cancer 2, early onset BRCA2 202437_s_at cytochrome P450, subfamily I (dioxin-inducible), CYP1B1 polypeptide 1 (glaucoma 3, primary infantile) 210845_s_at plasminogen activator, urokinase receptor PLAUR 213572_s_at serine (or cysteine) proteinase inhibitor, clade B SERPINB1 (ovalbumin), member 1 201989_s_at cAMP responsive element binding protein-like 2 CREBL2 218662_s_at chromosome condensation protein G HCAP-G 221882_s_at transmembrane protein 8 (five membrane-spanning TMEM8 domains) 206676_at carcinoembryonic antigen-related cell adhesion CEACAM8 molecule 8 205229_s_at coagulation factor C homolog, cochlin (Limulus COCH polyphemus) 204971_at cystatin A (stefin A) CSTA 216250_s_at leupaxin LPXN 221156_x_at cell cycle progression 8 protein CPR8 203960_s_at HSPCO34 protein LOC51668 219157_at kelch-like 2, Mayven (Drosophila) KLHL2 202207_at ADP-ribosylation factor-like 7 ARL7 209396_s_at chitinase 3-like 1 (cartilage glycoprotein-39) CHI3L1 213164_at Homo sapiens G21VN02 mRNA, mRNA sequence — 200962_at Homo sapiens cDNA FLJ36224 fis, clone — THYMU2000990, mRNA sequence 203046_s_at timeless homolog (Drosophila) TIMELESS 205041_s_at orosomucoid 1 ORM1 203974_at DNA segment, numerous copies, expressed probes DXF68S1E (GS1 gene) 202811_at associated molecule with the SH3 domain of STAM AMSH 202554_s_at glutathione S-transferase M3 (brain) GSTM3 207121_s_at mitogen-activated protein kinase 6 MAPK6 201999_s_at t-complex-associated-testis-expressed 1-like 1 TCTEL1 209301_at carbonic anhydrase II CA2 201034_at adducin 3 (gamma) ADD3 201471_s_at sequestosome 1 SQSTM1 203757_s_at carcinoembryonic antigen-related cell adhesion CEACAM6 molecule 6 (non-specific cross reacting antigen) 218145_at chromosome 20 open reading frame 97 C20orf97 204490_s_at CD44 antigen (homing function and Indian blood CD44 group system) 219494_at RAD54B homolog RAD54B 218966_at myosin 5C MYO5C 203761_at Src-like-adaptor SLA 204561_x_at apolipoprotein C-II APOC2 217967_s_at chromosome 1 open reading frame 24 C1orf24 203344_s_at retinoblastoma binding protein 8 RBBP8 209154_at Tax interaction protein 1 TIP-1 205053_at primase, polypeptide 1, 49 kDa PRIM1 213698_at Unknown (protein for MGC: 32701) [Homo sapiens], — mRNA sequence 205260_s_at acylphosphatase 1, erythrocyte (common) type ACYP1 203370_s_at enigma (LIM domain protein) ENIGMA 204220_at glia maturation factor, gamma GMFG 203574_at nuclear factor, interleukin 3 regulated NFIL3 205070_at inhibitor of growth family, member 3 ING3 200788_s_at phosphoprotein enriched in astrocytes 15 PEA15 213587_s_at vacuolar proton-ATPase subunit LOC155066 204603_at exonuclease 1 EXO1 218061_at male-enhanced antigen MEA 212501_at CCAAT/enhancer binding protein (C/EBP), beta CEBPB 201628_s_at Ras-related GTP-binding protein RAGA 212481_s_at tropomyosin 4 TPM4 217976_s_at dynein, cytoplasmic, light intermediate polypeptide 1 DNCLI1 203358_s_at enhancer of zeste homolog 2 (Drosophila) EZH2 207543_s_at procollagen-proline, 2-oxoglutarate 4-dioxygenase P4HA1 (proline 4-hydroxylase), alpha polypeptide I 205345_at BRCA1 associated RING domain 1 BARD1 206572_x_at zinc finger protein 85 (HPF4, HTF1) ZNF85 201422_at interferon, gamma-inducible protein 30 IFI30 200704_at LPS-induced TNF-alpha factor PIG7 209798_at nuclear protein, ataxia-telangiectasia locus NPAT 209272_at NGFI-A binding protein 1 (EGR1 binding protein 1) NAB1 218212_s_at molybdenum cofactor synthesis 2 MOCS2 206734_at jerky homolog-like (mouse) JRKL 213951_s_at GT198, complete ORF HUMGT198A 208771_s_at leukotriene A4 hydrolase LTA4H 202917_s_at S100 calcium binding protein A8 (calgranulin A) S100A8 202644_s_at tumor necrosis factor, alpha-induced protein 3 TNFAIP3 204887_s_at serine/threonine kinase 18 STK18 219296_at hypothetical protein similar to ankyrin repeat- FLJ10852 containing priotein AKR1 202111_at solute carrier family 4, anion exchanger, member 2 SLC4A2 (erythrocyte membrane protein band 3-like 1) 205204_at neuromedin B NMB 209930_s_at nuclear factor (erythroid-derived 2), 45 kDa NFE2 200931_s_at vinculin VCL 208398_s_at TBP-like 1 TBPL1 204143_s_at rTS beta protein HSRTSBETA 219649_at dolichyl-P-Glc:Man9GlcNAc2-PP- ALG6 dolichylglucosyltransferase 211004_s_at aldehyde dehydrogenase 3 family, member B1 ALDH3B1 219119_at U6 snRNA-associated Sm-like protein LSm8 LSM8 207008_at interleukin 8 receptor, beta IL8RB 201612_at aldehyde dehydrogenase 9 family, member A1 ALDH9A1 210555_s_at nuclear factor of activated T-cells, cytoplasmic, NFATC3 calcineurin-dependent 3 202679_at Niemann-Pick disease, type C1 NPC1 212410_at hypothetical protein FLJ34588 FLJ34588 220202_s_at membrane-associated nucleic acid binding protein MNAB 37424_at chromosome 6 open reading frame 18 C6orf18 201097_s_at ADP-ribosylation factor 4 ARF4

Gene Set 3

Affymetrix_ID Title Gene Symbol 204655_at chemokine (C-C motif) ligand 5 CCL5 206157_at pentaxin-related gene, rapidly induced by IL-1 beta PTX3 210946_at phosphatidic acid phosphatase type 2A PPAP2A 212657_s_at interleukin 1 receptor antagonist IL1RN 216598_s_at chemokine (C-C motif) ligand 2 CCL2 205681_at BCL2-related protein A1 BCL2A1 208949_s_at lectin, galactoside-binding, soluble, 3 (galectin 3) LGALS3 202769_at Homo sapiens mRNA; cDNA DKFZp434B142 (from — clone DKFZp434B142), mRNA sequence 211429_s_at serine (or cysteine) proteinase inhibitor, clade A (alpha-1 SERPINA1 antiproteinase, antitrypsin), member 1 220397_at nuclear protein double minute 1 MDM1 201666_at tissue inhibitor of metalloproteinase 1 (erythroid TIMP1 potentiating activity, collagenase inhibitor) 205034_at cyclin E2 CCNE2 204614_at serine (or cysteine) proteinase inhibitor, clade B SERPINB2 (ovalbumin), member 2 204351_at S100 calcium binding protein P S100P 202551_s_at cysteine-rich motor neuron 1 CRIM1 212223_at iduronate 2-sulfatase (Hunter syndrome) IDS 201426_s_at vimentin VIM 209457_at dual specificity phosphatase 5 DUSP5 211506_s_at interleukin 8 IL8 219890_at C-type (calcium dependent, carbohydrate-recognition CLECSF5 domain) lectin, superfamily member 5 203455_s_at spermidine/spermine N1-acetyltransferase SAT 201925_s_at decay accelerating factor for complement (CD55, DAF Cromer blood group system) 207339_s_at lymphotoxin beta (TNF superfamily, member 3) LTB 200660_at S100 calcium binding protein A11 (calgizzarin) S100A11 213915_at natural killer cell group 7 sequence NKG7 203303_at H1 histone family, member X H1FX 205260_s_at acylphosphatase 1, erythrocyte (common) type ACYP1 204961_s_at neutrophil cytosolic factor 1 (47 kDa, chronic NCF1 granulomatous disease, autosomal 1) 207275_s_at fatty-acid-Coenzyme A ligase, long-chain 1 FACL1 205807_s_at tuftelin 1 TUFT1 202814_s_at HMBA-inducible HIS1 204759_at chromosome condensation 1-like CHC1L 221840_at protein tyrosine phosphatase, receptor type, E PTPRE 221156_x_at cell cycle progression 8 protein CPR8 204174_at arachidonate 5-lipoxygenase-activating protein ALOX5AP 210942_s_at alpha2,3-sialyltransferase ST3GALVI 217762_s_at RAB31, member RAS oncogene family RAB31 203923_s_at cytochrome b-245, beta polypeptide (chronic CYBB granulomatous disease) 204286_s_at phorbol-12-myristate-13-acetate-induced protein 1 PMAIP1 201502_s_at nuclear factor of kappa light polypeptide gene enhancer NFKBIA in B-cells inhibitor, alpha 209906_at complement component 3a receptor 1 C3AR1 209473_at ectonucleoside triphosphate diphosphohydrolase 1 ENTPD1 202191_s_at growth arrest-specific 7 GAS7 203535_at S100 calcium binding protein A9 (calgranulin B) S100A9 218983_at complement C1r-like proteinase precursor, LOC51279 206643_at histidine ammonia-lyase HAL 201963_at fatty-acid-Coenzyme A ligase, long-chain 2 FACL2 200904_at major histocompatibility complex, class I, E HLA-E 204162_at highly expressed in cancer, rich in leucine heptad HEC repeats 205098_at chemokine (C-C motif) receptor 1 CCR1 205557_at bactericidal/permeability-increasing protein BPI 203388_at arrestin, beta 2 ARRB2 201590_x_at annexin A2 ANXA2 202207_at ADP-ribosylation factor-like 7 ARL7 214086_s_at ADP-ribosyltransferase (NAD+; poly(ADP-ribose) ADPRTL2 polymerase)-like 2 213326_at vesicle-associated membrane protein 1 (synaptobrevin VAMP1 1) 207563_s_at O-linked N-acetylglucosamine (GlcNAc) transferase OGT (UDP-N-acetylglucosamine:polypeptide-N- acetylglucosaminyl transferase) 201034_at adducin 3 (gamma) ADD3 201999_s_at t-complex-associated-testis-expressed 1-like 1 TCTEL1 200962_at Homo sapiens cDNA FLJ36224 fis, clone — THYMU2000990, mRNA sequence 203706_s_at frizzled homolog 7 (Drosophila) FZD7 221830_at RAP2A, member of RAS oncogene family RAP2A 216250_s_at leupaxin LPXN 210845_s_at plasminogen activator, urokinase receptor PLAUR 202437_s_at cytochrome P450, subfamily I (dioxin-inducible), CYP1B1 polypeptide 1 (glaucoma 3, primary infantile) 213951_s_at GT198, complete ORF HUMGT198A 214727_at breast cancer 2, early onset BRCA2 213457_at malignant fibrous histiocytoma amplified sequence 1 MFHAS1 203409_at damage-specific DNA binding protein 2, 48 kDa DDB2 214467_at G protein-coupled receptor 65 GPR65 209396_s_at chitinase 3-like 1 (cartilage glycoprotein-39) CHI3L1 218224_at paraneoplastic antigen MA1 PNMA1 203574_at nuclear factor, interleukin 3 regulated NFIL3 201012_at annexin A1 ANXA1 202644_s_at tumor necrosis factor, alpha-induced protein 3 TNFAIP3 203757_s_at carcinoembryonic antigen-related cell adhesion molecule CEACAM6 6 (non-specific cross reacting antigen) 218212_s_at molybdenum cofactor synthesis 2 MOCS2 206332_s_at interferon, gamma-inducible protein 16 IFI16 209585_s_at multiple inositol polyphosphate histidine phosphatase, 1 MINPP1 206676_at carcinoembryonic antigen-related cell adhesion molecule 8 CEACAM8 206734_at jerky homolog-like (mouse) JRKL 219373_at dolichyl-phosphate mannosyltransferase polypeptide 3 DPM3 216950_s_at FcRI b form (AA 1-344) [Homo sapiens], mRNA — sequence 204446_s_at arachidonate 5-lipoxygenase ALOX5 205229_s_at coagulation factor C homolog, cochlin (Limulus COCH polyphemus) 200644_at MARCKS-like protein MLP 203140_at B-cell CLL/lymphoma 6 (zinc finger protein 51) BCL6 219767_s_at crystallin, zeta (quinone reductase)-like 1 CRYZL1 218718_at platelet derived growth factor C PDGFC 218276_s_at WW45 protein WW45 218111_s_at cytidine monophosphate N-acetylneuraminic acid CMAS synthetase 213253_at SMC2 structural maintenance of chromosomes 2-like 1 SMC2L1 (yeast) 209666_s_at conserved helix-loop-helix ubiquitous kinase CHUK 206695_x_at zinc finger protein 43 (HTF6) ZNF43 205756_s_at coagulation factor VIII, procoagulant component F8 (hemophilia A) 205063_at survival of motor neuron protein interacting protein 1 SIP1 204742_s_at androgen-induced proliferation inhibitor APRIN 204605_at cell growth regulator with ring finger domain 1 CGRRF1 202611_s_at cofactor required for Sp1 transcriptional activation, CRSP2 subunit 2, 150 kDa 202405_at Homo sapiens cDNA FLJ43274 fis, clone — KIDNE2008914 201745_at PTK9 protein tyrosine kinase 9 /// PTK9 protein tyrosine PTK9 kinase 9 201656_at integrin, alpha 6 ITGA6

All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

The references cited herein throughout, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are all specifically incorporated herein by reference. Each of the tables, pages and figures of priority application No. 60/575,076 filed on May 27, 2004 are specifically incorporated by reference in their entirety. The following references are exemplary of the state of the art of the development and use of IMPDH inhibitors and are incorporated herein by reference in their entirety:

REFERENCES

-   Albrecht W. Storck M, Pfetch E Martin W, Abendroth D (2000)     Development and application of a high-performance liquid     chromatography-based assay for determination of the activity of     inosine 5′-monophosphate dehydrogenase in whole blood and isolated     mononuclear cells. Ther Drug Monitoring 22: 283-294. -   Allison, A C, Eugui, E M (2000) Mycophenolate mofetil and its     mechanisms of action. Immunopharmacology 47: 85-118. -   Budde K, Glander P, Bauer S, Braun K, Waiser J, Fritsche L, Mai I,     Roots I, Neumayer H-H (2000) Pharmacodynamic monitoring of     Mycophenolate Mofetil. Clin Chem Lab Med 38: 1213-1216. -   Davis, G L, Esteban-Mur, R, Rustgi, V, Hoefs, J, Gordon, S C, Trepo,     C, Shiffman, M L, Zeuzem, S, Craxi, A, Ling, M H, Albrecht, J (1998)     Interferon alfa-2b alone or in combination with ribavirin for the     treatment of relapse of chronic hepatitis C. International Hepatitis     Interventional Therapy Group. N. Engl. J. Med 339: 1493-1499. -   Daxecker H, Raab M, Cichna M, Markl P, Muller M M (2001)     Determination of the effects of mycophenolic acid on the nucleotide     pool of human peripheral blood mononuclear cells in vitro by     high-performance liquid chromatography. Clin Chim Acta 310: 81-87. -   Dayton J S, Lindsten T, Thompson C B, and Mitchell B S (1994)     Effects of human T lymphocyte activation in inosine monophosphate     dehyrogensase expression. J Immunol 152: 984-991. -   Decker C J, Jain J, Almquist S J, Heiser A D, Nimmesgern E, Lyons S     M, Shlyakhter D (2001) In vitro and in vivo characterization of     novel non-nucleoside uncompetitive inhibitors of IMPDH. 11^(th)     International Congress of Immunology, Stockholm, 22-27 Jul. 2001.     Published as a supplement to the Scandinavian J of Immunol 54: suppl     1: July/August 2001. -   Dhar T G M, Shen Z, Guo J, Liu C, Watterson S H, Gu H H, Pitts W J,     Fleener C A, Rouleau K A, Sherbina N Z, McIntyre K W, Witmer M R,     Tredup J A, Chen B-C, Zhao R, Bednarz M S, Cheney D L, MacMaster J     F, Miller L M, Berry K K, Harper T W, Barrish J C, Hollenbaugh D L,     Iwanowicz E J (2002) Discovery of     N-[2-[2-[[3-Methoxy-4-(5-0xazolyl)phenyl]-amino]-5-oxazolyl]phenyl]-N-methyl-4-morpholineacetamide     as a novel and potent inhibitor of inosine monophosphate     dehydrogenase with excellent in vivo activity. J Med Chem 45:     2127-2130. -   Eugui, E M, Almquist, S J, Muller C D, Allison, A C (1991a)     Lymphocyte-selective cytostatic and immunosuppressive effects of     mycophenolic acid in vitro: role of deoxyguanosine nucleotide     depletion. Scan J Immunol 33: 161-173. -   Eugui, E M, Mirkovich, A, Allison, A C (1991b) Lymphocyte-selective     antiproliferative and immunosuppressive effect of mycophenolic acid     in mice. Scand. J. Immunol 33: 175-183. -   Fairbanks L D, Bofill M, Ruckemann K and Simmonds A H. 1995.     Importance of ribonucleotide availability to proliferating     T-lymphocytes from healthy humans. J Biol Chem 270: 29682-29689. -   Franchetti P, and Grifantini M (1999) Nucleoside and non-nucleoside     IMP dehydrogenase inhibitors as antitumor and antiviral agents. Curr     Med Chem 6: 599-614. -   Griesmacher A, Weigel G, Seebacher G, Muller M M (1997)     IMP-dehydrogenase inhibition in human lymphocytes and lymphoblasts     by mycophenolic acid and mycophenolic acid glucuronide. Clin Chem     43: 2312-2317. -   Griesmacher A, Weigel G, Seebacher G, Mallinger R, Laufer G, Muller     M W (1998). Inhibition of inosine monophosphate dehyrogensase     activity by the plasma of heart transplant recipients receiving     mycophenolate mofetil. Adv Exp Med Biol 431: 537-541 -   Gummert J F, Barten M J, Sherwood S W, Gelder T V, Morris R E     (1999). Pharmacodynamics of immunosuppression by mycophenolic acid:     inhibition of both lymphocyte proliferation and activation     correlates with pharmacokinetics. J Pharmacol and Exp Ther 291:     1100-1112. -   Heiser A, Bridson G, Leon E, Jones P, Badia M, Saunders J, Armistead     D, Decker C, Chaturvedi P. 1996. Single dose mycophenolate mofetil     and mycophenolic acid metabolism and disposition in bile     duct-cannulated and intact rats. ISSX Proceedings, San Diego,     Calif.: October, 1996. -   Hirohata S and Yanagida T (1995). Inhibition of expression of cyclin     A in human B cells by an immunosuppressant mizoribine. J Immunol     155: 5175-5183. -   Ishikawa, H (1999) Mizoribine and mycophenolate mofetil. Curr Med     Chem 6: 575-597. -   Jain J, Almquist S J, Shlyakhter D, and Harding M W (2001) VX-497: a     novel, selective IMPDH inhibitor and immunosuppressive agent. J     Pharm Sci 90: 625-637. -   Jain J, Almquist S J, Heiser A D, Shlyakhter D, Leon E, Memmott C,     Moody C S, Nimmesgem E and Decker C (2002) Characterization of     pharmacological efficacy of VX-148, a new, potent immunosuppressive     inosine 5′-monophosphate dehydrogenase inhibitor. J Pharmacol Exp     Ther 302: 1272-1277. -   Jayaram H N, Grusch M, Cooney D A and Krupitza G. 1999. Consequences     of IMP dehydrogenase inhibition, and its relationship to cancer and     apoptosis. Curr Med Chem 6: 561-574. -   Laliberte J, Yee A, Xiong Y and Mitchell B S (1998). Effects of     guanine nucleotide depletion on cell cycle progression in human T     lymphocytes. Blood 91: 2896-2904.: -   Langman L J, LeGatt D F, Yatscoff R W 1995. Pharmacodynamic     assessment of mycophenolic acid induced immunosuppression. Clin Chem     41: 295-299. -   Langman L J, LeGatt D F, Halloran P F, Yatskoff R W 1996.     Pharmacodynamic assessment of mycophenolic acid induced     immunosuppression in renal transplant recipients. Transplantation     62: 666-672. -   Markland, W, McQuaid, T J, Jain, J, Kwong, A D (2000) Broad-spectrum     antiviral activity of the IMP dehydrogenase inhibitor VX-497: a     comparison with ribavirin and demonstration of antiviral additivity     with alpha interferon. Antimicrobial Agents Chemother 44: 859-866. -   McHutchison, J G, Gordon, S C, Schiff, E R, Shiffman, M L, Lee, W M,     Rustgi, V K, Goodman, Z D, Ling, M H, Cort, S, Albrecht, J K (1998)     Interferon alfa-2b alone or in combination with ribavirin as initial     treatment for chronic hepatitis C. Hepatitis Interventional Therapy     Group. N Engl J Med 339: 1485-1492. -   Mele T S and Halloran P F (2000) The use of mycophenolate mofetil in     transplant recipients. Immunopharmacology 47: 215-245. -   Millan O, Oppenheimer F, Brunet M, Vilardell J, Rojo I, Vives J,     Martorell J (2000). Assessment of mycophenolic acid-induced     immunosuppression: a new approach. Clin Chem 46: 1376-1383. -   Montero C, Duley J A, Fairbanks L D, McBride M B, Micheli V, Cant A     J, Morgan G. 1995. Demonstration of induction of erythrocyte inosine     monophosphate dehydrogenase activity in ribavirin-treated patients     using a high performance liquid chromatography linked method. Clin     Chim Acta 238: 169-178. -   Poynard, T, Marcellin, P, Lee, S S, Niederau, C, Minuk, G S, Ideo,     G, Bain, V, Heathcote, J, Zeuzem, S, Trepo, C, Albrecht, J K (1998)     Randomised trial of interferon alpha2b plus ribavirin for 48 weeks     or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks     for treatment of chronic infection with hepatitis C virus.     International Hepatitis Interventional Therapy Group. Lancet 352:     1426-1432. -   Qiu Y, Fairbanks L D, Ruckemann K, Hawrylowicz C M, Richards D F,     Kirschbaum B, Simmonds H A. 2000. Mycophenolic acid-induced GTP     depletion also affects ATP and pyrimidine synthesis in     mitogen-stimulated primary human T-lymphocytes. Transplantation 69:     890-897. -   Sanquer S, Breil M, Baron C, Dhamane D, Astier A, Lang P (1999)     Induction of inosine monophosphate dehydrogenase activity after     long-term treatment with mycophenolate mofetil. Clin Pharmacol Ther     65: 640-664. -   Saunders J O and Raybuck S A. 2000. Inosine monophosphate     dehydrogenase: consideration of structure, kinetics, and therapeutic     potential. Ann Reports in Med Chem 35: 201-210. -   Sintchak, M D, Fleming, M A, Futer, O, Raybuck, S A, Chambers, S P,     Caron, P R, Murcko, M A, Wilson, K P (1996) Structure and mechanism     of inosine monophosphate dehydrogenase in complex with the     immunosuppressant Mycophenolic acid. Cell 85: 921-930. -   Sintchak M D and Nimmesgem E (2000) The structure of inosine     5′-monophosphate dehydrogenase and the design of novel inhibitors.     Immunopharmacology 47: 163-184. -   Thomson A W, Woo J, Yao G Z, Todo S, Starzl T E, Zeevi A. 1993     Effect of combined administration of FK506 and the purine     biosynthesis inhibitors mizoribine or mycophenolic acid on     lymphocyte DNA synthesis and T cell activation molecule expression     in human mixed lymphocyte cultures. Transplant Immunology 1:     146-150. -   Weaver J L, Pine P S and Aszalos A. 1991 Comparison of the in vitro     and biophysical effects of cyclosporin A, FK-506, and mycophenolic     acid on human peripheral blood lymphocytes. Immunopharmacology and     Immunotoxicology 13: 563-576.

TABLE IX Gene Name Gene Description Target Description Gene Symbol Change_24 h Change_48 h Change_72 h 201110_s_at thrombospondin 1 gb: NM_003246.1 /DEF = Homo sapiens THBS1 1.9 86.1 61.4 thrombospondin 1 (THBS1), mRNA. /FEA = mRNA /GEN = THBS1 /PROD = thrombospondin 1 /DB_XREF = gi: 4507484 /UG = Hs.87409 thrombospondin 1 /FL = gb: NM_003246.1 206618_at interleukin 18 receptor 1 gb: NM_003855.1 /DEF = Homo sapiens interleukin IL18R1 1.5 1.3 1.0 18 receptor 1 (IL18R1), mRNA. /FEA = mRNA /GEN = IL18R1 /PROD = interleukin 18 receptor 1 /DB_XREF = gi: 4504654 /UG = Hs.159301 interleukin 18 receptor 1 /FL = gb: U43672.1 gb: NM_003855.1 212224_at aldehyde dehydrogenase 1 family, m

Consensus includes gb: NM_000689.1 ALDH1A1 1.0 −1.8 −1.8 /DEF = Homo sapiens aldehyde dehydrogenase 1, soluble (ALDH1), mRNA. /FEA = CDS /GEN = ALDH1 /PROD = aldehyde dehydrogenase 1, soluble /DB_XREF = gi: 4502030 /UG = Hs.76392 aldehyde dehydrogenase 1 family, member A1 /FL = gb: AF003341.1 gb: NM_000689.1 202953_at complement component 1, q subcom

gb: NM_000491.2 /DEF = Homo sapiens C1QB 1.0 −1.4 −1.5 complement component 1, q subcomponent, beta polypeptide (C1QB), mRNA. /FEA = mRNA /GEN = C1QB /PROD = complement component 1, q subcomponent, betapolypeptide precursor /DB_XREF = gi: 11038661 /UG = Hs.8986 complement component 1, q subcomponent, beta polypeptide /FL = gb: NM_000491.2 209396_s_at chitinase 3-like 1 (cartilage glycoprot

gb: M80927.1 /DEF = Human glycoprotein mRNA, CHI3L1 1.0 −1.4 −1.7 complete cds. /FEA = mRNA /PROD = glycoprotein /DB_XREF = gi: 348911 /UG = Hs.75184 chitinase 3-like 1 (cartilage glycoprotein-39) /FL = gb: M80927.1 gb: NM_001276.1 220059_at BCR downstream signaling 1 gb: NM_012108.1 /DEF = Homo sapiens BCR BRDG1 123.9 −1.5 −1.1 downstream signaling 1 (BRDG1), mRNA. /FEA = mRNA /GEN = BRDG1 /PROD = BCR downstream signaling 1 /DB_XREF = gi: 6912271 /UG = Hs.121128 BCR downstream signaling 1 /FL = gb: AB023483.1 gb: NM_012108.1 206133_at XIAP associated factor 1.0 gb: NM_017523.1 /DEF = Homo sapiens XIAP HSXIAPAF1 1.4 −2.4 1.4 associated factor1.0 (HSXIAPAF1), mRNA. /FEA = mRNA /GEN = HSXIAPAF1 /PROD = XIAP associated factor1.0 /DB_XREF = gi: 8923794 /UG = Hs.139262 XIAP associated factor1.0 /FL = gb: NM_017523.1 212628_at protein kinase N2 Consensus includes gb: BG292065 /FEA = EST PKN2 1.6 −1.6 −1.3 /DB_XREF = gi: 13050507 /DB_XREF = est: 602386350F1 /CLONE = IMAGE: 4515036 /UG = Hs.69171 protein kinase C-like 2 203595_s_at interferon-induced protein with tetratr

Consensus includes gb: N47725 /FEA = EST IFIT5 1.5 −2.2 1.0 /DB_XREF = gi: 1188891 /DB_XREF = est: yy92h11.s1 /CLONE = IMAGE: 281061 /UG = Hs.27610 retinoic acid- and interferon-inducible protein (58 kD) /FL = gb: U34605.1 gb: NM_012420.1 205692_s_at CD38 antigen (p45) gb: NM_001775.1 /DEF = Homo sapiens CD38 CD38 1.7 −2.1 −1.2 antigen (p45) (CD38), mRNA. /FEA = mRNA /GEN = CD38 /PROD = CD38 antigen (p45) /DB_XREF = gi: 4502664 /UG = Hs.66052 CD38 antigen (p45) /FL = gb: D84276.1 gb: NM_001775.1 gb: M34461.1 201707_at peroxisomal biogenesis factor 19 gb: NM_002857.1 /DEF = Homo sapiens PEX19 90.1 −1.5 −1.5 peroxisomal famesylated protein (PXF), mRNA. /FEA = mRNA /GEN = PXF /PROD = peroxisomal famesylated protein /DB_XREF = gi: 4506338 /UG = Hs.168670 peroxisomal famesylated protein /FL = gb: BC000496.1 gb: NM_002857.1 gb: AB018541.1 205033_s_at defensin, alpha 1, myeloid-related se

gb: NM_004084.2 /DEF = Homo sapiens defensin, DEFA1 1.2 1.6 −1.8 alpha 1, myeloid-related sequence (DEFA1), mRNA. /FEA = mRNA /GEN = DEFA1 /PROD = defensin, alpha 1, preproprotein /DB_XREF = gi: 12621915 /UG = Hs.274463 defensin, alpha 1, myeloid-related sequence /FL = gb: NM_004084.2 gb: M21130.1 gb: M26602.1 33132_at cleavage and polyadenylation specifi

Cluster Incl. U37012: Human cleavage and CPSF1 1.0 1.8 1.2 polyadenylation specificity factor mRNA, complete cds /cds = (51,4379) /gb = U37012 /gi = 1045573 /ug = Hs.83727 /len = 4463 211330_s_at hemochromatosis gb: AF144242.1 /DEF = Homo sapiens HFE 1.1 −1.1 82.1 hemochromatosis splice variant delE3 mRNA. complete cds. /FEA = mRNA /GEN = HFE /PROD = hemochromatosis splice variant delE3 /DB_XREF = gi: 11094324 /UG = Hs.20019 hemochromatosis /FL = gb: AF144242.1 204439_at chromosome 1 open reading frame 2 gb: NM_006820.1 /DEF = Homo sapiens C1orf29 1.0 −894.0 2.2 hypothetical protein, expressed in osteoblast (GS3686), mRNA. /FEA = mRNA /GEN = GS3686 /PROD = hypothetical protein, expressed in osteoblast /DB_XREF = gi: 5803026 /UG = Hs.75470 hypothetical protein, expressed in osteoblast /FL = gb: AB000115.1 gb: NM_006820.1 206632_s_at apolipoprotein B mRNA editing enzy

gb: NM_004900.1 /DEF = Homo sapiens phorbolin APOBEC3B 1.0 −113.2 1.2 (similar to apolipoprotein B mRNA editing protein) (DJ742C19.2), mRNA. /FEA = mRNA /GEN = DJ742C19.2 /PROD = phorbolin (similar to apolipoprotein B mRNAediting protein) /DB_XREF = gi: 4758159 /UG = Hs.226307 phorbolin (similar to apolipoprotein B mRNA editing protein) /FL = gb: U61083.1 gb: NM_004900.1 202411_at interferon, alpha-inducible protein 27 gb: NM_005532.1 /DEF = Homo sapiens interferon, IFI27 1.0 −120.6 1.2 alpha-inducible protein 27 (IFI27), mRNA. /FEA = mRNA /GEN = IFI27 /PROD = interferon, alpha-inducible protein 27 /DB_XREF = gi: 5031780 /UG = Hs.278613 interferon, alpha-inducible protein 27 /FL = gb: NM_005532.1 219211_at ubiquitin specific protease 18 gb: NM_017414.1 /DEF = Homo sapiens ubiquitin USP18 1.0 −183.7 1.0 specific protease 18 (USP18), mRNA. /FEA = mRNA /GEN = USP18 /PROD = ubiquitin specific protease 18 /DB_XREF = gi: 8394518 /UG = Hs.38260 ubiquitin specific protease 18 /FL = gb: AL136690.1 gb: AF176642.2 gb: NM_017414.1 203153_at interferon-induced protein with tetratr

gb: NM_001548.1 /DEF = Homo sapiens interferon- 1.0 −1084.5 1.0 induced protein with tetratricopeptide repeats 1 (IFIT1), mRNA. /FEA = mRNA /GEN = IFIT1 /PROD = interferon-induced protein withtetratricopeptide repeats 1 /DB_XREF = gi: 4504584 /UG = Hs.20315 interferon-induced protein with tetratricopeptide repeats 1 /FL = gb: M24594.1 gb: NM_001548.1 203167_at tissue inhibitor of metalloproteinase 2

gb: NM_003255.2 /DEF = Homo sapiens tissue TIMP2 1.2 −1.9 1.1 inhibitor of metalloproteinase 2 (TIMP2), mRNA. /FEA = mRNA /GEN = TIMP2 /PROD = tissue inhibitor of metalloproteinase 2precursor /DB_XREF = gi: 9257247 /UG = Hs.325495 tissue inhibitor of metalloproteinase 2 /FL = gb: M32304.1 gb: J05593.1 gb: NM_003255.2 202086_at myxovirus (influenza virus) resistance

gb: NM_002462.1 /DEF = Homo sapiens myxovirus MX1 1.1 −7.3 −1.2 (influenza) resistance 1, homolog of murine (interferon-inducible protein p78) (MX1), mRNA. /FEA = mRNA /GEN = MX1 /PROD = myxovirus (influenza) resistance 1, homolog ofmurine (interferon-inducible protein p78) /DB_XREF = gi: 4505290 /UG = Hs.76391 myxovirus (influenza) resistance 1, homolog of murine (interferon-inducible protein p78) /FL = gb: M30817.1 gb: M33882.1 gb: NM_002462.1 214038_at chemokine (C-C motif) ligand 8 Consensus includes gb: AI984980 /FEA = EST CCL8 1.1 −8.4 −1.2 /DB_XREF = gi: 5812257 /DB_XREF = est: wr88g11.x1 /CLONE = IMAGE: 2494820 /UG = Hs.271387 small inducible cytokine subfamily A (Cys-Cys), member 8 (monocyte chemotactic protein 2) /FL = gb: NM_005623.1 208436_s_at interferon regulatory factor 7 gb: NM_004030.1 /DEF = Homo sapiens interferon IRF7 1.0 −2.8 1.1 regulatory factor 7 (IRF7), transcript variant c, mRNA. /FEA = mRNA /GEN = IRF7 /PROD = interferon regulatory factor 7, transcriptvariant c /DB_XREF = gi: 4809285 /UG = Hs.166120 interferon regulatory factor 7 /FL = gb: NM_004030.1 218400_at 2′-5′-oligoadenylate synthetase 3, 10

gb: NM_006187.1 /DEF = Homo sapiens 2- OAS3 −1.1 −3.1 −1.2 5oligoadenylate synthetase 3 (OAS3), mRNA. /FEA = mRNA /GEN = OAS3 /PROD = 2- 5oligoadenylate synthetase 3 /DB_XREF = gi: 5453623 /UG = Hs.56009 2- 5oligoadenylate synthetase 3 /FL = gb: AB044545.1 gb: AF063613.1 gb: NM_006187.1 44673_at sialoadhesin Cluster Incl. N53555: yv43e09.s1 Homo sapiens SN −1.1 −3.0 1.0 cDNA, 3 end /clone = IMAGE-245512 /clone_end = 3′ /gb = N53555 /gi = 1194721 /ug = Hs.31869 /len = 680 214453_s_at interferon-induced protein 44 Consensus includes gb: NM_006417.1 IFI44 1.4 −4.9 1.1 /DEF = Homo sapiens interferon-induced, hepatitis C-associated microtubular aggregate protein (44 kD) (MTAP44), mRNA. /FEA = CDS /GEN = MTAP44 /PROD = interferon-induced, hepatitis C-associatedmicrotubular aggregate protein (44 kD) /DB_XREF = gi: 5453743 /UG = Hs.82316 interferon-induced, hepatitis C- associated microtubular aggregate protein (44 kD) /FL = gb: NM_006417.1 204994_at myxovirus (influenza virus) resistance

gb: NM_002463.1 /DEF = Homo sapiens myxovirus MX2 1.0 −2.8 1.1 (influenza) resistance 2, homolog of murine (MX2), mRNA. /FEA = mRNA /GEN = MX2 /PROD = myxovirus (influenza) resistance 2, homolog ofmurine /DB_XREF = gi: 11342663 /UG = Hs.926 myxovirus (influenza) resistance 2, homolog of murine /FL = gb: NM_002463.1 gb: M30818.1 gb: M33883.1 202446_s_at phospholipid scramblase 1 Consensus includes gb: AI825926 /FEA = EST PLSCR1 1.3 −2.5 −1.1 /DB_XREF = gi: 5446597 /DB_XREF = est: to92d05.x1 /CLONE = IMAGE: 2185737 /UG = Hs.198282 phospholipid scramblase 1 /FL = gb: NM_021105.1 gb: AB006746.1 gb: AF098642.1 219863_at hect domain and RLD 5 gb: NM_016323.1 /DEF = Homo sapiens cyclin-E HERC5 1.2 −3.6 −1.2 binding protein 1 (LOC51191), mRNA. /FEA = mRNA /GEN = LOC51191 /PROD = cyclin-E binding protein 1 /DB_XREF = gi: 7705930 /UG = Hs.26663 cyclin-E binding protein 1 /FL = gb: AB027289.1 gb: NM_016323.1 204415_at interferon, alpha-inducible protein (cl

gb: NM_022873.1 /DEF = Homo sapiens interferon, G1P3 −1.1 −3.5 1.4 alpha-inducible protein (clone IFI-61.06) (G1P3), transcript variant 3, mRNA. /FEA = mRNA /GEN = G1P3 /PROD = interferon induced 61.06 protein, isoform, c /DB_XREF = gi: 13259549 /UG = Hs.265827 interferon, alpha-inducible protein (clone IFI-61.06) /FL = gb: NM_022872.1 gb: NM_022873.1 gb: NM_002038.2 205483_s_at interferon, alpha-inducible protein (cl

gb: NM_005101.1 /DEF = Homo sapiens interferon- G1P2 1.0 −9.9 −1.1 stimulated protein, 15 kDa (ISG15), mRNA. /FEA = mRNA /GEN = ISG15 /PROD = interferon- stimulated protein, 15 kDa/DB_XREF = gi: 4826773 /UG = Hs.833 interferon-stimulated protein, 15 kDa /FL = gb: M13755.1 gb: NM_005101.1 210001_s_at suppressor of cytokine signaling 1 gb: AB005043.1 /DEF = Homo sapiens mRNA for SOCS1 1.1 −1.7 −2.7 STAT induced STAT inhibitor1.0, complete cds. /FEA = mRNA /PROD = STAT induced STAT inhibitor1.0 /DB_XREF = gi: 2443364 /UG = Hs.50640 JAK binding protein /FL = gb: U88326.1 gb: AB005043.1 gb: AB000734.1 gb: NM_003745.1 209196_at chromosome 6 open reading frame 1 gb: BC000388.1 /DEF = Homo sapiens, BING4, C6orf11 1.3 −1.3 −65.8 clone MGC: 8435, mRNA, complete cds. /FEA = mRNA /PROD = BING4 /DB_XREF = gi: 12653238 /UG = Hs.17930 chromosome 6 open reading frame 11 /FL = gb: BC000388.1 gb: NM_005452.2 206407_s_at chemokine (C-C motif) ligand 13 gb: NM_005408.1 /DEF = Homo sapiens small CCL13 1.0 −2.9 −2.1 inducible cytokine subfamily A (Cys-Cys), member 13 (SCYA13), mRNA. /FEA = mRNA /GEN = SCYA13 /PROD = small inducible cytokine subfamily A (Cys-Cys), member 13 /DB_XREF = gi: 4885586 /UG = Hs.11383 small inducible cytokine subfamily A (Cys-Cys), member 13 /FL = gb: U46767.1 gb: U59808.1 gb: NM_005408.1 216598_s_at chemokine (C-C motif) ligand 2 Consensus includes gb: S69738.1 CCL2 −1.3 −3.1 −2.4 /DEF = MCP1.0 = monocyte chemotactic protein human, aortic endothelial cells, mRNA, 661 nt. /FEA = mRNA /GEN = MCP1.0 /PROD = MCP1.0 /DB_XREF = gi: 545464 /UG = Hs.303649 small inducible cytokine A2 (monocyte chemotactic protein 1, homologous to mouse Sig-je) 212657_s_at interleukin 1 receptor antagonist Consensus includes gb: U65590 /DEF = Homo IL1RN −1.2 −2.6 −3.0 sapiens IL1.0 receptor antagonist IL1.0Ra (IL1.0RN) gene, alternatively spliced forms, complete cds /FEA = mRNA_2 /DB_XREF = gi: 2707374 /UG = Hs.81134 interleukin 1 receptor antagonist 204533_at chemokine (C—X—C motif) ligand 10 gb: NM_001565.1 /DEF = Homo sapiens small CXCL10 −1.2 −4.9 −3.9 inducible cytokine subfamily B (Cys-X-Cys), member 10 (SCYB10), mRNA. /FEA = mRNA /GEN = SCYB10 /PROD = interferon gamma- induced precursor /DB_XREF = gi: 4504700 /UG = Hs.2248 small inducible cytokine subfamily B (Cys-X-Cys), member 10 /FL = gb: NM_001565.1 203915_at chemokine (C—X—C motif) ligand 9 gb: NM_002416.1 /DEF = Homo sapiens monokine CXCL9 −1.2 −1.7 −3.2 induced by gamma interferon (MIG), mRNA. /FEA = mRNA /GEN = MIG /PROD = monokine induced by gamma interferon /DB_XREF = gi: 4505186 /UG = Hs.77367 monokine induced by gamma interferon /FL = gb: NM_002416.1 209396_s_at chitinase 3-like 1 (cartilage glycoprotei

gb: M80927.1 /DEF = Human glycoprotein CHI3L1 1.0 −1.4 −1.7 mRNA, complete cds. /FEA = mRNA /PROD = glycoprotein /DB_XREF = gi: 348911 /UG = Hs.75184 chitinase 3-like 1 (cartilage glycoprotein- 39) /FL = gb: M80927.1 gb: NM_001276.1 212657_s_at interleukin 1 receptor antagonist Consensus includes gb: U65590 IL1RN −1.2 −2.6 −3.0 /DEF = Homo sapiens IL-1 receptor antagonist IL-1Ra (IL-1RN) gene, alternatively spliced forms, complete cds /FEA = mRNA_2 /DB_XREF = gi: 2707374 /UG = Hs.81134 interleukin 1 receptor antagonist 209396_s_at chitinase 3-like 1 (c

gb: M80927.1 /DEF = Human CHI3L1 1.0 −1.4 −1.7 glycoprotein mRNA, complete cds. /FEA = mRNA /PROD = glycoprotein /DB_XREF = gi: 348911 /UG = Hs.75184 chitinase 3-like 1 (cartilage glycoprotein-39) /FL = gb: M80927.1 gb: NM_001276.1 212657_s_at interleukin 1 recept

Consensus includes gb: U65590 IL1RN −1.2 −2.6 −3.0 /DEF = Homo sapiens IL-1 receptor antagonist IL-1Ra (IL-1RN) gene, alternatively spliced forms, complete cds /FEA = mRNA_2 /DB_XREF = gi: 2707374 /UG = Hs.81134 interleukin 1 receptor antagonist 219494_at RAD54 homolog B gb: NM_012415.1 /DEF = Homo sapiens RAD54B 1.0 1.0 1.0 (S. cerevisiae) RAD54, S. cerevisiae, homolog of, B (RAD54B), mRNA. /FEA = mRNA /GEN = RAD54B /PROD = RAD54, S. cerevisiae, homolog of, B /DB_XREF = gi: 6912621 /UG = Hs.128501 RAD54, S. cerevisiae, homolog of, B /FL = gb: BC001965.1 gb: AF112481.1 gb: NM_012415.1 216598_s_at chemokine (C-C Consensus includes gb: S69738.1 CCL2 −1.3 −3.1 −2.4 motif) ligand 2 /DEF = MCP-1 = monocyte chemotactic protein human, aortic endothelial cells, mRNA, 661 nt. /FEA = mRNA /GEN = MCP- 1 /PROD = MCP-1 /DB_XREF = gi: 545464 /UG = Hs.303649 small inducible cytokine A2 (monocyte chemotactic protein 1, homologous to mouse Sig-je) 218355_at kinesin family gb: NM_012310.2 /DEF = Homo sapiens KIF4A −1.0 −1.2 −1.0 member 4A kinesin family member 4A (KIF4A), mRNA. /FEA = mRNA /GEN = KIF4A /PROD = kinesin family member 4 /DB_XREF = gi: 7305204 /UG = Hs.279766 kinesin family member 4A/FL = gb: AF179308.1 gb: AF071592.2 gb: NM_012310.2 205312_at spleen focus gb: NM_003120.1 /DEF = Homo sapiens SPI1 1.0 1.0 −1.2 forming virus spleen focus forming virus (SFFV) proviral (SFFV) proviral integration oncogene spi1 (SPI1), mRNA. integration /FEA = mRNA /GEN = SPI1 /PROD = spleen oncogene spi1 focus forming virus (SFFV) proviralintegration oncogene spi1 /DB_XREF = gi: 4507174 /UG = Hs.157441 spleen focus forming virus (SFFV) proviral integration oncogene spi1 /FL = gb: NM_003120.1 206499_s_at chromosome gb: NM_001269.1 /DEF = Homo sapiens CHC1 1.3 1.2 −1.5 condensation 1 chromosome condensation 1 (CHC1), mRNA. /FEA = mRNA /GEN = CHC1 /PROD = chromosome condensation 1 /DB_XREF = gi: 4502800 /UG = Hs.84746 chromosome condensation 1 /FL = gb: NM_001269.1 216950_s_at Fc fragment of IgG, Consensus includes gb: X14355.1 FCGR1A 1.0 −1.1 −1.2 high affinity Ia, receptor for (CD64) /DEF = Human mRNA for high affinity Fc receptor (FcRI) b form. /FEA = mRNA /DB_XREF = gi: 31333 /UG = Hs.77424 Fc fragment of IgG, high affinity Ia, receptor for (CD64) 206130_s_at asialoglycoprotein gb: NM_001181.1 /DEF = Homo sapiens ASGR2 1.4 1.0 −1.3 receptor 2 asialoglycoprotein receptor 2 (ASGR2), mRNA. /FEA = mRNA /GEN = ASGR2 /PROD = asialoglycoprotein receptor 2 /DB_XREF = gi: 4502252 /UG = Hs.1259 asialoglycoprotein receptor 2 /FL = gb: M11025.1 gb: NM_001181.1 209464_at aurora kinase B gb: AB011446.1 /DEF = Homo sapiens AURKB −1.0 −1.0 −1.1 mRNA for Aik2, complete cds. /FEA = mRNA /GEN = aik2 /PROD = Aik2 /DB_XREF = gi: 5688865 /UG = Hs.180655 serinethreonine kinase 12 /FL = gb: BC000442.1 gb: AF004022.1 gb: AF008552.1 gb: AB011450.1 gb: AF015254.1 gb: NM_004217.1 gb: AB011446.1 205997_at a disintegrin and gb: NM_021778.1 /DEF = Homo sapiens a ADAM28 1.0 −1.3 −1.2 metalloproteinase domain 28 disintegrin and metalloproteinase domain 28 (ADAM28), transcript variant 2, mRNA. /FEA = mRNA /GEN = ADAM28 /PROD = a disintegrin and metalloproteinase domain 28, isoform 2 preproprotein /DB_XREF = gi: 11496995 /UG = Hs.174030 a disintegrin and metalloproteinase domain 28 /FL = gb: NM_021778.1 gb: AF137334.1 gb: NM_014265.1 202191_s_at growth arrest- Consensus includes gb: BE439987 GAS7 1.2 −1.4 −1.1 specific 7 /FEA = EST /DB_XREF = gi: 9439470 /DB_XREF = est:HTM1-745F /UG = Hs.226133 growth arrest-specific 7 /FL = gb: AB007854.1 gb: NM_005890.1 219952_s_at mucolipin 1 gb: NM_020533.1 /DEF = Homo sapiens MCOLN1 1.8 −1.6 1.4 mucolipin 1 (MCOLN1), mRNA. /FEA = mRNA /GEN = MCOLN1 /PROD = mucolipin 1 /DB_XREF = gi: 10092596 /UG = Hs.12909 mucolipin 1 /FL = gb: NM_020533.1 gb: BC005149.1 gb: AF287269.1 gb: AF249319.1 204244_s_at activator of S gb: NM_006716.1 /DEF = Homo sapiens ASK 1.1 1.0 1.1 phase kinase activator of S phase kinase (ASK), mRNA. /FEA = mRNA /GEN = ASK /PROD = activator of S phase kinase /DB_XREF = gi: 5729733 /UG = Hs.152759 activator of S phase kinase /FL = gb: AB028069.1 gb: AF160249.1 gb: AF160876.1 gb: NM_006716.1 205936_s_at hexokinase 3 gb: NM_002115.1 /DEF = Homo sapiens HK3 2.4 −2.5 −1.8 (white cell) hexokinase 3 (white cell) (HK3), mRNA. /FEA = mRNA /GEN = HK3 /PROD = hexokinase 3 (white cell) /DB_XREF = gi: 4504394 /UG = Hs.159237 hexokinase 3 (white cell) /FL = gb: U51333.1 gb: NM_002115.1 204766_s_at nudix (nucleoside gb: NM_002452.1 /DEF = Homo sapiens NUDT1 67.7 −1.2 1.0 diphosphate linked moiety X)-type nudix (nucleoside diphosphate linked motif 1 moiety X)-type motif 1 (NUDT1), mRNA. /FEA = mRNA /GEN = NUDT1 /PROD = nudix (nucleoside diphosphate linked moietyX)- type motif 1 /DB_XREF = gi: 4505274 /UG = Hs.388 nudix (nucleoside diphosphate linked moiety X)-type motif 1 /FL = gb: D16581.1 gb: NM_002452.1 gb: AB025233.1 gb: AB025235.1 gb: AB025237.1 gb: AB025239.1 gb: AB025240.1 gb: AB025241.1 gb: AB025242.1 206760_s_at Fc fragment of IgE, gb: NM_002002.1 /DEF = Homo sapiens Fc FCER2 −1.0 −1.0 −1.0 low affinity II, fragment of IgE, low affinity II, receptor for receptor for (CD23A) (FCER2), mRNA. /FEA = mRNA (CD23A) /GEN = FCER2 /PROD = Fc fragment of IgE, low affinity II, receptorfor (CD23A) /DB_XREF = gi: 4503678 /UG = Hs.1416 Fc fragment of IgE, low affinity II, receptor for (CD23A) /FL = gb: M15059.1 gb: M14766.1 gb: NM_002002.1 208018_s_at hemopoietic cell gb: NM_002110.1 /DEF = Homo sapiens HCK 1.0 −1.4 −1.5 kinase hemopoietic cell kinase (HCK), mRNA. /FEA = mRNA /GEN = HCK /PROD = hemopoietic cell kinase /DB_XREF = gi: 4504356 /UG = Hs.89555 hemopoietic cell kinase /FL = gb: M16591.1 gb: NM_002110.1 204444_at kinesin family gb: NM_004523.2 /DEF = Homo sapiens KIF11 −1.0 −1.0 −1.0 member 11 kinesin-like 1 (KNSL1), mRNA. /FEA = mRNA /GEN = KNSL1 /PROD = kinesin-like 1 /DB_XREF = gi: 13699823 /UG = Hs.8878 kinesin-like 1 /FL = gb: U37426.1 gb: NM_004523.2 217785_s_at SNARE protein gb: NM_006555.1 /DEF = Homo sapiens YKT6 −1.0 −84.4 58.3 Ykt6 SNARE protein (YKT6), mRNA. /FEA = mRNA /GEN = YKT6 /PROD = SNARE protein /DB_XREF = gi: 5730119 /UG = Hs.296244 SNARE protein /FL = gb: U95735.1 gb: NM_006555.1 203711_s_at 3-hydroxyisobutyryl- gb: NM_014362.1 /DEF = Homo sapiens 3- HIBCH 50.6 −1.0 −1.0 Coenzyme A hydroxyisobutyryl-Coenzyme A hydrolase hydrolase (HIBCH), mRNA. /FEA = mRNA /GEN = HIBCH /PROD = 3-hydroxyisobutyryl- Coenzyme A hydrolase /DB_XREF = gi: 7657159 /UG = Hs.236642 3- hydroxyisobutyryl-Coenzyme A hydrolase /FL = gb: BC005190.1 gb: U66669.1 gb: NM_014362.1 202437_s_at cytochrome P450, gb: NM_000104.2 /DEF = Homo sapiens CYP1B1 1.3 1.1 −1.2 family 1, subfamily cytochrome P450, subfamily I (dioxin- B, polypeptide 1 inducible), polypeptide 1 (glaucoma 3, primary infantile) (CYP1B1), mRNA. /FEA = mRNA /GEN = CYP1B1 /PROD = cytochrome P450, subfamily I (dioxin-inducible), polypeptide 1 /DB_XREF = gi: 13325059 /UG = Hs.154654 cytochrome P450, subfamily I (dioxin- inducible), polypeptide 1 (glaucoma 3, primary infantile) /FL = gb: NM_000104.2 gb: U03688.1 214567_s_at chemokine (C Consensus includes gb: NM_003175.1 XCL1 /// 1.0 1.0 −1.2 motif) ligand 1 /DEF = Homo sapiens small inducible XCL2 cytokine subfamily C, member 2 (SCYC2), mRNA. /FEA = CDS /GEN = SCYC2 /PROD = small inducible cytokine subfamily C, member 2 /DB_XREF = gi: 4506854 /UG = Hs.174228 small inducible cytokine subfamily C, member 2 /FL = gb: NM_003175.1 204826_at cyclin F gb: NM_001761.1 /DEF = Homo sapiens CCNF −72.4 −1.0 −1.0 cyclin F (CCNF), mRNA. /FEA = mRNA /GEN = CCNF /PROD = cyclin F /DB_XREF = gi: 4502620 /UG = Hs.1973 cyclin F /FL = gb: NM_001761.1 gb: U17105.1 205628_at primase, gb: NM_000947.1 /DEF = Homo sapiens PRIM2A −1.0 −1.0 −1.0 polypeptide 2A, primase, polypeptide 2A (58 kD) (PRIM2A), 58 kDa mRNA. /FEA = mRNA /GEN = PRIM2A /PROD = primase, polypeptide 2A (58 kD) /DB_XREF = gi: 4506052 /UG = Hs.74519 primase, polypeptide 2A (58 kD) /FL = gb: NM_000947.1 206207_at Charot-Leyden gb: NM_001828.3 /DEF = Homo sapiens CLC 1.2 1.2 −2.1 crystal protein Charot-Leyden crystal protein (CLC), mRNA. /FEA = mRNA /GEN = CLC /PROD = Charot-Leyden crystal protein /DB_XREF = gi: 6325464 /UG = Hs.889 Charot-Leyden crystal protein /FL = gb: L01664.1 gb: NM_001828.3 217757_at alpha-2- gb: NM_000014.3 /DEF = Homo sapiens A2M 1.0 1.0 1.3 macroglobulin alpha-2-macroglobulin (A2M), mRNA. /FEA = mRNA /GEN = A2M /PROD = alpha 2 macroglobulin precursor /DB_XREF = gi: 6226959 /UG = Hs.74561 alpha-2-macroglobulin /FL = gb: M11313.1 gb: NM_000014.3 204603_at exonuclease 1 gb: NM_003686.1 /DEF = Homo sapiens EXO1 −1.0 −1.0 −1.0 exonuclease 1 (EXO1), mRNA. /FEA = mRNA /GEN = EXO1 /PROD = Rad2 nuclease family member, homolog of S. cerevisiae exonuclease 1 /DB_XREF = gi: 4504368 /UG = Hs.47504 exonuclease 1 /FL = gb: NM_006027.1 gb: AF042282.1 gb: AF060479.1 gb: AF091740.1 gb: AF084974.1 gb: NM_003686.1 203968_s_at CDC6 cell division gb: NM_001254.1 /DEF = Homo sapiens CDC6 −1.0 −1.0 1.1 cycle 6 homolog CDC6 (cell division cycle 6, S. cerevisiae) (S. cerevisiae) homolog (CDC6), mRNA. /FEA = mRNA /GEN = CDC6 /PROD = CDC6 (cell division cycle 6, S. cerevisiae)homolog /DB_XREF = gi: 4502702 /UG = Hs.69563 CDC6 (cell division cycle 6, S. cerevisiae) homolog /FL = gb: U77949.1 gb: AF022109.1 gb: NM_001254.1 204475_at matrix gb: NM_002421.2 /DEF = Homo sapiens MMP1 −1.0 −1.0 −1.0 metalloproteinase matrix metalloproteinase 1 (interstitial 1 (interstitial collagenase) (MMP1), mRNA. collagenase) /FEA = mRNA /GEN = MMP1 /PROD = matrix metalloproteinase 1 preproprotein /DB_XREF = gi: 13027798 /UG = Hs.83169 matrix metalloproteinase 1 (interstitial collagenase) /FL = gb: NM_002421.2 gb: M13509.1 218009_s_at protein regulator of gb: NM_003981.1 /DEF = Homo sapiens PRC1 1.1 1.0 −61.2 cytokinesis 1 protein regulator of cytokinesis 1 (PRC1), mRNA. /FEA = mRNA /GEN = PRC1 /PROD = protein regulator of cytokinesis 1 /DB_XREF = gi: 4506038 /UG = Hs.5101 protein regulator of cytokinesis 1 /FL = gb: BC003138.1 gb: AF044588.1 gb: NM_003981.1 207857_at leukocyte gb: NM_006866.1 /DEF = Homo sapiens LILRA2 1.2 1.1 −1.3 immunoglobulin- leukocyte immunoglobulin-like receptor, like receptor, subfamily A (with TM domain), member 2 subfamily B (with (LILRA2), mRNA. /FEA = mRNA TM and ITIM /GEN = LILRA2 /PROD = leukocyte domains), member 1 immunoglobulin-like receptor, subfamily A (with TM domain), member 2 /DB_XREF = gi: 5803067 /UG = Hs.94498 leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2 /FL = gb: U82275.1 gb: NM_006866.1 203973_s_at KIAA0146 protein gb: NM_005195.1 /DEF = Homo sapiens CEBPD 1.6 1.2 1.2 CCAATenhancer binding protein (CEBP), delta (CEBPD), mRNA. /FEA = mRNA /GEN = CEBPD /PROD = CCAATenhancer binding protein (CEBP), delta /DB_XREF = gi: 4885130 /UG = Hs.76722 CCAATenhancer binding protein (CEBP), delta /FL = gb: M83667.1 gb: NM_005195.1 201897_s_at CDC28 protein gb: NM_001826.1 /DEF = Homo sapiens CKS1B 1.1 1.0 −1.3 kinase regulatory CDC28 protein kinase 1 (CKS1), mRNA. subunit 1B /FEA = mRNA /GEN = CKS1 /PROD = CDC28 protein kinase 1 /DB_XREF = gi: 4502856 /UG = Hs.77550 CDC28 protein kinase 1 /FL = gb: BC001425.1 gb: AF274941.1 gb: AF279897.1 gb: NM_001826.1 202095_s_at baculoviral IAP gb: NM_001168.1 /DEF = Homo sapiens BIRC5 −1.0 −1.0 −1.0 repeat-containing 5 baculoviral IAP repeat-containing 5 (survivin) (survivin) (BIRC5), mRNA. /FEA = mRNA /GEN = BIRC5 /PROD = baculoviral IAP repeat-containing protein 5 /DB_XREF = gi: 4502144 /UG = Hs.1578 baculoviral IAP repeat-containing 5 (survivin) /FL = gb: NM_001168.1 gb: AF077350.1 222077_s_at Rac GTPase Consensus includes gb: AU153848 RACGAP1 2.0 −1.2 −1.2 activating protein 1 /FEA = EST /DB_XREF = gi: 11015369 /DB_XREF = est: AU153848 /CLONE = NT2RP3004175 /UG = Hs.23900 GTPase activating protein 203603_s_at zinc finger gb: NM_014795.1 /DEF = Homo sapiens ZFHX1B 1.6 1.0 −1.3 homeobox 1b zinc finger homeobox 1B (ZFHX1B), mRNA. /FEA = mRNA /GEN = ZFHX1B /PROD = zinc finger homeobox 1B /DB_XREF = gi: 7662183 /UG = Hs.34871 zinc finger homeobox 1B /FL = gb: AB011141.1 gb: NM_014795.1 201141_at glycoprotein gb: NM_002510.1 /DEF = Homo sapiens GPNMB 1.4 1.1 1.1 (transmembrane) glycoprotein (transmembrane) nmb nmb (GPNMB), mRNA. /FEA = mRNA /GEN = GPNMB /PROD = glycoprotein (transmembrane) nmb /DB_XREF = gi: 4505404 /UG = Hs.82226 glycoprotein (transmembrane) nmb /FL = gb: AF322909.1 gb: NM_002510.1 218847_at IGF-II mRNA- gb: NM_006548.1 /DEF = Homo sapiens IMP-2 1.5 −1.2 1.1 binding protein 2 IGF-II mRNA-binding protein 2 (IMP-2), mRNA. /FEA = mRNA /GEN = IMP-2 /PROD = IGF-II mRNA-binding protein 2 /DB_XREF = gi: 5729883 /UG = Hs.30299 IGF-II mRNA-binding protein 2 /FL = gb: AF057352.1 gb: NM_006548.1 205769_at solute carrier gb: NM_003645.1 /DEF = Homo sapiens SLC27A2 −1.0 −1.0 −1.0 family 27 (fatty acid fatty-acid-Coenzyme A ligase, very long- transporter), chain 1 (FACVL1), mRNA. /FEA = mRNA member 2 /GEN = FACVL1 /PROD = very long-chain fatty-acid-Coenzyme A ligase 1 /DB_XREF = gi: 4503652 /UG = Hs.11729 fatty-acid-Coenzyme A ligase, very long- chain 1 /FL = gb: D88308.1 gb: AF096290.1 gb: NM_003645.1 209714_s_at cyclin-dependent gb: AF213033.1 /DEF = Homo sapiens CDKN3 −1.3 1.0 −1.2 kinase inhibitor 3 isolate BX-01 cyclin-dependent kinase (CDK2-associated associated protein phosphatase mRNA, dual specificity complete cds. /FEA = mRNA phosphatase) /PROD = cyclin-dependent kinase associated proteinphosphatase /DB_XREF = gi: 12734643 /UG = Hs.84113 cyclin-dependent kinase inhibitor 3 (CDK2- associated dual specificity phosphatase) /FL = gb: AF213033.1 gb: AF213034.1 gb: AF213035.1 gb: AF213036.1 gb: AF213037.1 gb: AF213038.1 gb: AF213039.1 gb: AF213040.1 gb: AF213041.1 gb: AF213042.1 gb: AF213044.1 gb: AF213046.1 gb: AF213047.1 gb: AF213048.1 gb: AF213049.1 gb: AF213050.1 gb: AF213051.1 gb: AF213052.1 gb: AF213053.1 gb: U02681.1 gb: L25876.1 gb: NM_005192.1 gb: L27711.1 205898_at chemokine (C—X3—C gb: U20350.1 /DEF = Human G protein- CX3CR1 1.1 1.0 −1.2 motif) receptor 1 coupled receptor V28 mRNA, complete cds. /FEA = mRNA /PROD = V28 /DB_XREF = gi: 665580 /UG = Hs.78913 chemokine (C—X3—C) receptor 1 /FL = gb: NM_001337.1 gb: U20350.1 gb: U28934.1 203145_at sperm associated gb: NM_006461.1 /DEF = Homo sapiens SPAG5 1.1 1.3 94.7 antigen 5 mitotic spindle coiled-coil related protein (DEEPEST), mRNA. /FEA = mRNA /GEN = DEEPEST /PROD = mitotic spindle coiled-coil related protein /DB_XREF = gi: 5453631 /UG = Hs.16244 mitotic spindle coiled-coil related protein /FL = gb: BC000322.1 gb: AF063308.1 gb: NM_006461.1 205119_s_at formyl peptide gb: NM_002029.1 /DEF = Homo sapiens 1.3 1.0 −1.4 receptor 1 formyl peptide receptor 1 (FPR1), mRNA. /FEA = mRNA /GEN = FPR1 /PROD = formyl peptide receptor 1 /DB_XREF = gi: 4503778 /UG = Hs.753 formyl peptide receptor 1 /FL = gb: BC005315.1 gb: M60626.1 gb: M60627.1 gb: NM_002029.1 203256_at cadherin 3, type 1, gb: NM_001793.1 /DEF = Homo sapiens CDH3 −1.0 −1.0 −1.0 P-cadherin cadherin 3, type 1, P-cadherin (placental) (placental) (CDH3), mRNA. /FEA = mRNA /GEN = CDH3 /PROD = cadherin 3, type 1 P- cadherin (placental) /DB_XREF = gi: 4502722 /UG = Hs.2877 cadherin 3, type 1, P-cadherin (placental) /FL = gb: NM_001793.1 205085_at origin recognition gb: NM_004153.1 /DEF = Homo sapiens ORC1L −1.0 −1.0 −1.0 complex, subunit 1- origin recognition complex, subunit 1 like (yeast) (yeast homolog)-like (ORC1L), mRNA. /FEA = mRNA /GEN = ORC1L /PROD = origin recognition complex, subunit 1 (yeasthomolog)-like /DB_XREF = gi: 4758849 /UG = Hs.17908 origin recognition complex, subunit 1 (yeast homolog)-like /FL = gb: U40152.1 gb: U43416.1 gb: NM_004153.1 204759_at chromosome gb: NM_001268.1 /DEF = Homo sapiens CHC1L 1.6 1.0 1.2 condensation 1-like chromosome condensation 1-like (CHC1L), mRNA. /FEA = mRNA /GEN = CHC1L /PROD = RCC1-like G exchanging factor RLG /DB_XREF = gi: 4557444 /UG = Hs.27007 chromosome condensation 1-like /FL = gb: AF060219.1 gb: NM_001268.1 202006_at protein tyrosine gb: NM_002835.1 /DEF = Homo sapiens PTPN12 1.1 −1.2 −1.7 phosphatase, non- protein tyrosine phosphatase, non- receptor type 12 receptor type 12 (PTPN12), mRNA. /FEA = mRNA /GEN = PTPN12 /PROD = protein tyrosine phosphatase, non- receptor type12 /DB_XREF = gi: 4506286 /UG = Hs.62 protein tyrosine phosphatase, non-receptor type 12 /FL = gb: D13380.1 gb: M93425.1 gb: NM_002835.1 202086_at myxovirus gb: NM_002462.1 /DEF = Homo sapiens MX1 1.1 −7.3 −1.2 (influenza virus) myxovirus (influenza) resistance 1, resistance 1, homolog of murine (interferon-inducible interferon-inducible protein p78) (MX1), mRNA. /FEA = mRNA protein p78 /GEN = MX1 /PROD = myxovirus (influenza) (mouse) resistance 1, homolog ofmurine (interferon- inducible protein p78) /DB_XREF = gi: 4505290 /UG = Hs.76391 myxovirus (influenza) resistance 1, homolog of murine (interferon-inducible protein p78) /FL = gb: M30817.1 gb: M33882.1 gb: NM_002462.1 210423_s_at solute carrier gb: L32185.1 /DEF = Homo sapiens integral SLC11A1 1.1 1.1 1.1 family 11 (proton- membrane protein (NRAMP1) mRNA, coupled divalent complete cds. /FEA = mRNA metal ion /GEN = NRAMP1 /PROD = integral transporters), membrane protein /DB_XREF = gi: 600219 member 1 /UG = Hs.182611 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1 /FL = gb: D50402.1 gb: D50403.1 gb: NM_000578.1 gb: L32185.1 204588_s_at solute carrier gb: NM_003982.1 /DEF = Homo sapiens SLC7A7 1.0 −1.1 1.0 family 7 (cationic solute carrier family 7 (cationic amino acid amino acid transporter, y+ system), member 7 transporter, y+ (SLC7A7), mRNA. /FEA = mRNA system), member 7 /GEN = SLC7A7 /PROD = solute carrier family 7 (cationic amino acidtransporter, y+ system), member 7 /DB_XREF = gi: 4507054 /UG = Hs.194693 solute carrier family 7 (cationic amino acid transporter, y+ system), member 7 /FL = gb: BC003062.1 gb: AF092032.1 gb: NM_003982.1 gb: AB011263.1 214437_s_at serine Consensus includes gb: NM_005412.1 SHMT2 1.3 −1.3 −1.6 hydroxymethyltransferase 2 /DEF = Homo sapiens serine (mitochondrial) hydroxymethyltransferase 2 (mitochondrial) (SHMT2), mRNA. /FEA = CDS /GEN = SHMT2 /PROD = serine hydroxymethyltransferase 2(mitochondrial) /DB_XREF = gi: 4885594 /UG = Hs.75069 serine hydroxymethyltransferase 2 (mitochondrial) /FL = gb: NM_005412.1 216248_s_at nuclear receptor Consensus includes gb: S77154.1 NR4A2 1.2 1.0 −1.1 subfamily 4, group /DEF = TINUR = NGFI-Bnur77 beta-type A, member 2 transcription factor homolog human, T lymphoid cell line, PEER, mRNA, 2469 nt. /FEA = mRNA /GEN = TINUR /DB_XREF = gi: 913966 /UG = Hs.82120 nuclear receptor subfamily 4, group A, member 2 204170_s_at CDC28 protein gb: NM_001827.1 /DEF = Homo sapiens CKS2 1.1 −1.7 −1.9 kinase regulatory CDC28 protein kinase 2 (CKS2), mRNA. subunit 2 /FEA = mRNA /GEN = CKS2 /PROD = CDC28 protein kinase 2 /DB_XREF = gi: 4502858 /UG = Hs.83758 CDC28 protein kinase 2 /FL = gb: NM_001827.1 201425_at aldehyde gb: NM_000690.1 /DEF = Homo sapiens ALDH2 1.1 1.1 −1.3 dehydrogenase 2 aldehyde dehydrogenase 2, mitochondrial family (ALDH2), mRNA. /FEA = mRNA (mitochondrial) /GEN = ALDH2 /PROD = aldehyde dehydrogenase 2, mitochondrial /DB_XREF = gi: 4502032 /UG = Hs.195432 aldehyde dehydrogenase 2 family (mitochondrial) /FL = gb: BC002967.1 gb: NM_000690.1 204575_s_at matrix gb: U38321.1 /DEF = Homo sapiens clone MMP19 −1.4 −69.0 51.1 metalloproteinase rasi-11 matrix metalloproteinase RASI-1 19 mRNA, complete cds. /FEA = mRNA /PROD = matrix metalloproteinase RASI-1 /DB_XREF = gi: 2228243 /UG = Hs.154057 matrix metalloproteinase 19 /FL = gb: NM_002429.2 gb: U38321.1 gb: U37791.1 206414_s_at development and gb: NM_003887.1 /DEF = Homo sapiens DDEF2 −1.0 −1.0 −1.0 differentiation development and differentiation enhancing enhancing factor 2 factor 2 (DDEF2), mRNA. /FEA = mRNA /GEN = DDEF2 /PROD = ADP-ribosylation factorarf-directed GTPaseactivating protein /DB_XREF = gi: 4502248 /UG = Hs.12802 development and differentiation enhancing factor 2 /FL = gb: AB007860.1 gb: NM_003887.1 218567_x_at dipeptidylpeptidase 3 gb: NM_005700.1 /DEF = Homo sapiens DPP3 −1.2 −1.7 −1.6 dipeptidylpeptidase III (DPP3), mRNA. /FEA = mRNA /GEN = DPP3 /PROD = dipeptidylpeptidase III /DB_XREF = gi: 11342681 /UG = Hs.22880 dipeptidylpeptidase III /FL = gb: NM_005700.1 gb: BC001446.1 202820_at aryl hydrocarbon gb: NM_001621.2 /DEF = Homo sapiens AHR 1.2 1.1 1.2 receptor aryl hydrocarbon receptor (AHR), mRNA. /FEA = mRNA /GEN = AHR /PROD = aryl hydrocarbon receptor /DB_XREF = gi: 5016091 /UG = Hs.170087 aryl hydrocarbon receptor /FL = gb: L19872.1 gb: D16354.1 gb: NM_001621.2 214038_at chemokine (C-C Consensus includes gb: AI984980 CCL8 1.1 −8.4 −1.2 motif) ligand 8 /FEA = EST /DB_XREF = gi: 5812257 /DB_XREF = est: wr88g11.x1 /CLONE = IMAGE: 2494820 /UG = Hs.271387 small inducible cytokine subfamily A (Cys-Cys), member 8 (monocyte chemotactic protein 2) /FL = gb: NM_005623.1 204439_at chromosome 1 gb: NM_006820.1 /DEF = Homo sapiens C1orf29 −1.0 −894.0 2.2 open reading hypothetical protein, expressed in frame 29 osteoblast (GS3686), mRNA. /FEA = mRNA /GEN = GS3686 /PROD = hypothetical protein, expressed in osteoblast /DB_XREF = gi: 5803026 /UG = Hs.75470 hypothetical protein, expressed in osteoblast /FL = gb: AB000115.1 gb: NM_006820.1 217853_at tensin-like SH2 gb: NM_022748.1 /DEF = Homo sapiens TENS1 1.2 −1.4 −1.9 domain containing 1 hypothetical protein FLJ13732 similar to tensin (FLJ13732), mRNA. /FEA = mRNA /GEN = FLJ13732 /PROD = hypothetical protein FLJ13732 similar to tensin /DB_XREF = gi: 12232408 /UG = Hs.12210 hypothetical protein FLJ13732 similar to tensin /FL = gb: NM_022748.1 220646_s_at killer cell lectin-like gb: NM_016523.1 /DEF = Homo sapiens KLRF1 1.7 1.1 1.1 receptor subfamily killer cell lectin-like receptor F1 (KLRF1), F, member 1 mRNA. /FEA = mRNA /GEN = KLRF1 /PROD = killer cell lectin-like receptor F1 /DB_XREF = gi: 7705573 /UG = Hs.183125 killer cell lectin-like receptor F1 /FL = gb: AF175206.1 gb: NM_016523.1 201666_at tissue inhibitor of gb: NM_003254.1 /DEF = Homo sapiens TIMP1 1.0 −1.3 1.0 metalloproteinase tissue inhibitor of metalloproteinase 1 1 (erythroid (erythroid potentiating activity, collagenase potentiating inhibitor) (TIMP1), mRNA. /FEA = mRNA activity, /GEN = TIMP1 /PROD = tissue inhibitor of collagenase metalloproteinase 1precursor inhibitor) /DB_XREF = gi: 4507508 /UG = Hs.5831 tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) /FL = gb: BC000866.1 gb: M12670.1 gb: M59906.1 gb: NM_003254.1 219505_at cat eye syndrome gb: NM_017424.1 /DEF = Homo sapiens cat CECR1 −1.4 −1.2 1.1 chromosome eye syndrome chromosome region, region, candidate 1 candidate 1 (CECR1), mRNA. /FEA = mRNA /GEN = CECR1 /PROD = cat eye syndrome critical region protein 1 /DB_XREF = gi: 8393092 /UG = Hs.170310 cat eye syndrome chromosome region, candidate 1 /FL = gb: AF190746.1 gb: NM_017424.1 204936_at splicing factor 1 gb: NM_004579.1 /DEF = Homo sapiens MAP4K2 −1.0 −1.0 −1.0 [BLAST] mitogen-activating protein kinase kinase kinase kinase 2 (MAP4K2), mRNA. /FEA = mRNA /GEN = MAP4K2 /PROD = mitogen-activating protein kinase kinase kinasekinase 2 /DB_XREF = gi: 4759009 /UG = Hs.82979 mitogen-activating protein kinase kinase kinase kinase 2 /FL = gb: NM_004579.1 gb: U07349.1 209189_at v-fos FBJ murine gb: BC004490.1 /DEF = Homo sapiens, v- FOS 1.1 1.0 1.5 osteosarcoma viral fos FBJ murine osteosarcoma viral oncogene homolog oncogene homolog, clone MGC: 11074, mRNA, complete cds. /FEA = mRNA /PROD = v-fos FBJ murine osteosarcoma viral oncogenehomolog /DB_XREF = gi: 13325363 /UG = Hs.25647 v- fos FBJ murine osteosarcoma viral oncogene homolog /FL = gb: BC004490.1 gb: NM_005252.2 217996_at pleckstrin Consensus includes gb: AA576961 PHLDA1 1.2 63.7 −66.0 homology-like /FEA = EST /DB_XREF = gi: 2354435 domain, family A, /DB_XREF = est: nm82d08.s1 member 1 /CLONE = IMAGE: 1074735 /UG = Hs.82101 pleckstrin homology-like domain, family A, member 1 /FL = gb: NM_007350.1 218350_s_at geminin, DNA gb: NM_015895.1 /DEF = Homo sapiens GMNN 1.2 −1.3 −1.3 replication inhibitor geminin (LOC51053), mRNA. /FEA = mRNA /GEN = LOC51053 /PROD = geminin /DB_XREF = gi: 7705681 /UG = Hs.234896 geminin /FL = gb: AF067855.1 gb: NM_015895.1 209709_s_at hyaluronan- gb: U29343.1 /DEF = Homo sapiens HMMR −71.2 −1.0 −74.3 mediated motility hyaluronan receptor (RHAMM) mRNA, receptor (RHAMM) complete cds. /FEA = mRNA /GEN = RHAMM /PROD = hyaluronan receptor /DB_XREF = gi: 2959555 /UG = Hs.72550 hyaluronan-mediated motility receptor (RHAMM) /FL = gb: U29343.1 gb: AF032862.1 gb: NM_012484.1 220688_s_at chromosome 1 gb: NM_016183.1 /DEF = Homo sapiens C1orf33 1.3 −1.2 −1.3 open reading 60S acidic ribosomal protein PO frame 33 (LOC51154), mRNA. /FEA = mRNA /GEN = LOC51154 /PROD = 60S acidic ribosomal protein PO /DB_XREF = gi: 7705874 /UG = Hs.274201 60S acidic ribosomal protein PO /FL = gb: AF173378.1 gb: NM_016183.1 202388_at regulator of G- gb: NM_002923.1 /DEF = Homo sapiens RGS2 1.4 1.2 1.3 protein signalling 2, regulator of G-protein signalling 2, 24 kD 24 kDa (RGS2), mRNA. /FEA = mRNA /GEN = RGS2 /PROD = regulator of G- protein signalling 2, 24 kD /DB_XREF = gi: 4506516 /UG = Hs.78944 regulator of G-protein signalling 2, 24 kD /FL = gb: L13463.1 gb: NM_002923.1 201506_at transforming gb: NM_000358.1 /DEF = Homo sapiens TGFBI 1.0 −1.2 1.0 growth factor, beta- transforming growth factor, beta-induced, induced, 68 kDa 68 kD (TGFBI), mRNA. /FEA = mRNA /GEN = TGFBI /PROD = transforming growth factor, beta-induced, 68 kD /DB_XREF = gi: 4507466 /UG = Hs.118787 transforming growth factor, beta-induced, 68 kD /FL = gb: BC000097.1 gb: BC004972.1 gb: M77349.1 gb: NM_000358.1 204092_s_at serine/threonine gb: NM_003600.1 /DEF = Homo sapiens STK6 −1.0 −60.9 55.8 kinase 6 serinethreonine kinase 15 (STK15), mRNA. /FEA = mRNA /GEN = STK15 /PROD = serinethreonine kinase 15 /DB_XREF = gi: 4507274 /UG = Hs.48915 serinethreonine kinase 15 /FL = gb: AF008551.1 gb: AF011468.1 gb: NM_003600.1 203561_at Fc fragment of IgG, gb: NM_021642.1 /DEF = Homo sapiens Fc FCGR2A 1.1 −1.2 1.2 low affinity IIa, fragment of IgG, low affinity IIa, receptor receptor for (CD32) for (CD32) (FCGR2A), mRNA. /FEA = mRNA /GEN = FCGR2A /PROD = Fc fragment of IgG, low affinity IIa, receptorfor (CD32) /DB_XREF = gi: 11056051 /UG = Hs.78864 Fc fragment of IgG, low affinity IIa, receptor for (CD32) /FL = gb: NM_021642.1 gb: M31932.1 gb: J03619.1 gb: M28697.1 217983_s_at ribonuclease T2 gb: NM_003730.2 /DEF = Homo sapiens RNASET2 1.4 1.1 1.1 ribonuclease 6 precursor (RNASE6PL), mRNA. /FEA = mRNA /GEN = RNASE6PL /PROD = ribonuclease 6 precursor /DB_XREF = gi: 5231227 /UG = Hs.8297 ribonuclease 6 precursor /FL = gb: BC001660.1 gb: BC001819.1 gb: U85625.2 gb: NM_003730.2 204446_s_at arachidonate 5- gb: NM_000698.1 /DEF = Homo sapiens ALOX5 1.2 −1.3 −1.3 lipoxygenase arachidonate 5-lipoxygenase (ALOX5), mRNA. /FEA = mRNA /GEN = ALOX5 /PROD = arachidonate 5-lipoxygenase /DB_XREF = gi: 4502056 /UG = Hs.89499 arachidonate 5-lipoxygenase /FL = gb: J03600.1 gb: J03571.1 gb: NM_000698.1 208303_s_at cytokine receptor- gb: NM_022148.1 /DEF = Homo sapiens CRLF2 −65.7 67.0 56.7 like factor 2 cytokine receptor-like factor 2 (CRLF2), mRNA. /FEA = mRNA /GEN = CRLF2 /PROD = cytokine receptor-like factor 2 /DB_XREF = gi: 13375623 /UG = Hs.287729 cytokine receptor-like factor 2 /FL = gb: NM_022148.1 218589_at purinergic receptor gb: NM_005767.1 /DEF = Homo sapiens P2RY5 1.4 −1.1 1.1 P2Y, G-protein purinergic receptor (family A group 5) coupled, 5 (P2Y5), mRNA. /FEA = mRNA /GEN = P2Y5 /PROD = purinergic receptor (family A group 5) /DB_XREF = gi: 5031968 /UG = Hs.189999 purinergic receptor (family A group 5) /FL = gb: AF000546.1 gb: NM_005767.1 209715_at chromobox gb: L07515.1 /DEF = Human CBX5 −62.7 −1.0 −1.0 homolog 5 (HP1 heterochromatin protein homologue (HP1) alpha homolog, mRNA, complete cds. /FEA = mRNA Drosophila) /DB_XREF = gi: 184310 /UG = Hs.89232 chromobox homolog 5 (Drosophila HP1 alpha) /FL = gb: L07515.1 gb: NM_012117.1 203126_at inositol(myo)-1(or gb: NM_014214.1 /DEF = Homo sapiens IMPA2 1.0 −1.7 1.0 4)- inositol(myo)-1(or 4)-monophosphatase 2 monophosphatase 2 (IMPA2), mRNA. /FEA = mRNA /GEN = IMPA2 /PROD = inositol(myo)-1(or 4)-monophosphatase 2 /DB_XREF = gi: 7657235 /UG = Hs.5753 inositol(myo)-1(or 4)-monophosphatase 2 /FL = gb: AF200432.1 gb: NM_014214.1 gb: AF014398.2 218400_at 2′-5′-oligoadenylate gb: NM_006187.1 /DEF = Homo sapiens 2- OAS3 −1.1 −3.1 −1.2 synthetase 3, 5oligoadenylate synthetase 3 (OAS3), 100 kDa mRNA. /FEA = mRNA /GEN = OAS3 /PROD = 2-5oligoadenylate synthetase 3 /DB_XREF = gi: 5453823 /UG = Hs.56009 2- 5oligoadenylate synthetase 3 /FL = gb: AB044545.1 gb: AF063613.1 gb: NM_006187.1 206715_at transcription factor gb: NM_012252.1 /DEF = Homo sapiens TFEC 1.1 −1.3 −1.6 EC transcription factor EC (TFEC), mRNA. /FEA = mRNA /GEN = TFEC /PROD = transcription factor EC /DB_XREF = gi: 6912701 /UG = Hs.113274 transcription factor EC /FL = gb: D43945.1 gb: NM_012252.1 204620_s_at chondroitin sulfate gb: NM_004385.1 /DEF = Homo sapiens CSPG2 1.5 1.0 −1.1 proteoglycan 2 chondroitin sulfate proteoglycan 2 (versican) (versican) (CSPG2), mRNA. /FEA = mRNA /GEN = CSPG2 /PROD = chondroitin sulfate proteoglycan 2 (versican) /DB_XREF = gi: 4758081 /UG = Hs.81800 chondroitin sulfate proteoglycan 2 (versican) /FL = gb: NM_004385.1 215071_s_at histone 1, H2ac Consensus includes gb: AL353759 HIST1H2AC 1.5 1.4 65.8 /DEF = Human DNA sequence from clone RP1-221C16 on chromosome 6. Contains two genes for novel histone 4 family members, two genes for novel histone 1 family members, three genes for novel histone 2B family members, a gene for a novel histone 2A family me . . . /FEA = mRNA_18 /DB_XREF = gi: 8745068 /UG = Hs.28777 H2A histone family, member L 208581_x_at metallothionein 1X gb: NM_005952.1 /DEF = Homo sapiens MT1X 1.2 −1.4 −1.5 metallothionein 1X (MT1X), mRNA. /FEA = CDS /GEN = MT1X /PROD = metallothionein 1X /DB_XREF = gi: 10835231 /UG = Hs.278462 metallothionein 1X /FL = gb: NM_005952.1 39248_at aquaporin 3 Cluster Incl. N74607: za55a01.s1 Homo AQP3 1.5 1.0 1.1 sapiens cDNA, 3 end /clone = IMAGE- 296424 /clone_end = 3′ /gb = N74607 /gi = 1231892 /ug = Hs.234642 /len = 487 219466_s_at apolipoprotein A-II gb: NM_001643.1 /DEF = Homo sapiens APOA2 54.0 1.0 −1.0 apolipoprotein A-II (APOA2), mRNA. /FEA = mRNA /GEN = APOA2 /PROD = apolipoprotein A-II precursor /DB_XREF = gi: 4502148 /UG = Hs.237658 apolipoprotein A-II /FL = gb: BC005282.1 gb: M29882.1 gb: NM_001643.1 206365_at chemokine (C gb: NM_002995.1 /DEF = Homo sapiens XCL1 −1.0 −1.0 60.5 motif) ligand 1 small inducible cytokine subfamily C, member 1 (lymphotactin) (SCYC1), mRNA. /FEA = mRNA /GEN = SCYC1 /PROD = small inducible cytokine subfamily C, member 1(lymphotactin) /DB_XREF = gi: 4506852 /UG = Hs.3195 small inducible cytokine subfamily C, member 1 (lymphotactin) /FL = gb: NM_002995.1 gb: U23772.1 gb: D43768.1 205024_s_at RAD51 homolog gb: NM_002875.1 /DEF = Homo sapiens RAD51 −51.2 −1.3 1.1 (RecA homolog, E. coli) RAD51 (S. cerevisiae) homolog (E coli (S. cerevisiae) RecA homolog) (RAD51), mRNA. /FEA = mRNA /GEN = RAD51 /PROD = RAD51 (S. cerevisiae) homolog (E coli RecAhomolog) /DB_XREF = gi: 4506388 /UG = Hs.23044 RAD51 (S. cerevisiae) homolog (E coli RecA homolog) /FL = gb: D14134.1 gb: D13804.1 gb: NM_002875.1 219890_at C-type (calcium gb: NM_013252.1 /DEF = Homo sapiens C- CLECSF5 1.5 1.0 −1.2 dependent, type (calcium dependent, carbohydrate- carbohydrate- recognition domain) lectin, superfamily recognition member 5 (CLECSF5), mRNA. domain) lectin, /FEA = mRNA /GEN = CLECSF5 /PROD = C- superfamily type (calcium dependent, carbohydrate- member 5 recognition domain) lectin, superfamilymember 5 /DB_XREF = gi: 10281668 /UG = Hs.126355 C-type (calcium dependent, carbohydrate- recognition domain) lectin, superfamily member 5 /FL = gb: NM_013252.1 gb: AF139768.1 204122_at TYRO protein gb: NM_003332.1 /DEF = Homo sapiens TYROBP 1.0 −1.2 1.0 tyrosine kinase TYRO protein tyrosine kinase binding binding protein protein (TYROBP), mRNA. /FEA = mRNA /GEN = TYROBP /PROD = TYRO protein tyrosine kinase binding protein /DB_XREF = gi: 4507754 /UG = Hs.9963 TYRO protein tyrosine kinase binding protein /FL = gb: AF019562.1 gb: NM_003332.1 205909_at polymerase (DNA gb: NM_002692.1 /DEF = Homo sapiens POLE2 1.0 −1.1 1.0 directed), epsilon 2 polymerase (DNA directed), epsilon 2 (p59 subunit) (POLE2), mRNA. /FEA = mRNA /GEN = POLE2 /PROD = polymerase (DNA directed), epsilon 2 /DB_XREF = gi: 4505934 /UG = Hs.99185 polymerase (DNA directed), epsilon 2 /FL = gb: AF025840.1 gb: AF036899.1 gb: NM_002692.1 202768_at FBJ murine gb: NM_006732.1 /DEF = Homo sapiens FOSB 1.4 −1.5 53.4 osteosarcoma viral FBJ murine osteosarcoma viral oncogene oncogene homolog B homolog B (FOSB), mRNA. /FEA = mRNA /GEN = FOSB /PROD = FBJ murine osteosarcoma viral oncogene homologB /DB_XREF = gi: 5803016 /UG = Hs.75678 FBJ murine osteosarcoma viral oncogene homolog B /FL = gb: L49169.1 gb: NM_006732.1 203988_s_at fucosyltransferase gb: NM_004480.1 /DEF = Homo sapiens FUT8 51.5 −1.0 −1.0 8 (alpha (1,6) fucosyltransferase 8 (alpha (1,6) fucosyltransferase) fucosyltransferase) (FUT8), mRNA. /FEA = mRNA /GEN = FUT8 /PROD = fucosyltransferase 8 (alpha (1,6)fucosyltransferase) /DB_XREF = gi: 4758407 /UG = Hs.118722 fucosyltransferase 8 (alpha (1,6) fucosyltransferase) /FL = gb: D89289.1 gb: NM_004480.1 201743_at CD14 antigen gb: NM_000591.1 /DEF = Homo sapiens CD14 1.1 −1.1 1.2 CD14 antigen (CD14), mRNA. /FEA = mRNA /GEN = CD14 /PROD = CD14 antigen precursor /DB_XREF = gi: 4557416 /UG = Hs.75627 CD14 antigen /FL = gb: M86511.1 gb: AF097942.1 gb: NM_000591.1 204222_s_at GLI pathogenesis- gb: NM_006851.1 /DEF = Homo sapiens GLIPR1 1.0 −1.2 1.1 related 1 (glioma) glioma pathogenesis-related protein (RTVP1), mRNA. /FEA = mRNA /GEN = RTVP1 /PROD = glioma pathogenesis-related protein /DB_XREF = gi: 5803150 /UG = Hs.64639 glioma pathogenesis-related protein /FL = gb: U16307.1 gb: NM_006851.1 207277_at CD209 antigen gb: AF290886.1 /DEF = Homo sapiens DC- CD209 1.4 −1.2 −1.5 SIGN mRNA, complete cds. /FEA = mRNA /PROD = DC-SIGN /DB_XREF = gi: 13383467 /UG = Hs.278694 CD209 antigen /FL = gb: NM_021155.1 gb: AF290886.1 gb: M98457.1 202338_at thymidine kinase 1, gb: NM_003258.1 /DEF = Homo sapiens TK1 −1.0 −1.0 −1.4 soluble thymidine kinase 1, soluble (TK1), mRNA. /FEA = mRNA /GEN = TK1 /PROD = thymidine kinase 1, soluble /DB_XREF = gi: 4507518 /UG = Hs.105097 thymidine kinase 1, soluble /FL = gb: K02581.1 gb: NM_003258.1 208193_at interleukin 9 gb: NM_000590.1 /DEF = Homo sapiens IL9 −1.0 −1.0 −1.0 interleukin 9 (IL9), mRNA. /FEA = mRNA /GEN = IL9 /PROD = interleukin 9 /DB_XREF = gi: 10834979 /UG = Hs.960 interleukin 9 /FL = gb: NM_000590.1 gb: M30134.1 204646_at dihydropyrimidine gb: NM_000110.2 /DEF = Homo sapiens DPYD 1.8 −1.3 −1.4 dehydrogenase dihydropyrimidine dehydrogenase (DPYD), mRNA. /FEA = mRNA /GEN = DPYD /PROD = dihydropyrimidine dehydrogenase /DB_XREF = gi: 4557874 /UG = Hs.1602 dihydropyrimidine dehydrogenase /FL = gb: U20938.1 gb: NM_000110.2 gb: U09178.1 gb: AB003063.1 208450_at lectin, galactoside- gb: NM_006498.1 /DEF = Homo sapiens LGALS2 1.3 −1.3 −1.7 binding, soluble, 2 lectin, galactoside-binding, soluble, 2 (galectin 2) (galectin 2) (LGALS2), mRNA. /FEA = CDS /GEN = LGALS2 /PROD = lectin, galactoside- binding, soluble, 2(galectin 2) /DB_XREF = gi: 5729902 /UG = Hs.113987 lectin, galactoside-binding, soluble, 2 (galectin 2) /FL = gb: M87842.1 gb: NM_006498.1 221841_s_at Kruppel-like factor Consensus includes gb: BF514079 KLF4 1.4 −1.4 −1.2 4 (gut) /FEA = EST /DB_XREF = gi: 11599258 /DB_XREF = est: UI-H-BW1-amw-b-08-0- UI.s1 /CLONE = IMAGE: 3071198 /UG = Hs.7934 Kruppel-like factor 4 (gut) 209773_s_at ribonucleotide gb: BC001886.1 /DEF = Homo sapiens, RRM2 −1.9 −1.5 −1.5 reductase M2 ribonucleotide reductase M2 polypeptide, polypeptide clone MGC: 1551, mRNA, complete cds. /FEA = mRNA /PROD = ribonucleotide reductase M2 polypeptide /DB_XREF = gi: 12804874 /UG = Hs.75319 ribonucleotide reductase M2 polypeptide /FL = gb: BC001886.1 201202_at proliferating cell gb: NM_002592.1 /DEF = Homo sapiens PCNA 1.1 −1.1 −1.5 nuclear antigen proliferating cell nuclear antigen (PCNA), mRNA. /FEA = mRNA /GEN = PCNA /PROD = proliferating cell nuclear antigen /DB_XREF = gi: 4505640 /UG = Hs.78996 proliferating cell nuclear antigen /FL = gb: BC000491.1 gb: M15796.1 gb: NM_002592.1 202705_at cyclin B2 gb: NM_004701.2 /DEF = Homo sapiens CCNB2 −1.0 −1.3 1.0 cyclin B2 (CCNB2), mRNA. /FEA = mRNA /GEN = CCNB2 /PROD = cyclin B2 /DB_XREF = gi: 10938017 /UG = Hs.194698 cyclin B2 /FL = gb: NM_004701.2 gb: AF002822.1 gb: AB020981.1 gb: AL080146.1 214470_at killer cell lectin-like Consensus includes gb: NM_002258.1 KLRB1 1.2 1.4 −1.2 receptor subfamily /DEF = Homo sapiens killer cell lectin-like B, member 1 receptor subfamily B, member 1 (KLRB1), mRNA. /FEA = CDS /GEN = KLRB1 /PROD = killer cell lectin-like receptor subfamily B, member 1 /DB_XREF = gi: 4504878 /UG = Hs.169824 killer cell lectin-like receptor subfamily B, member 1 /FL = gb: NM_002258.1 gb: U11276.1 205098_at chemokine (C-C Consensus includes gb: AI421071 1.1 −1.7 −1.1 motif) receptor 1 /FEA = EST /DB_XREF = gi: 4267002 /DB_XREF = est: tf24a02.x1 /CLONE = IMAGE: 2097098 /UG = Hs.301921 chemokine (C-C motif) receptor 1 /FL = gb: L09230.1 gb: L10918.1 gb: NM_001295.1 210190_at syntaxin 11 gb: AF071504.1 /DEF = Homo sapiens STX11 −1.0 −1.0 −1.0 syntaxin 11 mRNA, complete cds. /FEA = mRNA /PROD = syntaxin 11 /DB_XREF = gi: 3243239 /UG = Hs.118958 syntaxin 11 /FL = gb: AF071504.1 gb: AF044309.1 gb: AF038898.1 gb: NM_003764.1 204438_at mannose receptor, gb: NM_002438.1 /DEF = Homo sapiens MRC1 1.1 −1.5 −1.6 C type 1 mannose receptor, C type 1 (MRC1), mRNA. /FEA = mRNA /GEN = MRC1 /PROD = mannose receptor, C type 1 /DB_XREF = gi: 4505244 /UG = Hs.75182 mannose receptor, C type 1 /FL = gb: J05550.1 gb: NM_002438.1 221898_at lung type-I cell Consensus includes gb: AU154455 T1A-2 −53.7 −1.0 −1.0 membrane- /FEA = EST /DB_XREF = gi: 11015976 associated /DB_XREF = est: AU154455 glycoprotein /CLONE = NT2RP4001145 /UG = Hs.135150 lung type-I cell membrane-associated glycoprotein 205354_at guanidinoacetate N

gb: NM_000156.3 /DEF = Homo sapiens GAMT −1.0 −1.0 −1.0 methyltransferase guanidinoacetate N-methyltransferase (GAMT), mRNA. /FEA = mRNA /GEN = GAMT /PROD = guanidinoacetate N- methyltransferase /DB_XREF = gi: 7549759 /UG = Hs.81131 guanidinoacetate N- methyltransferase /FL = gb: NM_000156.3 202888_s_at alanyl (membrane) gb: NM_001150.1 /DEF = Homo sapiens ANPEP −1.2 −1.2 1.1 aminopeptidase alanyl (membrane) aminopeptidase (aminopeptidase (aminopeptidase N, aminopeptidase M, N, aminopeptidase microsomal aminopeptidase, CD13, p150) M, microsomal (ANPEP), mRNA. /FEA = mRNA aminopeptidase, /GEN = ANPEP /PROD = membrane alanine CD13, p150) aminopeptidase precursor /DB_XREF = gi: 4502094 /UG = Hs.1239 alanyl (membrane) aminopeptidase (aminopeptidase N, aminopeptidase M, microsomal aminopeptidase, CD13, p150) /FL = gb: M22324.1 gb: NM_001150.1 211962_s_at zinc finger protein Consensus includes gb: BG250310 1.7 1.1 1.0 36, C3H type-like 1 /FEA = EST /DB_XREF = gi: 12760126 /DB_XREF = est: 602362443F1 /CLONE = IMAGE: 4470898 /UG = Hs.85155 butyrate response factor 1 (EGF-response factor 1) 200862_at 24- gb: NM_014762.1 /DEF = Homo sapiens DHCR24 1.2 −1.3 −1.2 dehydrocholesterol seladin-1 (KIAA0018), mRNA. reductase /FEA = mRNA /GEN = KIAA0018 /PROD = seladin-1 /DB_XREF = gi: 13375617 /UG = Hs.75616 seladin-1 /FL = gb: AF261758.1 gb: BC004375.1 gb: NM_014762.1 217755_at hematological and gb: NM_016185.1 /DEF = Homo sapiens HN1 1.0 1.1 −1.2 neurological hematological and neurological expressed expressed 1 1 (HN1), mRNA. /FEA = mRNA/GEN = HN1 /PROD = hematological and neurological expressed 1 /DB_XREF = gi: 7705876 /UG = Hs.109706 hematological and neurological expressed 1 /FL = gb: AF060925.1 gb: BC001420.1 gb: AF177862.1 gb: NM_016185.1 205235_s_at M-phase gb: NM_016195.1 /DEF = Homo sapiens M- MPHOSPH1 1.6 −55.4 −67.1 phosphoprotein 1 phase phosphoprotein 1 (MPHOSPH1), mRNA. /FEA = mRNA /GEN = MPHOSPH1 /PROD = M-phase phosphoprotein 1 /DB_XREF = gi: 7705347 /UG = Hs.240 M- phase phosphoprotein 1 /FL = gb: AL117496.1 gb: NM_016195.1 219841_at activation-induced gb: NM_020661.1 /DEF = Homo sapiens AICDA −1.0 −1.0 −1.0 cytidine deaminase activation-induced cytidine deaminase (AICDA), mRNA. /FEA = mRNA /GEN = AICDA /PROD = activation-induced cytidine deaminase /DB_XREF = gi: 10190699 /UG = Hs.149342 activation-induced cytidine deaminase /FL = gb: NM_020661.1 gb: AB040431.1 205403_at interleukin 1 gb: NM_004633.1 /DEF = Homo sapiens IL1R2 1.8 −1.0 −50.5 receptor, type II interleukin 1 receptor, type II (IL1R2), mRNA. /FEA = mRNA /GEN = IL1R2 /PROD = interleukin 1 receptor, type II /DB_XREF = gi: 4758597 /UG = Hs.25333 interleukin 1 receptor, type II /FL = gb: U74649.1 gb: NM_004633.1 205016_at transforming gb: NM_003236.1 /DEF = Homo sapiens TGFA −1.3 −1.1 1.7 growth factor, transforming growth factor, alpha (TGFA), alpha mRNA. /FEA = mRNA /GEN = TGFA /PROD = transforming growth factor, alpha /DB_XREF = gi: 4507460 /UG = Hs.170009 transforming growth factor, alpha /FL = gb: BC005308.1 gb: M31172.1 gb: K03222.1 gb: NM_003236.1 201438_at collagen, type VI, gb: NM_004369.1 /DEF = Homo sapiens COL6A3 −1.0 −1.0 −1.0 alpha 3 collagen, type VI, alpha 3 (COL6A3), mRNA. /FEA = mRNA /GEN = COL6A3 /PROD = collagen, type VI, alpha 3 /DB_XREF = gi: 4758027 /UG = Hs.80988 collagen, type VI, alpha 3 /FL = gb: NM_004369.1 203270_at deoxythymidylate gb: NM_012145.1 /DEF = Homo sapiens DTYMK 60.6 1.1 −73.1 kinase (thymidylate deoxythymidylate kinase (thymidylate kinase) kinase) (DTYMK), mRNA. /FEA = mRNA /GEN = DTYMK /PROD = deoxythymidylate kinase (thymidylate kinase) /DB_XREF = gi: 6912339 /UG = Hs.79006 deoxythymidylate kinase (thymidylate kinase) /FL = gb: BC001827.1 gb: L16991.1 gb: NM_012145.1 219024_at pleckstrin gb: NM_021622.1 /DEF = Homo sapiens PLEKHA1 1.4 1.0 1.1 homology domain pleckstrin homology domain-containing, containing, family A family A (phosphoinositide binding (phosphoinositide specific) member 1 (PLEKHA1), mRNA. binding specific) /FEA = mRNA /GEN = PLEKHA1 member 1 /PROD = pleckstrin homology domain- containing, family A(phosphoinositide binding specific) member 1 /DB_XREF = gi: 11055985 /UG = Hs.17757 pleckstrin homology domain-containing, family A (phosphoinositide binding specific) member 1 /FL = gb: AF286160.1 gb: NM_021622.1 gb: BC001136.1 204822_at TTK protein kinase gb: NM_003318.1 /DEF = Homo sapiens −1.0 0.8 −1.0 TTK protein kinase (TTK), mRNA. /FEA = mRNA /GEN = TTK /PROD = TTK protein kinase /DB_XREF = gi: 4507718 /UG = Hs.169840 TTK protein kinase /FL = gb: BC000633.1 gb: M86699.1 gb: NM_003318.1 212672_at ataxia Consensus includes gb: U82828 ATM 2.1 1.0 −1.1 telangiectasia /DEF = Homo sapiens ataxia telangiectasia mutated (includes (ATM) gene, complete cds /FEA = mRNA_1 complementation /DB_XREF = gi: 2304970 /UG = Hs.194382 groups A, C and D) ataxia telangiectasia mutated (includes complementation groups A, C and D) 207067_s_at histidine gb: NM_002112.1 /DEF = Homo sapiens HDC −1.3 1.0 −1.2 decarboxylase histidine decarboxylase (HDC), mRNA. /FEA = mRNA /GEN = HDC /PROD = histidine decarboxylase /DB_XREF = gi: 4504364 /UG = Hs.1481 histidine decarboxylase /FL = gb: M60445.1 gb: NM_002112.1 205639_at acyloxyacyl gb: NM_001637.1 /DEF = Homo sapiens AOAH 1.1 −1.3 1.1 hydrolase acyloxyacyl hydrolase (neutrophil) (neutrophil) (AOAH), mRNA. /FEA = mRNA /GEN = AOAH /PROD = acyloxyacyl hydrolase precursor /DB_XREF = gi: 4502114 /UG = Hs.82542 acyloxyacyl hydrolase (neutrophil) /FL = gb: M62840.1 gb: NM_001637.1 220088_at G protein-coupled gb: NM_001736.1 /DEF = Homo sapiens C5R1 1.2 −1.1 1.1 receptor 77 complement component 5 receptor 1 (C5a ligand) (C5R1), mRNA. /FEA = mRNA /GEN = C5R1 /PROD = complement component 5 receptor 1 (C5a ligand) /DB_XREF = gi: 4502508 /UG = Hs.2161 complement component 5 receptor 1 (C5a ligand) /FL = gb: M62505.1 gb: NM_001736.1 204614_at serine (or cysteine) gb: NM_002575.1 /DEF = Homo sapiens SERPINB2 1.4 1.2 1.3 proteinase serine (or cysteine) proteinase inhibitor, inhibitor, clade B clade B (ovalbumin), member 2 (ovalbumin), (SERPINB2), mRNA. /FEA = mRNA member 2 /GEN = SERPINB2 /PROD = serine (or cysteine) proteinase inhibitor, cladeB (ovalbumin), member 2 /DB_XREF = gi: 4505594 /UG = Hs.75716 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2 /FL = gb: J02685.1 gb: J03603.1 gb: M18082.1 gb: NM_002575.1 209921_at solute carrier gb: AB040875.1 /DEF = Homo sapiens SLC7A11 1.2 1.1 −1.2 family 7, (cationic hxCT mRNA for cystineglutamate amino acid exchanger, complete cds. /FEA = mRNA transporter, y+ /GEN = hxCT /PROD = cystineglutamate system) member exchanger /DB_XREF = gi: 13516845 11 /UG = Hs.6682 solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 /FL = gb: AB040875.1 208863_s_at splicing factor, gb: M72709.1 /DEF = Human alternative SFRS1 1.6 1.1 1.5 arginine/serine-rich splicing factor mRNA, complete cds. 1 (splicing factor 2, /FEA = mRNA /DB_XREF = gi: 179073 alternate splicing /UG = Hs.73737 splicing factor, factor) arginineserine-rich 1 (splicing factor 2, alternate splicing factor) /FL = gb: M72709.1 205174_s_at glutaminyl-peptide gb: NM_012413.2 /DEF = Homo sapiens QPCT 1.2 −1.6 −1.2 cyclotransferase glutaminyl-peptide cyclotransferase (glutaminyl (glutaminyl cyclase) (QPCT), mRNA. cyclase) /FEA = mRNA /GEN = QPCT /PROD = glutaminyl-peptide cyclotransferase precursor /DB_XREF = gi: 9257235 /UG = Hs.79033 glutaminyl-peptide cyclotransferase (glutaminyl cyclase) /FL = gb: NM_012413.2 207038_at solute carrier gb: NM_004694.1 /DEF = Homo sapiens SLC16A6 1.1 1.0 1.3 family 16 solute carrier family 16 (monocarboxylic (monocarboxylic acid transporters), member 6 (SLC16A6), acid transporters), mRNA. /FEA = mRNA /GEN = SLC16A6 member 6 /PROD = solute carrier family 16 (monocarboxylic acidtransporters), member 6 /DB_XREF = gi: 4759117 /UG = Hs.114924 solute carrier family 16 (monocarboxylic acid transporters), member 6 /FL = gb: U79745.1 gb: NM_004694.1 204039_at CCAAT/enhancer gb: NM_004364.1 /DEF = Homo sapiens CEBPA 1.3 −1.1 1.1 binding protein CCAATenhancer binding protein (CEBP), (C/EBP), alpha alpha (CEBPA), mRNA. /FEA = mRNA /GEN = CEBPA /PROD = CCAATenhancer binding protein (CEBP), alpha /DB_XREF = gi: 4757971 /UG = Hs.76171 CCAATenhancer binding protein (CEBP), alpha /FL = gb: NM_004364.1 217786_at SKB1 homolog (S. pombe) gb: NM_006109.1 /DEF = Homo sapiens SKB1 1.5 1.1 1.0 skb1 (S. pombe) homolog (SKB1), mRNA. /FEA = mRNA /GEN = SKB1 /PROD = skb1 (S. pombe) homolog /DB_XREF = gi: 5174682 /UG = Hs.12912 skb1 (S. pombe) homolog /FL = gb: AF015913.1 gb: NM_006109.1 gb: AF167572.1 201710_at v-myb gb: NM_002466.1 /DEF = Homo sapiens v- MYBL2 −1.0 −1.0 −1.0 myeloblastosis myb avian myeloblastosis viral oncogene viral oncogene homolog-like 2 (MYBL2), mRNA. homolog (avian)- /FEA = mRNA /GEN = MYBL2 /PROD = v- like 2 myb avian myeloblastosis viral oncogenehomolog-like 2 /DB_XREF = gi: 4505292 /UG = Hs.179718 v- myb avian myeloblastosis viral oncogene homolog-like 2 /FL = gb: NM_002466.1 204693_at CDC42 effector gb: NM_007061.1 /DEF = Homo sapiens CDC42EP1 −1.1 −88.6 1.0 protein (Rho serum constituent protein (MSE55), GTPase binding) 1 mRNA. /FEA = mRNA /GEN = MSE55 /PROD = serum constituent protein /DB_XREF = gi: 5902007 /UG = Hs.148101 serum constituent protein /FL = gb: M88338.1 gb: NM_007061.1 205786_s_at integrin, alpha M gb: NM_000632.2 /DEF = Homo sapiens ITGAM 1.0 −1.2 −1.6 (complement integrin, alpha M (complement component component receptor 3, alpha; also known as CD11b receptor 3, alpha; (p170), macrophage antigen alpha also known as polypeptide) (ITGAM), mRNA. CD11b (p170), /FEA = mRNA /GEN = ITGAM macrophage /PROD = integrin alpha M precursor antigen alpha /DB_XREF = gi: 6006013 /UG = Hs.172631 polypeptide) integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macrophage antigen alpha polypeptide) /FL = gb: J03925.1 gb: NM_000632.2 209172_s_at centromere protein gb: U30872.1 /DEF = Human mitosin CENPF −1.0 −1.0 −1.0 F, 350/400ka mRNA, complete cds. /FEA = mRNA (mitosin) /PROD = mitosin /DB_XREF = gi: 1000093 /UG = Hs.77204 centromere protein F (350400 kD, mitosin) /FL = gb: U30872.1 201360_at cystatin C (amyloid gb: NM_000099.1 /DEF = Homo sapiens CST3 1.0 −1.3 −1.3 angiopathy and cystatin C (amyloid angiopathy and cerebral cerebral hemorrhage) (CST3), mRNA. hemorrhage) /FEA = mRNA /GEN = CST3 /PROD = cystatin C (amyloid angiopathy and cerebralhemorrhage) /DB_XREF = gi: 4503106 /UG = Hs.135084 cystatin C (amyloid angiopathy and cerebral hemorrhage) /FL = gb: NM_000099.1 216537_s_at sialic acid binding Consensus includes gb: AJ130713.1 SIGLEC7 1.1 1.7 1.0 Ig-like lectin 7 /DEF = Homo sapiens mRNA for QA79 membrane protein, splice product airm-1. /FEA = mRNA /GEN = airm /PROD = QA79 membrane protein, splice product airm-1 /DB_XREF = gi: 5541875 /UG = Hs.274470 sialic acid binding Ig-like lectin 7 206682_at C-type (calcium gb: NM_006344.1 /DEF = Homo sapiens CLECSF14 1.3 −1.2 −1.4 dependent, macrophage lectin 2 (calcium dependent) carbohydrate- (HML2), mRNA. /FEA = mRNA recognition /GEN = HML2 /PROD = macrophage lectin 2 domain) lectin, (calcium dependent) superfamily /DB_XREF = gi: 5453683 /UG = Hs.54403 member 14 macrophage lectin 2 (calcium dependent) (macrophage- /FL = gb: D50532.1 gb: NM_006344.1 derived) 201739_at serum/glucocorticoid gb: NM_005627.1 /DEF = Homo sapiens SGK 1.3 1.0 1.0 regulated kinase serumglucocorticoid regulated kinase (SGK), mRNA. /FEA = mRNA /GEN = SGK /PROD = serumglucocorticoid regulated kinase /DB_XREF = gi: 5032090 /UG = Hs.296323 serumglucocorticoid regulated kinase /FL = gb: BC001263.1 gb: NM_005627.1 gb: AF153609.1 209825_s_at uridine gb: BC002906.1 /DEF = Homo sapiens, UCK2 1.0 1.0 68.1 monophosphate Similar to uridine monophosphate kinase, kinase clone MGC: 10318, mRNA, complete cds. /FEA = mRNA /PROD = Similar to uridine monophosphate kinase /DB_XREF = gi: 12804106 /UG = Hs.75939 uridine monophosphate kinase /FL = gb: BC002906.1 gb: AF236637.1 219371_s_at Kruppel-like factor gb: NM_016270.1 /DEF = Homo sapiens KLF2 1.1 1.1 1.0 2 (lung) Kruppel-like factor (LOC51713), mRNA. /FEA = mRNA /GEN = LOC51713 /PROD = Kruppel-like factor /DB_XREF = gi: 7706468 /UG = Hs.107740 Kruppel-like factor 2 (lung) /FL = gb: AF134053.1 gb: AF205849.1 gb: NM_016270.1 209696_at fructose-1,6- gb: D26054.1 /DEF = Human mRNA for FBP1 1.0 −1.5 −1.4 bisphosphatase 1 fructose-1,6-bisphosphatase, complete cds. /FEA = mRNA /PROD = fructose-1,6- bisphosphatase /DB_XREF = gi: 439225 /UG = Hs.574 fructose-1,6-bisphosphatase 1 /FL = gb: M19922.1 gb: L10320.1 gb: D26054.1 gb: D26055.1 gb: D26056.1 gb: NM_000507.1 209949_at neutrophil cytosolic gb: BC001606.1 /DEF = Homo sapiens, NCF2 1.2 −1.4 −1.5 factor 2 (65 kDa, Similar to neutrophil cytosolic factor 2 chronic (65 kD, chronic granulomatous disease, granulomatous autosomal 2), clone MGC: 2275, mRNA, disease, autosomal complete cds. /FEA = mRNA 2) /PROD = Similar to neutrophil cytosolic factor 2 (65 kD, chronic granulomatous disease, autosomal 2) /DB_XREF = gi: 12804408 /UG = Hs.949 neutrophil cytosolic factor 2 (65 kD, chronic granulomatous disease, autosomal 2) /FL = gb: BC001606.1 gb: M32011.1 gb: NM_000433.1 210220_at frizzled homolog 2 gb: L37882.1 /DEF = Human frizzled gene FZD2 −1.2 1.1 1.0 (Drosophila) product mRNA, complete cds. /FEA = mRNA /GEN = frizzled /DB_XREF = gi: 736678 /UG = Hs.81217 frizzled (Drosophila) homolog 2 /FL = gb: AB017364.1 gb: NM_001466.2 gb: L37882.1 205718_at integrin, beta 7 gb: NM_000889.1 /DEF = Homo sapiens ITGB7 1.3 1.1 −1.1 integrin, beta 7 (ITGB7), mRNA. /FEA = mRNA /GEN = ITGB7 /PROD = integrin, beta 7 /DB_XREF = gi: 4504776 /UG = Hs.1741 integrin, beta 7 /FL = gb: M68892.1 gb: M62880.1 gb: NM_000889.1 206999_at interleukin 12 gb: NM_001559.1 /DEF = Homo sapiens IL12RB2 1.0 59.9 −1.0 receptor, beta 2 interleukin 12 receptor, beta 2 (IL12RB2), mRNA. /FEA = mRNA /GEN = IL12RB2 /PROD = interleukin 12 receptor, beta 2 /DB_XREF = gi: 4504642 /UG = Hs.73165 interleukin 12 receptor, beta 2 /FL = gb: U64198.1 gb: NM_001559.1 203104_at colony stimulating gb: NM_005211.1 /DEF = Homo sapiens CSF1R 1.1 −1.1 1.1 factor 1 receptor, colony stimulating factor 1 receptor, formerly formerly McDonough feline sarcoma viral McDonough feline (v-fms) oncogene homolog (CSF1R), sarcoma viral (v- mRNA. /FEA = mRNA /GEN = CSF1R fms) oncogene /PROD = colony stimulating factor 1 homolog receptor, formerlyMcDonough feline sarcoma viral (v-fms) oncogene homolog /DB_XREF = gi: 4885158 /UG = Hs.174142 colony stimulating factor 1 receptor, formerly McDonough feline sarcoma viral (v-fms) oncogene homolog /FL = gb: NM_005211.1 209661_at kinesin family gb: BC001211.1 /DEF = Homo sapiens, KIFC3 1.1 −1.3 −1.4 member C3 kinesin family member C3, clone MGC: 3226, mRNA, complete cds. /FEA = mRNA /PROD = kinesin family member C3 /DB_XREF = gi: 12654738 /UG = Hs.23131 kinesin family member C3 /FL = gb: BC001211.1 gb: AF004426.1 gb: NM_005550.1 221210_s_at N- gb: NM_030769.1 /DEF = Homo sapiens NPL 1.5 −1.1 1.1 acetylneuraminate hypothetical protein similar to swine pyruvate lyase acylneuraminate lyase (C1ORF13), (dihydrodipicolinate mRNA. /FEA = mRNA /GEN = C1ORF13 synthase) /PROD = hypothetical protein similar to swineacylneuraminate lyase /DB_XREF = gi: 13540532 /FL = gb: NM_030769.1 221748_s_at tensin Consensus includes gb: AL046979 TNS 1.2 1.0 1.8 /FEA = EST /DB_XREF = gi: 5435035 /DB_XREF = est: DKFZp586K0617_s1 /CLONE = DKFZp586K0617 /UG = Hs.9973 tensin 202878_s_at complement gb: NM_012072.2 /DEF = Homo sapiens C1QR1 1.2 1.2 1.2 component 1, q complement component C1q receptor subcomponent, (C1QR), mRNA. /FEA = mRNA receptor 1 /GEN = C1QR /PROD = complement component C1q receptor /DB_XREF = gi: 11496985 /UG = Hs.97199 complement component C1q receptor /FL = gb: NM_012072.2 gb: U94333.1 210152_at leukocyte gb: U82979.1 /DEF = Human LILRB4 −1.3 −1.3 −1.2 immunoglobulin- immunoglobulin-like transcript-3 mRNA, like receptor, complete cds. /FEA = mRNA subfamily B (with /PROD = immunoglobulin-like transcript-3 TM and ITIM /DB_XREF = gi: 1857460 /UG = Hs.67846 domains), member 4 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4 /FL = gb: U82979.1 gb: U91925.1 gb: AF025532.1 gb: NM_006847.1 219306_at kinesin-like 7 gb: NM_020242.1 /DEF = Homo sapiens KNSL7 −1.0 −1.0 −1.0 kinesin-like protein 2 (hklp2), mRNA. /FEA = mRNA /GEN = hklp2 /PROD = kinesin- like protein 2 /DB_XREF = gi: 9910265 /UG = Hs.150587 kinesin-like protein 2 /FL = gb: AB035898.1 gb: NM_020242.1 208075_s_at chemokine (C-C gb: NM_006273.2 /DEF = Homo sapiens −1.0 −1.0 −1.0 motif) ligand 7 small inducible cytokine A7 (monocyte chemotactic protein 3) (SCYA7), mRNA. /FEA = mRNA /GEN = SCYA7 /PROD = monocyte chemotactic protein 3 precursor /DB_XREF = gi: 13435401 /FL = gb: NM_006273.2 204959_at myeloid cell gb: NM_002432.1 /DEF = Homo sapiens MNDA 1.1 −1.5 −1.5 nuclear myeloid cell nuclear differentiation antigen differentiation (MNDA), mRNA. /FEA = mRNA antigen /GEN = MNDA /PROD = myeloid cell nuclear differentiation antigen /DB_XREF = gi: 4505226 /UG = Hs.153837 myeloid cell nuclear differentiation antigen /FL = gb: NM_002432.1 gb: M81750.1 201849_at BCL2/adenovirus gb: NM_004052.2 /DEF = Homo sapiens BNIP3 1.6 1.0 −1.3 E1B 19 kDa BCL2adenovirus E1B 19 kD-interacting interacting protein 3 protein 3 (BNIP3), nuclear gene encoding mitochondrial protein, mRNA. /FEA = mRNA /GEN = BNIP3 /PROD = BCL2adenovirus E1B 19 kD- interacting protein 3 /DB_XREF = gi: 7669480 /UG = Hs.79428 BCL2adenovirus E1B 19 kD-interacting protein 3 /FL = gb: AF002697.1 gb: U15174.1 gb: NM_004052.2 203554_x_at pituitary tumor- gb: NM_004219.2 /DEF = Homo sapiens PTTG1 −1.5 −1.2 −1.2 transforming 1 pituitary tumor-transforming 1 (PTTG1), mRNA. /FEA = mRNA /GEN = PTTG1 /PROD = pituitary tumor-transforming protein 1 /DB_XREF = gi: 11038651 /UG = Hs.252587 pituitary tumor- transforming 1 /FL = gb: NM_004219.2 gb: AF095287.1 gb: AF062649.1 gb: AF075242.1 214453_s_at interferon-induced Consensus includes gb: NM_006417.1 IFI44 1.4 −4.9 1.1 protein 44 /DEF = Homo sapiens interferon-induced, hepatitis C-associated microtubular aggregate protein (44 kD) (MTAP44), mRNA. /FEA = CDS /GEN = MTAP44 /PROD = interferon-induced, hepatitis C- associatedmicrotubular aggregate protein (44 kD) /DB_XREF = gi: 5453743 /UG = Hs.82316 interferon-induced, hepatitis C-associated microtubular aggregate protein (44 kD) /FL = gb: NM_006417.1 209774_x_at chemokine (C—X—C gb: M57731.1 /DEF = Human gro-beta CXCL2 1.3 1.1 1.4 motif) ligand 2 mRNA, complete cds. /FEA = mRNA /GEN = gro-beta /PROD = cytokine gro-beta /DB_XREF = gi: 183626 /UG = Hs.75765 GRO2 oncogene /FL = gb: M57731.1 gb: M36820.1 gb: NM_002089.1 219386_s_at SLAM family gb: NM_020125.1 /DEF = Homo sapiens SLAMF8 −1.2 −1.3 −2.1 member 8 BCM-like membrane protein precursor (SBBI42), mRNA. /FEA = mRNA /GEN = SBBI42 /PROD = BCM-like membrane protein precursor /DB_XREF = gi: 9910341 /UG = Hs.20450 BCM-like membrane protein precursor /FL = gb: AF144235.1 gb: NM_014036.1 gb: AF146761.1 gb: NM_020125.1 210215_at transferrin receptor 2 gb: AF067864.1 /DEF = Homo sapiens TFR2 −1.0 −1.0 −1.0 transferrin receptor 2 alpha (TFR2) mRNA, complete cds. /FEA = mRNA /GEN = TFR2 /PROD = transferrin receptor 2 alpha /DB_XREF = gi: 5596369 /UG = Hs.63758 transferrin receptor 2 /FL = gb: AF067864.1 210184_at integrin, alpha X gb: M81695.1 /DEF = H. sapiens leukocyte ITGAX 1.1 1.0 −1.2 (antigen CD11C adhesion glycoprotein p150,95 mRNA, (p150), alpha complete cds. /FEA = mRNA /GEN = ITGAX polypeptide) /DB_XREF = gi: 487829 /UG = Hs.51077 integrin, alpha X (antigen CD11C (p150), alpha polypeptide) /FL = gb: M81695.1 gb: NM_000887.2 208079_s_at serine/threonine gb: NM_003158.1 /DEF = Homo sapiens STK6 −1.0 −1.0 1.1 kinase 6 serinethreonine kinase 6 (STK6), mRNA. /FEA = mRNA /GEN = STK6 /PROD = serinethreonine kinase 6 /DB_XREF = gi: 4507278 /UG = Hs.250822 serinethreonine kinase 6 /FL = gb: D84212.1 gb: NM_003158.1 205237_at ficolin gb: NM_002003.2 /DEF = Homo sapiens FCN1 −1.2 −1.2 1.0 (collagen/fibrinogen ficolin (collagenfibrinogen domain- domain containing) 1 (FCN1), mRNA. containing) 1 /FEA = mRNA /GEN = FCN1 /PROD = ficolin 1 precursor /DB_XREF = gi: 8051583 /UG = Hs.252136 ficolin (collagenfibrinogen domain-containing) 1 /FL = gb: D83920.1 gb: NM_002003.2 207645_s_at chromodomain gb: NM_004284.1 /DEF = Homo sapiens CHD1L −1.0 −1.0 −1.0 helicase DNA chromodomain helicase DNA binding binding protein 1- protein 1-like (CHD1L), mRNA. like /FEA = mRNA /GEN = CHD1L /PROD = chromodomain helicase DNA binding protein1-like /DB_XREF = gi: 4757977 /UG = Hs.159273 chromodomain helicase DNA binding protein 1-like /FL = gb: AF054177.1 gb: NM_004284.1 210889_s_at Fc fragment of IgG, gb: M31933.1 /DEF = Human IgG low FCGR2B 1.2 −1.2 1.0 low affinity IIb, affinity Fc fragment receptor (FcRIIb3) receptor for (CD32) mRNA, complete cds. /FEA = mRNA /DB_XREF = gi: 182598 /UG = Hs.278443 Fc fragment of IgG, low affinity IIb, receptor for (CD32) /FL = gb: M31933.1 209875_s_at secreted gb: M83248.1 /DEF = Human nephropontin SPP1 −1.4 1.2 1.2 phosphoprotein 1 mRNA, complete cds. /FEA = mRNA (osteopontin, bone /GEN = nephropontin /PROD = nephropontin sialoprotein I, early /DB_XREF = gi: 189150 /UG = Hs.313 T-lymphocyte secreted phosphoprotein 1 (osteopontin, activation 1) bone sialoprotein I, early T-lymphocyte activation 1) /FL = gb: M83248.1 205686_s_at CD86 antigen gb: NM_006889.1 /DEF = Homo sapines CD86 1.1 −1.1 1.0 (CD28 antigen CD86 antigen (CD28 antigen ligand 2, B7- ligand 2, B7-2 2 antigen) (CD86), mRNA. /FEA = mRNA antigen) /GEN = CD86 /PROD = CD86 antigen (CD28 antigen ligand 2, B7-2antigen) /DB_XREF = gi: 5901919 /UG = Hs.27954 CD86 antigen (CD28 antigen ligand 2, B7- 2 antigen) /FL = gb: U04343.1 gb: NM_006889.1 218075_at achalasia, gb: NM_015665.1 /DEF = Homo sapiens AAAS 1.1 −1.2 −1.4 adrenocortical aladin (AAAS), mRNA. /FEA = mRNA insufficiency, /GEN = AAAS /PROD = aladin alacrimia (Allgrove, /DB_XREF = gi: 12962936 /UG = Hs.125262 triple-A) aladin /FL = gb: BC000659.1 gb: NM_015665.1 gb: AF226048.1 202240_at polo-like kinase 1 gb: NM_005030.1 /DEF = Homo sapiens (Drosophila) polo (Drosophia)-like kinase (PLK), mRNA. /FEA = mRNA /GEN = PLK /PROD = polo (Drosophia)-like kinase /DB_XREF = gi: 4826915 /UG = Hs.77597 polo (Drosophia)-like kinase /FL = gb: BC002369.1 gb: BC003002.1 gb: U01038.1 gb: L19559.1 gb: NM_005030.1 209392_at ectonucleotide gb: L35594.1 /DEF = Human autotaxin ENPP2 1.0 −2.1 −1.7 pyrophosphatase/phosphodiesterase mRNA, complete cds. /FEA = mRNA 2 (autotaxin) /PROD = autotaxin /DB_XREF = gi: 537905 /UG = Hs.174185 ectonucleotide pyrophosphatasephosphodiesterase 2 (autotaxin) /FL = gb: L35594.1 202600_s_at nuclear receptor Consensus includes gb: AI824012 NRIP1 61.3 −1.3 −1.0 interacting protein 1 /FEA = EST /DB_XREF = gi: 5444683 /DB_XREF = est: wj29e06.x1 /CLONE = IMAGE: 2404258 /UG = Hs.155017 nuclear receptor interacting protein 1 /FL = gb: NM_003489.1 202589_at thymidylate gb: NM_001071.1 /DEF = Homo sapiens TYMS 1.0 −1.2 −1.7 synthetase thymidylate synthetase (TYMS), mRNA. /FEA = mRNA /GEN = TYMS /PROD = thymidylate synthetase /DB_XREF = gi: 4507750 /UG = Hs.82962 thymidylate synthetase /FL = gb: BC002567.1 gb: NM_001071.1 221521_s_at DNA replication gb: BC003186.1 /DEF = Homo sapiens, Pfs2 −1.0 −1.0 −1.0 complex GINS HSPC037 protein, clone MGC: 673, protein PSF2 mRNA, complete cds. /FEA = mRNA /PROD = HSPC037 protein /DB_XREF = gi: 13112024 /UG = Hs.108196 HSPC037 protein /FL = gb: BC003186.1 gb: AF201939.1 201005_at CD9 antigen (p24) gb: NM_001769.1 /DEF = Homo sapiens CD9 1.3 1.1 1.2 CD9 antigen (p24) (CD9), mRNA. /FEA = mRNA /GEN = CD9 /PROD = CD9 antigen (p24) /DB_XREF = gi: 4502692 /UG = Hs.1244 CD9 antigen (p24) /FL = gb: M38690.1 gb: NM_001769.1 gb: L34068.1 219148_at T-LAK cell- gb: NM_018492.1 /DEF = Homo sapiens TOPK −1.0 −1.0 −1.0 originated protein PDZ-binding kinase; T-cell originated kinase protein kinase (TOPK), mRNA. /FEA = mRNA /GEN = TOPK /PROD = PDZ- binding kinase /DB_XREF = gi: 8923876 /UG = Hs.104741 PDZ-binding kinase; T- cell originated protein kinase /FL = gb: AF189722.1 gb: AF237709.1 gb: NM_018492.1 gb: AB027249.1 gb: AB027250.1 217762_s_at RAB31, member Consensus includes gb: BE789881 RAB31 1.3 −1.3 −1.1 RAS oncogene /FEA = EST /DB_XREF = gi: 10211079 family /DB_XREF = est: 601476750F1 /CLONE = IMAGE: 3879493 /UG = Hs.223025 RAB31, member RAS oncogene family /FL = gb: AF234995.1 gb: BC001148.1 gb: U59877.1 gb: U57091.1 gb: NM_006868.1 gb: AF183421.1 205046_at centromere protein gb: NM_001813.1 /DEF = Homo sapiens CENPE −1.0 −1.0 −1.0 E, 312 kDa centromere protein E (312 kD) (CENPE), mRNA. /FEA = mRNA /GEN = CENPE /PROD = centromere protein E /DB_XREF = gi: 4502780 /UG = Hs.75573 centromere protein E (312 kD) /FL = gb: NM_001813.1 204026_s_at ZW10 interactor gb: NM_007057.1 /DEF = Homo sapiens ZWINT 1.2 1.1 −1.4 ZW10 interactor (ZWINT), mRNA. /FEA = mRNA /GEN = ZWINT /PROD = ZW10 interactor /DB_XREF = gi: 6857828 /UG = Hs.42650 ZW10 interactor /FL = gb: AF067656.1 gb: NM_007057.1 204834_at fibrinogen-like 2 gb: NM_006682.1 /DEF = Homo sapiens FGL2 1.0 −1.5 −1.3 fibrinogen-like 2 (FGL2), mRNA. /FEA = mRNA /GEN = FGL2 /PROD = fibrinogen-like 2 /DB_XREF = gi: 5730074 /UG = Hs.2659 fibrinogen-like 2 /FL = gb: NM_006682.1 207369_at bombesin-like Consensus includes gb: Z97632 BRS3 −66.2 74.8 1.4 receptor 3 /DEF = Human DNA sequence from PAC 196E23 on chromosome Xq26.1-27.2. Contains the TAT-SF1 (HIV-1 transcriptional elongation factor TAT cofactor TAT-SF1) gene, the BRS3 (Bombesin Receptor subtype-3 (Uterine Bombesin Receptor, BRS-3) gene, an unknown gene . . . /FEA = mRNA_2 /DB_XREF = gi: 2808417 /UG = Hs.121484 bombesin-like receptor 3 /FL = gb: L08893.1 gb: NM_001727.1 204580_at matrix gb: NM_002426.1 /DEF = Homo sapiens MMP12 −56.1 −1.0 −50.9 metalloproteinase matrix metalloproteinase 12 (macrophage 12 (macrophage elastase) (MMP12), mRNA. /FEA = mRNA elastase) /GEN = MMP12 /PROD = matrix metalloproteinase 12 preproprotein /DB_XREF = gi: 4505206 /UG = Hs.1695 matrix metalloproteinase 12 (macrophage elastase) /FL = gb: L23808.1 gb: NM_002426.1 208892_s_at dual specificity gb: BC003143.1 /DEF = Homo sapiens, dual DUSP6 1.3 −1.4 −1.2 phosphatase 6 specificity phosphatase 6, clone MGC: 3789, mRNA, complete cds. /FEA = mRNA /PROD = dual specificity phosphatase 6 /DB_XREF = gi: 13111942 /UG = Hs.180383 dual specificity phosphatase 6 /FL = gb: BC003562.1 gb: BC003143.1 gb: BC005047.1 gb: AB013382.1 gb: NM_001946.1 207850_at chemokine (C—X—C gb: NM_002090.1 /DEF = Homo sapiens CXCL3 1.1 1.0 1.0 motif) ligand 3 GRO3 oncogene (GRO3), mRNA. /FEA = mRNA /GEN = GRO3 /PROD = GRO3 oncogene /DB_XREF = gi: 4504156 /UG = Hs.89690 GRO3 oncogene /FL = gb: M36821.1 gb: NM_002090.1 203362_s_at MAD2 mitotic gb: NM_002358.2 /DEF = Homo sapiens MAD2L1 −1.0 −1.0 −1.1 arrest deficient-like MAD2 (mitotic arrest deficient, yeast, 1 (yeast) homolog)-like 1 (MAD2L1), mRNA. /FEA = mRNA /GEN = MAD2L1 /PROD = MAD2-like 1 /DB_XREF = gi: 6466452 /UG = Hs.79078 MAD2 (mitotic arrest deficient, yeast, homolog)-like 1 /FL = gb: BC000356.1 gb: U65410.1 gb: NM_002358.2 gb: U31278.1 210146_x_at leukocyte gb: AF004231.1 /DEF = Homo sapiens LILRB2 1.2 −1.7 −1.5 immunoglobulin- monocytemacrophage Ig-related receptor like receptor, MIR-10 (MIR cl-10) mRNA, complete cds. subfamily B (with /FEA = mRNA /GEN = MIR cl-10 TM and ITIM /PROD = MIR-10 /DB_XREF = gi: 2343110 domains), member 2 /UG = Hs.22405 leukocyte immunoglobulin- like receptor, subfamily B (with TM and ITIM domains), member 2 /FL = gb: AF000574.1 gb: AF004231.1 gb: AF011565.1 215925_s_at CD72 antigen Consensus includes gb: AF283777.2 CD72 69.7 −1.4 1.4 /DEF = Homo sapiens clone TCBAP0702 mRNA sequence. /FEA = mRNA /DB_XREF = gi: 10281735 /UG = Hs.116481 CD72 antigen 201200_at cellular repressor gb: NM_003851.1 /DEF = Homo sapiens CREG1 1.4 −1.7 1.0 of E1A-stimulated cellular repressor of E1A-stimulated genes genes (CREG), mRNA. /FEA = mRNA /GEN = CREG /PROD = cellular repressor of E1A-stimulated genes /DB_XREF = gi: 4503036 /UG = Hs.5710 cellular repressor of E1A-stimulated genes /FL = gb: AF084523.1 gb: NM_003851.1 205393_s_at CHK1 checkpoint gb: NM_001274.1 /DEF = Homo sapiens CHEK1 −1.0 −1.0 −1.0 homolog (S. pombe) CHK1 (checkpoint, S. pombe) homolog (CHEK1), mRNA. /FEA = mRNA /GEN = CHEK1 /PROD = CHK1 (checkpoint, S. pombe) homolog /DB_XREF = gi: 4502802 /UG = Hs.20295 CHK1 (checkpoint, S. pombe) homolog /FL = gb: AF016582.1 gb: NM_001274.1 201422_at interferon, gamma- gb: NM_006332.1 /DEF = Homo sapiens IFI30 −1.4 1.1 1.1 inducible protein interferon, gamma-inducible protein 30 30 (IFI30), mRNA. /FEA = mRNA /GEN = IFI30 /PROD = interferon, gamma-inducible protein 30 /DB_XREF = gi: 5453695 /UG = Hs.14623 interferon, gamma- inducible protein 30 /FL = gb: J03909.1 gb: NM_006332.1 gb: AF097362.1 202779_s_at ubiquitin- gb: NM_014501.1 /DEF = Homo sapiens UBE2S 1.1 −1.5 −1.2 conjugating ubiquitin carrier protein (E2-EPF), mRNA. enzyme E2S /FEA = mRNA /GEN = E2-EPF /PROD = ubiquitin carrier protein /DB_XREF = gi: 7657045 /UG = Hs.174070 ubiquitin carrier protein /FL = gb: M91670.1 gb: NM_014501.1 57540_at ribokinase Cluster Incl. AI823980: wj29b03.x1 Homo RBKS −59.7 −1.0 −1.0 sapiens cDNA, 3 end /clone = IMAGE- 2404205 /clone_end = 3′ /gb = AI823980 /gi = 5444651 /ug = Hs.11916 /len = 620 204068_at serine/threonine gb: NM_006281.1 /DEF = Homo sapiens STK3 51.1 −1.0 −1.0 kinase 3 (STE20 serinethreonine kinase 3 (Ste20, yeast homolog, yeast) homolog) (STK3), mRNA. /FEA = mRNA /GEN = STK3 /PROD = serinethreonine kinase 3 (Ste20, yeasthomolog) /DB_XREF = gi: 5454093 /UG = Hs.166684 serinethreonine kinase 3 (Ste20, yeast homolog) /FL = gb: U26424.1 gb: U60206.1 gb: NM_006281.1 218559_s_at v-maf gb: NM_005461.1 /DEF = Homo sapiens MAFB 1.1 −1.5 1.1 musculoaponeurotic Kreisler (mouse) maf-related leucine fibrosarcoma zipper homolog (KRML), mRNA. oncogene homolog /FEA = mRNA /GEN = KRML B (avian) /PROD = Kreisler (mouse) maf-related leucine zipperhomolog /DB_XREF = gi: 4885446 /UG = Hs.169487 Kreisler (mouse) maf-related leucine zipper homolog /FL = gb: AF134157.1 gb: NM_005461.1 208107_s_at exonuclease NEF- gb: NM_030941.1 /DEF = Homo sapiens −1.0 −1.0 −1.0 sp exonuclease NEF-sp (LOC81691), mRNA. /FEA = mRNA /GEN = LOC81691 /PROD = exonuclease NEF-sp /DB_XREF = gi: 13569912 /FL = gb: NM_030941.1 210512_s_at vascular gb: AF022375.1 /DEF = Homo sapiens VEGF 80.6 −73.5 −1.2 endothelial growth vascular endothelial growth factor mRNA, factor complete cds. /FEA = mRNA /PROD = vascular endothelial growth factor /DB_XREF = gi: 3719220 /UG = Hs.73793 vascular endothelial growth factor /FL = gb: M32977.1 gb: AF022375.1 gb: NM_003376.1 gb: AB021221.1 gb: AF091352.1 200783_s_at stathmin gb: NM_005563.2 /DEF = Homo sapiens STMN1 −1.2 1.6 1.1 1/oncoprotein 18 leukemia-associated phosphoprotein p18 (stathmin) (LAP18), mRNA. /FEA = mRNA /GEN = LAP18 /PROD = leukemia- associated phosphoprotein p18 /DB_XREF = gi: 13518023 /UG = Hs.81915 leukemia-associated phosphoprotein p18 (stathmin) /FL = gb: NM_005563.2 gb: J04991.1 202107_s_at MCM2 gb: NM_004526.1 /DEF = Homo sapiens MCM2 1.1 −1.5 −1.5 minichromosome minichromosome maintenance deficient maintenance (S. cerevisiae) 2 (mitotin) (MCM2), mRNA. deficient 2, mitotin /FEA = mRNA /GEN = MCM2 (S. cerevisiae) /PROD = minichromosome maintenance deficient (S. cerevisiae) 2 (mitotin) /DB_XREF = gi: 4758705 /UG = Hs.57101 minichromosome maintenance deficient (S. cerevisiae) 2 (mitotin) /FL = gb: D83987.1 gb: NM_004526.1 213566_at ribonuclease, Consensus includes gb: NM_005615.1 RNASE6 1.2 −1.2 1.7 RNase A family, k6 /DEF = Homo sapiens ribonuclease, RNase A family, k6 (RNASE6), mRNA. /FEA = CDS /GEN = RNASE6 /PROD = ribonuclease, RNase A family, k6 /DB_XREF = gi: 5032044 /UG = Hs.23262 ribonuclease, RNase A family, k6 /FL = gb: NM_005615.1 205240_at G-protein signalling gb: NM_013296.1 /DEF = Homo sapiens GPSM2 −1.0 −1.0 −1.0 modulator 2 (AGS3 LGN protein (HSU54999), mRNA. like, C. elegans) /FEA = mRNA /GEN = HSU54999 /PROD = LGN protein /DB_XREF = gi: 9558734 /UG = Hs.278338 LGN protein /FL = gb: U54999.1 gb: NM_013296.1 208498_s_at amylase, alpha 2B; gb: NM_004038.1 /DEF = Homo sapiens AMY2B 2.0 −1.3 1.1 pancreatic amylase, alpha 1A; salivary (AMY1A), mRNA. /FEA = CDS /GEN = AMY1A /PROD = amylase, alpha 1A; salivary /DB_XREF = gi: 4757749 /UG = Hs.274376 amylase, alpha 1A; salivary /FL = gb: NM_004038.1 202241_at tribbles homolog 1 gb: NM_025195.1 /DEF = Homo sapiens TRIB1 1.4 −1.3 1.1 (Drosophila) phosphoprotein regulated by mitogenic pathways (C8FW), mRNA. /FEA = mRNA /GEN = C8FW /PROD = G-protein-coupled receptor induced protein /DB_XREF = gi: 13399327 /UG = Hs.7837 phosphoprotein regulated by mitogenic pathways /FL = gb: AF205437.1 gb: NM_025195.1 219947_at C-type (calcium gb: NM_016184.1 /DEF = Homo sapiens C- CLECSF6 1.5 −1.2 −1.8 dependent, type (calcium dependent, carbohydrate- carbohydrate- recognition domain) lectin, superfamily recognition member 6 (CLECSF6), mRNA. domain) lectin, /FEA = mRNA /GEN = CLECSF6 /PROD = C- superfamily type (calcium dependent, carbohydrate- member 6 recognition domain) lectin, superfamilymember 6 /DB_XREF = gi: 7705337 /UG = Hs.115515 C- type (calcium dependent, carbohydrate- recognition domain) lectin, superfamily member 6 /FL = gb: AF109146.1 gb: NM_016184.1 gb: AF067800.1 204787_at Ig superfamily gb: NM_007268.1 /DEF = Homo sapiens Ig VSIG4 1.1 1.0 1.2 protein superfamily protein (Z39IG), mRNA. /FEA = mRNA /GEN = Z39IG /PROD = Ig superfamily protein /DB_XREF = gi: 6005957 /UG = Hs.8904 Ig superfamily protein /FL = gb: NM_007268.1 204860_s_at baculoviral IAP Consensus includes gb: AI817801 BIRC1 1.2 1.0 1.1 repeat-containing 1 /FEA = EST /DB_XREF = gi: 5436880 /DB_XREF = est: wk40d12.x1 /CLONE = IMAGE: 2417879 /UG = Hs.79019 baculoviral IAP repeat-containing 1 /FL = gb: U19251.1 gb: NM_004536.1 205547_s_at transgelin gb: NM_003186.2 /DEF = Homo sapiens TAGLN 1.4 1.0 1.1 transgelin (TAGLN), mRNA. /FEA = mRNA /GEN = TAGLN /PROD = transgelin /DB_XREF = gi: 12621918 /UG = Hs.75777 transgelin /FL = gb: NM_003186.2 gb: M95787.1 gb: D17409.1 218755_at kinesin family gb: NM_005733.1 /DEF = Homo sapiens KIF20A −1.0 −1.0 −1.0 member 20A RAB6 interacting, kinesin-like (rabkinesin6) (RAB6KIFL), mRNA. /FEA = mRNA /GEN = RAB6KIFL /PROD = RAB6 interacting, kinesin-like (rabkinesin6) /DB_XREF = gi: 5032012 /UG = Hs.73625 RAB6 interacting, kinesin- like (rabkinesin6) /FL = gb: AF070672.1 gb: AF153329.1 gb: NM_005733.1 207906_at interleukin 3 gb: NM_000588.1 /DEF = Homo sapiens IL3 −1.0 −1.0 −1.0 (colony-stimulating interleukin 3 (colony-stimulating factor, factor, multiple) multiple) (IL3), mRNA. /FEA = mRNA /GEN = IL3 /PROD = interleukin 3 (colony- stimulating factor, multiple) /DB_XREF = gi: 4504666 /UG = Hs.694 interleukin 3 (colony-stimulating factor, multiple) /FL = gb: M17115.1 gb: M14743.1 gb: M20137.1 gb: NM_000588.1 210004_at oxidised low gb: AF035776.1 /DEF = Homo sapiens OLR1 1.2 −1.6 −2.0 density lipoprotein oxidized low-density lipoprotein receptor (lectin-like) mRNA, complete cds. /FEA = mRNA receptor 1 /PROD = oxidized low-density lipoprotein receptor /DB_XREF = gi: 3941299 /UG = Hs.77729 oxidised low density lipoprotein (lectin-like) receptor 1 /FL = gb: AB010710.1 gb: AF035776.1 gb: NM_002543.1 221419_s_at Similar to gb: NM_013307.1 /DEF = Homo sapiens −1.5 1.0 −1.1 ribosomal protein non-functional folate binding protein L13a; 60S (HSAF000381), mRNA. /FEA = CDS ribosomal protein /GEN = HSAF000381 /PROD = non- L13a; 23 kD highly functional folate binding protein basic protein /DB_XREF = gi: 7019412 (LOC399810), /FL = gb: NM_013307.1 mRNA [BLAST] 218436_at endoplasmic gb: NM_022464.1 /DEF = Homo sapiens SIL1 115.9 −1.8 −1.7 reticulum endoplasmic reticulum chaperone SIL1, chaperone SIL1, homolog of yeast (SIL1), mRNA. homolog of yeast /FEA = mRNA /GEN = SIL1 /PROD = endoplasmic reticulum chaperone SIL1, homolog ofyeast /DB_XREF = gi: 11968008 /UG = Hs.297875 endoplasmic reticulum chaperone SIL1, homolog of yeast /FL = gb: NM_022464.1 205727_at telomerase- gb: NM_007110.1 /DEF = Homo sapiens TEP1 −1.0 −1.0 −1.0 associated protein 1 telomerase-associated protein 1 (TEP1), mRNA. /FEA = mRNA /GEN = TEP1 /PROD = telomerase-associated protein 1 /DB_XREF = gi: 6005893 /UG = Hs.232070 telomerase-associated protein 1 /FL = gb: U86136.1 gb: NM_007110.1 218831_s_at Fc fragment of IgG, gb: NM_004107.1 /DEF = Homo sapiens Fc FCGRT −1.2 −1.2 1.0 receptor, fragment of IgG, receptor, transporter, transporter, alpha alpha (FCGRT), mRNA. /FEA = mRNA /GEN = FCGRT /PROD = Fc fragment of IgG, receptor, transporter, alpha /DB_XREF = gi: 4758345 /UG = Hs.111903 Fc fragment of IgG, receptor, transporter, alpha /FL = gb: NM_004107.1 gb: U12255.1 217963_s_at nerve growth factor gb: NM_014380.1 /DEF = Homo sapiens NGFRAP1 1.2 1.0 1.3 receptor p75NTR-associated cell death executor; (TNFRSF16) ovarian granulosa cell protein (13 kD) associated protein 1 (DXS6984E), mRNA. /FEA = mRNA /GEN = DXS6984E /PROD = p75NTR- associated cell death executor; ovariangranulosa cell protein (13 kD) /DB_XREF = gi: 7657043 /UG = Hs.17775 p75NTR-associated cell death executor; ovarian granulosa cell protein (13 kD) /FL = gb: NM_014380.1 gb: AF187064.1 209642_at BUB1 budding gb: AF043294.2 /DEF = Homo sapiens BUB1 −1.0 −50.6 −52.7 uninhibited by putative mitotic checkpoint kinase mRNA, benzimidazoles 1 complete cds. /FEA = mRNA homolog (yeast) /PROD = putative mitotic checkpoint kinase /DB_XREF = gi: 6970210 /UG = Hs.98658 budding uninhibited by benzimidazoles 1 (yeast homolog) /FL = gb: AF047471.1 gb: AF053305.1 gb: AF046078.1 gb: NM_004336.1 gb: AF043294.2 203418_at cyclin A2 gb: NM_001237.1 /DEF = Homo sapiens CCNA2 −1.0 −1.0 −72.9 cyclin A2 (CCNA2), mRNA. /FEA = mRNA /GEN = CCNA2 /PROD = cyclin A /DB_XREF = gi: 4502612 /UG = Hs.85137 cyclin A2 /FL = gb: NM_001237.1 203755_at BUB1 budding gb: NM_001211.2 /DEF = Homo sapiens BUB1B 1.1 −1.3 −1.1 uninhibited by budding uninhibited by benzimidazoles 1 benzimidazoles 1 (yeast homolog), beta (BUB1B), mRNA. homolog beta /FEA = mRNA /GEN = BUB1B (yeast) /PROD = budding uninhibited by benzimidazoles 1 (yeasthomolog), beta /DB_XREF = gi: 5729749 /UG = Hs.36708 budding uninhibited by benzimidazoles 1 (yeast homolog), beta /FL = gb: AF053306.1 gb: AF035933.1 gb: AF068760.1 gb: AF046918.1 gb: AF107297.1 gb: AF046079.2 gb: NM_001211.2 205582_s_at gamma- gb: NM_004121.1 /DEF = Homo sapiens GGTLA1 −1.0 −1.0 −55.9 glutamyltransferase- gamma-glutamyltransferase-like activity 1 like activity 1 (GGTLA1), mRNA. /FEA = mRNA /GEN = GGTLA1 /PROD = gamma- glutamyltransferase-like activity 1 /DB_XREF = gi: 4758431 /UG = Hs.1675 gamma-glutamyltransferase-like activity 1 /FL = gb: M64099.1 gb: NM_004121.1 206420_at immunoglobulin gb: NM_005849.1 /DEF = Homo sapiens IGSF6 −1.2 −1.4 −1.3 superfamily, immunoglobulin superfamily, member 6 member 6 (IGSF6), mRNA. /FEA = mRNA /GEN = IGSF6 /PROD = immunoglobulin superfamily, member 6 /DB_XREF = gi: 5031672 /UG = Hs.135194 immunoglobulin superfamily, member 6 /FL = gb: NM_005849.1 204072_s_at hypothetical gb: NM_023037.1 /DEF = Homo sapiens 13CDNA73 1.3 1.2 −1.5 protein CG003 putative gene product (13CDNA73), mRNA. /FEA = mRNA /GEN = 13CDNA73 /PROD = putative gene product /DB_XREF = gi: 12957487 /UG = Hs.181304 putative gene product /FL = gb: NM_023037.1 201798_s_at fer-1-like 3, gb: NM_013451.1 /DEF = Homo sapiens fer- FER1L3 −1.3 −1.7 −2.0 myoferlin (C. elegans) 1 (C. elegans)-like 3 (myoferlin) (FER1L3), mRNA. /FEA = mRNA /GEN = FER1L3 /PROD = fer-1 (C. elegans)-like 3 (myoferlin) /DB_XREF = gi: 7305052 /UG = Hs.234680 fer-1 (C. elegans)-like 3 (myoferlin) /FL = gb: AF182316.1 gb: NM_013451.1 203213_at cell division cycle Consensus includes gb: AL524035 CDC2 −1.0 −1.0 −1.0 2, G1 to S and G2 /FEA = EST /DB_XREF = gi: 12787528 to M /DB_XREF = est: AL524035 /CLONE = CS0DC003YN06 (3 prime) /UG = Hs.184572 cell division cycle 2, G1 to S and G2 to M /FL = gb: NM_001786.1 212681_at erythrocyte Consensus includes gb: AI770004 EPB41L3 1.6 1.1 −1.1 membrane protein /FEA = EST /DB_XREF = gi: 5236513 band 4.1-like 3 /DB_XREF = est: wh66d06.x1 /CLONE = IMAGE: 2385707 /UG = Hs.103839 erythrocyte membrane protein band 4.1-like 3 205167_s_at cell division cycle gb: NM_001790.2 /DEF = Homo sapiens cell CDC25C −1.0 −1.0 −1.0 25C division cycle 25C (CDC25C), transcript variant 1, mRNA. /FEA = mRNA /GEN = CDC25C /PROD = cell division cycle 25C protein, isoform a /DB_XREF = gi: 12408659 /UG = Hs.656 cell division cycle 25C /FL = gb: NM_001790.2 gb: M34065.1 204033_at thyroid hormone gb: NM_004237.1 /DEF = Homo sapiens TRIP13 −67.9 1.3 1.0 receptor interactor thyroid hormone receptor interactor 13 13 (TRIP13), mRNA. /FEA = mRNA /GEN = TRIP13 /PROD = thyroid hormone receptor interactor 13 /DB_XREF = gi: 11321606 /UG = Hs.6566 thyroid hormone receptor interactor 13 /FL = gb: NM_004237.1 gb: BC000404.1 gb: U96131.1 201110_s_at thrombospondin 1 gb: NM_003246.1 /DEF = Homo sapiens THBS1 1.9 86.1 61.4 thrombospondin 1 (THBS1), mRNA. /FEA = mRNA /GEN = THBS1 /PROD = thrombospondin 1 /DB_XREF = gi: 4507484 /UG = Hs.87409 thrombospondin 1 /FL = gb: NM_003246.1 210052_s_at TPX2, microtubule- gb: AF098158.1 /DEF = Homo sapiens TPX2 −61.8 −73.1 −83.2 associated protein restricted expressed proliferation homolog (Xenopus associated protein 100 mRNA, complete laevis) cds. /FEA = mRNA /PROD = restricted expressed proliferation associatedprotein 100 /DB_XREF = gi: 6073830 /UG = Hs.9329 chromosome 20 open reading frame 1 /FL = gb: NM_012112.1 gb: BC004136.1 gb: AB024704.1 gb: AF146731.1 gb: AF098158.1 gb: AB027467.1 202870_s_at CDC20 cell gb: NM_001255.1 /DEF = Homo sapiens CDC20 −1.0 −1.0 −63.0 division cycle 20 CDC20 (cell division cycle 20, S. cerevisiae, homolog (S. cerevisiae) homolog) (CDC20), mRNA. /FEA = mRNA /GEN = CDC20 /PROD = cell division cycle 20 /DB_XREF = gi: 4557436 /UG = Hs.82906 CDC20 (cell division cycle 20, S. cerevisiae, homolog) /FL = gb: BC001088.1 gb: AF099644.1 gb: NM_001255.1 gb: U05340.1 203005_at lymphotoxin beta gb: NM_002342.1 /DEF = Homo sapiens LTBR 1.2 1.5 1.2 receptor (TNFR lymphotoxin beta receptor (TNFR superfamily, superfamily, member 3 (LTBR), mRNA. member 3) /FEA = mRNA /GEN = LTBR /PROD = lymphotoxin B receptor /DB_XREF = gi: 4505038 /UG = Hs.1116 lymphotoxin beta receptor (TNFR superfamily, member 3 /FL = gb: L04270.1 gb: NM_002342.1 219607_s_at membrane- gb: NM_024021.1 /DEF = Homo sapiens MS4A4A −1.0 1.0 2.0 spanning 4- membrane-spanning 4-domains, subfamily domains subfamily A, member 4 (MS4A4), mRNA. A, member 4 /FEA = mRNA /GEN = MS4A4 /PROD = membrane-spanning 4-domains, subfamily A, member4 /DB_XREF = gi: 13430865 /UG = Hs.325960 membrane-spanning 4-domains, subfamily A, member 4 /FL = gb: AB013102.1 gb: NM_024021.1 gb: AF068288.1 gb: NM_016650.1 204887_s_at polo-like kinase 4 gb: NM_014264.1 /DEF = Homo sapiens PLK4 −1.0 −1.0 −1.2 (Drosophila) serinethreonine kinase 18 (STK18), mRNA. /FEA = mRNA /GEN = STK18 /PROD = serinethreonine kinase 18 /DB_XREF = gi: 7657626 /UG = Hs.172052 serinethreonine kinase 18 /FL = gb: NM_014264.1 204159_at cyclin-dependent gb: NM_001262.1 /DEF = Homo sapiens CDKN2C −1.0 −1.0 52.9 kinase inhibitor 2C cyclin-dependent kinase inhibitor 2C (p18, (p18, inhibits inhibits CDK4) (CDKN2C), mRNA. CDK4) /FEA = mRNA /GEN = CDKN2C /PROD = cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) /DB_XREF = gi: 4502750 /UG = Hs.4854 cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) /FL = gb: AF041248.1 gb: NM_001262.1 220832_at toll-like receptor 8 gb: NM_016610.1 /DEF = Homo sapiens TLR8 1.4 −2.0 −95.0 Toll-like receptor 8 (LOC51311), mRNA. /FEA = mRNA /GEN = LOC51311 /PROD = Toll-like receptor 8 /DB_XREF = gi: 7706147 /UG = Hs.272410 Toll-like receptor 8 /FL = gb: AF246971.1 gb: NM_016610.1 gb: AF245703.1 204112_s_at histamine N- gb: NM_006895.1 /DEF = Homo sapiens HNMT 1.1 −1.2 1.1 methyltransferase histamine N-methyltransferase (HNMT), mRNA. /FEA = mRNA /GEN = HNMT /PROD = histamine N-methyltransferase /DB_XREF = gi: 5901969 /UG = Hs.81182 histamine N-methyltransferase /FL = gb: U08092.1 gb: D16224.1 gb: NM_006895.1 206148_at interleukin 3 gb: NM_002183.1 /DEF = Homo sapiens IL3RA −1.0 −1.0 −1.0 receptor, alpha interleukin 3 receptor, alpha (low affinity) (low affinity) (IL3RA), mRNA. /FEA = mRNA /GEN = IL3RA /PROD = interleukin 3 receptor, alpha (low affinity) /DB_XREF = gi: 13324709 /UG = Hs.172689 interleukin 3 receptor, alpha (low affinity) /FL = gb: NM_002183.1 gb: M74782.1 202087_s_at cathepsin L gb: NM_001912.1 /DEF = Homo sapiens CTSL 1.2 −1.5 1.4 cathepsin L (CTSL), mRNA. /FEA = mRNA /GEN = CTSL /PROD = cathepsin L /DB_XREF = gi: 4503154 /UG = Hs.78056 cathepsin L /FL = gb: NM_001912.1 218308_at transforming, gb: NM_006342.1 /DEF = Homo sapiens TACC3 1.1 −1.1 1.0 acidic coiled-coil transforming, acidic coiled-coil containing containing protein 3 protein 3 (TACC3), mRNA. /FEA = mRNA /GEN = TACC3 /PROD = transforming acidic coiled-coil containingprotein 3 /DB_XREF = gi: 5454101 /UG = Hs.104019 transforming, acidic coiled-coil containing protein 3 /FL = gb: AF093543.1 gb: NM_006342.1 208322_s_at sialyltransferase gb: NM_003033.1 /DEF = Homo sapiens SIAT4A 1.1 −1.2 1.2 4A (beta- sialyltransferase 4A (beta-galactosidase galactoside alpha- alpha-2,3-sialytransferase) (SIAT4A), 2,3- mRNA. /FEA = mRNA /GEN = SIAT4A sialyltransferase) /PROD = sialyltransferase 4A (beta- galactosidasealpha-2,3-sialytransferase) /DB_XREF = gi: 4506950 /UG = Hs.301698 sialyltransferase 4A (beta-galactosidase alpha-2,3-sialytransferase) /FL = gb: L13972.1 gb: NM_003033.1 gb: L29555.1 213226_at exosome Consensus includes gb: AI346350 CCNA2 −1.3 −1.4 −69.4 component 9 /FEA = EST /DB_XREF = gi: 4083556 /DB_XREF = est: qp50c06.x1 /CLONE = IMAGE: 1926442 /UG = Hs.91728 polymyositisscleroderma autoantigen 1 (75 kD) 205345_at BRCA1 associated gb: NM_000465.1 /DEF = Homo sapiens BARD1 79.0 −1.3 −1.2 RING domain 1 BRCA1 associated RING domain 1 (BARD1), mRNA. /FEA = mRNA /GEN = BARD1 /PROD = BRCA1 associated RING domain 1 /DB_XREF = gi: 4557348 /UG = Hs.54089 BRCA1 associated RING domain 1 /FL = gb: U76638.1 gb: NM_000465.1 203485_at reticulon 1 gb: NM_021136.1 /DEF = Homo sapiens RTN1 1.3 −1.3 −1.7 reticulon 1 (RTN1), mRNA. /FEA = mRNA /GEN = RTN1 /PROD = reticulon 1 /DB_XREF = gi: 10863934 /UG = Hs.99947 reticulon 1 /FL = gb: NM_021136.1 gb: L10333.1 gb: L10334.1 211336_x_at leukocyte gb: AF009007.1 /DEF = Homo sapiens LILRB1 −1.1 −1.2 1.0 immunoglobulin- immunoglobulin-like transcript 2c mRNA, like receptor, complete cds. /FEA = mRNA subfamily B (with /PROD = immunoglobulin-like transcript 2c TM and ITIM /DB_XREF = gi: 2660705 /UG = Hs.204040 domains), member 1 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1 /FL = gb: AF009007.1 206978_at Transcribed gb: NM_000647.2 /DEF = Homo sapiens CCR2 1.2 −1.4 −1.6 sequences chemokine (C-C motif) receptor 2 (CCR2), mRNA. /FEA = mRNA /GEN = CCR2 /PROD = chemokine (C-C motif) receptor 2 /DB_XREF = gi: 4827072 /UG = Hs.395 chemokine (C-C motif) receptor 2 /FL = gb: U03882.1 gb: NM_000647.2 200853_at H2A histone family, gb: NM_002106.1 /DEF = Homo sapiens 1.3 −1.3 −1.3 member Z H2A histone family, member Z (H2AFZ), mRNA. /FEA = mRNA /GEN = H2AFZ /PROD = H2A histone family, member Z /DB_XREF = gi: 4504254 /UG = Hs.119192 H2A histone family, member Z /FL = gb: M37583.1 gb: NM_002106.1 204558_at RAD54-like (S. cerevisiae) gb: NM_003579.1 /DEF = Homo sapiens RAD54L −1.0 −1.0 −1.0 RAD54 (S. cerevisiae)-like (RAD54L), mRNA. /FEA = mRNA /GEN = RAD54L /PROD = RAD54 (S. cerevisiae)-like /DB_XREF = gi: 4506396 /UG = Hs.66718 RAD54 (S. cerevisiae)-like /FL = gb: NM_003579.1 218662_s_at chromosome gb: NM_022346.1 /DEF = Homo sapiens HCAP-G −1.0 −1.0 −51.5 condensation chromosome condensation protein G protein G (HCAP-G), mRNA. /FEA = mRNA /GEN = HCAP-G /PROD = chromosome condensation protein G /DB_XREF = gi: 11641252 /UG = Hs.193602 chromosome condensation protein G /FL = gb: AF235023.1 gb: NM_022346.1 gb: AF331796.1 gb: BC000827.1 gb: AB013299.1 209531_at glutathione gb: BC001453.1 /DEF = Homo sapiens, GSTZ1 −109.4 −1.2 1.1 transferase zeta 1 glutathione transferase zeta 1 (maleylacetoacetate (maleylacetoacetate isomerase), clone isomerase) MGC: 2029, mRNA, complete cds. /FEA = mRNA /PROD = glutathione transferase zeta 1(maleylacetoacetate isomerase) /DB_XREF = gi: 12655190 /UG = Hs.26403 glutathione transferase zeta 1 (maleylacetoacetate isomerase) /FL = gb: BC001453.1 gb: U86529.1 gb: NM_001513.1 211519_s_at kinesin family gb: AY026505.1 /DEF = Homo sapiens KIF2C −1.4 −1.1 1.1 member 2C testis specific mitotic centromere- associated kinesin mRNA, complete cds. /FEA = mRNA /PROD = testis specific mitotic centromere-associatedkinesin /DB_XREF = gi: 13432054 /UG = Hs.69360 kinesin-like 6 (mitotic centromere- associated kinesin) /FL = gb: AY026505.1 202954_at ubiquitin- gb: NM_007019.1 /DEF = Homo sapiens UBE2C 1.1 1.0 −1.1 conjugating ubiquitin carrier protein E2-C (UBCH10), enzyme E2C mRNA. /FEA = mRNA /GEN = UBCH10 /PROD = ubiquitin carrier protein E2-C /DB_XREF = gi: 5902145 /UG = Hs.93002 ubiquitin carrier protein E2-C /FL = gb: U73379.1 gb: NM_007019.1 203232_s_at spinocerebellar gb: NM_000332.1 /DEF = Homo sapiens ATXN1 1.7 1.2 −1.4 ataxia 1 spinocerebellar ataxia 1 (olivopontocerebellar (olivopontocerebellar ataxia 1, autosomal ataxia 1, dominant, ataxin 1) (SCA1), mRNA. autosomal /FEA = mRNA /GEN = SCA1 /PROD = ataxin dominant, ataxin 1) 1 /DB_XREF = gi: 4506792 /UG = Hs.74520 spinocerebellar ataxia 1 (olivopontocerebellar ataxia 1, autosomal dominant, ataxin 1) /FL = gb: NM_000332.1 204798_at v-myb gb: NM_005375.1 /DEF = Homo sapiens v- MYB 1.4 1.1 −1.4 myeloblastosis myb avian myeloblastosis viral oncogene viral oncogene homolog (MYB), mRNA. /FEA = mRNA homolog (avian) /GEN = MYB /PROD = v-myb avian myeloblastosis viral oncogenehomolog /DB_XREF = gi: 4885496 /UG = Hs.1334 v- myb avian myeloblastosis viral oncogene homolog /FL = gb: M15024.1 gb: AF104863.1 gb: NM_005375.1 203887_s_at thrombomodulin gb: NM_000361.1 /DEF = Homo sapiens THBD −1.2 1.1 52.6 thrombomodulin (THBD), mRNA. /FEA = mRNA /GEN = THBD /PROD = thrombomodulin /DB_XREF = gi: 4507482 /UG = Hs.2030 thrombomodulin /FL = gb: M16552.1 gb: NM_000361.1 204962_s_at centromere protein gb: NM_001809.2 /DEF = Homo sapiens CENPA −1.0 −1.0 −52.3 A, 17 kDa centromere protein A (17 kD) (CENPA), mRNA. /FEA = mRNA /GEN = CENPA /PROD = centromere protein A /DB_XREF = gi: 4585861 /UG = Hs.1594 centromere protein A (17 kD) /FL = gb: NM_001809.2 gb: U14518.1 203923_s_at cytochrome b-245, gb: NM_000397.2 /DEF = Homo sapiens CYBB 1.1 −1.2 −1.3 beta polypeptide cytochrome b-245, beta polypeptide (chronic (chronic granulomatous disease) (CYBB), granulomatous mRNA. /FEA = mRNA /GEN = CYBB disease) /PROD = cytochrome b-245, beta polypeptide (chronicgranulomatous disease) /DB_XREF = gi: 6996020 /UG = Hs.88974 cytochrome b-245, beta polypeptide (chronic granulomatous disease) /FL = gb: NM_000397.2 201809_s_at endoglin (Osler- gb: NM_000118.1 /DEF = Homo sapiens ENG 1.2 −1.4 1.2 Rendu-Weber endoglin (Osler-Rendu-Weber syndrome syndrome 1) 1) (ENG), mRNA. /FEA = mRNA /GEN = ENG /PROD = endoglin precursor /DB_XREF = gi: 4557554 /UG = Hs.76753 endoglin (Osler-Rendu-Weber syndrome 1) /FL = gb: NM_000118.1 214560_at formyl peptide Consensus includes gb: NM_002030.2 FPRL2 −1.3 −1.2 1.0 receptor-like 2 /DEF = Homo sapiens formyl peptide receptor-like 2 (FPRL2), mRNA. /FEA = CDS /GEN = FPRL2 /PROD = formyl peptide receptor-like 2 /DB_XREF = gi: 4758401 /UG = Hs.158314 formyl peptide receptor-like 2 /FL = gb: M76673.1 gb: NM_002030.2 218039_at nucleolar and gb: NM_016359.1 /DEF = Homo sapiens NUSAP1 1.2 −1.2 −1.4 spindle associated clone HQ0310 PRO0310p1 (LOC51203), protein 1 mRNA. /FEA = mRNA /GEN = LOC51203 /PROD = clone HQ0310 PRO0310p1 /DB_XREF = gi: 7705950 /UG = Hs.279905 clone HQ0310 PRO0310p1 /FL = gb: AF305711.1 gb: BC001308.1 gb: AF290612.1 gb: AF090915.1 gb: NM_016359.1 213754_s_at tripartite motif- Consensus includes gb: AW613203 PAIP1 69.5 1.0 1.2 containing 26 /FEA = EST /DB_XREF = gi: 7318389 /DB_XREF = est: hh67h11.x1 /CLONE = IMAGE: 2967909 /UG = Hs.109643 polyadenylate binding protein-interacting protein 1 218264_at BRCA2 and gb: NM_016567.1 /DEF = Homo sapiens BCCIP 53.2 50.0 −1.0 CDKN1A cdk inhibitor p21 binding protein (TOK-1), interacting protein mRNA. /FEA = mRNA /GEN = TOK-1 /PROD = cdk inhibitor p21 binding protein /DB_XREF = gi: 7706580 /UG = Hs.279862 cdk inhibitor p21 binding protein /FL = gb: AB040450.1 gb: NM_016567.1 219211_at ubiquitin specific gb: NM_017414.1 /DEF = Homo sapiens USP18 −1.0 −183.7 1.0 protease 18 ubiquitin specific protease 18 (USP18), mRNA. /FEA = mRNA /GEN = USP18 /PROD = ubiquitin specific protease 18 /DB_XREF = gi: 8394518 /UG = Hs.38260 ubiquitin specific protease 18 /FL = gb: AL136690.1 gb: AF176642.2 gb: NM_017414.1 204638_at acid phosphatase gb: NM_001611.2 /DEF = Homo sapiens ACP5 1.0 −1.3 −1.1 5, tartrate resistant acid phosphatase 5, tartrate resistant (ACP5), mRNA. /FEA = mRNA /GEN = ACP5 /PROD = tartrate resistant acid phosphatase 5 precursor /DB_XREF = gi: 6138970 /UG = Hs.1211 acid phosphatase 5, tartrate resistant /FL = gb: J04430.1 gb: NM_001611.2 206461_x_at metallothionein 1H gb: NM_005951.1 /DEF = Homo sapiens MT1H 1.2 −1.9 −1.2 metallothionein 1H (MT1H), mRNA. /FEA = mRNA /GEN = MT1H /PROD = metallothionein 1H /DB_XREF = gi: 10835084 /UG = Hs.2667 metallothionein 1H /FL = gb: NM_005951.1 204641_at NIMA (never in gb: NM_002497.1 /DEF = Homo sapiens NEK2 −1.0 −1.0 −1.0 mitosis gene a)- NIMA (never in mitosis gene a)-related related kinase 2 kinase 2 (NEK2), mRNA. /FEA = mRNA /GEN = NEK2 /PROD = NIMA (never in mitosis gene a)-related kinase 2 /DB_XREF = gi: 4505372 /UG = Hs.153704 NIMA (never in mitosis gene a)-related kinase 2 /FL = gb: NM_002497.1 gb: U11050.1 201041_s_at dual specificity gb: NM_004417.2 /DEF = Homo sapiens DUSP1 1.4 −1.1 1.0 phosphatase 1 dual specificity phosphatase 1 (DUSP1), mRNA. /FEA = mRNA /GEN = DUSP1 /PROD = dual specificity phosphatase 1 /DB_XREF = gi: 7108342 /UG = Hs.171695 dual specificity phosphatase 1 /FL = gb: NM_004417.2 204531_s_at breast cancer 1, gb: NM_007295.1 /DEF = Homo sapiens BRCA1 −1.0 −1.0 −1.0 early onset breast cancer 1, early onset (BRCA1), transcript variant BRCA1b, mRNA. /FEA = mRNA /GEN = BRCA1 /PROD = breast cancer 1, early onset /DB_XREF = gi: 6552300 /UG = Hs.194143 breast cancer 1, early onset /FL = gb: NM_007295.1 202218_s_at fatty acid gb: NM_004265.1 /DEF = Homo sapiens FADS2 −1.4 1.1 −2.0 desaturase 2 delta-6 fatty acid desaturase (FADSD6), mRNA. /FEA = mRNA /GEN = FADSD6 /PROD = delta-6 fatty acid desaturase /DB_XREF = gi: 4758333 /UG = Hs.184641 fatty acid desaturase 2 /FL = gb: AF084559.1 gb: AF126799.1 gb: NM_004265.1 201292_at topoisomerase Consensus includes gb: AL561834 TOP2A −1.0 −1.0 −1.0 (DNA) II alpha /FEA = EST /DB_XREF = gi: 12909658 170 kDa /DB_XREF = est: AL561834 /CLONE = CS0DB005YC15 (3 prime) /UG = Hs.156346 topoisomerase (DNA) II alpha (170 kD) /FL = gb: J04088.1 gb: NM_001067.1 212298_at neuropilin 1 Consensus includes gb: BE620457 NRP1 1.6 1.4 1.2 /FEA = EST /DB_XREF = gi: 9891395 /DB_XREF = est: 601483690F1 /CLONE = IMAGE: 3886055 /UG = Hs.69285 neuropilin 1 /FL = gb: AF018956.1 gb: AF016050.1 gb: NM_003873.1 204249_s_at LIM domain only 2 gb: NM_005574.2 /DEF = Homo sapiens LMO2 1.0 −1.5 −1.3 (rhombotin-like 1) LIM domain only 2 (rhombotin-like 1) (LMO2), mRNA. /FEA = mRNA /GEN = LMO2 /PROD = LIM domain only 2 /DB_XREF = gi: 6633806 /UG = Hs.184585 LIM domain only 2 (rhombotin-like 1) /FL = gb: NM_005574.2 203167_at tissue inhibitor of gb: NM_003255.2 /DEF = Homo sapiens TIMP2 1.2 −1.9 1.1 metalloproteinase 2 tissue inhibitor of metalloproteinase 2 (TIMP2), mRNA. /FEA = mRNA /GEN = TIMP2 /PROD = tissue inhibitor of metalloproteinase 2precursor /DB_XREF = gi: 9257247 /UG = Hs.325495 tissue inhibitor of metalloproteinase 2 /FL = gb: M32304.1 gb: J05593.1 gb: NM_003255.2 214637_at oncostatin M Consensus includes gb: BG437034 OSM −1.1 −1.0 −1.0 /FEA = EST /DB_XREF = gi: 13343540 /DB_XREF = est: 602488622F1 /CLONE = IMAGE: 4620821 /UG = Hs.248156 oncostatin M /FL = gb: NM_020530.1 203535_at S100 calcium gb: NM_002965.2 /DEF = Homo sapiens S100A9 −1.1 −1.4 −1.5 binding protein A9 S100 calcium-binding protein A9 (calgranulin B) (calgranulin B) (S100A9), mRNA. /FEA = mRNA /GEN = S100A9 /PROD = S100 calcium-binding protein A9 /DB_XREF = gi: 9845520 /UG = Hs.112405 S100 calcium-binding protein A9 (calgranulin B) /FL = gb: M26311.1 gb: NM_002965.2 221463_at chemokine (C-C gb: NM_002991.1 /DEF = Homo sapiens CCL24 2.4 −1.0 −56.9 motif) ligand 24 small inducible cytokine subfamily A (Cys- Cys), member 24 (SCYA24), mRNA. /FEA = CDS /GEN = SCYA24 /PROD = small inducible cytokine subfamily A (Cys- Cys), member 24 /DB_XREF = gi: 4506838 /UG = Hs.247838 small inducible cytokine subfamily A (Cys-Cys), member 24 /FL = gb: U85768.1 gb: NM_002991.1 204194_at BTB and CNC gb: NM_001186.1 /DEF = Homo sapiens BACH1 1.5 −1.3 −1.3 homology 1, basic BTB and CNC homology 1, basic leucine leucine zipper zipper transcription factor 1 (BACH1), transcription factor 1 mRNA. /FEA = mRNA /GEN = BACH1 /PROD = BTB and CNC homology 1, basic leucine zippertranscription factor 1 /DB_XREF = gi: 4502352 /UG = Hs.154276 BTB and CNC homology 1, basic leucine zipper transcription factor 1 /FL = gb: AB002803.1 gb: NM_001186.1 210784_x_at leukocyte gb: AF009634.1 /DEF = Homo sapiens LILRB3 1.0 −1.2 −1.2 immunoglobulin- clone 17.6 immunoglobulin-like transcript like receptor, 5 protein mRNA, complete cds. subfamily B (with /FEA = mRNA /PROD = immunoglobulin-like TM and ITIM transcript 5 protein /DB_XREF = gi: 2662427 domains), member 3 /UG = Hs.105928 leukocyte immunoglobulin like receptor, subfamily B (with TM and ITIM domains), member 3 /FL = gb: AF009634.1 gb: AF009636.1 gb: AF009640.1 201785_at ribonuclease, gb: NM_002933.1 /DEF = Homo sapiens RNASE1 1.0 1.2 2.2 RNase A family, 1 ribonuclease, RNase A family, 1 (pancreatic) (pancreatic) (RNASE1), mRNA. /FEA = mRNA /GEN = RNASE1 /PROD = ribonuclease, RNase A family, 1 (pancreatic) /DB_XREF = gi: 4506546 /UG = Hs.78224 ribonuclease, RNase A family, 1 (pancreatic) /FL = gb: BC005324.1 gb: NM_002933.1 gb: D26129.1 214146_s_at pro-platelet basic Consensus includes gb: R64130 PPBP 1.5 1.1 1.6 protein (chemokine /FEA = EST /DB_XREF = gi: 836009 (C—X—C motif) /DB_XREF = est: yi18h03.s1 ligand 7) /CLONE = IMAGE: 139637 /UG = Hs.2164 pro-platelet basic protein (includes platelet basic protein, beta-thromboglobulin, connective tissue-activating peptide III, neutrophil-activating peptide-2) 206214_at phospholipase A2, gb: NM_005084.1 /DEF = Homo sapiens PLA2G7 1.2 −1.3 1.1 group VII (platelet- phospholipase A2, group VII (platelet- activating factor activating factor acetylhydrolase, plasma) acetylhydrolase, (PLA2G7), mRNA. /FEA = mRNA plasma) /GEN = PLA2G7 /PROD = phospholipase A2, group VII (platelet-activatingfactor acetylhydrolase, plasma) /DB_XREF = gi: 4826883 /UG = Hs.93304 phospholipase A2, group VII (platelet- activating factor acetylhydrolase, plasma) /FL = gb: U24577.1 gb: NM_005084.1 gb: U20157.1 218355_at kinesin family member gb: NM_012310.2 /DEF = Homo KIF4A −1.0 −1.0 −1.0 sapiens kinesin family member 4A (KIF4A), mRNA. /FEA = mRNA /GEN = KIF4A /PROD = kinesin family member 4 /DB_XREF = gi: 7305204 /UG = Hs.279766 kinesin family member 4A /FL = gb: AF179308.1 gb: AF071592.2 gb: NM_012310.2 216950_s_at Fc fragment of IgG, hi

Consensus includes gb: X14355.1 FCGR1A 1.0 −1.1 −1.2 /DEF = Human mRNA for high affinity Fc receptor (FcRI) b form. /FEA = mRNA /DB_XREF = gi: 31333 /UG = Hs.77424 Fc fragment of IgG, high affinity Ia, receptor for (CD64) 209464_at aurora kinase B gb: AB011446.1 /DEF = Homo AURKB −1.0 −1.0 −1.1 sapiens mRNA for Aik2, complete cds. /FEA = mRNA /GEN = aik2 /PROD = Aik2 /DB_XREF = gi: 5688865 /UG = Hs.180655 serinethreonine kinase 12 /FL = gb: BC000442.1 gb: AF004022.1 gb: AF008552.1 gb: AB011450.1 gb: AF015254.1 gb: NM_004217.1 gb: AB011446.1 202191_s_at growth arrest-specific Consensus includes gb: BE439987 GAS7 1.2 −1.4 −1.1 /FEA = EST /DB_XREF = gi: 9439470 /DB_XREF = est: HTM1-745F /UG = Hs.226133 growth arrest- specific 7 /FL = gb: AB007854.1 gb: NM_005890.1 205769_at solute carrier family 27 gb: NM_003645.1 /DEF = Homo SLC27A2 −1.0 −1.0 −1.0 sapiens fatty-acid-Coenzyme A ligase, very long-chain 1 (FACVL1), mRNA. /FEA = mRNA /GEN = FACVL1 /PROD = very long- chain fatty-acid-Coenzyme A ligase 1 /DB_XREF = gi: 4503652 /UG = Hs.11729 fatty-acid- Coenzyme A ligase, very long- chain 1 /FL = gb: D88308.1 gb: AF096290.1 gb: NM_003645.1 209714_s_at cyclin-dependent kinas gb: AF213033.1 /DEF = Homo CDKN3 −1.3 −1.0 −1.2 sapiens isolate BX-01 cyclin- dependent kinase associated protein phosphatase mRNA, complete cds. /FEA = mRNA /PROD = cyclin-dependent kinase associated proteinphosphatase /DB_XREF = gi: 12734643 /UG = Hs.84113 cyclin-dependent kinase inhibitor 3 (CDK2- associated dual specificity phosphatase) /FL = gb: AF213033.1 gb: AF213034.1 gb: AF213035.1 gb: AF213036.1 gb: AF213037.1 gb: AF213038.1 gb: AF213039.1 gb: AF213040.1 gb: AF213041.1 gb: AF213042.1 gb: AF213044.1 gb: AF213046.1 gb: AF213047.1 gb: AF213048.1 gb: AF213049.1 gb: AF213050.1 gb: AF213051.1 gb: AF213052.1 gb: AF213053.1 gb: U02681.1 gb: L25876.1 gb: NM_005192.1 gb: L27711.1 203145_at sperm associated anti

gb: NM_006461.1 /DEF = Homo SPAG5 1.1 1.3 94.7 sapiens mitotic spindle coiled-coil related protein (DEEPEST), mRNA. /FEA = mRNA /GEN = DEEPEST /PROD = mitotic spindle coiled-coil related protein /DB_XREF = gi: 5453631 /UG = Hs.16244 mitotic spindle coiled-coil related protein /FL = gb: BC000322.1 gb: AF063308.1 gb: NM_006461.1 205119_s_at formyl peptide recepto gb: NM_002029.1 /DEF = Homo 1.3 −1.0 −1.4 sapiens formyl peptide receptor 1 (FPR1), mRNA. /FEA = mRNA /GEN = FPR1 /PROD = formyl peptide receptor 1 /DB_XREF = gi: 4503778 /UG = Hs.753 formyl peptide receptor 1 /FL = gb: BC005315.1 gb: M60626.1 gb: M60627.1 gb: NM_002029.1 204759_at chromosome condens

gb: NM_001268.1 /DEF = Homo CHC1L 1.6 −1.0 1.2 sapiens chromosome condensation 1-like (CHC1L), mRNA. /FEA = mRNA /GEN = CHC1L /PROD = RCC1-like G exchanging factor RLG /DB_XREF = gi: 4557444 /UG = Hs.27007 chromosome condensation 1-like /FL = gb: AF060219.1 gb: NM_001268.1 201666_at tissue inhibitor of meta gb: NM_003254.1 /DEF = Homo TIMP1 1.0 −1.3 1.0 sapiens tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) (TIMP1), mRNA. /FEA = mRNA /GEN = TIMP1 /PROD = tissue inhibitor of metalloproteinase 1precursor /DB_XREF = gi: 4507508 /UG = Hs.5831 tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) /FL = gb: BC000866.1 gb: M12670.1 gb: M59906.1 gb: NM_003254.1 217996_at pleckstrin homology-lik Consensus includes gb: AA576961 PHLDA1 1.2 63.7 −66.0 /FEA = EST /DB_XREF = gi: 2354435 /DB_XREF = est: nm82d08.s1 /CLONE = IMAGE: 1074735 /UG = Hs.82101 pleckstrin homology-like domain, family A, member 1 /FL = gb: NM_007350.1 209709_s_at hyaluronan-mediated r gb: U29343.1 /DEF = Homo sapiens HMMR −71.2 −1.0 −74.3 hyaluronan receptor (RHAMM) mRNA, complete cds. /FEA = mRNA /GEN = RHAMM /PROD = hyaluronan receptor /DB_XREF = gi: 2959555 /UG = Hs. 72550 hyaluronan- mediated motility receptor (RHAMM) /FL = gb: U29343.1 gb: AF032862.1 gb: NM_012484.1 202388_at regulator of G-protein

gb: NM_002923.1 /DEF = Homo RGS2 1.4 1.2 1.3 sapiens regulator of G-protein signalling 2, 24 kD (RGS2), mRNA. /FEA = mRNA /GEN = RGS2 /PROD = regulator of G-protein signalling 2, 24 kD /DB_XREF = gi: 4506516 /UG = Hs.78944 regulator of G- protein signalling 2, 24 kD /FL = gb: L13463.1 gb: NM_002923.1 204092_s_at serine/threonine kinas

gb: NM_003600.1 /DEF = Homo STK6 −1.0 −60.9 55.8 sapiens serinethreonine kinase 15 (STK15), mRNA. /FEA = mRNA /GEN = STK15 /PROD = serinethreonine kinase 15 /DB_XREF = gi: 4507274 /UG = Hs.48915 serinethreonine kinase 15 /FL = gb: AF008551.1 gb: AF011468.1 gb: NM_003600.1 204446_s_at arachidonate 5-lipoxyg gb: NM_000698.1 /DEF = Homo ALOX5 1.2 −1.3 −1.3 sapiens arachidonate 5- lipoxygenase (ALOX5), mRNA. /FEA = mRNA /GEN = ALOX5 /PROD = arachidonate 5- lipoxygenase /DB_XREF = gi: 4502056 /UG = Hs.89499 arachidonate 5- lipoxygenase /FL = gb: J03600.1 gb: J03571.1 gb: NM_000698.1 203126_at inositol(myo)-1(or 4)-

gb: NM_014214.1 /DEF = Homo IMPA2 −1.0 −1.7 1.0 sapiens inositol(myo)-1(or 4)- monophosphatase 2 (IMPA2), mRNA. /FEA = mRNA /GEN = IMPA2 /PROD = inositol(myo)-1(or 4)- monophosphatase 2 /DB_XREF = gi: 7657235 /UG = Hs.5753 inositol(myo)-1(or 4)- monophosphatase 2 /FL = gb: AF200432.1 gb: NM_014214.1 gb: AF014398.2 208581_x_at metallothionein 1X gb: NM_005952.1 /DEF = Homo MT1X 1.2 −1.4 −1.5 sapiens metallothionein 1X (MT1X), mRNA. /FEA = CDS /GEN = MT1X /PROD = metallothionein 1X /DB_XREF = gi: 10835231 /UG = Hs.278462 metallothionein 1X /FL = gb: NM_005952.1 219890_at C-type (calcium depen

gb: NM_013252.1 /DEF = Homo CLECSF5 1.5 −1.0 −1.2 sapiens C-type (calcium dependent, carbohydrate- recognition domain) lectin, superfamily member 5 (CLECSF5), mRNA. /FEA = mRNA /GEN = CLECSF5 /PROD = C-type (calcium dependent, carbohydrate- recognition domain) lectin, superfamilymember 5 /DB_XREF = gi: 10281668 /UG = Hs.126355 C-type (calcium dependent, carbohydrate- recognition domain) lectin, superfamily member 5 /FL = gb: NM_013252.1 gb: AF139768.1 209773_s_at ribonucleotide reducta

gb: BC001886.1 /DEF = Homo RRM2 −1.9 −1.5 −1.5 sapiens, ribonucleotide reductase M2 polypeptide, clone MGC: 1551, mRNA, complete cds. /FEA = mRNA /PROD = ribonucleotide reductase M2 polypeptide /DB_XREF = gi: 12804874 /UG = Hs.75319 ribonucleotide reductase M2 polypeptide /FL = gb: BC001886.1 202705_at cyclin B2 gb: NM_004701.2 /DEF = Homo CCNB2 −1.0 −1.3 1.0 sapiens cyclin B2 (CCNB2), mRNA. /FEA = mRNA /GEN = CCNB2 /PROD = cyclin B2 /DB_XREF = gi: 10938017 /UG = Hs.194698 cyclin B2 /FL = gb: NM_004701.2 gb: AF002822.1 gb: AB020981.1 gb: AL080146.1 205098_at chemokine (C-C motif) Consensus includes gb: AI421071 −1.1 −1.7 −1.1 /FEA = EST /DB_XREF = gi: 4267002 /DB_XREF = est: tf24a02.x1 /CLONE = IMAGE: 2097098 /UG = Hs.301921 chemokine (C-C motif) receptor 1 /FL = gb: L09230.1 gb: L10918.1 gb: NM_001295.1 204438_at mannose receptor, C t

gb: NM_002438.1 /DEF = Homo MRC1 1.1 −1.5 −1.6 sapiens mannose receptor, C type 1 (MRC1), mRNA. /FEA = mRNA /GEN = MRC1 /PROD = mannose receptor, C type 1 /DB_XREF = gi: 4505244 /UG = Hs.75182 mannose receptor, C type 1 /FL = gb: J05550.1 gb: NM_002438.1 201438_at collagen, type VI, alpha

gb: NM_004369.1 /DEF = Homo COL6A3 −1.0 −1.0 −1.0 sapiens collagen, type VI, alpha 3 (COL6A3), mRNA. /FEA = mRNA /GEN = COL6A3 /PROD = collagen, type VI, alpha 3 /DB_XREF = gi: 4758027 /UG = Hs.80988 collagen, type VI, alpha 3 /FL = gb: NM_004369.1 207067_s_at histidine decarboxylase

gb: NM_002112.1 /DEF = Homo HDC −1.3 −1.0 −1.2 sapiens histidine decarboxylase (HDC), mRNA. /FEA = mRNA /GEN = HDC /PROD = histidine decarboxylase /DB_XREF = gi: 4504364 /UG = Hs.1481 histidine decarboxylase /FL = gb: M60445.1 gb: NM_002112.1 220088_at G protein-coupled rece

gb: NM_001736.1 /DEF = Homo C5R1 1.2 −1.1 1.1 sapiens complement component 5 receptor 1 (C5a ligand) (C5R1), mRNA. /FEA = mRNA /GEN = C5R1 /PROD = complement component 5 receptor 1 (C5a ligand) /DB_XREF = gi: 4502508 /UG = Hs.2161 complement component 5 receptor 1 (C5a ligand) /FL = gb: M62505.1 gb: NM_001736.1 204614_at serine (or cysteine) pro

gb: NM_002575.1 /DEF = Homo SERPINB2 1.4 1.2 1.3 sapiens serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2 (SERPINB2), mRNA. /FEA = mRNA /GEN = SERPINB2 /PROD = serine (or cysteine) proteinase inhibitor, cladeB (ovalbumin), member 2 /DB_XREF = gi: 4505594 /UG = Hs.75716 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2 /FL = gb: J02685.1 gb: J03603.1 gb: M18082.1 gb: NM_002575.1 204039_at CCAAT/enhancer bind

gb: NM_004364.1 /DEF = Homo CEBPA 1.3 −1.1 −1.1 sapiens CCAATenhancer binding protein (CEBP), alpha (CEBPA), mRNA. /FEA = mRNA /GEN = CEBPA /PROD = CCAATenhancer binding protein (CEBP), alpha /DB_XREF = gi: 4757971 /UG = Hs.76171 CCAATenhancer binding protein (CEBP), alpha /FL = gb: NM_004364.1 205786_s_at integrin, alpha M (com

gb: NM_000632.2 /DEF = Homo ITGAM 1.0 −1.2 −1.6 sapiens integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macrophage antigen alpha polypeptide) (ITGAM), mRNA. /FEA = mRNA /GEN = ITGAM /PROD = integrin alpha M precursor /DB_XREF = gi: 6006013 /UG = Hs.172631 integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macrophage antigen alpha polypeptide) /FL = gb: J03925.1 gb: NM_000632.2 201739_at serum/glucocorticoid re

gb: NM_005627.1 /DEF = Homo SGK 1.3 1.0 1.0 sapiens serumglucocorticoid regulated kinase (SGK), mRNA. /FEA = mRNA /GEN = SGK /PROD = serumglucocorticoid regulated kinase /DB_XREF = gi: 5032090 /UG = Hs.296323 serumglucocorticoid regulated kinase /FL = gb: BC001263.1 gb: NM_005627.1 gb: AF153609.1 209949_at neutrophil cytosolic fac

gb: BC001606.1 /DEF = Homo NCF2 1.2 −1.4 −1.5 sapiens, Similar to neutrophil cytosolic factor 2 (65 kD, chronic granulomatous disease, autosomal 2), clone MGC: 2275, mRNA, complete cds. /FEA = mRNA /PROD = Similar to neutrophil cytosolic factor 2 (65 kD, chronic granulomatous disease, autosomal 2) /DB_XREF = gi: 12804408 /UG = Hs.949 neutrophil cytosolic factor 2 (65 kD, chronic granulomatous disease, autosomal 2) /FL = gb: BC001606.1 gb: M32011.1 gb: NM_000433.1 221210_s_at N-acetylneuraminate p

gb: NM_030769.1 /DEF = Homo NPL 1.5 −1.1 1.1 sapiens hypothetical protein similar to swine acylneuraminate lyase (C1ORF13), mRNA. /FEA = mRNA /GEN = C1ORF13 /PROD = hypothetical protein similar to swineacylneuraminate lyase /DB_XREF = gi: 13540532 /FL = gb: NM_030769.1 203554_x_at pituitary tumor-transfor

gb: NM_004219.2 /DEF = Homo PTTG1 −1.5 −1.2 −1.2 sapiens pituitary tumor- transforming 1 (PTTG1), mRNA. /FEA = mRNA /GEN = PTTG1 /PROD = pituitary tumor- transforming protein 1 /DB_XREF = gi: 11038651 /UG = Hs.252587 pituitary tumor- transforming 1 /FL = gb: NM_004219.2 gb: AF095287.1 gb: AF062649.1 gb: AF075242.1 210184_at integrin, alpha X (antig

gb: M81695.1 /DEF = H. sapiens ITGAX 1.1 −1.0 −1.2 leukocyte adhesion glycoprotein p150, 95 mRNA, complete cds. /FEA = mRNA /GEN = ITGAX /DB_XREF = gi: 487829 /UG = Hs.51077 integrin, alpha X (antigen CD11C (p150), alpha polypeptide) /FL = gb: M81695.1 gb: NM_000887.2 208079_s_at serine/threonine kinase

gb: NM_003158.1 /DEF = Homo STK6 −1.0 −1.0 1.1 sapiens serinethreonine kinase 6 (STK6), mRNA. /FEA = mRNA /GEN = STK6 /PROD = serinethreonine kinase 6 /DB_XREF = gi: 4507278 /UG = Hs.250822 serinethreonine kinase 6 /FL = gb: D84212.1 gb: NM_003158.1 202240_at polo-like kinase 1 (Dro

gb: NM_005030.1 /DEF = Homo PLK1 −78.4 61.4 −1.8 sapiens polo (Drosophia)-like kinase (PLK), mRNA. /FEA = mRNA /GEN = PLK /PROD = polo (Drosophia)-like kinase /DB_XREF = gi: 4826915 /UG = Hs.77597 polo (Drosophia)- like kinase /FL = gb: BC002369.1 gb: BC003002.1 gb: U01038.1 gb: L19559.1 gb: NM_005030.1 217762_s_at RAB31, member RAS Consensus includes gb: BE789881 RAB31 1.3 −1.3 −1.1 /FEA = EST /DB_XREF = gi: 10211079 /DB_XREF = est: 601476750F1 /CLONE = IMAGE: 3879493 /UG = Hs.223025 RAB31, member RAS oncogene family /FL = gb: AF234995.1 gb: BC001148.1 gb: U59877.1 gb: U57091.1 gb: NM_006868.1 gb: AF183421.1 215925_s_at CD72 antigen Consensus includes CD72 69.7 −1.4 1.4 gb: AF283777.2 /DEF = Homo sapiens clone TCBAP0702 mRNA sequence. /FEA = mRNA /DB_XREF = gi: 10281735 /UG = Hs.116481 CD72 antigen 201422_at interferon, gamma-ind

gb: NM_006332.1 /DEF = Homo IFI30 −1.4 −1.1 −1.1 sapiens interferon, gamma- inducible protein 30 (IFI30), mRNA. /FEA = mRNA /GEN = IFI30 /PROD = interferon, gamma- inducible protein 30 /DB_XREF = gi: 5453695 /UG = Hs.14623 interferon, gamma- inducible protein 30 /FL = gb: J03909.1 gb: NM_006332.1 gb: AF097362.1 218559_s_at v-maf musculoaponeu

gb: NM_005461.1 /DEF = Homo MAFB 1.1 −1.5 1.1 sapiens Kreisler (mouse) maf- related leucine zipper homolog (KRML), mRNA. /FEA = mRNA /GEN = KRML /PROD = Kreisler (mouse) maf-related leucine zipperhomolog /DB_XREF = gi: 4885446 /UG = Hs.169487 Kreisler (mouse) maf-related leucine zipper homolog /FL = gb: AF134157.1 gb: NM_005461.1 202241_at tribbles homolog 1 (Dr

gb: NM_025195.1 /DEF = Homo TRIB1 1.4 −1.3 1.1 sapiens phosphoprotein regulated by mitogenic pathways (C8FW), mRNA. /FEA = mRNA /GEN = C8FW /PROD = G-protein- coupled receptor induced protein /DB_XREF = gi: 13399327 /UG = Hs.7837 phosphoprotein regulated by mitogenic pathways /FL = gb: AF205437.1 gb: NM_025195.1 210004_at oxidised low density lip

gb: AF035776.1 /DEF = Homo OLR1 1.2 −1.6 −2.0 sapiens oxidized low-density lipoprotein receptor mRNA, complete cds. /FEA = mRNA /PROD = oxidized low-density lipoprotein receptor /DB_XREF = gi: 3941299 /UG = Hs.77729 oxidised low density lipoprotein (lectin-like) receptor 1 /FL = gb: AB010710.1 gb: AF035776.1 gb: NM_002543.1 203755_at BUB1 budding uninhib

gb: NM_001211.2 /DEF = Homo BUB1B −1.1 −1.3 −1.1 sapiens budding uninhibited by benzimidazoles 1 (yeast homolog), beta (BUB1B), mRNA. /FEA = mRNA /GEN = BUB1B /PROD = budding uninhibited by benzimidazoles 1 (yeasthomolog), beta /DB_XREF = gi: 5729749 /UG = Hs.36708 budding uninhibited by benzimidazoles 1 (yeast homolog), beta /FL = gb: AF053306.1 gb: AF035933.1 gb: AF068760.1 gb: AF046918.1 gb: AF107297.1 gb: AF046079.2 gb: NM_001211.2 204072_s_at hypothetical protein C

gb: NM_023037.1 /DEF = Homo 13CDNA73 1.3 1.2 −1.5 sapiens putative gene product (13CDNA73), mRNA. /FEA = mRNA /GEN = 13CDNA73 /PROD = putative gene product /DB_XREF = gi: 12957487 /UG = Hs.181304 putative gene product /FL = gb: NM_023037.1 202870_s_at CDC20 cell division cy

gb: NM_001255.1 /DEF = Homo CDC20 −1.0 −1.0 −63.0 sapiens CDC20 (cell division cycle 20, S. cerevisiae, homolog) (CDC20), mRNA. /FEA = mRNA /GEN = CDC20 /PROD = cell division cycle 20 /DB_XREF = gi: 4557436 /UG = Hs.82906 CDC20 (cell division cycle 20, S. cerevisiae, homolog) /FL = gb: BC001088.1 gb: AF099644.1 gb: NM_001255.1 gb: U05340.1 220832_at toll-like receptor 8 gb: NM_016610.1 /DEF = Homo TLR8 1.4 −2.0 −95.0 sapiens Toll-like receptor 8 (LOC51311), mRNA. /FEA = mRNA /GEN = LOC51311 /PROD = Toll-like receptor 8 /DB_XREF = gi: 7706147 /UG = Hs.272410 Toll-like receptor 8 /FL = gb: AF246971.1 gb: NM_016610.1 gb: AF245703.1 211519_s_at kinesin family member gb: AY026505.1 /DEF = Homo KIF2C −1.4 −1.1 −1.1 sapiens testis specific mitotic centromere-associated kinesin mRNA, complete cds. /FEA = mRNA /PROD = testis specific mitotic centromere- associatedkinesin /DB_XREF = gi: 13432054 /UG = Hs.69360 kinesin-like 6 (mitotic centromere-associated kinesin) /FL = gb: AY026505.1 202954_at ubiquitin-conjugating e

gb: NM_007019.1 /DEF = Homo UBE2C −1.1 1.0 −1.1 sapiens ubiquitin carrier protein E2 C (UBCH10), mRNA. /FEA = mRNA /GEN = UBCH10 /PROD = ubiquitin carrier protein E2-C /DB_XREF = gi: 5902145 /UG = Hs.93002 ubiquitin carrier protein E2-C /FL = gb: U73379.1 gb: NM_007019.1 204798_at v-myb myeloblastosis

gb: NM_005375.1 /DEF = Homo MYB 1.4 −1.1 −1.4 sapiens v-myb avian myeloblastosis viral oncogene homolog (MYB), mRNA. /FEA = mRNA /GEN = MYB /PROD = v-myb avian myeloblastosis viral oncogenehomolog /DB_XREF = gi: 4885496 /UG = Hs.1334 v-myb avian myeloblastosis viral oncogene homolog /FL = gb: M15024.1 gb: AF104863.1 gb: NM_005375.1 204962_s_at centromere protein A, gb: NM_001809.2 /DEF = Homo CENPA −1.0 −1.0 −52.3 sapiens centromere protein A (17 kD) (CENPA), mRNA. /FEA = mRNA /GEN = CENPA /PROD = centromere protein A /DB_XREF = gi: 4585861 /UG = Hs.1594 centromere protein A (17 kD) /FL = gb: NM_001809.2 gb: U14518.1 203923_s_at cytochrome b-245, bet

gb: NM_000397.2 /DEF = Homo CYBB 1.1 −1.2 −1.3 sapiens cytochrome b-245, beta polypeptide (chronic granulomatous disease) (CYBB), mRNA. /FEA = mRNA /GEN = CYBB /PROD = cytochrome b-245, beta polypeptide (chronicgranulomatous disease) /DB_XREF = gi: 6996020 /UG = Hs.88974 cytochrome b-245, beta polypeptide (chronic granulomatous disease) /FL = gb: NM_000397.2 218039_at nucleolar and spindle

gb: NM_016359.1 /DEF = Homo NUSAP1 1.2 −1.2 −1.4 sapiens clone HQ0310 PRO0310p1 (LOC51203), mRNA. /FEA = mRNA /GEN = LOC51203 /PROD = clone HQ0310 PRO0310p1 /DB_XREF = gi: 7705950 /UG = Hs.279905 clone HQ0310 PRO0310p1 /FL = gb: AF305711.1 gb: BC001308.1 gb: AF290612.1 gb: AF090915.1 gb: NM_016359.1 206461_x_at metallothionein 1H gb: NM_005951.1 /DEF = Homo MT1H 1.2 −1.9 −1.2 sapiens metallothionein 1H (MT1H), mRNA. /FEA = mRNA /GEN = MT1H /PROD = metallothionein 1H /DB_XREF = gi: 10835084 /UG = Hs.2667 metallothionein 1H /FL = gb: NM_005951.1 203535_at S100 calcium binding

gb: NM_002965.2 /DEF = Homo S100A9 −1.1 −1.4 −1.5 sapiens S100 calcium-binding protein A9 (calgranulin B) (S100A9), mRNA. /FEA = mRNA /GEN = S100A9 /PROD = S100 calcium-binding protein A9 /DB_XREF = gi: 9845520 /UG = Hs.112405 S100 calcium- binding protein A9 (calgranulin B) /FL = gb: M26311.1 gb: NM_002965.2 218355_at kinesin family gb: NM_012310.2 /DEF = Homo sapiens kinesin KIF4A −1.0 −1.0 −1.0 member 4A family member 4A (KIF4A), mRNA. /FEA = mRNA /GEN = KIF4A /PROD = kinesin family member 4 /DB_XREF = gi: 7305204 /UG = Hs.279766 kinesin family member 4A /FL = gb: AF179308.1 gb: AF071592.2 gb: NM_012310.2 216950_s_at Fc fragment of Consensus includes gb: X14355.1 /DEF = Human FCGR1A 1.0 −1.1 −1.2 IgG, high affinity mRNA for high affinity Fc receptor (FcRI) b form. Ia, receptor for /FEA = mRNA /DB_XREF = gi: 31333 (CD64) /UG = Hs.77424 Fc fragment of IgG, high affinity Ia, receptor for (CD64) 202191_s_at growth arrest- Consensus includes gb: BE439987 /FEA = EST GAS7 1.2 −1.4 −1.1 specific 7 /DB_XREF = gi: 9439470 /DB_XREF = est: HTM1- 745F /UG = Hs.226133 growth arrest-specific 7 /FL = gb: AB007854.1 gb: NM_005890.1 205769_at solute carrier gb: NM_003645.1 /DEF = Homo sapiens fatty-acid- SLC27A2 −1.0 −1.0 −1.0 family 27 (fatty Coenzyme A ligase, very long-chain 1 (FACVL1), acid transporter), mRNA. /FEA = mRNA /GEN = FACVL1 member 2 /PROD = very long-chain fatty-acid-Coenzyme A ligase 1 /DB_XREF = gi: 4503652 /UG = Hs.11729 fatty-acid-Coenzyme A ligase, very long-chain 1 /FL = gb: D88308.1 gb: AF096290.1 gb: NM_003645.1 209714_s_at cyclin-dependent gb: AF213033.1 /DEF = Homo sapiens isolate BX- CDKN3 −1.3 −1.0 −1.2 kinase inhibitor 3 01 cyclin-dependent kinase associated protein (CDK2- phosphatase mRNA, complete cds. associated dual /FEA = mRNA /PROD = cyclin-dependent kinase specificity associated proteinphosphatase phosphatase) /DB_XREF = gi: 12734643 /UG = Hs.84113 cyclin- dependent kinase inhibitor 3 (CDK2-associated dual specificity phosphatase) /FL = gb: AF213033.1 gb: AF213034.1 gb: AF213035.1 gb: AF213036.1 gb: AF213037.1 gb: AF213038.1 gb: AF213039.1 gb: AF213040.1 gb: AF213041.1 gb: AF213042.1 gb: AF213044.1 gb: AF213046.1 gb: AF213047.1 gb: AF213048.1 gb: AF213049.1 gb: AF213050.1 gb: AF213051.1 gb: AF213052.1 gb: AF213053.1 gb: U02681.1 gb: L25876.1 gb: NM_005192.1 gb: L27711.1 203145_at sperm associated gb: NM_006461.1 /DEF = Homo sapiens mitotic SPAG5 1.1 1.3 94.7 antigen 5 spindle coiled-coil related protein (DEEPEST), mRNA. /FEA = mRNA /GEN = DEEPEST /PROD = mitotic spindle coiled-coil related protein /DB_XREF = gi: 5453631 /UG = Hs.16244 mitotic spindle coiled-coil related protein /FL = gb: BC000322.1 gb: AF063308.1 gb: NM_006461.1 205119_s_at formyl peptide gb: NM_002029.1 /DEF = Homo sapiens formyl 1.3 −1.0 −1.4 receptor 1 peptide receptor 1 (FPR1), mRNA. /FEA = mRNA /GEN = FPR1 /PROD = formyl peptide receptor 1 /DB_XREF = gi: 4503778 /UG = Hs.753 formyl peptide receptor 1 /FL = gb: BC005315.1 gb: M60626.1 gb: M60627.1 gb: NM_002029.1 204759_at chromosome gb: NM_001268.1 /DEF = Homo sapiens CHC1L 1.6 −1.0 1.2 condensation 1- chromosome condensation 1-like (CHC1L), like mRNA. /FEA = mRNA /GEN = CHC1L /PROD = RCC1-like G exchanging factor RLG /DB_XREF = gi: 4557444 /UG = Hs.27007 chromosome condensation 1-like /FL = gb: AF060219.1 gb: NM_001268.1 201666_at tissue inhibitor of gb: NM_003254.1 /DEF = Homo sapiens tissue TIMP1 1.0 −1.3 1.0 metalloproteinase inhibitor of metalloproteinase 1 (erythroid 1 (erythroid potentiating activity, collagenase inhibitor) potentiating (TIMP1), mRNA. /FEA = mRNA /GEN = TIMP1 activity, /PROD = tissue inhibitor of metalloproteinase collagenase 1 precursor /DB_XREF = gi: 4507508 /UG = Hs.5831 tissue inhibitor of inhibitor) metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) /FL = gb: BC000866.1 gb: M12670.1 gb: M59906.1 gb: NM_003254.1 217996_at pleckstrin Consensus includes gb: AA576961 /FEA = EST PHLDA1 1.2 63.7 −66.0 homology-like /DB_XREF = gi: 2354435 domain, family A, /DB_XREF = est: nm82d08.s1 member 1 /CLONE = IMAGE: 1074735 /UG = Hs.82101 pleckstrin homology-like domain, family A, member 1 /FL = gb: NM_007350.1 202388_at regulator of G- gb: NM_002923.1 /DEF = Homo sapiens regulator RGS2 1.4 1.2 1.3 protein signalling of G-protein signalling 2, 24 kD (RGS2), mRNA. 2, 24 kDa /FEA = mRNA /GEN = RGS2 /PROD = regulator of G-protein signalling 2, 24 kD /DB_XREF = gi: 4506516 /UG = Hs.78944 regulator of G-protein signalling 2, 24 kD /FL = gb: L13463.1 gb: NM_002923.1 204446_s_at arachidonate 5- gb: NM_000698.1 /DEF = Homo sapiens ALOX5 1.2 −1.3 −1.3 lipoxygenase arachidonate 5-lipoxygenase (ALOX5), mRNA. /FEA = mRNA /GEN = ALOX5 /PROD = arachidonate 5-lipoxygenase /DB_XREF = gi: 4502056 /UG = Hs.89499 arachidonate 5-lipoxygenase /FL = gb: J03600.1 gb: J03571.1 gb: NM_000698.1 203126_at inositol(myo)-1(or gb: NM_014214.1 /DEF = Homo sapiens IMPA2 −1.0 −1.7 1.0 4)- inositol(myo)-1(or 4)-monophosphatase 2 monophosphatase 2 (IMPA2), mRNA. /FEA = mRNA /GEN = IMPA2 /PROD = inositol(myo)-1(or 4)-monophosphatase 2 /DB_XREF = gi: 7657235 /UG = Hs.5753 inositol(myo)-1(or 4)-monophosphatase 2 /FL = gb: AF200432.1 gb: NM_014214.1 gb: AF014398.2 208581_x_at metallothionein gb: NM_005952.1 /DEF = Homo sapiens MT1X 1.2 −1.4 −1.5 1X metallothionein 1X (MT1X), mRNA. /FEA = CDS /GEN = MT1X /PROD = metallothionein 1X /DB_XREF = gi: 10835231 /UG = Hs.278462 metallothionein 1X /FL = gb: NM_005952.1 219890_at C-type (calcium gb: NM_013252.1 /DEF = Homo sapiens C-type CLECSF5 1.5 −1.0 −1.2 dependent, (calcium dependent, carbohydrate-recognition carbohydrate- domain) lectin, superfamily member 5 recognition (CLECSF5), mRNA. /FEA = mRNA domain) lectin, /GEN = CLECSF5 /PROD = C-type (calcium superfamily dependent, carbohydrate-recognition domain) member 5 lectin, superfamilymember 5 /DB_XREF = gi: 10281668 /UG = Hs.126355 C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 5 /FL = gb: NM_013252.1 gb: AF139768.1 209773_s_at ribonucleotide gb: BC001886.1 /DEF = Homo sapiens, RRM2 −1.9 −1.5 −1.5 reductase M2 ribonucleotide reductase M2 polypeptide, clone polypeptide MGC: 1551, mRNA, complete cds. /FEA = mRNA /PROD = ribonucleotide reductase M2 polypeptide /DB_XREF = gi: 12804874 /UG = Hs.75319 ribonucleotide reductase M2 polypeptide /FL = gb: BC001886.1 205098_at chemokine (C-C Consensus includes gb: AI421071 /FEA = EST −1.1 −1.7 −1.1 motif) receptor 1 /DB_XREF = gi: 4267002 /DB_XREF = est: tf24a02.x1 /CLONE = IMAGE: 2097098 /UG = Hs.301921 chemokine (C-C motif) receptor 1 /FL = gb: L09230.1 gb: L10918.1 gb: NM_001295.1 201438_at collagen, type VI, gb: NM_004369.1 /DEF = Homo sapiens collagen, COL6A3 −1.0 −1.0 −1.0 alpha 3 type VI, alpha 3 (COL6A3), mRNA. /FEA = mRNA /GEN = COL6A3 /PROD = collagen, type VI, alpha 3 /DB_XREF = gi: 4758027 /UG = Hs.80988 collagen, type VI, alpha 3 /FL = gb: NM_004369.1 207067_s_at histidine gb: NM_002112.1 /DEF = Homo sapiens histidine HDC −1.3 −1.0 −1.2 decarboxylase decarboxylase (HDC), mRNA. /FEA = mRNA /GEN = HDC /PROD = histidine decarboxylase /DB_XREF = gi: 4504364 /UG = Hs.1481 histidine decarboxylase /FL = gb: M60445.1 gb: NM_002112.1 204614_at serine (or gb: NM_002575.1 /DEF = Homo sapiens serine (or SERPINB2 1.4 1.2 1.3 cysteine) cysteine) proteinase inhibitor, clade B proteinase (ovalbumin), member 2 (SERPINB2), mRNA. inhibitor, clade B /FEA = mRNA /GEN = SERPINB2 /PROD = serine (ovalbumin), (or cysteine) proteinase inhibitor, cladeB member 2 (ovalbumin), member 2 /DB_XREF = gi: 4505594 /UG = Hs.75716 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2 /FL = gb: J02685.1 gb: J03603.1 gb: M18082.1 gb: NM_002575.1 205786_s_at integrin, alpha M gb: NM_000632.2 /DEF = Homo sapiens integrin, ITGAM 1.0 −1.2 −1.6 (complement alpha M (complement component receptor 3, component alpha; also known as CD11b (p170), receptor 3, alpha; macrophage antigen alpha polypeptide) also known as (ITGAM), mRNA. /FEA = mRNA /GEN = ITGAM CD11b (p170), /PROD = integrin alpha M precursor macrophage /DB_XREF = gi: 6006013 /UG = Hs.172631 integrin, antigen alpha alpha M (complement component receptor 3, polypeptide) alpha; also known as CD11b (p170), macrophage antigen alpha polypeptide) /FL = gb: J03925.1 gb: NM_000632.2 201739_at serum/glucocorticoid gb: NM_005627.1 /DEF = Homo sapiens SGK 1.3 1.0 1.0 regulated serumglucocorticoid regulated kinase (SGK), kinase mRNA. /FEA = mRNA /GEN = SGK /PROD = serumglucocorticoid regulated kinase /DB_XREF = gi: 5032090 /UG = Hs.296323 serumglucocorticoid regulated kinase /FL = gb: BC001263.1 gb: NM_005627.1 gb: AF153609.1 209949_at neutrophil gb: BC001606.1 /DEF = Homo sapiens, Similar to NCF2 1.2 −1.4 −1.5 cytosolic factor 2 neutrophil cytosolic factor 2 (65 kD, chronic (65 kDa, chronic granulomatous disease, autosomal 2), clone granulomatous MGC: 2275, mRNA, complete cds. /FEA = mRNA disease, /PROD = Similar to neutrophil cytosolic factor 2 autosomal 2) (65 kD, chronic granulomatous disease, autosomal 2) /DB_XREF = gi: 12804408 /UG = Hs.949 neutrophil cytosolic factor 2 (65 kD, chronic granulomatous disease, autosomal 2) /FL = gb: BC001606.1 gb: M32011.1 gb: NM_000433.1 221210_s_at N- gb: NM_030769.1 /DEF = Homo sapiens NPL 1.5 −1.1 1.1 acetylneuraminate hypothetical protein similar to swine pyruvate lyase acylneuraminate lyase (C1ORF13), mRNA. (dihydrodipicolinate /FEA = mRNA /GEN = C1ORF13 synthase) /PROD = hypothetical protein similar to swineacylneuraminate lyase /DB_XREF = gi: 13540532 /FL = gb: NM_030769.1 210184_at integrin, alpha X gb: M81695.1 /DEF = H. sapiens leukocyte ITGAX 1.1 −1.0 −1.2 (antigen CD11C adhesion glycoprotein p150, 95 mRNA, complete (p150), alpha cds. /FEA = mRNA /GEN = ITGAX polypeptide) /DB_XREF = gi: 487829 /UG = Hs.51077 integrin, alpha X (antigen CD11C (p150), alpha polypeptide) /FL = gb: M81695.1 gb: NM_000887.2 217762_s_at RAB31, member Consensus includes gb: BE789881 /FEA = EST RAB31 1.3 −1.3 −1.1 RAS oncogene /DB_XREF = gi: 10211079 family /DB_XREF = est: 601476750F1 /CLONE = IMAGE: 3879493 /UG = Hs.223025 RAB31, member RAS oncogene family /FL = gb: AF234995.1 gb: BC001148.1 gb: U59877.1 gb: U57091.1 gb: NM_006868.1 gb: AF183421.1 215925_s_at CD72 antigen Consensus includes gb: AF283777.2 CD72 69.7 −1.4 1.4 /DEF = Homo sapiens clone TCBAP0702 mRNA sequence. /FEA = mRNA /DB_XREF = gi: 10281735 /UG = Hs.116481 CD72 antigen 201422_at interferon, gb: NM_006332.1 /DEF = Homo sapiens IFI30 −1.4 −1.1 −1.1 gamma-inducible interferon, gamma-inducible protein 30 (IFI30), protein 30 mRNA. /FEA = mRNA /GEN = IFI30 /PROD = interferon, gamma-inducible protein 30 /DB_XREF = gi: 5453695 /UG = Hs.14623 interferon, gamma-inducible protein 30 /FL = gb: J03909.1 gb: NM_006332.1 gb: AF097362.1 218559_s_at v-maf gb: NM_005461.1 /DEF = Homo sapiens Kreisler MAFB 1.1 −1.5 1.1 musculoaponeurotic (mouse) maf-related leucine zipper homolog fibrosarcoma (KRML), mRNA. /FEA = mRNA /GEN = KRML oncogene /PROD = Kreisler (mouse) maf-related leucine homolog B zipperhomolog /DB_XREF = gi: 4885446 (avian) /UG = Hs.169487 Kreisler (mouse) maf-related leucine zipper homolog /FL = gb: AF134157.1 gb: NM_005461.1 202241_at tribbles homolog gb: NM_025195.1 /DEF = Homo sapiens TRIB1 1.4 −1.3 1.1 1 (Drosophila) phosphoprotein regulated by mitogenic pathways (C8FW), mRNA. /FEA = mRNA /GEN = C8FW /PROD = G-protein-coupled receptor induced protein /DB_XREF = gi: 13399327 /UG = Hs.7837 phosphoprotein regulated by mitogenic pathways /FL = gb: AF205437.1 gb: NM_025195.1 204798_at v-myb gb: NM_005375.1 /DEF = Homo sapiens v-myb MYB 1.4 −1.1 −1.4 myeloblastosis avian myeloblastosis viral oncogene homolog viral oncogene (MYB), mRNA. /FEA = mRNA /GEN = MYB homolog (avian) /PROD = v-myb avian myeloblastosis viral oncogenehomolog /DB_XREF = gi: 4885496 /UG = Hs.1334 v-myb avian myeloblastosis viral oncogene homolog /FL = gb: M15024.1 gb: AF104863.1 gb: NM_005375.1 203923_s_at cytochrome b- gb: NM_000397.2 /DEF = Homo sapiens CYBB 1.1 −1.2 −1.3 245, beta cytochrome b-245, beta polypeptide (chronic polypeptide granulomatous disease) (CYBB), mRNA. (chronic /FEA = mRNA /GEN = CYBB /PROD = cytochrome granulomatous b-245, beta polypeptide (chronicgranulomatous disease) disease) /DB_XREF = gi: 6996020 /UG = Hs.88974 cytochrome b-245, beta polypeptide (chronic granulomatous disease) /FL = gb: NM_000397.2 218039_at nucleolar and gb: NM_016359.1 /DEF = Homo sapiens clone NUSAP1 1.2 −1.2 −1.4 spindle HQ0310 PRO0310p1 (LOC51203), mRNA. associated /FEA = mRNA /GEN = LOC51203 /PROD = clone protein 1 HQ0310 PRO0310p1 /DB_XREF = gi: 7705950 /UG = Hs.279905 clone HQ0310 PRO0310p1 /FL = gb: AF305711.1 gb: BC001308.1 gb: AF290612.1 gb: AF090915.1 gb: NM_016359.1 206461_x_at metallothionein gb: NM_005951.1 /DEF = Homo sapiens MT1H 1.2 −1.9 −1.2 1H metallothionein 1H (MT1H), mRNA. /FEA = mRNA /GEN = MT1H /PROD = metallothionein 1H /DB_XREF = gi: 10835084 /UG = Hs.2667 metallothionein 1H /FL = gb: NM_005951.1 203535_at S100 calcium gb: NM_002965.2 /DEF = Homo sapiens S100 S100A9 −1.1 −1.4 −1.5 binding protein A9 calcium-binding protein A9 (calgranulin B) (calgranulin B) (S100A9), mRNA. /FEA = mRNA /GEN = S100A9 /PROD = S100 calcium-binding protein A9 /DB_XREF = gi: 9845520 /UG = Hs.112405 S100 calcium-binding protein A9 (calgranulin B) /FL = gb: M26311.1 gb: NM_002965.2 204415_at interferon, alpha- gb: NM_022873.1 /DEF = Homo sapiens G1P3 −1.1 −3.5 1.4 inducible protein interferon, alpha-inducible protein (clone IFI-6- (clone IFI-6-16) 16) (G1P3), transcript variant 3, mRNA. /FEA = mRNA /GEN = G1P3 /PROD = interferon induced 6-16 protein, isoform c /DB_XREF = gi: 13259549 /UG = Hs.265827 interferon, alpha-inducible protein (clone IFI-6- 16) /FL = gb: NM_022872.1 gb: NM_022873.1 gb: NM_002038.2 205483_s_at interferon, alpha- gb: NM_005101.1 /DEF = Homo sapiens G1P2 1.0 −9.9 −1.1 inducible protein interferon-stimulated protein, 15 kDa (ISG15), (clone IFI-15K) mRNA. /FEA = mRNA /GEN = ISG15 /PROD = interferon-stimulated protein, 15 kDa /DB_XREF = gi: 4826773 /UG = Hs.833 interferon-stimulated protein, 15 kDa /FL = gb: M13755.1 gb: NM_005101.1 203595_s_at interferon-induced Consensus includes gb: N47725 /FEA = EST IFIT5 1.5 −2.2 1.0 protein with /DB_XREF = gi: 1188891 tetratricopeptide /DB_XREF = est: yy92h11.s1 repeats 5 /CLONE = IMAGE: 281061 /UG = Hs.27610 retinoic acid- and interferon-inducible protein (58 kD) /FL = gb: U34605.1 gb: NM_012420.1 203153_at interferon-induced gb: NM_001548.1 /DEF = Homo sapiens −1.0 −1084.5 −1.0 protein with interferon-induced protein with tetratricopeptide tetratricopeptide repeats 1 (IFIT1), mRNA. /FEA = mRNA repeats 1 /GEN = IFIT1 /PROD = interferon-induced protein withtetratricopeptide repeats 1 /DB_XREF = gi: 4504584 /UG = Hs.20315 interferon-induced protein with tetratricopeptide repeats 1 /FL = gb: M24594.1 gb: NM_001548.1 214453_s_at interferon-induced Consensus includes gb: NM_006417.1 IFI44 1.4 −4.9 1.1 protein 44 /DEF = Homo sapiens interferon-induced, hepatitis C-associated microtubular aggregate protein (44 kD) (MTAP44), mRNA. /FEA = CDS /GEN = MTAP44 /PROD = interferon-induced, hepatitis C-associatedmicrotubular aggregate protein (44 kD) /DB_XREF = gi: 5453743 /UG = Hs.82316 interferon-induced, hepatitis C- associated microtubular aggregate protein (44 kD) /FL = gb: NM_006417.1 202086_at myxovirus (influenza gb: NM_002462.1 /DEF = Homo sapiens MX1 1.1 −7.3 −1.2 virus) resistance 1, myxovirus (influenza) resistance 1, homolog of interferon-inducible murine (interferon-inducible protein p78) (MX1), protein p78 (mouse) mRNA. /FEA = mRNA /GEN = MX1 /PROD = myxovirus (influenza) resistance 1, homolog ofmurine (interferon-inducible protein p78) /DB_XREF = gi: 4505290 /UG = Hs.76391 myxovirus (influenza) resistance 1, homolog of murine (interferon-inducible protein p78) /FL = gb: M30817.1 gb: M33882.1 gb: NM_002462.1 216598_s_at chemokine (C-C Consensus includes gb: S69738.1 /DEF = MCP- CCL2 −1.3 −3.1 −2.4 motif) ligand 2 1 = monocyte chemotactic protein human, aortic endothelial cells, mRNA, 661 nt. /FEA = mRNA /GEN = MCP-1 /PROD = MCP-1 /DB_XREF = gi: 545464 /UG = Hs.303649 small inducible cytokine A2 (monocyte chemotactic protein 1, homologous to mouse Sig-je) 204533_at chemokine (C—X—C gb: NM_001565.1 /DEF = Homo sapiens small CXCL10 −1.2 −4.9 −3.9 motif) ligand 10 inducible cytokine subfamily B (Cys-X-Cys), member 10 (SCYB10), mRNA. /FEA = mRNA /GEN = SCYB10 /PROD = interferon gamma- induced precursor /DB_XREF = gi: 4504700 /UG = Hs.2248 small inducible cytokine subfamily B (Cys-X-Cys), member 10 /FL = gb: NM_001565.1 203915_at chemokine (C—X—C gb: NM_002416.1 /DEF = Homo sapiens CXCL9 −1.2 −1.7 −3.2 motif) ligand 9 monokine induced by gamma interferon (MIG), mRNA. /FEA = mRNA /GEN = MIG /PROD = monokine induced by gamma interferon /DB_XREF = gi: 4505186 /UG = Hs.77367 monokine induced by gamma interferon /FL = gb: NM_002416.1 209714_s_at cyclin-dependent gb: AF213033.1 /DEF = Homo sapiens isolate CDKN3 −1.3 −1.0 −1.2 kinase inhibitor 3 BX-01 cyclin-dependent kinase associated (CDK2-associated protein phosphatase mRNA, complete cds. dual specificity /FEA = mRNA /PROD = cyclin-dependent kinase phosphatase) associated proteinphosphatase /DB_XREF = gi: 12734643 /UG = Hs.84113 cyclin-dependent kinase inhibitor 3 (CDK2- associated dual specificity phosphatase) /FL = gb: AF213033.1 gb: AF213034.1 gb: AF213035.1 gb: AF213036.1 gb: AF213037.1 gb: AF213038.1 gb: AF213039.1 gb: AF213040.1 gb: AF213041.1 gb: AF213042.1 gb: AF213044.1 gb: AF213046.1 gb: AF213047.1 gb: AF213048.1 gb: AF213049.1 gb: AF213050.1 gb: AF213051.1 gb: AF213052.1 gb: AF213053.1 gb: U02681.1 gb: L25876.1 gb: NM_005192.1 gb: L27711.1 204170_s_at CDC28 protein gb: NM_001827.1 /DEF = Homo sapiens CKS2 −1.1 −1.7 −1.9 kinase regulatory CDC28 protein kinase 2 (CKS2), mRNA. subunit 2 /FEA = mRNA /GEN = CKS2 /PROD = CDC28 protein kinase 2 /DB_XREF = gi: 4502858 /UG = Hs.83758 CDC28 protein kinase 2 /FL = gb: NM_001827.1 203213_at cell division cycle Consensus includes gb: AL524035 /FEA = EST CDC2 −1.0 −1.0 −1.0 2, G1 to S and G2 /DB_XREF = gi: 12787528 to M /DB_XREF = est: AL524035 /CLONE = CS0DC003YN06 (3 prime) /UG = Hs.184572 cell division cycle 2, G1 to S and G2 to M /FL = gb: NM_001786.1 201292_at topoisomerase Consensus includes gb: AL561834 /FEA = EST TOP2A −1.0 −1.0 −1.0 (DNA) II alpha /DB_XREF = gi: 12909658 170 kDa /DB_XREF = est: AL561834 /CLONE = CS0DB005YC15 (3 prime) /UG = Hs.156346 topoisomerase (DNA) II alpha (170 kD) /FL = gb: J04088.1 gb: NM_001067.1

indicates data missing or illegible when filed 

1-9. (canceled)
 10. A nucleic acid array of comprising at least 4 distinct nucleic acid sequences selected from the group consisting of the polynucleotides listed in any one of Gene Tables I, V, VI, VII or Table IV, immobilized on a surface at discrete and known positions, wherein said nucleic acids hybridize to nucleic acids in a sample of a subject that are either up-regulated or down-regulated in response to inhibition of IMPDH. 11-13. (canceled)
 14. The nucleic acid array of claim 10, wherein the surface is selected from the group consisting of a metal, silicon, a polymer plastic, paper, ceramic, quartz, gallium arsenide, metal, metalloid, cellulose, celluose acetate, nitrocellulose, and a glass.
 15. (canceled)
 16. The nucleic acid array of claim 10, further comprising at least one control spot consisting of one or more nucleic acids that are known not to be modulated with IMPDH inhibition.
 17. (canceled)
 18. The nucleic acid array of claim 10, wherein said surface comprises a plurality of microarrays separated from each other with a hydrophobic polymer strip.
 19. (canceled)
 20. A set of polynucleotides for use in the detection of IMPDH inhibition, wherein said polynucleotides hybridize to 4 to 314 genes selected from the group consisting of the genes set forth in any one or more of Gene Table I, Gene Table II, Gene Table III, Gene Table IV, Gene Table V, Gene Table VI, Gene Table VII and Gene Table VIII wherein the expression of each said polynucleotides is either up- or down-regulated in response to inhibition of IMPDH. 21-26. (canceled)
 27. A method for predicting whether a candidate IMPDH inhibitory agent will produce a therapeutic effect in a subject comprising: contacting a biological sample from said subject with said candidate IMPDH inhibitory agent and determining the expression level in said biological sample of four or more prognostic genes selected from the group consisting of the genes set forth in one or more of Gene Table I, Gene Table II, Gene Table III, Gene Table IV, Gene Table V, Gene Table VI, Gene Table VII and Gene Table VIII, wherein a modulation of the expression level of the four or more of genes is similar to the modulation resulting from contacting the biological sample with VX-944 and is indicative that said agent is a therapeutically effective IMPDH inhibitory agent. 28-29. (canceled)
 30. The method of claim 27, wherein said subject is human.
 31. The method of claim 27, wherein said biological sample is a sample from a cancer patient, and wherein said cancer is selected from the group consisting of breast cancer, ovarian cancer, gastric cancer, colorectal cancer, prostate cancer, pancreatic cancer, and lung cancer.
 32. The method of claim 27, wherein the modulation of expression in response to said candidate IMPDH inhibitory agent is similar to the modulation in expression seen in response to contacting said biological sample with VX-944.
 33. The method of claim 27, wherein said biological sample is a tissue sample comprising cancer cells.
 34. The method of claim 27, wherein said tissue is fixed, paraffin-embedded, fresh, or frozen.
 35. The method of claim 34, where the tissue is from a biopsy.
 36. (canceled)
 37. The method of claim 27, wherein the expression level of said prognostic genes is determined by PCR, immunohistochemistry or in situ hybridization. 38-39. (canceled)
 40. The method of claim 27, wherein the assay for the measurement of said prognostic genes or their expression products is provided in the form of a kit or kits.
 41. A method of preparing a prognostic profile for a subject's response to an IMPDH inhibitor comprising the steps of: (a) exposing ex vivo cells of said subject to an IMPDH inhibitor; (b) subjecting RNA extracted from the cells of step (a) to gene expression profiling; (c) determining the expression levels of at least four genes selected from the group consisting of the genes set forth in one or more of Gene Table I, Gene Table II, Gene Table III, Gene Table IV, Gene Table V, Gene Table VI, Gene Table VII and Gene Table VIII in said cells; and (d) comparing the expression levels obtained in step (c) to expression levels obtained in the absence of said IMPDH inhibitor, wherein a modulation of the expression level of said four or more of genes in response to said IMPDH inhibitor indicates that said subject is likely to be responsive to said inhibitor.
 42. A method of preparing a prognostic profile for a subject's response to an IMPDH inhibitor comprising the steps of: (a) administering an IMPDH inhibitor to said subject; (b) subjecting RNA extracted from cells of said subject to gene expression profiling; (c) determining the expression level of at least four genes selected from the group consisting of the genes set forth in one or more of Gene Table I, Gene Table II, Gene Table III, Gene Table IV, Gene Table V, Gene Table VI, Gene Table VII and Gene Table VIII in said cells of said subject; and (d) comparing the expression levels obtained in step (c) to expression levels obtained in the absence of said IMPDH inhibitor, wherein a modulation of the expression level of said four or more of genes in response to said IMPDH inhibitor administration indicates that said IMPDH inhibitor will likely predict the subject's response to said IMPDH inhibitor administration.
 43. (canceled)
 44. The method of claim 41 or 42 wherein said cells are cancer cells obtained from said subject.
 45. The method of claim 44, wherein said cancer cells are selected from the group consisting of breast cancer cells, ovarian cancer cells, hematological cancer cells, gastric cancer cells, colorectal cancer cells, pancreatic cancer cells, and lung cancer cells. 46-48. (canceled)
 49. The method of claim 41 or 42 wherein said expression profile is compiled into a report that includes recommendation for a treatment for said subject with an IMPDH inhibitor.
 50. The method of claim 41 or 42 wherein if altered expression of one or more of the genes selected from the genes set forth in Gene Tables 1, II, III, IV, V, VI, VII, and VIII, or a corresponding expression product is determined, said report includes a prediction that said subject is a suitable candidate for IMPDH inhibition-based therapy.
 51. The method of claim 42, further comprising the step of treating said patient with an IMPDH inhibitory agent.
 52. The method of claim 42, wherein the IMPDH inhibitory agent is identified according to the method of claim
 27. 53-55. (canceled) 